

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp077, Report 3 of 3

Request ID: cder_mpl1p_wp077

Request Description: In this report, we describe the incidence rate of hospitalized tachyarrhythmia, defined as tachyarrhythmia, overall and by subtype, that occurred from May 13, 2022 (the approval date of Mounjaro (tirzepatide) in the U.S.) to June 30, 2023, in adult type 2 diabetes mellitus (T2DM) patients who newly initiated Mounjaro (tirzepatide) or other long-acting glucagon-like peptide-1 (LA GLP-1) receptor agonists (RAs), by product and patient characteristics including race/ethnicity groups.

This is report 3 of 3 and contains the results from the second sensitivity analysis. In this sensitivity analysis, events were allowed to occur on index date. In Report 1 of 3, the lookback period for enrollment, inclusion or exclusion criteria, and most covariates was 365 days in length, and patients were excluded from the analysis if an event occurred on index date (i.e., the blackout period is set to 1 day). In Report 2 of 3, the first sensitivity analysis, the lookback period was 183 days in length.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 12.1.2 with custom programming

Data Source: We distributed this query to seven Sentinel Data Partners (DPs) on September 28, 2023. Six of these Data Partners are a subset of the SDD that rapidly refresh to provide freshest feasible data. Data from Medicare patients having both fee-for-service medical coverage and Part D drug coverage are included. The study period included data from May 13, 2022 through June 30, 2023. See Appendix A for a list of dates of available data for each DP.

Study Design: We identified all individuals with incident use of tirzepatide or other LA GLP-1 RAs and evaluated the occurrence of hospitalized tachyarrhythmia within each LA GLP-1 RA exposure cohorts.

In addition to the overall exposure cohorts, analyses were also conducted by the following subgroups:

- Age groups (0-40, 41-64, 65-74, 75-84, 85 years of age or greater)
- Sex (male, female)
- Calendar year of index date
- Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial)
- Calendar year * race
- Age group * race
- Other cardiac disease at baseline (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea, and hypertrophic cardiomyopathy)

For the primary analysis, the lookback period for enrollment, inclusion or exclusion criteria, and most covariates was 365 days in length, and patients were excluded from the analysis if an event occurred on index date (i.e., the blackout period is set to 1 day). Two sensitivity analyses were conducted. For the first sensitivity analysis, the lookback period was 183 days in length. For the second sensitivity analysis, events were allowed to occur on index date.

This is a Type 2 analysis with custom programming in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were defined as the first qualifying dispensing of one of the following LA GLP-1 RA brand names, each as its own separate cohort: Mounjaro (tirzepatide), Bydureon or Bydureon BCISE (exenatide synthetic), Ozempic (semaglutide), Rybelsus (semaglutide), Wegovy (semaglutide), Saxenda (liraglutide), Victoza (liraglutide), Trulicity (dulaglutide) or Xultophy (insulin degludec/liraglutide). We defined exposures using National Drug Codes (NDCs). Only the first qualifying (index) dispensings of the exposures of interest were included; cohort re-entry was not allowed. See Appendix B for generic and brand names of medical products used to define exposures of interest.

Stockpiling Rules: Brand names within a single exposure definition were stockpiled together, and dispensing dates were not adjusted in case of early refills. If multiple dispensings occurred on the same day, the maximum value for days supply and amount supply among these dispensings were taken to be days supply and amount supply values on that day.

Overview for Request: cder_mpl1r_wp077, Report 3 of 3

Outcomes of Interest: The following health outcomes of interest (HOI) were evaluated for each of the exposure definitions:

- Hospitalized tachyarrhythmia (defined as the presence of any of the conditions below)
- Atrial fibrillation and flutter
- Sinus tachycardia
- Supraventricular tachycardia
- Other tachycardia
- Cardiac arrest
- Ventricular fibrillation and flutter
- Ventricular tachycardia

Outcomes were defined in the inpatient caresetting in principal position (IPP) and in the emergency department caresetting (ED*).

We defined outcomes using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. See Appendix C for diagnosis codes used to define the outcome.

Cohort Eligibility Criteria: We required eligible members to be aged 18 years or older and to be continuously enrolled in health plans with medical and drug coverage for at least 365 days prior to the index date, during which gaps in coverage of up to 45 days were allowed. We defined new use as no evidence use of the index-defining exposure or any other LA GLP-1 RA in the 365 days prior to index date.

Inclusion criteria: We required exposure episodes to have a T2DM diagnosis and usage of any oral anti-diabetic drug in the 365 days prior to index date.

Exclusion criteria: We excluded exposure episodes with a T1DM diagnosis, gestational diabetes, other secondary diabetes illnesses, use of any short-acting (SA) GLP-1 RAs, pregnancy, or insulin-only use (defined as evidence of insulin use without evidence of use of any other anti-diabetic drug) in the 365 days prior to the index date.

We defined inclusion and exclusion criteria using NDCs, ICD-10-CM diagnosis and procedure codes, Healthcare Common Procedure Coding System (HCPCS), Level II codes, and Current Procedural Terminology, Fourth Edition (CPT-4) codes.

See Appendix D for diagnosis or procedure codes used to define inclusion and exclusion characteristics and Appendix E for generic and brand names of medical products.

Follow-up Time: We created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We bridged together episodes less than 5 days apart and added 5 days to the end of each episode.

Outcome evaluation began on index date and continued until the earliest occurrence of the following:

- Outcome
- Treatment discontinuation
- Disenrollment
- Death (except for when all-cause mortality is the outcome)
- End of DP data
- Pregnancy
- Inpatient (IP*) or ED* encounter (other than the HOI-defining hospitalized tachyarrhythmia)
- Non-index LA GLP-1 RA

Baseline Characteristics: The following demographic and clinical characteristics of our study population were ascertained on index date: continuous age, age groups (0-40, 41-64, 65-74, 75-84, 85 years of age or greater), sex (male, female), race (American Indian or Alaska native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, Unknown, Multi-racial), calendar year of treatment initiation, tachyarrhythmia, hospitalized tachyarrhythmia, drugs with a known risk of prolonged QT and torsades de pointes, drugs with a known or possible or conditional risk of prolonged QT and torsades de pointes.

Overview for Request: cder_mpl1r_wp077, Report 3 of 3

The following clinical characteristics were ascertained in the 365 days prior to cohort entry in the primary analysis and second sensitivity analysis or in the 183 days prior to cohort entry in the first sensitivity analysis: alcohol use or abuse, obesity, tobacco use, arrhythmia, cerebrovascular disease or stroke or transient ischemic attack, chronic kidney disease, chronic obstructive pulmonary disease, congenital heart disease, heart failure, hyperlipidemia, hypertensive disease, thyroid disease, ischemic heart disease or coronary artery disease or myocardial infarction, left ventricular hypertrophy, peripheral artery disease, valvular or mitral valve disease, disease of veins and lymphatics and other diseases of the circulatory system, obstructive sleep apnea, hypertrophic cardiomyopathy, other cardiac disease (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea or hypertrophic cardiomyopathy), history of serious hypoglycemia (ED* or IP*), antidiabetic drugs [alpha-glucosidase inhibitor, amylin analogs, dipeptidyl peptidase 4 (DPP-4) inhibitors, incretin mimetics, meglitinides, insulin, biguanides, sodium-glucose cotransporter-2 (SGLT2) inhibitors, sulfonylureas, and thiazolidinediones], no baseline use of any of the previous antidiabetic drugs, other antidiabetic drugs (bromocriptine, mifepristone), antiarrhythmic agents [sodium channel blocker, beta blocker, potassium channel blockers or openers, non-dihydropyridine calcium channel blockers, digoxin, other antiarrhythmic agents], any of the previous antiarrhythmic agents, antihypertensives [angiotensin-converting-enzyme (ACE) inhibitor, angiotensin II receptor blockers (ARB), dihydropyridines, diuretics, other antihypertensives], any of the previous antihypertensives, cardiac medications [oral anticoagulants, vitamin K antagonists, other cardiac medications (not including oral anticoagulants or vitamin K antagonists)], any of previous cardiac medications, lipid lowering therapy, drugs with a known risk of prolonged QT and torsades de pointes, drugs with a known or possible or conditional risk of prolonged QT and torsades de pointes, health care services and drug utilization metrics, continuous Charlson/Elixhauser combined comorbidity index¹ (CCI), CCI groups (0, 1-2, 3-4, 5 or greater), continuous adapted diabetes complications severity index² (ADCSI), and ADCSI groups (0, 1-2, 3-4, 5 or greater). These characteristics were defined using NDCs; ICD-10-CM diagnosis codes; ICD-10-PCS procedure codes; HCPCS, Level II codes; CPT-4, Category I; and CPT-4, Category III codes. See Appendix F for diagnosis or procedure codes used to define baseline characteristics and Appendix G for generic and brand names of medical products.

Please see Appendices H - J for the specifications of parameters used in this request.

Please see Appendix K for a diagram detailing the design of this request.

Limitations: Algorithms to define exposures, outcomes, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

²Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table of Contents

Glossary (CIDA) List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report

Table 1a Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1b Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1c Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1d Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1e Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1f Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1g Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1h Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1i Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1j Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1k Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1l Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1m Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1n Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1o Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1p Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1q Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1r Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1s Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1t Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

Table 1u Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1v Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1w Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1x Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1y Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1z Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1aa Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1ab Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1ac Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1ad Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1ae Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1af Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1ag Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1ah Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1ai Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1aj Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1ak Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1al Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1am Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1an Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table 1ao Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

<u>Table 1ap</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1aq</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ar</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1as</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1at</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1au</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1av</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1aw</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ax</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ay</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1az</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ba</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bb</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bc</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bd</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1be</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bf</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bg</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bh</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bi</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

<u>Table 1bj</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bk</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bl</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bm</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bn</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bo</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bp</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bq</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1br</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bs</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bt</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bu</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bv</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bw</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bx</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1by</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bz</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ca</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1cb</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1cc</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

<u>Table 1cd</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ce</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1cf</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1cg</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ch</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ci</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1cj</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ck</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1cl</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 2</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 3</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, bv Sex
<u>Table 4</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, bv Age Group
<u>Table 5</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, bv Year
<u>Table 6</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, bv Race
<u>Table 7</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, bv Other cardiac disease
<u>Table 8</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, bv Race and Age Group
<u>Table 9</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, bv Race and Year
<u>Table 10</u>	Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 11</u>	Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 12</u>	Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 13</u>	Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 14</u>	Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 15</u>	Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

<u>Table 16</u>	Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 17</u>	Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 18</u>	Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 19</u>	Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 20</u>	Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 21</u>	Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 22</u>	Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 23a</u>	Full Code Distribution of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23b</u>	Total Code Counts of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23c</u>	Full Code Distribution of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23d</u>	Total Code Counts of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23e</u>	Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23f</u>	Total Code Counts of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23g</u>	Full Code Distribution of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23h</u>	Total Code Counts of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23i</u>	Full Code Distribution of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23j</u>	Total Code Counts of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23k</u>	Full Code Distribution of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23l</u>	Total Code Counts of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23m</u>	Full Code Distribution of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23n</u>	Total Code Counts of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23o</u>	Full Code Distribution of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23p</u>	Total Code Counts of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23q</u>	Full Code Distribution of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23r</u>	Total Code Counts of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23s</u>	Full Code Distribution of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23t</u>	Total Code Counts of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Table of Contents

[illegible]

Table of Contents

[illegible]

Table of Contents

[illegible]

Table of Contents

<u>Table 23dy</u>	Full Code Distribution of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dz</u>	Total Code Counts of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ea</u>	Full Code Distribution of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23eb</u>	Total Code Counts of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ec</u>	Full Code Distribution of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ed</u>	Total Code Counts of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ee</u>	Full Code Distribution of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ef</u>	Total Code Counts of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23eg</u>	Full Code Distribution of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23eh</u>	Total Code Counts of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ei</u>	Full Code Distribution of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ej</u>	Total Code Counts of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ek</u>	Full Code Distribution of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23el</u>	Total Code Counts of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23em</u>	Full Code Distribution of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23en</u>	Total Code Counts of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 24</u>	Summary of Patient Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 28, 2023)
<u>Appendix B</u>	Generic and Brand Names of Medical Products Used to Define Exposures or Exposure Washout in this Request
<u>Appendix C</u>	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Tachyarrhythmia in this Request
<u>Appendix D</u>	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request
<u>Appendix E</u>	Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request
<u>Appendix F</u>	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request
<u>Appendix G</u>	Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request
<u>Appendix H</u>	Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window)
<u>Appendix I</u>	Specifications Defining Parameters for Baseline Characteristics in this Request (Sensitivity Analysis for Day 0 Event Window)

Table of Contents

Appendix J Specifications Defining Combination Code Parameters Used in this Request (Sensitivity Analysis for Day 0 Event Window)
Appendix K Design Diagrams for this Request

Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,328	N/A
Demographic Characteristics		
Age (years)	64.0	10.2
Age		
0-40 years	79	5.9%
41-64 years	500	37.7%
65-74 years	538	40.5%
75-84 years	196	14.8%
≥ 85 years	15	1.1%
Sex		
Female	680	51.2%
Male	648	48.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	44	3.3%
Black or African American	165	12.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	247	18.6%
White	837	63.0%
Hispanic origin		
Yes	*****	*****
No	963	72.5%
Unknown	289	21.8%
Year		
2022	1,080	81.3%
2023	248	18.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	432	32.5%
1-2	463	34.9%
3-4	263	19.8%
5+	170	12.8%
Combined comorbidity score ⁴	2.5	2.6
Combined comorbidity score categories ⁴		
<0	54	4.1%
0	253	19.1%
1-2	510	38.4%
3-4	254	19.1%
5+	257	19.4%
Alcohol use or abuse	31	2.3%
Obesity	728	54.8%

Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	361	27.2%
Arrhythmia	337	25.4%
Cerebrovascular disease/stroke/transient ischemic attack	181	13.6%
Chronic kidney disease	252	19.0%
Chronic obstructive pulmonary disease	166	12.5%
Congenital heart disease	166	12.5%
Heart failure	174	13.1%
Hyperlipidemia	1,058	79.7%
Hypertensive disease	1,112	83.7%
Thyroid disease	296	22.3%
Ischemic heart disease/coronary artery disease/myocardial infarction	337	25.4%
Left ventricular hypertrophy	66	5.0%
Peripheral artery disease	66	5.0%
Valvular/mitral valve disease	54	4.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	176	13.3%
Obstructive sleep apnea	341	25.7%
Hypertrophic cardiomyopathy	74	5.6%
Other cardiac disease	601	45.3%
Tachyarrhythmia day 0	15	1.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	16	1.2%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	199	15.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	16	1.2%
Insulin	447	33.7%
Biguanides (metformin, phenformin, etc.)	1,098	82.7%
SGLT2 inhibitors	438	33.0%
Sulfonylurea	553	41.6%
Thiazolidinedione	148	11.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	*****	*****
Beta blockers	548	41.3%
Potassium channel blockers/openers	15	1.1%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	13	1.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	558	42.0%
Angiotensin-converting-enzyme (ACE) inhibitor	552	41.6%
Angiotensin ii receptor blockers (ARBs)	462	34.8%
Dihydropyridines	325	24.5%
Diuretics	515	38.8%
Other antihypertensives	103	7.8%
Antihypertensives (any of the above antihypertensives)	1,107	83.4%
Oral anticoagulants	142	10.7%

Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Vitamin K antagonists	25	1.9%
Other cardiac medications not mentioned above	84	6.3%
Other cardiac medications (any of the other cardiac medications)	224	16.9%
Lipid lowering therapy	1,114	83.9%
Baseline known risk of prolonged QT and torsades de pointes	582	43.8%
Baseline possible risk of prolonged QT and torsades de pointes	1,136	85.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	180	13.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.9	17.6
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	6.8	14.8
Mean number of filled prescriptions	48.6	36.8
Mean number of generics dispensed	12.9	6.3
Mean number of unique drug classes dispensed	11.2	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	15	N/A
Demographic Characteristics		
Age (years)	71.5	10.7
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.8	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	0	0.0%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	5.3	3.7
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	0	0.0%
Obesity	13	86.7%

Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	*****	*****
Arrhythmia	13	86.7%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	13	86.7%
Hypertensive disease	13	86.7%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	15	100.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	12	80.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	80.0%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****
Diuretics	12	80.0%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	14	93.3%
Oral anticoagulants	*****	*****

Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	12	80.0%
Lipid lowering therapy	15	100.0%
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	15	100.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.2	16.6
Mean number of emergency room encounters	0.7	0.0
Mean number of inpatient hospital encounters	1.1	2.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	26.1	70.1
Mean number of filled prescriptions	59.7	48.0
Mean number of generics dispensed	17.1	12.2
Mean number of unique drug classes dispensed	14.5	8.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.

Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	.	.
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.

Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	247	N/A
Demographic Characteristics		
Age (years)	62.1	11.3
Age		
0-40 years	*****	*****
41-64 years	119	48.2%
65-74 years	88	35.6%
75-84 years	26	10.5%
≥ 85 years	*****	*****
Sex		
Female	120	48.6%
Male	127	51.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	247	100.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	184	74.5%
Year		
2022	181	73.3%
2023	66	26.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	87	35.2%
1-2	88	35.6%
3-4	43	17.4%
5+	29	11.7%
Combined comorbidity score ⁴	2.1	2.5
Combined comorbidity score categories ⁴		
<0	12	4.9%
0	59	23.9%
1-2	99	40.1%
3-4	42	17.0%
5+	35	14.2%
Alcohol use or abuse	*****	*****
Obesity	131	53.0%

Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	55	22.3%
Arrhythmia	56	22.7%
Cerebrovascular disease/stroke/transient ischemic attack	35	14.2%
Chronic kidney disease	37	15.0%
Chronic obstructive pulmonary disease	22	8.9%
Congenital heart disease	22	8.9%
Heart failure	26	10.5%
Hyperlipidemia	196	79.4%
Hypertensive disease	205	83.0%
Thyroid disease	44	17.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	54	21.9%
Left ventricular hypertrophy	13	5.3%
Peripheral artery disease	13	5.3%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	32	13.0%
Obstructive sleep apnea	55	22.3%
Hypertrophic cardiomyopathy	11	4.5%
Other cardiac disease	97	39.3%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	36	14.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	86	34.8%
Biguanides (metformin, phenformin, etc.)	205	83.0%
SGLT2 inhibitors	92	37.2%
Sulfonylurea	101	40.9%
Thiazolidinedione	26	10.5%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	*****	*****
Beta blockers	103	41.7%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	104	42.1%
Angiotensin-converting-enzyme (ACE) inhibitor	103	41.7%
Angiotensin ii receptor blockers (ARBs)	77	31.2%
Dihydropyridines	57	23.1%
Diuretics	86	34.8%
Other antihypertensives	17	6.9%

Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	199	80.6%
Oral anticoagulants	23	9.3%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	13	5.3%
Other cardiac medications (any of the other cardiac medications)	36	14.6%
Lipid lowering therapy	210	85.0%
Baseline known risk of prolonged QT and torsades de pointes	100	40.5%
Baseline possible risk of prolonged QT and torsades de pointes	194	78.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	32	13.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.1	15.8
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.2	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	7.5
Mean number of filled prescriptions	43.7	33.1
Mean number of generics dispensed	12.3	6.4
Mean number of unique drug classes dispensed	10.6	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	57.8	7.4
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	*****	*****
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	*****	*****
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	0	0.0%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	0.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	0	0.0%
3-4	*****	*****
5+	0	0.0%
Combined comorbidity score ⁴	0.8	1.0
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Alcohol use or abuse	0	0.0%
Obesity	*****	*****

Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	*****	*****
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	0	0.0%

Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.8	4.9
Mean number of emergency room encounters	0.5	0.4
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.3	0.0
Mean number of other ambulatory encounters	2.5	1.4
Mean number of filled prescriptions	48.0	16.8
Mean number of generics dispensed	11.2	2.3
Mean number of unique drug classes dispensed	9.5	2.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	44	N/A
Demographic Characteristics		
Age (years)	57.2	10.6
Age		
0-40 years	11	25.0%
41-64 years	17	38.6%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	27	61.4%
Male	17	38.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	44	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	29	65.9%
2023	15	34.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	1.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	22	50.0%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.8	1.8
Combined comorbidity score categories ⁴		
<0	*****	*****
0	12	27.3%
1-2	16	36.4%
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	*****	*****
Obesity	15	34.1%

Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	24	54.5%
Hypertensive disease	27	61.4%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	15	34.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	13	29.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	17	38.6%
Biguanides (metformin, phenformin, etc.)	41	93.2%
SGLT2 inhibitors	14	31.8%
Sulfonylurea	20	45.5%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	11	25.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	11	25.0%
Angiotensin-converting-enzyme (ACE) inhibitor	12	27.3%
Angiotensin ii receptor blockers (ARBs)	18	40.9%
Dihydropyridines	11	25.0%
Diuretics	12	27.3%
Other antihypertensives	*****	*****

Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	32	72.7%
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	32	72.7%
Baseline known risk of prolonged QT and torsades de pointes	15	34.1%
Baseline possible risk of prolonged QT and torsades de pointes	29	65.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.1	16.2
Mean number of emergency room encounters	0.3	0.4
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.8	3.0
Mean number of filled prescriptions	42.6	29.7
Mean number of generics dispensed	10.2	4.9
Mean number of unique drug classes dispensed	8.6	4.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	165	N/A
Demographic Characteristics		
Age (years)	58.9	11.2
Age		
0-40 years	14	8.5%
41-64 years	88	53.3%
65-74 years	49	29.7%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	99	60.0%
Male	66	40.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	165	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	152	92.1%
Unknown	*****	*****
Year		
2022	120	72.7%
2023	45	27.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	56	33.9%
1-2	64	38.8%
3-4	27	16.4%
5+	18	10.9%
Combined comorbidity score ⁴	2.2	2.4
Combined comorbidity score categories ⁴		
<0	*****	*****
0	35	21.2%
1-2	77	46.7%
3-4	*****	*****
5+	32	19.4%
Alcohol use or abuse	*****	*****
Obesity	95	57.6%

Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	38	23.0%
Arrhythmia	35	21.2%
Cerebrovascular disease/stroke/transient ischemic attack	19	11.5%
Chronic kidney disease	25	15.2%
Chronic obstructive pulmonary disease	16	9.7%
Congenital heart disease	16	9.7%
Heart failure	21	12.7%
Hyperlipidemia	114	69.1%
Hypertensive disease	139	84.2%
Thyroid disease	20	12.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	31	18.8%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	12	7.3%
Obstructive sleep apnea	38	23.0%
Hypertrophic cardiomyopathy	14	8.5%
Other cardiac disease	69	41.8%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	26	15.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	64	38.8%
Biguanides (metformin, phenformin, etc.)	137	83.0%
SGLT2 inhibitors	56	33.9%
Sulfonylurea	75	45.5%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	66	40.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	67	40.6%
Angiotensin-converting-enzyme (ACE) inhibitor	58	35.2%
Angiotensin ii receptor blockers (ARBs)	68	41.2%
Dihydropyridines	56	33.9%
Diuretics	61	37.0%

Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Other antihypertensives	26	15.8%
Antihypertensives (any of the above antihypertensives)	136	82.4%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	12	7.3%
Other cardiac medications (any of the other cardiac medications)	19	11.5%
Lipid lowering therapy	130	78.8%
Baseline known risk of prolonged QT and torsades de pointes	62	37.6%
Baseline possible risk of prolonged QT and torsades de pointes	137	83.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	14	8.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.6	17.3
Mean number of emergency room encounters	0.8	2.1
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.6	11.6
Mean number of filled prescriptions	44.0	32.3
Mean number of generics dispensed	12.7	5.6
Mean number of unique drug classes dispensed	11.0	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1h. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1i. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	837	N/A
Demographic Characteristics		
Age (years)	66.4	9.4
Age		
0-40 years	34	4.1%
41-64 years	252	30.1%
65-74 years	389	46.5%
75-84 years	150	17.9%
≥ 85 years	12	1.4%
Sex		
Female	412	49.2%
Male	425	50.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	837	100.0%
Hispanic origin		
Yes	12	1.4%
No	747	89.2%
Unknown	78	9.3%
Year		
2022	726	86.7%
2023	111	13.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	250	29.9%
1-2	286	34.2%
3-4	181	21.6%
5+	120	14.3%
Combined comorbidity score ⁴	2.8	2.7
Combined comorbidity score categories ⁴		
<0	33	3.9%
0	138	16.5%
1-2	302	36.1%
3-4	181	21.6%
5+	183	21.9%
Alcohol use or abuse	23	2.7%
Obesity	470	56.2%

Table 1i. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	257	30.7%
Arrhythmia	234	28.0%
Cerebrovascular disease/stroke/transient ischemic attack	119	14.2%
Chronic kidney disease	182	21.7%
Chronic obstructive pulmonary disease	123	14.7%
Congenital heart disease	123	14.7%
Heart failure	123	14.7%
Hyperlipidemia	701	83.8%
Hypertensive disease	720	86.0%
Thyroid disease	221	26.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	242	28.9%
Left ventricular hypertrophy	44	5.3%
Peripheral artery disease	44	5.3%
Valvular/mitral valve disease	42	5.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	126	15.1%
Obstructive sleep apnea	232	27.7%
Hypertrophic cardiomyopathy	48	5.7%
Other cardiac disease	409	48.9%
Tachyarrhythmia day 0	13	1.6%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	117	14.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	268	32.0%
Biguanides (metformin, phenformin, etc.)	683	81.6%
SGLT2 inhibitors	268	32.0%
Sulfonylurea	347	41.5%
Thiazolidinedione	110	13.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	*****	*****
Beta blockers	360	43.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	368	44.0%
Angiotensin-converting-enzyme (ACE) inhibitor	368	44.0%
Angiotensin ii receptor blockers (ARBs)	290	34.6%
Dihydropyridines	196	23.4%
Diuretics	350	41.8%
Other antihypertensives	57	6.8%
Antihypertensives (any of the above antihypertensives)	720	86.0%
Oral anticoagulants	112	13.4%

Table 1i. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Vitamin K antagonists	18	2.2%
Other cardiac medications not mentioned above	57	6.8%
Other cardiac medications (any of the other cardiac medications)	166	19.8%
Lipid lowering therapy	716	85.5%
Baseline known risk of prolonged QT and torsades de pointes	396	47.3%
Baseline possible risk of prolonged QT and torsades de pointes	745	89.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	131	15.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.3	18.2
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	7.6	17.4
Mean number of filled prescriptions	51.3	38.9
Mean number of generics dispensed	13.2	6.4
Mean number of unique drug classes dispensed	11.6	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1j. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	28	N/A
Demographic Characteristics		
Age (years)	48.7	12.5
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	*****	*****
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	28	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	17	60.7%
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.0	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	13	46.4%
1-2	*****	*****
3-4	*****	*****
5+	0	0.0%
Combined comorbidity score ⁴	1.9	1.9
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	11	39.3%
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	0	0.0%
Obesity	14	50.0%

Table 1j. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	19	67.9%
Hypertensive disease	16	57.1%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	26	92.9%
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	15	53.6%
Oral anticoagulants	0	0.0%

Table 1j. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	20	71.4%
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	25	89.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.0	16.8
Mean number of emergency room encounters	0.9	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.4	3.6
Mean number of filled prescriptions	48.0	37.9
Mean number of generics dispensed	12.5	7.3
Mean number of unique drug classes dispensed	11.2	6.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	18,996	N/A
Demographic Characteristics		
Age (years)	61.6	10.0
Age		
0-40 years	1,043	5.5%
41-64 years	9,324	49.1%
65-74 years	6,649	35.0%
75-84 years	1,885	9.9%
≥ 85 years	95	0.5%
Sex		
Female	10,895	57.4%
Male	8,101	42.6%
Race ²		
American Indian or Alaska Native	32	0.2%
Asian	108	0.6%
Black or African American	1,659	8.7%
Multi-racial	60	0.3%
Native Hawaiian or Other Pacific Islander	58	0.3%
Unknown	8,068	42.5%
White	9,011	47.4%
Hispanic origin		
Yes	322	1.7%
No	10,373	54.6%
Unknown	8,301	43.7%
Year		
2022	9,542	50.2%
2023	9,454	49.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.6	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	7,492	39.4%
1-2	6,630	34.9%
3-4	3,174	16.7%
5+	1,700	8.9%
Combined comorbidity score ⁴	2.2	2.4
Combined comorbidity score categories ⁴		
<0	1,493	7.9%
0	4,028	21.2%
1-2	6,893	36.3%
3-4	3,510	18.5%
5+	3,072	16.2%
Alcohol use or abuse	330	1.7%
Obesity	12,986	68.4%

Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	4,459	23.5%
Arrhythmia	4,421	23.3%
Cerebrovascular disease/stroke/transient ischemic attack	1,962	10.3%
Chronic kidney disease	3,087	16.3%
Chronic obstructive pulmonary disease	2,092	11.0%
Congenital heart disease	2,092	11.0%
Heart failure	2,210	11.6%
Hyperlipidemia	15,727	82.8%
Hypertensive disease	16,275	85.7%
Thyroid disease	4,755	25.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	4,286	22.6%
Left ventricular hypertrophy	1,001	5.3%
Peripheral artery disease	1,001	5.3%
Valvular/mitral valve disease	695	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	2,315	12.2%
Obstructive sleep apnea	6,030	31.7%
Hypertrophic cardiomyopathy	793	4.2%
Other cardiac disease	9,025	47.5%
Tachyarrhythmia day 0	257	1.4%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	117	0.6%
Medical Product Use		
Alpha-glucosidase inhibitors	56	0.3%
Amylin analogs (pramlintide)	*****	*****
DPP-4 inhibitors	2,236	11.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	123	0.6%
Insulin	4,544	23.9%
Biguanides (metformin, phenformin, etc.)	15,725	82.8%
SGLT2 inhibitors	5,077	26.7%
Sulfonylurea	5,367	28.3%
Thiazolidinedione	1,739	9.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	148	0.8%
Beta blockers	7,391	38.9%
Potassium channel blockers/openers	252	1.3%
Non-dihydropyridine calcium channel blockers	28	0.1%
Digoxin	103	0.5%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	7,489	39.4%
Angiotensin-converting-enzyme (ACE) inhibitor	7,032	37.0%
Angiotensin ii receptor blockers (ARBs)	7,143	37.6%
Dihydropyridines	4,748	25.0%
Diuretics	6,955	36.6%
Other antihypertensives	1,633	8.6%
Antihypertensives (any of the above antihypertensives)	15,781	83.1%
Oral anticoagulants	1,458	7.7%

Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Vitamin K antagonists	290	1.5%
Other cardiac medications not mentioned above	1,145	6.0%
Other cardiac medications (any of the other cardiac medications)	2,631	13.9%
Lipid lowering therapy	15,135	79.7%
Baseline known risk of prolonged QT and torsades de pointes	9,606	50.6%
Baseline possible risk of prolonged QT and torsades de pointes	16,427	86.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	3,181	16.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.2	16.7
Mean number of emergency room encounters	0.6	1.8
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.7	9.4
Mean number of filled prescriptions	46.1	32.0
Mean number of generics dispensed	13.6	6.6
Mean number of unique drug classes dispensed	11.9	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1I. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	257	N/A
Demographic Characteristics		
Age (years)	68.6	9.0
Age		
0-40 years	*****	*****
41-64 years	72	28.0%
65-74 years	115	44.7%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	103	40.1%
Male	154	59.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	37	14.4%
White	195	75.9%
Hispanic origin		
Yes	*****	*****
No	215	83.7%
Unknown	*****	*****
Year		
2022	115	44.7%
2023	142	55.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.5	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	20	7.8%
1-2	70	27.2%
3-4	90	35.0%
5+	77	30.0%
Combined comorbidity score ⁴	4.5	2.9
Combined comorbidity score categories ⁴		
<0	*****	*****
0	15	5.8%
1-2	55	21.4%
3-4	69	26.8%
5+	116	45.1%
Alcohol use or abuse	*****	*****
Obesity	200	77.8%

Table 1I. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	96	37.4%
Arrhythmia	241	93.8%
Cerebrovascular disease/stroke/transient ischemic attack	56	21.8%
Chronic kidney disease	69	26.8%
Chronic obstructive pulmonary disease	66	25.7%
Congenital heart disease	66	25.7%
Heart failure	99	38.5%
Hyperlipidemia	233	90.7%
Hypertensive disease	244	94.9%
Thyroid disease	60	23.3%
Ischemic heart disease/coronary artery disease/myocardial infarction	116	45.1%
Left ventricular hypertrophy	39	15.2%
Peripheral artery disease	39	15.2%
Valvular/mitral valve disease	30	11.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	53	20.6%
Obstructive sleep apnea	128	49.8%
Hypertrophic cardiomyopathy	42	16.3%
Other cardiac disease	205	79.8%
Tachyarrhythmia day 0	257	100.0%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	26	10.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	70	27.2%
Biguanides (metformin, phenformin, etc.)	210	81.7%
SGLT2 inhibitors	77	30.0%
Sulfonylurea	85	33.1%
Thiazolidinedione	22	8.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	16	6.2%
Beta blockers	197	76.7%
Potassium channel blockers/openers	40	15.6%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	209	81.3%
Angiotensin-converting-enzyme (ACE) inhibitor	81	31.5%
Angiotensin ii receptor blockers (ARBs)	125	48.6%
Dihydropyridines	80	31.1%
Diuretics	154	59.9%
Other antihypertensives	33	12.8%

Table 1I. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antihypertensives (any of the above antihypertensives)	241	93.8%
Oral anticoagulants	147	57.2%
Vitamin K antagonists	34	13.2%
Other cardiac medications not mentioned above	32	12.5%
Other cardiac medications (any of the other cardiac medications)	189	73.5%
Lipid lowering therapy	228	88.7%
Baseline known risk of prolonged QT and torsades de pointes	157	61.1%
Baseline possible risk of prolonged QT and torsades de pointes	247	96.1%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	77	30.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.4	19.6
Mean number of emergency room encounters	1.5	3.1
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	7.9	17.4
Mean number of filled prescriptions	56.4	33.2
Mean number of generics dispensed	16.2	6.4
Mean number of unique drug classes dispensed	14.4	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	71.6	11.2
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	0	0.0%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	4.6	0.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	0	0.0%
1-2	0	0.0%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	7.2	1.9
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	0	0.0%
3-4	0	0.0%
5+	*****	*****

Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****

Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	39.0	34.6
Mean number of emergency room encounters	2.0	2.4
Mean number of inpatient hospital encounters	0.6	0.8
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	9.8	13.0
Mean number of filled prescriptions	54.4	10.8
Mean number of generics dispensed	17.6	5.0
Mean number of unique drug classes dispensed	14.8	2.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	8,068	N/A
Demographic Characteristics		
Age (years)	54.2	10.3
Age		
0-40 years	862	10.7%
41-64 years	6,131	76.0%
65-74 years	905	11.2%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	4,358	54.0%
Male	3,710	46.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	8,068	100.0%
White	0	0.0%
Hispanic origin		
Yes	301	3.7%
No	0	0.0%
Unknown	7,767	96.3%
Year		
2022	4,067	50.4%
2023	4,001	49.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.9	1.4
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	4,696	58.2%
1-2	2,404	29.8%
3-4	720	8.9%
5+	248	3.1%
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	961	11.9%
0	2,377	29.5%
1-2	3,212	39.8%
3-4	1,031	12.8%
5+	487	6.0%
Alcohol use or abuse	112	1.4%
Obesity	5,197	64.4%

Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	1,217	15.1%
Arrhythmia	1,256	15.6%
Cerebrovascular disease/stroke/transient ischemic attack	378	4.7%
Chronic kidney disease	612	7.6%
Chronic obstructive pulmonary disease	309	3.8%
Congenital heart disease	309	3.8%
Heart failure	376	4.7%
Hyperlipidemia	6,115	75.8%
Hypertensive disease	6,224	77.1%
Thyroid disease	1,604	19.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,012	12.5%
Left ventricular hypertrophy	264	3.3%
Peripheral artery disease	264	3.3%
Valvular/mitral valve disease	144	1.8%
Diseases of veins and lymphatics, and other diseases of circulatory system	619	7.7%
Obstructive sleep apnea	2,218	27.5%
Hypertrophic cardiomyopathy	182	2.3%
Other cardiac disease	2,959	36.7%
Tachyarrhythmia day 0	37	0.5%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	23	0.3%
Medical Product Use		
Alpha-glucosidase inhibitors	21	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	861	10.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	32	0.4%
Insulin	1,539	19.1%
Biguanides (metformin, phenformin, etc.)	7,017	87.0%
SGLT2 inhibitors	2,213	27.4%
Sulfonylurea	1,809	22.4%
Thiazolidinedione	574	7.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	43	0.5%
Beta blockers	2,262	28.0%
Potassium channel blockers/openers	50	0.6%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	16	0.2%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	2,285	28.3%
Angiotensin-converting-enzyme (ACE) inhibitor	2,928	36.3%
Angiotensin ii receptor blockers (ARBs)	2,629	32.6%
Dihydropyridines	1,542	19.1%
Diuretics	2,113	26.2%
Other antihypertensives	436	5.4%

Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antihypertensives (any of the above antihypertensives)	6,108	75.7%
Oral anticoagulants	360	4.5%
Vitamin K antagonists	57	0.7%
Other cardiac medications not mentioned above	251	3.1%
Other cardiac medications (any of the other cardiac medications)	624	7.7%
Lipid lowering therapy	5,748	71.2%
Baseline known risk of prolonged QT and torsades de pointes	3,757	46.6%
Baseline possible risk of prolonged QT and torsades de pointes	6,495	80.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	1,080	13.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.6	14.6
Mean number of emergency room encounters	0.3	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.2	7.1
Mean number of filled prescriptions	38.0	29.0
Mean number of generics dispensed	11.5	6.3
Mean number of unique drug classes dispensed	10.1	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	32	N/A
Demographic Characteristics		
Age (years)	62.2	12.7
Age		
0-40 years	*****	*****
41-64 years	15	46.9%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	18	56.3%
Male	14	43.8%
Race ²		
American Indian or Alaska Native	32	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	13	40.6%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	3.2	2.8
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	11	34.4%
Alcohol use or abuse	*****	*****
Obesity	25	78.1%

Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	26	81.3%
Hypertensive disease	29	90.6%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	14	43.8%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	27	84.4%
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	12	37.5%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	37.5%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	14	43.8%
Dihydropyridines	*****	*****
Diuretics	12	37.5%
Other antihypertensives	*****	*****

Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	24	75.0%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	26	81.3%
Baseline known risk of prolonged QT and torsades de pointes	16	50.0%
Baseline possible risk of prolonged QT and torsades de pointes	30	93.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	24.3	19.2
Mean number of emergency room encounters	1.0	1.7
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.1	0.2
Mean number of other ambulatory encounters	6.6	8.3
Mean number of filled prescriptions	53.4	38.3
Mean number of generics dispensed	14.5	6.6
Mean number of unique drug classes dispensed	12.9	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1p. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	108	N/A
Demographic Characteristics		
Age (years)	65.1	10.6
Age		
0-40 years	*****	*****
41-64 years	29	26.9%
65-74 years	53	49.1%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	55	50.9%
Male	53	49.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	108	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	86	79.6%
Unknown	22	20.4%
Year		
2022	68	63.0%
2023	40	37.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.8	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	35	32.4%
1-2	42	38.9%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	2.4	2.6
Combined comorbidity score categories ⁴		
<0	*****	*****
0	25	23.1%
1-2	41	38.0%
3-4	23	21.3%
5+	*****	*****
Alcohol use or abuse	*****	*****
Obesity	47	43.5%

Table 1p. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	17	15.7%
Arrhythmia	16	14.8%
Cerebrovascular disease/stroke/transient ischemic attack	16	14.8%
Chronic kidney disease	17	15.7%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	97	89.8%
Hypertensive disease	95	88.0%
Thyroid disease	29	26.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	29	26.9%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	16	14.8%
Obstructive sleep apnea	16	14.8%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	41	38.0%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	33	30.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	34	31.5%
Biguanides (metformin, phenformin, etc.)	81	75.0%
SGLT2 inhibitors	36	33.3%
Sulfonylurea	38	35.2%
Thiazolidinedione	22	20.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	43	39.8%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	43	39.8%
Angiotensin-converting-enzyme (ACE) inhibitor	33	30.6%
Angiotensin ii receptor blockers (ARBs)	54	50.0%
Dihydropyridines	29	26.9%
Diuretics	31	28.7%
Other antihypertensives	*****	*****

Table 1p. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	99	91.7%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	15	13.9%
Lipid lowering therapy	95	88.0%
Baseline known risk of prolonged QT and torsades de pointes	40	37.0%
Baseline possible risk of prolonged QT and torsades de pointes	85	78.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.0	16.2
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.7
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.2	8.1
Mean number of filled prescriptions	46.1	34.5
Mean number of generics dispensed	13.3	7.0
Mean number of unique drug classes dispensed	11.3	6.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1q. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,659	N/A
Demographic Characteristics		
Age (years)	64.7	9.7
Age		
0-40 years	*****	*****
41-64 years	678	40.9%
65-74 years	754	45.4%
75-84 years	174	10.5%
≥ 85 years	*****	*****
Sex		
Female	1,209	72.9%
Male	450	27.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	1,659	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	1,591	95.9%
Unknown	68	4.1%
Year		
2022	640	38.6%
2023	1,019	61.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	377	22.7%
1-2	641	38.6%
3-4	369	22.2%
5+	272	16.4%
Combined comorbidity score ⁴	3.0	2.8
Combined comorbidity score categories ⁴		
<0	69	4.2%
0	257	15.5%
1-2	527	31.8%
3-4	365	22.0%
5+	441	26.6%
Alcohol use or abuse	24	1.4%
Obesity	1,329	80.1%

Table 1q. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	436	26.3%
Arrhythmia	412	24.8%
Cerebrovascular disease/stroke/transient ischemic attack	253	15.3%
Chronic kidney disease	450	27.1%
Chronic obstructive pulmonary disease	238	14.3%
Congenital heart disease	238	14.3%
Heart failure	335	20.2%
Hyperlipidemia	1,435	86.5%
Hypertensive disease	1,598	96.3%
Thyroid disease	284	17.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	404	24.4%
Left ventricular hypertrophy	147	8.9%
Peripheral artery disease	147	8.9%
Valvular/mitral valve disease	70	4.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	256	15.4%
Obstructive sleep apnea	519	31.3%
Hypertrophic cardiomyopathy	119	7.2%
Other cardiac disease	843	50.8%
Tachyarrhythmia day 0	21	1.3%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	20	1.2%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	187	11.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	500	30.1%
Biguanides (metformin, phenformin, etc.)	1,289	77.7%
SGLT2 inhibitors	442	26.6%
Sulfonylurea	490	29.5%
Thiazolidinedione	128	7.7%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	808	48.7%
Potassium channel blockers/openers	16	1.0%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	816	49.2%
Angiotensin-converting-enzyme (ACE) inhibitor	487	29.4%
Angiotensin ii receptor blockers (ARBs)	841	50.7%
Dihydropyridines	768	46.3%
Diuretics	915	55.2%
Other antihypertensives	290	17.5%

Table 1q. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	1,554	93.7%
Oral anticoagulants	134	8.1%
Vitamin K antagonists	22	1.3%
Other cardiac medications not mentioned above	118	7.1%
Other cardiac medications (any of the other cardiac medications)	242	14.6%
Lipid lowering therapy	1,416	85.4%
Baseline known risk of prolonged QT and torsades de pointes	812	48.9%
Baseline possible risk of prolonged QT and torsades de pointes	1,529	92.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	234	14.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	24.1	19.1
Mean number of emergency room encounters	1.3	3.2
Mean number of inpatient hospital encounters	0.1	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.9	11.3
Mean number of filled prescriptions	50.6	33.0
Mean number of generics dispensed	15.4	7.0
Mean number of unique drug classes dispensed	13.6	6.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1r. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	58	N/A
Demographic Characteristics		
Age (years)	71.0	7.2
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	38	65.5%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	27	46.6%
Male	31	53.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	58	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	58	100.0%
Unknown	0	0.0%
Year		
2022	19	32.8%
2023	39	67.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	26	44.8%
3-4	16	27.6%
5+	*****	*****
Combined comorbidity score ⁴	2.9	2.9
Combined comorbidity score categories ⁴		
<0	*****	*****
0	12	20.7%
1-2	18	31.0%
3-4	*****	*****
5+	15	25.9%
Alcohol use or abuse	*****	*****
Obesity	34	58.6%

Table 1r. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	*****	*****
Arrhythmia	12	20.7%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	22	37.9%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	51	87.9%
Hypertensive disease	56	96.6%
Thyroid disease	14	24.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	17	29.3%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	11	19.0%
Obstructive sleep apnea	12	20.7%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	23	39.7%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	18	31.0%
Biguanides (metformin, phenformin, etc.)	46	79.3%
SGLT2 inhibitors	17	29.3%
Sulfonylurea	20	34.5%
Thiazolidinedione	12	20.7%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	27	46.6%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	27	46.6%
Angiotensin-converting-enzyme (ACE) inhibitor	23	39.7%
Angiotensin ii receptor blockers (ARBs)	26	44.8%
Dihydropyridines	19	32.8%
Diuretics	21	36.2%

Table 1r. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	55	94.8%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	53	91.4%
Baseline known risk of prolonged QT and torsades de pointes	28	48.3%
Baseline possible risk of prolonged QT and torsades de pointes	52	89.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	11	19.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.8	19.4
Mean number of emergency room encounters	0.4	1.3
Mean number of inpatient hospital encounters	0.1	0.6
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.9	5.0
Mean number of filled prescriptions	42.2	25.4
Mean number of generics dispensed	13.8	6.8
Mean number of unique drug classes dispensed	11.8	5.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1s. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	9,011	N/A
Demographic Characteristics		
Age (years)	67.5	8.9
Age		
0-40 years	116	1.3%
41-64 years	2,416	26.8%
65-74 years	4,885	54.2%
75-84 years	1,519	16.9%
≥ 85 years	75	0.8%
Sex		
Female	5,197	57.7%
Male	3,814	42.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	9,011	100.0%
Hispanic origin		
Yes	*****	*****
No	8,608	95.5%
Unknown	*****	*****
Year		
2022	4,689	52.0%
2023	4,322	48.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	2,320	25.7%
1-2	3,492	38.8%
3-4	2,039	22.6%
5+	1,160	12.9%
Combined comorbidity score ⁴	2.8	2.7
Combined comorbidity score categories ⁴		
<0	450	5.0%
0	1,330	14.8%
1-2	3,068	34.0%
3-4	2,065	22.9%
5+	2,098	23.3%
Alcohol use or abuse	187	2.1%
Obesity	6,319	70.1%

Table 1s. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	2,763	30.7%
Arrhythmia	2,709	30.1%
Cerebrovascular disease/stroke/transient ischemic attack	1,308	14.5%
Chronic kidney disease	1,974	21.9%
Chronic obstructive pulmonary disease	1,526	16.9%
Congenital heart disease	1,526	16.9%
Heart failure	1,479	16.4%
Hyperlipidemia	7,955	88.3%
Hypertensive disease	8,228	91.3%
Thyroid disease	2,799	31.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	2,817	31.3%
Left ventricular hypertrophy	569	6.3%
Peripheral artery disease	569	6.3%
Valvular/mitral valve disease	470	5.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,407	15.6%
Obstructive sleep apnea	3,238	35.9%
Hypertrophic cardiomyopathy	483	5.4%
Other cardiac disease	5,125	56.9%
Tachyarrhythmia day 0	195	2.2%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	70	0.8%
Medical Product Use		
Alpha-glucosidase inhibitors	30	0.3%
Amylin analogs (pramlintide)	*****	*****
DPP-4 inhibitors	1,135	12.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	78	0.9%
Insulin	2,439	27.1%
Biguanides (metformin, phenformin, etc.)	7,211	80.0%
SGLT2 inhibitors	2,348	26.1%
Sulfonylurea	2,989	33.2%
Thiazolidinedione	994	11.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	97	1.1%
Beta blockers	4,227	46.9%
Potassium channel blockers/openers	179	2.0%
Non-dihydropyridine calcium channel blockers	20	0.2%
Digoxin	81	0.9%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	4,294	47.7%
Angiotensin-converting-enzyme (ACE) inhibitor	3,532	39.2%
Angiotensin ii receptor blockers (ARBs)	3,562	39.5%
Dihydropyridines	2,378	26.4%
Diuretics	3,854	42.8%
Other antihypertensives	885	9.8%

Table 1s. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	7,900	87.7%
Oral anticoagulants	953	10.6%
Vitamin K antagonists	207	2.3%
Other cardiac medications not mentioned above	766	8.5%
Other cardiac medications (any of the other cardiac medications)	1,740	19.3%
Lipid lowering therapy	7,757	86.1%
Baseline known risk of prolonged QT and torsades de pointes	4,934	54.8%
Baseline possible risk of prolonged QT and torsades de pointes	8,193	90.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	1,839	20.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.5	17.7
Mean number of emergency room encounters	0.7	1.9
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	10.8
Mean number of filled prescriptions	52.6	33.8
Mean number of generics dispensed	15.1	6.7
Mean number of unique drug classes dispensed	13.3	5.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1t. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	60	N/A
Demographic Characteristics		
Age (years)	53.2	10.6
Age		
0-40 years	*****	*****
41-64 years	46	76.7%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	31	51.7%
Male	29	48.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	60	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	41	68.3%
Year		
2022	34	56.7%
2023	26	43.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	41	68.3%
1-2	*****	*****
3-4	*****	*****
5+	0	0.0%
Combined comorbidity score ⁴	1.3	1.9
Combined comorbidity score categories ⁴		
<0	*****	*****
0	22	36.7%
1-2	18	30.0%
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	*****	*****
Obesity	35	58.3%

Table 1t. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	48	80.0%
Hypertensive disease	45	75.0%
Thyroid disease	15	25.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	17	28.3%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	20	33.3%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	54	90.0%
SGLT2 inhibitors	17	28.3%
Sulfonylurea	11	18.3%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	12	20.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	20.0%
Angiotensin-converting-enzyme (ACE) inhibitor	21	35.0%
Angiotensin ii receptor blockers (ARBs)	17	28.3%
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	*****	*****

Table 1t. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	41	68.3%
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	40	66.7%
Baseline known risk of prolonged QT and torsades de pointes	19	31.7%
Baseline possible risk of prolonged QT and torsades de pointes	43	71.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.7	10.7
Mean number of emergency room encounters	0.4	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.7	3.5
Mean number of filled prescriptions	33.8	24.7
Mean number of generics dispensed	9.9	4.4
Mean number of unique drug classes dispensed	8.5	3.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	117,721	N/A
Demographic Characteristics		
Age (years)	63.2	10.2
Age		
0-40 years	5,541	4.7%
41-64 years	51,127	43.4%
65-74 years	44,620	37.9%
75-84 years	15,174	12.9%
≥ 85 years	1,259	1.1%
Sex		
Female	65,903	56.0%
Male	51,818	44.0%
Race ²		
American Indian or Alaska Native	828	0.7%
Asian	1,399	1.2%
Black or African American	9,900	8.4%
Multi-racial	818	0.7%
Native Hawaiian or Other Pacific Islander	335	0.3%
Unknown	45,728	38.8%
White	58,713	49.9%
Hispanic origin		
Yes	3,261	2.8%
No	62,490	53.1%
Unknown	51,970	44.1%
Year		
2022	79,303	67.4%
2023	38,418	32.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	43,593	37.0%
1-2	41,381	35.2%
3-4	20,630	17.5%
5+	12,117	10.3%
Combined comorbidity score ⁴	2.3	2.5
Combined comorbidity score categories ⁴		
<0	8,729	7.4%
0	24,260	20.6%
1-2	41,890	35.6%
3-4	22,172	18.8%
5+	20,670	17.6%
Alcohol use or abuse	2,071	1.8%
Obesity	73,385	62.3%

Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	28,258	24.0%
Arrhythmia	29,554	25.1%
Cerebrovascular disease/stroke/transient ischemic attack	14,115	12.0%
Chronic kidney disease	20,871	17.7%
Chronic obstructive pulmonary disease	13,051	11.1%
Congenital heart disease	13,051	11.1%
Heart failure	14,646	12.4%
Hyperlipidemia	97,484	82.8%
Hypertensive disease	100,811	85.6%
Thyroid disease	27,136	23.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	29,303	24.9%
Left ventricular hypertrophy	6,870	5.8%
Peripheral artery disease	6,870	5.8%
Valvular/mitral valve disease	4,644	3.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	15,234	12.9%
Obstructive sleep apnea	34,783	29.5%
Hypertrophic cardiomyopathy	5,815	4.9%
Other cardiac disease	56,326	47.8%
Tachyarrhythmia day 0	1,981	1.7%
Hospitalized tachyarrhythmia day 0	24	0.0%
History of serious hypoglycemia (ED and/or IP)	923	0.8%
Medical Product Use		
Alpha-glucosidase inhibitors	405	0.3%
Amylin analogs (pramlintide)	*****	*****
DPP-4 inhibitors	16,980	14.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	1,027	0.9%
Insulin	29,311	24.9%
Biguanides (metformin, phenformin, etc.)	98,366	83.6%
SGLT2 inhibitors	30,586	26.0%
Sulfonylurea	36,879	31.3%
Thiazolidinedione	9,508	8.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	31	0.0%
Sodium channel blockers	846	0.7%
Beta blockers	48,615	41.3%
Potassium channel blockers/openers	1,801	1.5%
Non-dihydropyridine calcium channel blockers	159	0.1%
Digoxin	848	0.7%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	49,154	41.8%
Angiotensin-converting-enzyme (ACE) inhibitor	44,305	37.6%
Angiotensin ii receptor blockers (ARBs)	43,230	36.7%
Dihydropyridines	30,690	26.1%
Diuretics	43,529	37.0%
Other antihypertensives	9,734	8.3%

Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antihypertensives (any of the above antihypertensives)	97,644	82.9%
Oral anticoagulants	10,222	8.7%
Vitamin K antagonists	2,196	1.9%
Other cardiac medications not mentioned above	8,109	6.9%
Other cardiac medications (any of the other cardiac medications)	18,544	15.8%
Lipid lowering therapy	95,376	81.0%
Baseline known risk of prolonged QT and torsades de pointes	55,124	46.8%
Baseline possible risk of prolonged QT and torsades de pointes	100,311	85.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	17,952	15.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.9	18.6
Mean number of emergency room encounters	0.6	1.6
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.6	10.7
Mean number of filled prescriptions	45.5	33.6
Mean number of generics dispensed	13.0	6.4
Mean number of unique drug classes dispensed	11.4	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,981	N/A
Demographic Characteristics		
Age (years)	69.5	8.9
Age		
0-40 years	30	1.5%
41-64 years	425	21.5%
65-74 years	984	49.7%
75-84 years	486	24.5%
≥ 85 years	56	2.8%
Sex		
Female	903	45.6%
Male	1,078	54.4%
Race ²		
American Indian or Alaska Native	20	1.0%
Asian	14	0.7%
Black or African American	130	6.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	429	21.7%
White	1,376	69.5%
Hispanic origin		
Yes	25	1.3%
No	1,397	70.5%
Unknown	559	28.2%
Year		
2022	1,429	72.1%
2023	552	27.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.4	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	171	8.6%
1-2	610	30.8%
3-4	686	34.6%
5+	514	25.9%
Combined comorbidity score ⁴	4.4	3.0
Combined comorbidity score categories ⁴		
<0	19	1.0%
0	124	6.3%
1-2	509	25.7%
3-4	491	24.8%
5+	838	42.3%
Alcohol use or abuse	42	2.1%
Obesity	1,381	69.7%

Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	630	31.8%
Arrhythmia	1,835	92.6%
Cerebrovascular disease/stroke/transient ischemic attack	425	21.5%
Chronic kidney disease	556	28.1%
Chronic obstructive pulmonary disease	376	19.0%
Congenital heart disease	376	19.0%
Heart failure	724	36.5%
Hyperlipidemia	1,754	88.5%
Hypertensive disease	1,865	94.1%
Thyroid disease	470	23.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	942	47.6%
Left ventricular hypertrophy	318	16.1%
Peripheral artery disease	318	16.1%
Valvular/mitral valve disease	247	12.5%
Diseases of veins and lymphatics, and other diseases of circulatory system	493	24.9%
Obstructive sleep apnea	893	45.1%
Hypertrophic cardiomyopathy	297	15.0%
Other cardiac disease	1,494	75.4%
Tachyarrhythmia day 0	1,981	100.0%
Hospitalized tachyarrhythmia day 0	24	1.2%
History of serious hypoglycemia (ED and/or IP)	15	0.8%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	314	15.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	21	1.1%
Insulin	475	24.0%
Biguanides (metformin, phenformin, etc.)	1,582	79.9%
SGLT2 inhibitors	592	29.9%
Sulfonylurea	692	34.9%
Thiazolidinedione	139	7.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	111	5.6%
Beta blockers	1,525	77.0%
Potassium channel blockers/openers	252	12.7%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	126	6.4%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	1,590	80.3%
Angiotensin-converting-enzyme (ACE) inhibitor	724	36.5%
Angiotensin ii receptor blockers (ARBs)	830	41.9%
Dihydropyridines	515	26.0%
Diuretics	1,146	57.8%
Other antihypertensives	221	11.2%

Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	1,760	88.8%
Oral anticoagulants	1,125	56.8%
Vitamin K antagonists	254	12.8%
Other cardiac medications not mentioned above	258	13.0%
Other cardiac medications (any of the other cardiac medications)	1,401	70.7%
Lipid lowering therapy	1,689	85.3%
Baseline known risk of prolonged QT and torsades de pointes	1,137	57.4%
Baseline possible risk of prolonged QT and torsades de pointes	1,843	93.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	550	27.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.0	21.2
Mean number of emergency room encounters	1.0	2.9
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	8.5	17.2
Mean number of filled prescriptions	54.1	37.1
Mean number of generics dispensed	15.0	6.3
Mean number of unique drug classes dispensed	13.3	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	24	N/A
Demographic Characteristics		
Age (years)	67.7	8.1
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	13	54.2%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	13	54.2%
Male	11	45.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.5	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	4.6	3.4
Combined comorbidity score categories ⁴		
<0	*****	*****
0	0	0.0%
1-2	*****	*****
3-4	*****	*****
5+	11	45.8%

Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	17	70.8%
Tobacco use	*****	*****
Arrhythmia	20	83.3%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	22	91.7%
Hypertensive disease	24	100.0%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	17	70.8%
Tachyarrhythmia day 0	24	100.0%
Hospitalized tachyarrhythmia day 0	24	100.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	23	95.8%
SGLT2 inhibitors	13	54.2%
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	17	70.8%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	17	70.8%
Angiotensin-converting-enzyme (ACE) inhibitor	14	58.3%
Angiotensin ii receptor blockers (ARBs)	*****	*****

Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Dihydropyridines	*****	*****
Diuretics	13	54.2%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	23	95.8%
Oral anticoagulants	12	50.0%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	16	66.7%
Lipid lowering therapy	17	70.8%
Baseline known risk of prolonged QT and torsades de pointes	20	83.3%
Baseline possible risk of prolonged QT and torsades de pointes	22	91.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.8	18.2
Mean number of emergency room encounters	2.2	2.0
Mean number of inpatient hospital encounters	0.8	1.4
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	20.3	35.6
Mean number of filled prescriptions	52.9	20.2
Mean number of generics dispensed	16.0	4.9
Mean number of unique drug classes dispensed	13.6	4.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1x. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	45,728	N/A
Demographic Characteristics		
Age (years)	56.4	10.8
Age		
0-40 years	4,065	8.9%
41-64 years	31,892	69.7%
65-74 years	7,803	17.1%
75-84 years	1,823	4.0%
≥ 85 years	145	0.3%
Sex		
Female	24,478	53.5%
Male	21,250	46.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	45,728	100.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	42,732	93.4%
Year		
2022	27,644	60.5%
2023	18,084	39.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	24,608	53.8%
1-2	14,358	31.4%
3-4	4,693	10.3%
5+	2,069	4.5%
Combined comorbidity score ⁴	1.4	2.0
Combined comorbidity score categories ⁴		
<0	5,113	11.2%
0	12,913	28.2%
1-2	17,784	38.9%
3-4	6,189	13.5%
5+	3,729	8.2%
Alcohol use or abuse	638	1.4%
Obesity	27,619	60.4%

Table 1x. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	7,686	16.8%
Arrhythmia	7,997	17.5%
Cerebrovascular disease/stroke/transient ischemic attack	2,918	6.4%
Chronic kidney disease	4,334	9.5%
Chronic obstructive pulmonary disease	2,454	5.4%
Congenital heart disease	2,454	5.4%
Heart failure	2,933	6.4%
Hyperlipidemia	34,994	76.5%
Hypertensive disease	35,924	78.6%
Thyroid disease	8,315	18.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	6,832	14.9%
Left ventricular hypertrophy	1,750	3.8%
Peripheral artery disease	1,750	3.8%
Valvular/mitral valve disease	992	2.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	3,910	8.6%
Obstructive sleep apnea	11,969	26.2%
Hypertrophic cardiomyopathy	1,380	3.0%
Other cardiac disease	17,237	37.7%
Tachyarrhythmia day 0	429	0.9%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	184	0.4%
Medical Product Use		
Alpha-glucosidase inhibitors	129	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	6,102	13.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	287	0.6%
Insulin	8,780	19.2%
Biguanides (metformin, phenformin, etc.)	40,119	87.7%
SGLT2 inhibitors	11,810	25.8%
Sulfonylurea	11,821	25.9%
Thiazolidinedione	2,856	6.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	12	0.0%
Sodium channel blockers	223	0.5%
Beta blockers	14,387	31.5%
Potassium channel blockers/openers	336	0.7%
Non-dihydropyridine calcium channel blockers	42	0.1%
Digoxin	162	0.4%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	14,506	31.7%
Angiotensin-converting-enzyme (ACE) inhibitor	16,767	36.7%
Angiotensin ii receptor blockers (ARBs)	15,052	32.9%
Dihydropyridines	9,678	21.2%
Diuretics	12,964	28.4%
Other antihypertensives	2,619	5.7%

Table 1x. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	35,109	76.8%
Oral anticoagulants	2,402	5.3%
Vitamin K antagonists	434	0.9%
Other cardiac medications not mentioned above	1,872	4.1%
Other cardiac medications (any of the other cardiac medications)	4,356	9.5%
Lipid lowering therapy	33,794	73.9%
Baseline known risk of prolonged QT and torsades de pointes	19,868	43.4%
Baseline possible risk of prolonged QT and torsades de pointes	36,474	79.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	5,848	12.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.5	16.5
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.6	7.1
Mean number of filled prescriptions	38.5	29.9
Mean number of generics dispensed	11.6	6.2
Mean number of unique drug classes dispensed	10.1	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1y. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	828	N/A
Demographic Characteristics		
Age (years)	67.1	10.9
Age		
0-40 years	23	2.8%
41-64 years	259	31.3%
65-74 years	362	43.7%
75-84 years	166	20.0%
≥ 85 years	18	2.2%
Sex		
Female	476	57.5%
Male	352	42.5%
Race ²		
American Indian or Alaska Native	828	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	773	93.4%
Unknown	*****	*****
Year		
2022	697	84.2%
2023	131	15.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	274	33.1%
1-2	276	33.3%
3-4	188	22.7%
5+	90	10.9%
Combined comorbidity score ⁴	2.5	2.6
Combined comorbidity score categories ⁴		
<0	48	5.8%
0	153	18.5%
1-2	290	35.0%
3-4	183	22.1%
5+	154	18.6%
Alcohol use or abuse	21	2.5%
Obesity	376	45.4%

Table 1y. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	256	30.9%
Arrhythmia	206	24.9%
Cerebrovascular disease/stroke/transient ischemic attack	105	12.7%
Chronic kidney disease	181	21.9%
Chronic obstructive pulmonary disease	120	14.5%
Congenital heart disease	120	14.5%
Heart failure	127	15.3%
Hyperlipidemia	593	71.6%
Hypertensive disease	696	84.1%
Thyroid disease	187	22.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	229	27.7%
Left ventricular hypertrophy	48	5.8%
Peripheral artery disease	48	5.8%
Valvular/mitral valve disease	40	4.8%
Diseases of veins and lymphatics, and other diseases of circulatory system	123	14.9%
Obstructive sleep apnea	190	22.9%
Hypertrophic cardiomyopathy	46	5.6%
Other cardiac disease	369	44.6%
Tachyarrhythmia day 0	20	2.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	13	1.6%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	163	19.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	372	44.9%
Biguanides (metformin, phenformin, etc.)	654	79.0%
SGLT2 inhibitors	224	27.1%
Sulfonylurea	277	33.5%
Thiazolidinedione	94	11.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	330	39.9%
Potassium channel blockers/openers	14	1.7%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	333	40.2%
Angiotensin-converting-enzyme (ACE) inhibitor	358	43.2%
Angiotensin ii receptor blockers (ARBs)	306	37.0%
Dihydropyridines	225	27.2%
Diuretics	344	41.5%
Other antihypertensives	81	9.8%

Table 1y. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	717	86.6%
Oral anticoagulants	92	11.1%
Vitamin K antagonists	20	2.4%
Other cardiac medications not mentioned above	73	8.8%
Other cardiac medications (any of the other cardiac medications)	163	19.7%
Lipid lowering therapy	682	82.4%
Baseline known risk of prolonged QT and torsades de pointes	377	45.5%
Baseline possible risk of prolonged QT and torsades de pointes	708	85.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	100	12.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.8	15.0
Mean number of emergency room encounters	0.8	1.9
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.2	10.7
Mean number of filled prescriptions	69.3	47.4
Mean number of generics dispensed	13.6	6.2
Mean number of unique drug classes dispensed	12.1	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1z. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,399	N/A
Demographic Characteristics		
Age (years)	65.9	10.3
Age		
0-40 years	79	5.6%
41-64 years	363	25.9%
65-74 years	658	47.0%
75-84 years	251	17.9%
≥ 85 years	48	3.4%
Sex		
Female	782	55.9%
Male	617	44.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,399	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	1,057	75.6%
Unknown	*****	*****
Year		
2022	1,026	73.3%
2023	373	26.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	463	33.1%
1-2	493	35.2%
3-4	268	19.2%
5+	175	12.5%
Combined comorbidity score ⁴	2.4	2.5
Combined comorbidity score categories ⁴		
<0	85	6.1%
0	274	19.6%
1-2	490	35.0%
3-4	278	19.9%
5+	272	19.4%
Alcohol use or abuse	16	1.1%
Obesity	508	36.3%

Table 1z. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	183	13.1%
Arrhythmia	301	21.5%
Cerebrovascular disease/stroke/transient ischemic attack	177	12.7%
Chronic kidney disease	345	24.7%
Chronic obstructive pulmonary disease	97	6.9%
Congenital heart disease	97	6.9%
Heart failure	178	12.7%
Hyperlipidemia	1,216	86.9%
Hypertensive disease	1,187	84.8%
Thyroid disease	328	23.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	385	27.5%
Left ventricular hypertrophy	79	5.6%
Peripheral artery disease	79	5.6%
Valvular/mitral valve disease	50	3.6%
Diseases of veins and lymphatics, and other diseases of circulatory system	148	10.6%
Obstructive sleep apnea	206	14.7%
Hypertrophic cardiomyopathy	58	4.1%
Other cardiac disease	573	41.0%
Tachyarrhythmia day 0	14	1.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	13	0.9%
Medical Product Use		
Alpha-glucosidase inhibitors	21	1.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	299	21.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	30	2.1%
Insulin	457	32.7%
Biguanides (metformin, phenformin, etc.)	1,194	85.3%
SGLT2 inhibitors	478	34.2%
Sulfonylurea	514	36.7%
Thiazolidinedione	155	11.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	*****	*****
Beta blockers	591	42.2%
Potassium channel blockers/openers	17	1.2%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	594	42.5%
Angiotensin-converting-enzyme (ACE) inhibitor	402	28.7%
Angiotensin ii receptor blockers (ARBs)	698	49.9%
Dihydropyridines	464	33.2%
Diuretics	383	27.4%
Other antihypertensives	130	9.3%

Table 1z. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	1,159	82.8%
Oral anticoagulants	81	5.8%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	120	8.6%
Other cardiac medications (any of the other cardiac medications)	197	14.1%
Lipid lowering therapy	1,199	85.7%
Baseline known risk of prolonged QT and torsades de pointes	526	37.6%
Baseline possible risk of prolonged QT and torsades de pointes	1,061	75.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	143	10.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.9	20.3
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.7	10.5
Mean number of filled prescriptions	42.5	33.7
Mean number of generics dispensed	12.4	6.3
Mean number of unique drug classes dispensed	10.6	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1aa. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	9,900	N/A
Demographic Characteristics		
Age (years)	64.6	10.3
Age		
0-40 years	315	3.2%
41-64 years	3,829	38.7%
65-74 years	4,535	45.8%
75-84 years	1,119	11.3%
≥ 85 years	102	1.0%
Sex		
Female	7,117	71.9%
Male	2,783	28.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	9,900	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	8,693	87.8%
Unknown	1,207	12.2%
Year		
2022	6,083	61.4%
2023	3,817	38.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.4	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	2,343	23.7%
1-2	3,594	36.3%
3-4	2,370	23.9%
5+	1,593	16.1%
Combined comorbidity score ⁴	3.1	2.8
Combined comorbidity score categories ⁴		
<0	458	4.6%
0	1,471	14.9%
1-2	3,041	30.7%
3-4	2,271	22.9%
5+	2,659	26.9%
Alcohol use or abuse	201	2.0%
Obesity	7,169	72.4%

Table 1aa. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	2,687	27.1%
Arrhythmia	2,668	26.9%
Cerebrovascular disease/stroke/transient ischemic attack	1,535	15.5%
Chronic kidney disease	2,766	27.9%
Chronic obstructive pulmonary disease	1,314	13.3%
Congenital heart disease	1,314	13.3%
Heart failure	2,020	20.4%
Hyperlipidemia	8,413	85.0%
Hypertensive disease	9,372	94.7%
Thyroid disease	1,543	15.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	2,464	24.9%
Left ventricular hypertrophy	804	8.1%
Peripheral artery disease	804	8.1%
Valvular/mitral valve disease	390	3.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,474	14.9%
Obstructive sleep apnea	2,987	30.2%
Hypertrophic cardiomyopathy	746	7.5%
Other cardiac disease	5,024	50.7%
Tachyarrhythmia day 0	130	1.3%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	142	1.4%
Medical Product Use		
Alpha-glucosidase inhibitors	40	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	1,579	15.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	76	0.8%
Insulin	3,227	32.6%
Biguanides (metformin, phenformin, etc.)	7,618	76.9%
SGLT2 inhibitors	2,549	25.7%
Sulfonylurea	3,266	33.0%
Thiazolidinedione	688	6.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	52	0.5%
Beta blockers	4,795	48.4%
Potassium channel blockers/openers	124	1.3%
Non-dihydropyridine calcium channel blockers	13	0.1%
Digoxin	68	0.7%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	4,823	48.7%
Angiotensin-converting-enzyme (ACE) inhibitor	3,161	31.9%
Angiotensin ii receptor blockers (ARBs)	4,692	47.4%
Dihydropyridines	4,569	46.2%
Diuretics	5,169	52.2%
Other antihypertensives	1,569	15.8%

Table 1aa. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	9,110	92.0%
Oral anticoagulants	803	8.1%
Vitamin K antagonists	158	1.6%
Other cardiac medications not mentioned above	757	7.6%
Other cardiac medications (any of the other cardiac medications)	1,550	15.7%
Lipid lowering therapy	8,307	83.9%
Baseline known risk of prolonged QT and torsades de pointes	4,494	45.4%
Baseline possible risk of prolonged QT and torsades de pointes	8,922	90.1%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	1,314	13.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.6	20.7
Mean number of emergency room encounters	1.0	2.2
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.1	13.7
Mean number of filled prescriptions	49.1	34.6
Mean number of generics dispensed	14.3	6.5
Mean number of unique drug classes dispensed	12.6	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ab. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	335	N/A
Demographic Characteristics		
Age (years)	69.1	8.3
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	185	55.2%
75-84 years	82	24.5%
≥ 85 years	*****	*****
Sex		
Female	158	47.2%
Male	177	52.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	335	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	317	94.6%
Unknown	18	5.4%
Year		
2022	156	46.6%
2023	179	53.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	83	24.8%
1-2	115	34.3%
3-4	87	26.0%
5+	50	14.9%
Combined comorbidity score ⁴	2.7	2.6
Combined comorbidity score categories ⁴		
<0	14	4.2%
0	55	16.4%
1-2	123	36.7%
3-4	76	22.7%
5+	67	20.0%
Alcohol use or abuse	*****	*****
Obesity	178	53.1%

Table 1ab. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	72	21.5%
Arrhythmia	72	21.5%
Cerebrovascular disease/stroke/transient ischemic attack	57	17.0%
Chronic kidney disease	98	29.3%
Chronic obstructive pulmonary disease	26	7.8%
Congenital heart disease	26	7.8%
Heart failure	51	15.2%
Hyperlipidemia	308	91.9%
Hypertensive disease	304	90.7%
Thyroid disease	73	21.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	93	27.8%
Left ventricular hypertrophy	20	6.0%
Peripheral artery disease	20	6.0%
Valvular/mitral valve disease	14	4.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	35	10.4%
Obstructive sleep apnea	65	19.4%
Hypertrophic cardiomyopathy	22	6.6%
Other cardiac disease	150	44.8%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	44	13.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	112	33.4%
Biguanides (metformin, phenformin, etc.)	283	84.5%
SGLT2 inhibitors	91	27.2%
Sulfonylurea	136	40.6%
Thiazolidinedione	43	12.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	147	43.9%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	148	44.2%
Angiotensin-converting-enzyme (ACE) inhibitor	132	39.4%
Angiotensin ii receptor blockers (ARBs)	148	44.2%
Dihydropyridines	113	33.7%
Diuretics	113	33.7%
Other antihypertensives	26	7.8%

Table 1ab. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	294	87.8%
Oral anticoagulants	23	6.9%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	17	5.1%
Other cardiac medications (any of the other cardiac medications)	43	12.8%
Lipid lowering therapy	301	89.9%
Baseline known risk of prolonged QT and torsades de pointes	125	37.3%
Baseline possible risk of prolonged QT and torsades de pointes	271	80.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	31	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.8	14.2
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.8	7.5
Mean number of filled prescriptions	40.6	27.6
Mean number of generics dispensed	13.0	5.8
Mean number of unique drug classes dispensed	11.2	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ac. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	58,713	N/A
Demographic Characteristics		
Age (years)	68.2	9.2
Age		
0-40 years	931	1.6%
41-64 years	14,102	24.0%
65-74 years	31,009	52.8%
75-84 years	11,726	20.0%
≥ 85 years	945	1.6%
Sex		
Female	32,449	55.3%
Male	26,264	44.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	58,713	100.0%
Hispanic origin		
Yes	27	0.0%
No	51,584	87.9%
Unknown	7,102	12.1%
Year		
2022	43,289	73.7%
2023	15,424	26.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	15,311	26.1%
1-2	22,330	38.0%
3-4	12,953	22.1%
5+	8,119	13.8%
Combined comorbidity score ⁴	2.8	2.8
Combined comorbidity score categories ⁴		
<0	2,914	5.0%
0	9,151	15.6%
1-2	19,827	33.8%
3-4	13,076	22.3%
5+	13,745	23.4%
Alcohol use or abuse	1,178	2.0%
Obesity	37,033	63.1%

Table 1ac. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	17,266	29.4%
Arrhythmia	18,176	31.0%
Cerebrovascular disease/stroke/transient ischemic attack	9,287	15.8%
Chronic kidney disease	13,084	22.3%
Chronic obstructive pulmonary disease	9,026	15.4%
Congenital heart disease	9,026	15.4%
Heart failure	9,302	15.8%
Hyperlipidemia	51,347	87.5%
Hypertensive disease	52,741	89.8%
Thyroid disease	16,548	28.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	19,205	32.7%
Left ventricular hypertrophy	4,150	7.1%
Peripheral artery disease	4,150	7.1%
Valvular/mitral valve disease	3,149	5.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	9,488	16.2%
Obstructive sleep apnea	19,149	32.6%
Hypertrophic cardiomyopathy	3,542	6.0%
Other cardiac disease	32,694	55.7%
Tachyarrhythmia day 0	1,376	2.3%
Hospitalized tachyarrhythmia day 0	16	0.0%
History of serious hypoglycemia (ED and/or IP)	563	1.0%
Medical Product Use		
Alpha-glucosidase inhibitors	206	0.4%
Amylin analogs (pramlintide)	*****	*****
DPP-4 inhibitors	8,716	14.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	625	1.1%
Insulin	16,197	27.6%
Biguanides (metformin, phenformin, etc.)	47,767	81.4%
SGLT2 inhibitors	15,226	25.9%
Sulfonylurea	20,698	35.3%
Thiazolidinedione	5,629	9.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	16	0.0%
Sodium channel blockers	557	0.9%
Beta blockers	28,159	48.0%
Potassium channel blockers/openers	1,300	2.2%
Non-dihydropyridine calcium channel blockers	104	0.2%
Digoxin	600	1.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	28,544	48.6%
Angiotensin-converting-enzyme (ACE) inhibitor	23,196	39.5%
Angiotensin ii receptor blockers (ARBs)	22,063	37.6%
Dihydropyridines	15,488	26.4%
Diuretics	24,369	41.5%
Other antihypertensives	5,269	9.0%

Table 1ac. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antihypertensives (any of the above antihypertensives)	50,664	86.3%
Oral anticoagulants	6,790	11.6%
Vitamin K antagonists	1,564	2.7%
Other cardiac medications not mentioned above	5,245	8.9%
Other cardiac medications (any of the other cardiac medications)	12,180	20.7%
Lipid lowering therapy	50,523	86.1%
Baseline known risk of prolonged QT and torsades de pointes	29,413	50.1%
Baseline possible risk of prolonged QT and torsades de pointes	52,274	89.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	10,440	17.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.9	19.7
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.2	12.4
Mean number of filled prescriptions	50.2	35.8
Mean number of generics dispensed	13.9	6.4
Mean number of unique drug classes dispensed	12.3	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ad. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	818	N/A
Demographic Characteristics		
Age (years)	52.5	10.1
Age		
0-40 years	119	14.5%
41-64 years	624	76.3%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	443	54.2%
Male	375	45.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	818	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	240	29.3%
No	62	7.6%
Unknown	516	63.1%
Year		
2022	408	49.9%
2023	410	50.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.8	1.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	511	62.5%
1-2	215	26.3%
3-4	71	8.7%
5+	21	2.6%
Combined comorbidity score ⁴	1.2	1.8
Combined comorbidity score categories ⁴		
<0	97	11.9%
0	243	29.7%
1-2	335	41.0%
3-4	99	12.1%
5+	44	5.4%
Alcohol use or abuse	11	1.3%
Obesity	502	61.4%

Table 1ad. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	108	13.2%
Arrhythmia	134	16.4%
Cerebrovascular disease/stroke/transient ischemic attack	36	4.4%
Chronic kidney disease	63	7.7%
Chronic obstructive pulmonary disease	14	1.7%
Congenital heart disease	14	1.7%
Heart failure	35	4.3%
Hyperlipidemia	613	74.9%
Hypertensive disease	587	71.8%
Thyroid disease	142	17.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	95	11.6%
Left ventricular hypertrophy	19	2.3%
Peripheral artery disease	19	2.3%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	56	6.8%
Obstructive sleep apnea	217	26.5%
Hypertrophic cardiomyopathy	21	2.6%
Other cardiac disease	279	34.1%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	77	9.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	166	20.3%
Biguanides (metformin, phenformin, etc.)	731	89.4%
SGLT2 inhibitors	208	25.4%
Sulfonylurea	167	20.4%
Thiazolidinedione	43	5.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	206	25.2%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	206	25.2%
Angiotensin-converting-enzyme (ACE) inhibitor	289	35.3%
Angiotensin ii receptor blockers (ARBs)	271	33.1%
Dihydropyridines	153	18.7%
Diuretics	187	22.9%
Other antihypertensives	40	4.9%

Table 1ad. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antihypertensives (any of the above antihypertensives)	591	72.2%
Oral anticoagulants	31	3.8%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	25	3.1%
Other cardiac medications (any of the other cardiac medications)	55	6.7%
Lipid lowering therapy	570	69.7%
Baseline known risk of prolonged QT and torsades de pointes	321	39.2%
Baseline possible risk of prolonged QT and torsades de pointes	601	73.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	76	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.3	15.7
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.5	6.6
Mean number of filled prescriptions	34.3	25.4
Mean number of generics dispensed	10.3	5.5
Mean number of unique drug classes dispensed	9.1	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	34,260	N/A
Demographic Characteristics		
Age (years)	65.8	10.2
Age		
0-40 years	1,136	3.3%
41-64 years	12,352	36.1%
65-74 years	13,749	40.1%
75-84 years	6,139	17.9%
≥ 85 years	884	2.6%
Sex		
Female	17,559	51.3%
Male	16,701	48.7%
Race ²		
American Indian or Alaska Native	68	0.2%
Asian	1,089	3.2%
Black or African American	3,424	10.0%
Multi-racial	181	0.5%
Native Hawaiian or Other Pacific Islander	129	0.4%
Unknown	12,876	37.6%
White	16,493	48.1%
Hispanic origin		
Yes	1,274	3.7%
No	18,817	54.9%
Unknown	14,169	41.4%
Year		
2022	25,319	73.9%
2023	8,941	26.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	13,014	38.0%
1-2	12,184	35.6%
3-4	5,880	17.2%
5+	3,182	9.3%
Combined comorbidity score ⁴	2.1	2.5
Combined comorbidity score categories ⁴		
<0	2,850	8.3%
0	7,609	22.2%
1-2	12,175	35.5%
3-4	6,216	18.1%
5+	5,410	15.8%
Alcohol use or abuse	518	1.5%
Obesity	17,074	49.8%

Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	7,105	20.7%
Arrhythmia	7,702	22.5%
Cerebrovascular disease/stroke/transient ischemic attack	4,090	11.9%
Chronic kidney disease	6,353	18.5%
Chronic obstructive pulmonary disease	3,156	9.2%
Congenital heart disease	3,156	9.2%
Heart failure	3,580	10.4%
Hyperlipidemia	28,822	84.1%
Hypertensive disease	29,418	85.9%
Thyroid disease	7,013	20.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	7,718	22.5%
Left ventricular hypertrophy	1,682	4.9%
Peripheral artery disease	1,682	4.9%
Valvular/mitral valve disease	1,269	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	3,902	11.4%
Obstructive sleep apnea	7,151	20.9%
Hypertrophic cardiomyopathy	1,431	4.2%
Other cardiac disease	13,847	40.4%
Tachyarrhythmia day 0	526	1.5%
Hospitalized tachyarrhythmia day 0	14	0.0%
History of serious hypoglycemia (ED and/or IP)	221	0.6%
Medical Product Use		
Alpha-glucosidase inhibitors	180	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	6,829	19.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	479	1.4%
Insulin	4,381	12.8%
Biguanides (metformin, phenformin, etc.)	28,442	83.0%
SGLT2 inhibitors	11,395	33.3%
Sulfonylurea	13,419	39.2%
Thiazolidinedione	3,466	10.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	199	0.6%
Beta blockers	13,292	38.8%
Potassium channel blockers/openers	443	1.3%
Non-dihydropyridine calcium channel blockers	45	0.1%
Digoxin	249	0.7%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	13,448	39.3%
Angiotensin-converting-enzyme (ACE) inhibitor	13,423	39.2%
Angiotensin ii receptor blockers (ARBs)	12,399	36.2%
Dihydropyridines	9,203	26.9%
Diuretics	11,049	32.3%
Other antihypertensives	2,622	7.7%

Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antihypertensives (any of the above antihypertensives)	28,444	83.0%
Oral anticoagulants	2,717	7.9%
Vitamin K antagonists	540	1.6%
Other cardiac medications not mentioned above	1,915	5.6%
Other cardiac medications (any of the other cardiac medications)	4,705	13.7%
Lipid lowering therapy	28,667	83.7%
Baseline known risk of prolonged QT and torsades de pointes	13,787	40.2%
Baseline possible risk of prolonged QT and torsades de pointes	27,410	80.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	4,016	11.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.6	16.7
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.6	8.4
Mean number of filled prescriptions	40.8	30.5
Mean number of generics dispensed	11.7	5.8
Mean number of unique drug classes dispensed	10.1	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1af. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	526	N/A
Demographic Characteristics		
Age (years)	72.3	9.2
Age		
0-40 years	*****	*****
41-64 years	91	17.3%
65-74 years	216	41.1%
75-84 years	174	33.1%
≥ 85 years	*****	*****
Sex		
Female	225	42.8%
Male	301	57.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	33	6.3%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	115	21.9%
White	362	68.8%
Hispanic origin		
Yes	12	2.3%
No	379	72.1%
Unknown	135	25.7%
Year		
2022	405	77.0%
2023	121	23.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.4	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	42	8.0%
1-2	166	31.6%
3-4	162	30.8%
5+	156	29.7%
Combined comorbidity score ⁴	4.6	3.0
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	115	21.9%
3-4	143	27.2%
5+	240	45.6%
Alcohol use or abuse	18	3.4%
Obesity	290	55.1%

Table 1af. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	170	32.3%
Arrhythmia	481	91.4%
Cerebrovascular disease/stroke/transient ischemic attack	119	22.6%
Chronic kidney disease	176	33.5%
Chronic obstructive pulmonary disease	111	21.1%
Congenital heart disease	111	21.1%
Heart failure	193	36.7%
Hyperlipidemia	461	87.6%
Hypertensive disease	494	93.9%
Thyroid disease	113	21.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	254	48.3%
Left ventricular hypertrophy	96	18.3%
Peripheral artery disease	96	18.3%
Valvular/mitral valve disease	67	12.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	127	24.1%
Obstructive sleep apnea	165	31.4%
Hypertrophic cardiomyopathy	93	17.7%
Other cardiac disease	382	72.6%
Tachyarrhythmia day 0	526	100.0%
Hospitalized tachyarrhythmia day 0	14	2.7%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	100	19.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	66	12.5%
Biguanides (metformin, phenformin, etc.)	403	76.6%
SGLT2 inhibitors	198	37.6%
Sulfonylurea	219	41.6%
Thiazolidinedione	48	9.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	21	4.0%
Beta blockers	406	77.2%
Potassium channel blockers/openers	57	10.8%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	28	5.3%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	420	79.8%
Angiotensin-converting-enzyme (ACE) inhibitor	204	38.8%
Angiotensin ii receptor blockers (ARBs)	185	35.2%
Dihydropyridines	140	26.6%
Diuretics	291	55.3%
Other antihypertensives	46	8.7%

Table 1af. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antihypertensives (any of the above antihypertensives)	465	88.4%
Oral anticoagulants	289	54.9%
Vitamin K antagonists	60	11.4%
Other cardiac medications not mentioned above	62	11.8%
Other cardiac medications (any of the other cardiac medications)	357	67.9%
Lipid lowering therapy	453	86.1%
Baseline known risk of prolonged QT and torsades de pointes	269	51.1%
Baseline possible risk of prolonged QT and torsades de pointes	470	89.4%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	107	20.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.7	19.2
Mean number of emergency room encounters	0.9	2.5
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	7.9	13.5
Mean number of filled prescriptions	51.5	43.7
Mean number of generics dispensed	14.0	6.0
Mean number of unique drug classes dispensed	12.3	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ag. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	14	N/A
Demographic Characteristics		
Age (years)	70.6	10.2
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	4.4	3.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	6.9	2.9
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	0	0.0%
3-4	*****	*****
5+	*****	*****

Table 1ag. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	12	85.7%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	13	92.9%
Hypertensive disease	13	92.9%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	11	78.6%
Tachyarrhythmia day 0	14	100.0%
Hospitalized tachyarrhythmia day 0	14	100.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	11	78.6%
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****

Table 1ag. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	12	85.7%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	14	100.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	31.0	25.2
Mean number of emergency room encounters	2.8	1.7
Mean number of inpatient hospital encounters	0.7	1.0
Mean number of non-acute institutional encounters	0.1	0.2
Mean number of other ambulatory encounters	11.6	14.0
Mean number of filled prescriptions	41.5	24.5
Mean number of generics dispensed	14.7	5.4
Mean number of unique drug classes dispensed	13.3	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ah. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	12,876	N/A
Demographic Characteristics		
Age (years)	59.4	10.9
Age		
0-40 years	776	6.0%
41-64 years	7,993	62.1%
65-74 years	3,052	23.7%
75-84 years	904	7.0%
≥ 85 years	151	1.2%
Sex		
Female	6,058	47.0%
Male	6,818	53.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	12,876	100.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	11,653	90.5%
Year		
2022	8,927	69.3%
2023	3,949	30.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	6,807	52.9%
1-2	4,095	31.8%
3-4	1,399	10.9%
5+	575	4.5%
Combined comorbidity score ⁴	1.4	2.1
Combined comorbidity score categories ⁴		
<0	1,538	11.9%
0	3,781	29.4%
1-2	4,872	37.8%
3-4	1,634	12.7%
5+	1,051	8.2%

Table 1ah. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	159	1.2%
Obesity	6,254	48.6%
Tobacco use	1,837	14.3%
Arrhythmia	2,028	15.8%
Cerebrovascular disease/stroke/transient ischemic attack	905	7.0%
Chronic kidney disease	1,382	10.7%
Chronic obstructive pulmonary disease	618	4.8%
Congenital heart disease	618	4.8%
Heart failure	738	5.7%
Hyperlipidemia	10,230	79.5%
Hypertensive disease	10,206	79.3%
Thyroid disease	2,114	16.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,852	14.4%
Left ventricular hypertrophy	403	3.1%
Peripheral artery disease	403	3.1%
Valvular/mitral valve disease	270	2.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,049	8.1%
Obstructive sleep apnea	2,444	19.0%
Hypertrophic cardiomyopathy	336	2.6%
Other cardiac disease	4,093	31.8%
Tachyarrhythmia day 0	115	0.9%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	46	0.4%
Medical Product Use		
Alpha-glucosidase inhibitors	52	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	2,342	18.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	121	0.9%
Insulin	1,359	10.6%
Biguanides (metformin, phenformin, etc.)	11,216	87.1%
SGLT2 inhibitors	4,376	34.0%
Sulfonylurea	4,295	33.4%
Thiazolidinedione	1,123	8.7%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	54	0.4%
Beta blockers	3,779	29.3%
Potassium channel blockers/openers	97	0.8%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	50	0.4%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	3,806	29.6%
Angiotensin-converting-enzyme (ACE) inhibitor	4,936	38.3%
Angiotensin ii receptor blockers (ARBs)	4,286	33.3%

Table 1ah. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Dihydropyridines	2,839	22.0%
Diuretics	3,216	25.0%
Other antihypertensives	663	5.1%
Antihypertensives (any of the above antihypertensives)	9,988	77.6%
Oral anticoagulants	643	5.0%
Vitamin K antagonists	114	0.9%
Other cardiac medications not mentioned above	460	3.6%
Other cardiac medications (any of the other cardiac medications)	1,131	8.8%
Lipid lowering therapy	10,211	79.3%
Baseline known risk of prolonged QT and torsades de pointes	4,787	37.2%
Baseline possible risk of prolonged QT and torsades de pointes	9,508	73.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	1,200	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.8	14.7
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.0	6.0
Mean number of filled prescriptions	35.3	27.1
Mean number of generics dispensed	10.5	5.6
Mean number of unique drug classes dispensed	9.0	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ai. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	68	N/A
Demographic Characteristics		
Age (years)	61.3	13.6
Age		
0-40 years	*****	*****
41-64 years	25	36.8%
65-74 years	24	35.3%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	41	60.3%
Male	27	39.7%
Race ²		
American Indian or Alaska Native	68	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	58	85.3%
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.5	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	27	39.7%
1-2	26	38.2%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	2.2	2.2
Combined comorbidity score categories ⁴		
<0	*****	*****
0	12	17.6%
1-2	30	44.1%
3-4	*****	*****
5+	15	22.1%
Alcohol use or abuse	*****	*****

Table 1ai. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	38	55.9%
Tobacco use	18	26.5%
Arrhythmia	13	19.1%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	51	*****
Hypertensive disease	52	76.5%
Thyroid disease	16	23.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	14	20.6%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	20	29.4%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	19	27.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	12	17.6%
Biguanides (metformin, phenformin, etc.)	58	85.3%
SGLT2 inhibitors	18	26.5%
Sulfonylurea	25	36.8%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	25	36.8%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	25	36.8%
Angiotensin-converting-enzyme (ACE) inhibitor	31	45.6%
Angiotensin ii receptor blockers (ARBs)	14	20.6%
Dihydropyridines	15	22.1%
Diuretics	19	27.9%

Table 1ai. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard
		Deviation ¹
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	53	77.9%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	55	80.9%
Baseline known risk of prolonged QT and torsades de pointes	34	50.0%
Baseline possible risk of prolonged QT and torsades de pointes	61	89.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.9	11.2
Mean number of emergency room encounters	0.9	2.0
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	7.0	14.7
Mean number of filled prescriptions	61.9	45.9
Mean number of generics dispensed	12.9	5.5
Mean number of unique drug classes dispensed	11.1	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1aj. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,089	N/A
Demographic Characteristics		
Age (years)	70.6	9.9
Age		
0-40 years	26	2.4%
41-64 years	174	16.0%
65-74 years	525	48.2%
75-84 years	292	26.8%
≥ 85 years	72	6.6%
Sex		
Female	601	55.2%
Male	488	44.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,089	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	933	85.7%
Unknown	*****	*****
Year		
2022	923	84.8%
2023	166	15.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.8	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	362	33.2%
1-2	401	36.8%
3-4	208	19.1%
5+	118	10.8%
Combined comorbidity score ⁴	2.4	2.6
Combined comorbidity score categories ⁴		
<0	67	6.2%
0	222	20.4%
1-2	383	35.2%
3-4	225	20.7%
5+	192	17.6%
Alcohol use or abuse	*****	*****
Obesity	251	23.0%

Table 1aj. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	122	11.2%
Arrhythmia	220	20.2%
Cerebrovascular disease/stroke/transient ischemic attack	148	13.6%
Chronic kidney disease	306	28.1%
Chronic obstructive pulmonary disease	85	7.8%
Congenital heart disease	85	7.8%
Heart failure	115	10.6%
Hyperlipidemia	957	87.9%
Hypertensive disease	953	87.5%
Thyroid disease	206	18.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	268	24.6%
Left ventricular hypertrophy	43	3.9%
Peripheral artery disease	43	3.9%
Valvular/mitral valve disease	42	3.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	92	8.4%
Obstructive sleep apnea	87	8.0%
Hypertrophic cardiomyopathy	41	3.8%
Other cardiac disease	377	34.6%
Tachyarrhythmia day 0	15	1.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	25	2.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	340	31.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	35	3.2%
Insulin	158	14.5%
Biguanides (metformin, phenformin, etc.)	917	84.2%
SGLT2 inhibitors	492	45.2%
Sulfonylurea	504	46.3%
Thiazolidinedione	173	15.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	440	40.4%
Potassium channel blockers/openers	13	1.2%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	446	41.0%
Angiotensin-converting-enzyme (ACE) inhibitor	295	27.1%
Angiotensin ii receptor blockers (ARBs)	578	53.1%
Dihydropyridines	398	36.5%
Diuretics	259	23.8%

Table 1aj. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Other antihypertensives	101	9.3%
Antihypertensives (any of the above antihypertensives)	935	85.9%
Oral anticoagulants	67	6.2%
Vitamin K antagonists	11	1.0%
Other cardiac medications not mentioned above	106	9.7%
Other cardiac medications (any of the other cardiac medications)	166	15.2%
Lipid lowering therapy	991	91.0%
Baseline known risk of prolonged QT and torsades de pointes	346	31.8%
Baseline possible risk of prolonged QT and torsades de pointes	780	71.6%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	80	7.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.6	18.8
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.2	8.7
Mean number of filled prescriptions	42.8	32.7
Mean number of generics dispensed	11.9	6.0
Mean number of unique drug classes dispensed	9.9	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ak. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	3,424	N/A
Demographic Characteristics		
Age (years)	67.1	10.3
Age		
0-40 years	89	2.6%
41-64 years	995	29.1%
65-74 years	1,694	49.5%
75-84 years	570	16.6%
≥ 85 years	76	2.2%
Sex		
Female	2,268	66.2%
Male	1,156	33.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	3,424	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	3,017	88.1%
Unknown	*****	*****
Year		
2022	2,347	68.5%
2023	1,077	31.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	944	27.6%
1-2	1,308	38.2%
3-4	736	21.5%
5+	436	12.7%
Combined comorbidity score ⁴	2.6	2.7
Combined comorbidity score categories ⁴		
<0	210	6.1%
0	622	18.2%
1-2	1,129	33.0%
3-4	764	22.3%
5+	699	20.4%
Alcohol use or abuse	74	2.2%
Obesity	2,019	59.0%

Table 1ak. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	845	24.7%
Arrhythmia	741	21.6%
Cerebrovascular disease/stroke/transient ischemic attack	443	12.9%
Chronic kidney disease	904	26.4%
Chronic obstructive pulmonary disease	373	10.9%
Congenital heart disease	373	10.9%
Heart failure	505	14.7%
Hyperlipidemia	2,908	84.9%
Hypertensive disease	3,221	94.1%
Thyroid disease	474	13.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	692	20.2%
Left ventricular hypertrophy	235	6.9%
Peripheral artery disease	235	6.9%
Valvular/mitral valve disease	127	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	446	13.0%
Obstructive sleep apnea	672	19.6%
Hypertrophic cardiomyopathy	186	5.4%
Other cardiac disease	1,364	39.8%
Tachyarrhythmia day 0	33	1.0%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	45	1.3%
Medical Product Use		
Alpha-glucosidase inhibitors	19	0.6%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	691	20.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	44	1.3%
Insulin	556	16.2%
Biguanides (metformin, phenformin, etc.)	2,651	77.4%
SGLT2 inhibitors	1,020	29.8%
Sulfonylurea	1,420	41.5%
Thiazolidinedione	309	9.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	1,466	42.8%
Potassium channel blockers/openers	26	0.8%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	13	0.4%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	1,482	43.3%
Angiotensin-converting-enzyme (ACE) inhibitor	1,209	35.3%
Angiotensin ii receptor blockers (ARBs)	1,517	44.3%
Dihydropyridines	1,524	44.5%
Diuretics	1,563	45.6%

Table 1ak. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Other antihypertensives	475	13.9%
Antihypertensives (any of the above antihypertensives)	3,131	91.4%
Oral anticoagulants	214	6.3%
Vitamin K antagonists	41	1.2%
Other cardiac medications not mentioned above	190	5.5%
Other cardiac medications (any of the other cardiac medications)	408	11.9%
Lipid lowering therapy	2,869	83.8%
Baseline known risk of prolonged QT and torsades de pointes	1,338	39.1%
Baseline possible risk of prolonged QT and torsades de pointes	2,940	85.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	330	9.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.3	17.7
Mean number of emergency room encounters	0.8	1.9
Mean number of inpatient hospital encounters	0.1	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	4.6	10.8
Mean number of filled prescriptions	42.1	29.0
Mean number of generics dispensed	12.4	5.9
Mean number of unique drug classes dispensed	10.9	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1a. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	129	N/A
Demographic Characteristics		
Age (years)	71.4	7.6
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	67	51.9%
75-84 years	35	27.1%
≥ 85 years	*****	*****
Sex		
Female	53	41.1%
Male	76	58.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	129	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	70	54.3%
2023	59	45.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	34	26.4%
1-2	49	38.0%
3-4	26	20.2%
5+	20	15.5%
Combined comorbidity score ⁴	2.5	2.7
Combined comorbidity score categories ⁴		
<0	15	11.6%
0	19	14.7%
1-2	35	27.1%
3-4	37	28.7%
5+	23	17.8%
Alcohol use or abuse	*****	*****
Obesity	50	38.8%

Table 1a. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	19	14.7%
Arrhythmia	35	27.1%
Cerebrovascular disease/stroke/transient ischemic attack	16	12.4%
Chronic kidney disease	43	33.3%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	17	13.2%
Hyperlipidemia	117	90.7%
Hypertensive disease	117	90.7%
Thyroid disease	22	17.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	33	25.6%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	16	12.4%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	50	38.8%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	26	20.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	17	13.2%
Biguanides (metformin, phenformin, etc.)	107	82.9%
SGLT2 inhibitors	41	31.8%
Sulfonylurea	72	55.8%
Thiazolidinedione	26	20.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	0	0.0%
Beta blockers	56	43.4%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	57	44.2%
Angiotensin-converting-enzyme (ACE) inhibitor	46	35.7%
Angiotensin ii receptor blockers (ARBs)	58	45.0%
Dihydropyridines	39	30.2%
Diuretics	38	29.5%

Table 1a. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Other antihypertensives	11	8.5%
Antihypertensives (any of the above antihypertensives)	115	89.1%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	17	13.2%
Lipid lowering therapy	112	86.8%
Baseline known risk of prolonged QT and torsades de pointes	43	33.3%
Baseline possible risk of prolonged QT and torsades de pointes	94	72.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	11	8.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.1	13.6
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.9	6.8
Mean number of filled prescriptions	33.1	18.4
Mean number of generics dispensed	11.2	5.0
Mean number of unique drug classes dispensed	9.2	4.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1am. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	16,493	N/A
Demographic Characteristics		
Age (years)	70.2	9.3
Age		
0-40 years	209	1.3%
41-64 years	3,018	18.3%
65-74 years	8,362	50.7%
75-84 years	4,328	26.2%
≥ 85 years	576	3.5%
Sex		
Female	8,449	51.2%
Male	8,044	48.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	16,493	100.0%
Hispanic origin		
Yes	*****	*****
No	14,674	89.0%
Unknown	*****	*****
Year		
2022	12,878	78.1%
2023	3,615	21.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	4,723	28.6%
1-2	6,255	37.9%
3-4	3,489	21.2%
5+	2,026	12.3%
Combined comorbidity score ⁴	2.6	2.7
Combined comorbidity score categories ⁴		
<0	991	6.0%
0	2,903	17.6%
1-2	5,645	34.2%
3-4	3,533	21.4%
5+	3,421	20.7%
Alcohol use or abuse	265	1.6%
Obesity	8,362	50.7%

Table 1am. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	4,239	25.7%
Arrhythmia	4,637	28.1%
Cerebrovascular disease/stroke/transient ischemic attack	2,563	15.5%
Chronic kidney disease	3,698	22.4%
Chronic obstructive pulmonary disease	2,065	12.5%
Congenital heart disease	2,065	12.5%
Heart failure	2,192	13.3%
Hyperlipidemia	14,427	87.5%
Hypertensive disease	14,736	89.3%
Thyroid disease	4,156	25.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	4,840	29.3%
Left ventricular hypertrophy	986	6.0%
Peripheral artery disease	986	6.0%
Valvular/mitral valve disease	820	5.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	2,289	13.9%
Obstructive sleep apnea	3,885	23.6%
Hypertrophic cardiomyopathy	859	5.2%
Other cardiac disease	7,888	47.8%
Tachyarrhythmia day 0	362	2.2%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	121	0.7%
Medical Product Use		
Alpha-glucosidase inhibitors	84	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	3,391	20.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	276	1.7%
Insulin	2,270	13.8%
Biguanides (metformin, phenformin, etc.)	13,331	80.8%
SGLT2 inhibitors	5,392	32.7%
Sulfonylurea	7,044	42.7%
Thiazolidinedione	1,810	11.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	135	0.8%
Beta blockers	7,485	45.4%
Potassium channel blockers/openers	305	1.8%
Non-dihydropyridine calcium channel blockers	28	0.2%
Digoxin	176	1.1%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	7,591	46.0%
Angiotensin-converting-enzyme (ACE) inhibitor	6,838	41.5%
Angiotensin ii receptor blockers (ARBs)	5,890	35.7%
Dihydropyridines	4,354	26.4%
Diuretics	5,918	35.9%

Table 1am. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Other antihypertensives	1,362	8.3%
Antihypertensives (any of the above antihypertensives)	14,088	85.4%
Oral anticoagulants	1,776	10.8%
Vitamin K antagonists	366	2.2%
Other cardiac medications not mentioned above	1,140	6.9%
Other cardiac medications (any of the other cardiac medications)	2,963	18.0%
Lipid lowering therapy	14,300	86.7%
Baseline known risk of prolonged QT and torsades de pointes	7,175	43.5%
Baseline possible risk of prolonged QT and torsades de pointes	13,900	84.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	2,380	14.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.4	17.8
Mean number of emergency room encounters	0.5	1.4
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	9.5
Mean number of filled prescriptions	44.7	32.9
Mean number of generics dispensed	12.4	5.8
Mean number of unique drug classes dispensed	10.8	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1an. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	181	N/A
Demographic Characteristics		
Age (years)	53.3	10.7
Age		
0-40 years	25	13.8%
41-64 years	129	71.3%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	89	49.2%
Male	92	50.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	181	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	46	25.4%
No	12	6.6%
Unknown	123	68.0%
Year		
2022	111	61.3%
2023	70	38.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	117	64.6%
1-2	50	27.6%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.0	1.8
Combined comorbidity score categories ⁴		
<0	26	14.4%
0	50	27.6%
1-2	81	44.8%
3-4	15	8.3%
5+	*****	*****
Alcohol use or abuse	*****	*****
Obesity	100	55.2%

Table 1an. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	25	13.8%
Arrhythmia	28	15.5%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	12	6.6%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	132	72.9%
Hypertensive disease	133	73.5%
Thyroid disease	25	13.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	19	10.5%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	38	21.0%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	55	30.4%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	20	11.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	162	89.5%
SGLT2 inhibitors	56	30.9%
Sulfonylurea	59	32.6%
Thiazolidinedione	16	8.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	41	22.7%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	41	22.7%
Angiotensin-converting-enzyme (ACE) inhibitor	68	37.6%
Angiotensin ii receptor blockers (ARBs)	56	30.9%
Dihydropyridines	34	18.8%
Diuretics	36	19.9%

Table 1an. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	134	74.0%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	14	7.7%
Lipid lowering therapy	129	71.3%
Baseline known risk of prolonged QT and torsades de pointes	64	35.4%
Baseline possible risk of prolonged QT and torsades de pointes	127	70.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.0	10.7
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.3	2.3
Mean number of filled prescriptions	30.3	20.0
Mean number of generics dispensed	9.6	4.6
Mean number of unique drug classes dispensed	8.1	3.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1ao. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	386	N/A
Demographic Characteristics		
Age (years)	50.6	10.0
Age		
0-40 years	70	18.1%
41-64 years	292	75.6%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	294	76.2%
Male	92	23.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	342	88.6%
White	31	8.0%
Hispanic origin		
Yes	0	0.0%
No	13	3.4%
Unknown	373	96.6%
Year		
2022	333	86.3%
2023	53	13.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	276	71.5%
1-2	88	22.8%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	44	11.4%
0	123	31.9%
1-2	144	37.3%
3-4	53	13.7%
5+	22	5.7%
Alcohol use or abuse	*****	*****
Obesity	332	86.0%

Table 1ao. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	50	13.0%
Arrhythmia	67	17.4%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	18	4.7%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	14	3.6%
Hyperlipidemia	257	66.6%
Hypertensive disease	274	71.0%
Thyroid disease	105	27.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	25	6.5%
Left ventricular hypertrophy	12	3.1%
Peripheral artery disease	12	3.1%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	38	9.8%
Obstructive sleep apnea	137	35.5%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	159	41.2%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	21	5.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	18	4.7%
Biguanides (metformin, phenformin, etc.)	358	92.7%
SGLT2 inhibitors	47	12.2%
Sulfonylurea	39	10.1%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	115	29.8%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	115	29.8%
Angiotensin-converting-enzyme (ACE) inhibitor	101	26.2%
Angiotensin ii receptor blockers (ARBs)	106	27.5%
Dihydropyridines	72	18.7%
Diuretics	152	39.4%

Table 1ao. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Other antihypertensives	26	6.7%
Antihypertensives (any of the above antihypertensives)	281	72.8%
Oral anticoagulants	16	4.1%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	21	5.4%
Lipid lowering therapy	206	53.4%
Baseline known risk of prolonged QT and torsades de pointes	213	55.2%
Baseline possible risk of prolonged QT and torsades de pointes	345	89.4%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	68	17.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.0	16.9
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.2	5.2
Mean number of filled prescriptions	38.7	26.9
Mean number of generics dispensed	12.7	6.4
Mean number of unique drug classes dispensed	11.5	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ap. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Alcohol use or abuse	.	.
Obesity	.	.

Table 1ap. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.

Table 1ap. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1a. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.

Table 1a. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	.	.
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.

Table 1a. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1ar. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	342	N/A
Demographic Characteristics		
Age (years)	50.0	9.9
Age		
0-40 years	64	18.7%
41-64 years	266	77.8%
65-74 years	12	3.5%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	263	76.9%
Male	79	23.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	342	100.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	342	100.0%
Year		
2022	298	87.1%
2023	44	12.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	244	71.3%
1-2	78	22.8%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	39	11.4%
0	112	32.7%
1-2	127	37.1%
3-4	45	13.2%
5+	19	5.6%
Alcohol use or abuse	*****	*****

Table 1ar. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	296	86.5%
Tobacco use	40	11.7%
Arrhythmia	56	16.4%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	16	4.7%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	13	3.8%
Hyperlipidemia	220	64.3%
Hypertensive disease	245	71.6%
Thyroid disease	93	27.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	21	6.1%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	32	9.4%
Obstructive sleep apnea	119	34.8%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	136	39.8%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	19	5.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	14	4.1%
Biguanides (metformin, phenformin, etc.)	318	93.0%
SGLT2 inhibitors	39	11.4%
Sulfonylurea	29	8.5%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	99	28.9%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	99	28.9%
Angiotensin-converting-enzyme (ACE) inhibitor	93	27.2%
Angiotensin ii receptor blockers (ARBs)	94	27.5%
Dihydropyridines	61	17.8%

Table 1ar. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	133	38.9%
Other antihypertensives	24	7.0%
Antihypertensives (any of the above antihypertensives)	250	73.1%
Oral anticoagulants	13	3.8%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	16	4.7%
Lipid lowering therapy	179	52.3%
Baseline known risk of prolonged QT and torsades de pointes	192	56.1%
Baseline possible risk of prolonged QT and torsades de pointes	305	89.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	59	17.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.4	16.8
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.5	5.1
Mean number of filled prescriptions	37.9	26.2
Mean number of generics dispensed	12.6	6.4
Mean number of unique drug classes dispensed	11.4	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1as. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Alcohol use or abuse	.	.
Obesity	.	.

Table 1as. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.

Table 1as. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1at. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Alcohol use or abuse	.	.
Obesity	.	.

Table 1at. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.

Table 1at. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1au. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	51.1	10.1
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.2	0.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	0.8	1.5
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	0	0.0%
Alcohol use or abuse	0	0.0%
Obesity	*****	*****

Table 1au. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	0	0.0%
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	0	0.0%
Sulfonylurea	0	0.0%
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	0	0.0%
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	0	0.0%
Diuretics	*****	*****

Table 1au. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.8	23.8
Mean number of emergency room encounters	0.9	1.5
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.4	8.0
Mean number of filled prescriptions	29.4	20.9
Mean number of generics dispensed	10.1	5.6
Mean number of unique drug classes dispensed	9.4	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1av. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Alcohol use or abuse	.	.
Obesity	.	.

Table 1av. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.

Table 1av. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1aw. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	31	N/A
Demographic Characteristics		
Age (years)	57.2	10.6
Age		
0-40 years	*****	*****
41-64 years	14	45.2%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	20	64.5%
Male	11	35.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	31	100.0%
Hispanic origin		
Yes	0	0.0%
No	12	38.7%
Unknown	19	61.3%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	22	71.0%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.7	2.1
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	14	45.2%
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	0	0.0%
Obesity	23	74.2%

Table 1aw. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	*****	*****
Arrhythmia	11	35.5%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	30	96.8%
Hypertensive disease	24	77.4%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	13	41.9%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	18	58.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	28	90.3%
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	15	48.4%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	15	48.4%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	11	35.5%
Dihydropyridines	*****	*****
Diuretics	16	51.6%

Table 1aw. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	25	80.6%
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	23	74.2%
Baseline known risk of prolonged QT and torsades de pointes	18	58.1%
Baseline possible risk of prolonged QT and torsades de pointes	29	93.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.8	16.3
Mean number of emergency room encounters	0.9	3.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	3.8	5.1
Mean number of filled prescriptions	51.4	35.5
Mean number of generics dispensed	15.2	6.8
Mean number of unique drug classes dispensed	13.3	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ax. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	47.7	6.3
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.0	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	1.8	2.1
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	0	0.0%
3-4	*****	*****
5+	0	0.0%
Alcohol use or abuse	0	0.0%
Obesity	*****	*****

Table 1ax. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	*****	*****
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	0	0.0%
Dihydropyridines	*****	*****
Diuretics	*****	*****

Table 1ax. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	32.5	20.1
Mean number of emergency room encounters	1.3	0.5
Mean number of inpatient hospital encounters	0.5	0.6
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.0	2.8
Mean number of filled prescriptions	26.8	17.0
Mean number of generics dispensed	11.0	6.3
Mean number of unique drug classes dispensed	9.5	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

NaN: Not a number

N/A: Not applicable

Table 1ay. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	67,310	N/A
Demographic Characteristics		
Age (years)	65.7	10.5
Age		
0-40 years	2,438	3.6%
41-64 years	23,872	35.5%
65-74 years	27,508	40.9%
75-84 years	11,909	17.7%
≥ 85 years	1,583	2.4%
Sex		
Female	34,980	52.0%
Male	32,330	48.0%
Race ²		
American Indian or Alaska Native	259	0.4%
Asian	1,205	1.8%
Black or African American	6,463	9.6%
Multi-racial	293	0.4%
Native Hawaiian or Other Pacific Islander	248	0.4%
Unknown	21,889	32.5%
White	36,953	54.9%
Hispanic origin		
Yes	2,486	3.7%
No	41,147	61.1%
Unknown	23,677	35.2%
Year		
2022	53,098	78.9%
2023	14,212	21.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	21,463	31.9%
1-2	23,437	34.8%
3-4	13,093	19.5%
5+	9,317	13.8%
Combined comorbidity score ⁴	2.7	2.8
Combined comorbidity score categories ⁴		
<0	4,005	6.0%
0	12,530	18.6%
1-2	22,871	34.0%
3-4	13,154	19.5%
5+	14,750	21.9%
Alcohol use or abuse	1,381	2.1%
Obesity	36,138	53.7%

Table 1ay. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Tobacco use	17,724	26.3%
Arrhythmia	18,116	26.9%
Cerebrovascular disease/stroke/transient ischemic attack	9,861	14.7%
Chronic kidney disease	14,886	22.1%
Chronic obstructive pulmonary disease	8,357	12.4%
Congenital heart disease	8,357	12.4%
Heart failure	9,744	14.5%
Hyperlipidemia	56,476	83.9%
Hypertensive disease	58,578	87.0%
Thyroid disease	14,861	22.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	18,381	27.3%
Left ventricular hypertrophy	4,292	6.4%
Peripheral artery disease	4,292	6.4%
Valvular/mitral valve disease	2,957	4.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	9,385	13.9%
Obstructive sleep apnea	16,727	24.9%
Hypertrophic cardiomyopathy	3,704	5.5%
Other cardiac disease	31,574	46.9%
Tachyarrhythmia day 0	1,280	1.9%
Hospitalized tachyarrhythmia day 0	26	0.0%
History of serious hypoglycemia (ED and/or IP)	905	1.3%
Medical Product Use		
Alpha-glucosidase inhibitors	274	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	12,241	18.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	907	1.3%
Insulin	20,406	30.3%
Biguanides (metformin, phenformin, etc.)	54,903	81.6%
SGLT2 inhibitors	19,678	29.2%
Sulfonylurea	26,746	39.7%
Thiazolidinedione	6,314	9.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	11	0.0%
Sodium channel blockers	372	0.6%
Beta blockers	28,944	43.0%
Potassium channel blockers/openers	1,083	1.6%
Non-dihydropyridine calcium channel blockers	95	0.1%
Digoxin	611	0.9%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	29,268	43.5%
Angiotensin-converting-enzyme (ACE) inhibitor	27,454	40.8%
Angiotensin ii receptor blockers (ARBs)	23,399	34.8%
Dihydropyridines	18,511	27.5%
Diuretics	24,806	36.9%

Table 1ay. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Other antihypertensives	5,877	8.7%
Antihypertensives (any of the above antihypertensives)	56,683	84.2%
Oral anticoagulants	6,422	9.5%
Vitamin K antagonists	1,487	2.2%
Other cardiac medications not mentioned above	5,018	7.5%
Other cardiac medications (any of the other cardiac medications)	11,534	17.1%
Lipid lowering therapy	56,577	84.1%
Baseline known risk of prolonged QT and torsades de pointes	29,863	44.4%
Baseline possible risk of prolonged QT and torsades de pointes	56,725	84.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	10,014	14.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.8	19.4
Mean number of emergency room encounters	0.7	1.7
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	6.9	14.9
Mean number of filled prescriptions	47.2	37.5
Mean number of generics dispensed	12.8	6.3
Mean number of unique drug classes dispensed	11.1	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1az. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,280	N/A
Demographic Characteristics		
Age (years)	71.6	9.5
Age		
0-40 years	13	1.0%
41-64 years	223	17.4%
65-74 years	566	44.2%
75-84 years	404	31.6%
≥ 85 years	74	5.8%
Sex		
Female	511	39.9%
Male	769	60.1%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	84	6.6%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	238	18.6%
White	933	72.9%
Hispanic origin		
Yes	25	2.0%
No	948	74.1%
Unknown	307	24.0%
Year		
2022	1,013	79.1%
2023	267	20.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.8	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	82	6.4%
1-2	359	28.0%
3-4	403	31.5%
5+	436	34.1%
Combined comorbidity score ⁴	5.0	3.2
Combined comorbidity score categories ⁴		
<0	13	1.0%
0	59	4.6%
1-2	262	20.5%
3-4	286	22.3%
5+	660	51.6%
Alcohol use or abuse	33	2.6%
Obesity	769	60.1%

Table 1az. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Tobacco use	453	35.4%
Arrhythmia	1,186	92.7%
Cerebrovascular disease/stroke/transient ischemic attack	304	23.8%
Chronic kidney disease	458	35.8%
Chronic obstructive pulmonary disease	257	20.1%
Congenital heart disease	257	20.1%
Heart failure	555	43.4%
Hyperlipidemia	1,126	88.0%
Hypertensive disease	1,220	95.3%
Thyroid disease	303	23.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	613	47.9%
Left ventricular hypertrophy	218	17.0%
Peripheral artery disease	218	17.0%
Valvular/mitral valve disease	194	15.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	318	24.8%
Obstructive sleep apnea	500	39.1%
Hypertrophic cardiomyopathy	239	18.7%
Other cardiac disease	988	77.2%
Tachyarrhythmia day 0	1,280	100.0%
Hospitalized tachyarrhythmia day 0	26	2.0%
History of serious hypoglycemia (ED and/or IP)	35	2.7%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	236	18.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	21	1.6%
Insulin	398	31.1%
Biguanides (metformin, phenformin, etc.)	981	76.6%
SGLT2 inhibitors	392	30.6%
Sulfonylurea	554	43.3%
Thiazolidinedione	84	6.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	62	4.8%
Beta blockers	984	76.9%
Potassium channel blockers/openers	161	12.6%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	100	7.8%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	1,025	80.1%
Angiotensin-converting-enzyme (ACE) inhibitor	497	38.8%
Angiotensin ii receptor blockers (ARBs)	489	38.2%
Dihydropyridines	336	26.3%
Diuretics	745	58.2%

Table 1az. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Other antihypertensives	143	11.2%
Antihypertensives (any of the above antihypertensives)	1,145	89.5%
Oral anticoagulants	752	58.8%
Vitamin K antagonists	194	15.2%
Other cardiac medications not mentioned above	156	12.2%
Other cardiac medications (any of the other cardiac medications)	940	73.4%
Lipid lowering therapy	1,129	88.2%
Baseline known risk of prolonged QT and torsades de pointes	697	54.5%
Baseline possible risk of prolonged QT and torsades de pointes	1,181	92.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	344	26.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.9	19.1
Mean number of emergency room encounters	1.1	2.3
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	11.8	24.8
Mean number of filled prescriptions	56.8	39.9
Mean number of generics dispensed	14.8	6.1
Mean number of unique drug classes dispensed	13.1	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ba. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	26	N/A
Demographic Characteristics		
Age (years)	69.5	9.9
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	12	46.2%
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	4.4	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	12	46.2%
Combined comorbidity score ⁴	6.1	3.1
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	15	57.7%

Table 1ba. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	12	46.2%
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	14	53.8%
Hyperlipidemia	*****	*****
Hypertensive disease	26	100.0%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	14	53.8%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	14	53.8%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	26	100.0%
Hospitalized tachyarrhythmia day 0	26	100.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	15	57.7%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****

Table 1ba. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Angiotensin-converting-enzyme (ACE) inhibitor	13	50.0%
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****
Diuretics	13	50.0%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	15	57.7%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	12	46.2%
Baseline possible risk of prolonged QT and torsades de pointes	26	100.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	35.8	35.2
Mean number of emergency room encounters	4.6	7.0
Mean number of inpatient hospital encounters	0.7	0.9
Mean number of non-acute institutional encounters	0.3	0.5
Mean number of other ambulatory encounters	11.6	11.9
Mean number of filled prescriptions	59.2	31.1
Mean number of generics dispensed	18.3	8.5
Mean number of unique drug classes dispensed	15.8	6.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bb. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	21,889	N/A
Demographic Characteristics		
Age (years)	58.8	11.3
Age		
0-40 years	1,585	7.2%
41-64 years	13,656	62.4%
65-74 years	4,908	22.4%
75-84 years	1,540	7.0%
≥ 85 years	200	0.9%
Sex		
Female	10,644	48.6%
Male	11,245	51.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	21,889	100.0%
White	0	0.0%
Hispanic origin		
Yes	*****	10.9%
No	*****	0.0%
Unknown	19,506	89.1%
Year		
2022	15,460	70.6%
2023	6,429	29.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	10,605	48.4%
1-2	7,091	32.4%
3-4	2,670	12.2%
5+	1,523	7.0%
Combined comorbidity score ⁴	1.7	2.3
Combined comorbidity score categories ⁴		
<0	2,084	9.5%
0	5,985	27.3%
1-2	8,299	37.9%
3-4	3,135	14.3%
5+	2,386	10.9%
Alcohol use or abuse	332	1.5%

Table 1bb. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	11,205	51.2%
Tobacco use	4,028	18.4%
Arrhythmia	4,011	18.3%
Cerebrovascular disease/stroke/transient ischemic attack	1,805	8.2%
Chronic kidney disease	2,768	12.6%
Chronic obstructive pulmonary disease	1,403	6.4%
Congenital heart disease	1,403	6.4%
Heart failure	1,713	7.8%
Hyperlipidemia	17,050	77.9%
Hypertensive disease	17,469	79.8%
Thyroid disease	3,641	16.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	3,684	16.8%
Left ventricular hypertrophy	892	4.1%
Peripheral artery disease	892	4.1%
Valvular/mitral valve disease	534	2.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,965	9.0%
Obstructive sleep apnea	4,744	21.7%
Hypertrophic cardiomyopathy	717	3.3%
Other cardiac disease	7,805	35.7%
Tachyarrhythmia day 0	238	1.1%
Hospitalized tachyarrhythmia day 0	*****	0.0%
History of serious hypoglycemia (ED and/or IP)	158	0.7%
Medical Product Use		
Alpha-glucosidase inhibitors	71	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	3,759	17.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	189	0.9%
Insulin	5,598	25.6%
Biguanides (metformin, phenformin, etc.)	18,776	85.8%
SGLT2 inhibitors	6,518	29.8%
Sulfonylurea	7,687	35.1%
Thiazolidinedione	1,753	8.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	0.0%
Sodium channel blockers	88	0.4%
Beta blockers	7,026	32.1%
Potassium channel blockers/openers	196	0.9%
Non-dihydropyridine calcium channel blockers	24	0.1%
Digoxin	120	0.5%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	7,099	32.4%
Angiotensin-converting-enzyme (ACE) inhibitor	8,935	40.8%
Angiotensin ii receptor blockers (ARBs)	6,773	30.9%
Dihydropyridines	4,860	22.2%

Table 1bb. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	6,110	27.9%
Other antihypertensives	1,326	6.1%
Antihypertensives (any of the above antihypertensives)	17,166	78.4%
Oral anticoagulants	1,246	5.7%
Vitamin K antagonists	224	1.0%
Other cardiac medications not mentioned above	1,004	4.6%
Other cardiac medications (any of the other cardiac medications)	2,265	10.3%
Lipid lowering therapy	17,169	78.4%
Baseline known risk of prolonged QT and torsades de pointes	8,675	39.6%
Baseline possible risk of prolonged QT and torsades de pointes	16,926	77.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	2,584	11.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.0	17.7
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.9	9.4
Mean number of filled prescriptions	39.0	31.1
Mean number of generics dispensed	11.3	6.1
Mean number of unique drug classes dispensed	9.7	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bc. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	259	N/A
Demographic Characteristics		
Age (years)	64.7	11.8
Age		
0-40 years	*****	*****
41-64 years	101	39.0%
65-74 years	95	36.7%
75-84 years	43	16.6%
≥ 85 years	*****	*****
Sex		
Female	147	56.8%
Male	112	43.2%
Race ²		
American Indian or Alaska Native	259	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	241	93.1%
Unknown	18	6.9%
Year		
2022	234	90.3%
2023	25	9.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	72	27.8%
1-2	96	37.1%
3-4	49	18.9%
5+	42	16.2%
Combined comorbidity score ⁴	2.6	2.6
Combined comorbidity score categories ⁴		
<0	13	5.0%
0	40	15.4%
1-2	97	37.5%
3-4	59	22.8%
5+	50	19.3%
Alcohol use or abuse	13	5.0%

Table 1bc. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	117	45.2%
Tobacco use	86	33.2%
Arrhythmia	60	23.2%
Cerebrovascular disease/stroke/transient ischemic attack	43	16.6%
Chronic kidney disease	54	20.8%
Chronic obstructive pulmonary disease	30	11.6%
Congenital heart disease	30	11.6%
Heart failure	35	13.5%
Hyperlipidemia	202	78.0%
Hypertensive disease	226	87.3%
Thyroid disease	55	21.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	68	26.3%
Left ventricular hypertrophy	15	5.8%
Peripheral artery disease	15	5.8%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	36	13.9%
Obstructive sleep apnea	58	22.4%
Hypertrophic cardiomyopathy	14	5.4%
Other cardiac disease	108	41.7%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	55	21.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	118	45.6%
Biguanides (metformin, phenformin, etc.)	210	81.1%
SGLT2 inhibitors	67	25.9%
Sulfonylurea	96	37.1%
Thiazolidinedione	26	10.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	93	35.9%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	94	36.3%
Angiotensin-converting-enzyme (ACE) inhibitor	136	52.5%
Angiotensin ii receptor blockers (ARBs)	73	28.2%
Dihydropyridines	65	25.1%

Table 1bc. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	88	34.0%
Other antihypertensives	27	10.4%
Antihypertensives (any of the above antihypertensives)	222	85.7%
Oral anticoagulants	19	7.3%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	20	7.7%
Other cardiac medications (any of the other cardiac medications)	36	13.9%
Lipid lowering therapy	216	83.4%
Baseline known risk of prolonged QT and torsades de pointes	119	45.9%
Baseline possible risk of prolonged QT and torsades de pointes	221	85.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	42	16.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.8	18.7
Mean number of emergency room encounters	0.9	1.8
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.4	31.3
Mean number of filled prescriptions	63.1	49.5
Mean number of generics dispensed	13.4	6.7
Mean number of unique drug classes dispensed	11.6	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bd. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,205	N/A
Demographic Characteristics		
Age (years)	69.3	10.8
Age		
0-40 years	46	3.8%
41-64 years	222	18.4%
65-74 years	571	47.4%
75-84 years	297	24.6%
≥ 85 years	69	5.7%
Sex		
Female	630	52.3%
Male	575	47.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,205	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	1,049	87.1%
Unknown	156	12.9%
Year		
2022	1,048	87.0%
2023	157	13.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	313	26.0%
1-2	442	36.7%
3-4	276	22.9%
5+	174	14.4%
Combined comorbidity score ⁴	2.9	2.8
Combined comorbidity score categories ⁴		
<0	29	2.4%
0	210	17.4%
1-2	416	34.5%
3-4	256	21.2%
5+	294	24.4%
Alcohol use or abuse	19	1.6%

Table 1bd. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	309	25.6%
Tobacco use	178	14.8%
Arrhythmia	312	25.9%
Cerebrovascular disease/stroke/transient ischemic attack	203	16.8%
Chronic kidney disease	372	30.9%
Chronic obstructive pulmonary disease	97	8.0%
Congenital heart disease	97	8.0%
Heart failure	179	14.9%
Hyperlipidemia	1,050	87.1%
Hypertensive disease	1,053	87.4%
Thyroid disease	271	22.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	347	28.8%
Left ventricular hypertrophy	63	5.2%
Peripheral artery disease	63	5.2%
Valvular/mitral valve disease	50	4.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	145	12.0%
Obstructive sleep apnea	149	12.4%
Hypertrophic cardiomyopathy	61	5.1%
Other cardiac disease	498	41.3%
Tachyarrhythmia day 0	20	1.7%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	20	1.7%
Medical Product Use		
Alpha-glucosidase inhibitors	31	2.6%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	360	29.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	43	3.6%
Insulin	437	36.3%
Biguanides (metformin, phenformin, etc.)	985	81.7%
SGLT2 inhibitors	476	39.5%
Sulfonylurea	551	45.7%
Thiazolidinedione	137	11.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	532	44.1%
Potassium channel blockers/openers	18	1.5%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	536	44.5%
Angiotensin-converting-enzyme (ACE) inhibitor	360	29.9%
Angiotensin ii receptor blockers (ARBs)	597	49.5%
Dihydropyridines	422	35.0%

Table 1bd. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	347	28.8%
Other antihypertensives	131	10.9%
Antihypertensives (any of the above antihypertensives)	1,032	85.6%
Oral anticoagulants	97	8.0%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	105	8.7%
Other cardiac medications (any of the other cardiac medications)	193	16.0%
Lipid lowering therapy	1,097	91.0%
Baseline known risk of prolonged QT and torsades de pointes	430	35.7%
Baseline possible risk of prolonged QT and torsades de pointes	936	77.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	142	11.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.9	26.0
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	7.2	15.4
Mean number of filled prescriptions	45.4	35.2
Mean number of generics dispensed	12.4	6.0
Mean number of unique drug classes dispensed	10.4	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1be. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	6,463	N/A
Demographic Characteristics		
Age (years)	66.1	10.8
Age		
0-40 years	220	3.4%
41-64 years	2,128	32.9%
65-74 years	2,967	45.9%
75-84 years	1,029	15.9%
≥ 85 years	119	1.8%
Sex		
Female	4,255	65.8%
Male	2,208	34.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	6,463	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	5,827	90.2%
Unknown	636	9.8%
Year		
2022	4,913	76.0%
2023	1,550	24.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.6	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	1,354	21.0%
1-2	2,285	35.4%
3-4	1,540	23.8%
5+	1,284	19.9%
Combined comorbidity score ⁴	3.3	3.0
Combined comorbidity score categories ⁴		
<0	228	3.5%
0	861	13.3%
1-2	2,010	31.1%
3-4	1,448	22.4%
5+	1,916	29.6%
Alcohol use or abuse	155	2.4%

Table 1be. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	3,940	61.0%
Tobacco use	1,944	30.1%
Arrhythmia	1,782	27.6%
Cerebrovascular disease/stroke/transient ischemic attack	1,214	18.8%
Chronic kidney disease	2,026	31.3%
Chronic obstructive pulmonary disease	897	13.9%
Congenital heart disease	897	13.9%
Heart failure	1,312	20.3%
Hyperlipidemia	5,514	85.3%
Hypertensive disease	6,087	94.2%
Thyroid disease	997	15.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,702	26.3%
Left ventricular hypertrophy	568	8.8%
Peripheral artery disease	568	8.8%
Valvular/mitral valve disease	274	4.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,038	16.1%
Obstructive sleep apnea	1,504	23.3%
Hypertrophic cardiomyopathy	466	7.2%
Other cardiac disease	3,069	47.5%
Tachyarrhythmia day 0	84	1.3%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	164	2.5%
Medical Product Use		
Alpha-glucosidase inhibitors	23	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	1,230	19.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	95	1.5%
Insulin	2,563	39.7%
Biguanides (metformin, phenformin, etc.)	4,853	75.1%
SGLT2 inhibitors	1,821	28.2%
Sulfonylurea	2,520	39.0%
Thiazolidinedione	490	7.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	21	0.3%
Beta blockers	3,098	47.9%
Potassium channel blockers/openers	72	1.1%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	33	0.5%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	3,120	48.3%
Angiotensin-converting-enzyme (ACE) inhibitor	2,240	34.7%
Angiotensin ii receptor blockers (ARBs)	2,851	44.1%
Dihydropyridines	3,083	47.7%

Table 1be. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	3,159	48.9%
Other antihypertensives	1,035	16.0%
Antihypertensives (any of the above antihypertensives)	5,953	92.1%
Oral anticoagulants	581	9.0%
Vitamin K antagonists	118	1.8%
Other cardiac medications not mentioned above	520	8.0%
Other cardiac medications (any of the other cardiac medications)	1,080	16.7%
Lipid lowering therapy	5,538	85.7%
Baseline known risk of prolonged QT and torsades de pointes	2,747	42.5%
Baseline possible risk of prolonged QT and torsades de pointes	5,714	88.4%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	830	12.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.6	21.5
Mean number of emergency room encounters	1.0	2.3
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	8.1	18.5
Mean number of filled prescriptions	50.4	38.9
Mean number of generics dispensed	13.7	6.4
Mean number of unique drug classes dispensed	12.0	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bf. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	248	N/A
Demographic Characteristics		
Age (years)	71.0	7.3
Age		
0-40 years	*****	*****
41-64 years	39	15.7%
65-74 years	136	54.8%
75-84 years	62	25.0%
≥ 85 years	*****	*****
Sex		
Female	116	46.8%
Male	132	53.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	248	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	145	58.5%
2023	103	41.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	59	23.8%
1-2	99	39.9%
3-4	59	23.8%
5+	31	12.5%
Combined comorbidity score ⁴	2.7	2.7
Combined comorbidity score categories ⁴		
<0	13	5.2%
0	40	16.1%
1-2	92	37.1%
3-4	51	20.6%
5+	52	21.0%
Alcohol use or abuse	*****	*****

Table 1bf. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	108	43.5%
Tobacco use	59	23.8%
Arrhythmia	48	19.4%
Cerebrovascular disease/stroke/transient ischemic attack	39	15.7%
Chronic kidney disease	85	34.3%
Chronic obstructive pulmonary disease	23	9.3%
Congenital heart disease	23	9.3%
Heart failure	33	13.3%
Hyperlipidemia	217	87.5%
Hypertensive disease	221	89.1%
Thyroid disease	34	13.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	64	25.8%
Left ventricular hypertrophy	11	4.4%
Peripheral artery disease	11	4.4%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	28	11.3%
Obstructive sleep apnea	36	14.5%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	91	36.7%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	46	18.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	82	33.1%
Biguanides (metformin, phenformin, etc.)	204	82.3%
SGLT2 inhibitors	71	28.6%
Sulfonylurea	125	50.4%
Thiazolidinedione	32	12.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	103	41.5%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	103	41.5%
Angiotensin-converting-enzyme (ACE) inhibitor	114	46.0%
Angiotensin ii receptor blockers (ARBs)	97	39.1%
Dihydropyridines	84	33.9%

Table 1bf. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	74	29.8%
Other antihypertensives	24	9.7%
Antihypertensives (any of the above antihypertensives)	220	88.7%
Oral anticoagulants	18	7.3%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	18	7.3%
Other cardiac medications (any of the other cardiac medications)	35	14.1%
Lipid lowering therapy	223	89.9%
Baseline known risk of prolonged QT and torsades de pointes	89	35.9%
Baseline possible risk of prolonged QT and torsades de pointes	200	80.6%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	13	5.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.0	17.0
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	2.3	5.9
Mean number of filled prescriptions	35.9	20.3
Mean number of generics dispensed	12.4	5.3
Mean number of unique drug classes dispensed	10.4	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bg. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	36,953	N/A
Demographic Characteristics		
Age (years)	69.6	9.6
Age		
0-40 years	539	1.5%
41-64 years	7,502	20.3%
65-74 years	18,807	50.9%
75-84 years	8,928	24.2%
≥ 85 years	1,177	3.2%
Sex		
Female	19,047	51.5%
Male	17,906	48.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	36,953	100.0%
Hispanic origin		
Yes	*****	0.0%
No	33,777	91.4%
Unknown	*****	8.6%
Year		
2022	31,108	84.2%
2023	5,845	15.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.4	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	8,886	24.0%
1-2	13,335	36.1%
3-4	8,477	22.9%
5+	6,255	16.9%
Combined comorbidity score ⁴	3.2	3.0
Combined comorbidity score categories ⁴		
<0	1,617	4.4%
0	5,309	14.4%
1-2	11,819	32.0%
3-4	8,171	22.1%
5+	10,037	27.2%
Alcohol use or abuse	855	2.3%

Table 1bg. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	20,304	54.9%
Tobacco use	11,401	30.9%
Arrhythmia	11,858	32.1%
Cerebrovascular disease/stroke/transient ischemic attack	6,544	17.7%
Chronic kidney disease	9,557	25.9%
Chronic obstructive pulmonary disease	5,903	16.0%
Congenital heart disease	5,903	16.0%
Heart failure	6,462	17.5%
Hyperlipidemia	32,222	87.2%
Hypertensive disease	33,320	90.2%
Thyroid disease	9,824	26.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	12,491	33.8%
Left ventricular hypertrophy	2,734	7.4%
Peripheral artery disease	2,734	7.4%
Valvular/mitral valve disease	2,080	5.6%
Diseases of veins and lymphatics, and other diseases of circulatory system	6,156	16.7%
Obstructive sleep apnea	10,173	27.5%
Hypertrophic cardiomyopathy	2,431	6.6%
Other cardiac disease	19,921	53.9%
Tachyarrhythmia day 0	933	2.5%
Hospitalized tachyarrhythmia day 0	21	0.1%
History of serious hypoglycemia (ED and/or IP)	554	1.5%
Medical Product Use		
Alpha-glucosidase inhibitors	145	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	6,748	18.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	574	1.6%
Insulin	11,544	31.2%
Biguanides (metformin, phenformin, etc.)	29,611	80.1%
SGLT2 inhibitors	10,637	28.8%
Sulfonylurea	15,666	42.4%
Thiazolidinedione	3,853	10.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	0.0%
Sodium channel blockers	258	0.7%
Beta blockers	18,028	48.8%
Potassium channel blockers/openers	787	2.1%
Non-dihydropyridine calcium channel blockers	63	0.2%
Digoxin	442	1.2%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	18,251	49.4%
Angiotensin-converting-enzyme (ACE) inhibitor	15,570	42.1%
Angiotensin ii receptor blockers (ARBs)	12,913	34.9%
Dihydropyridines	9,950	26.9%

Table 1bg. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	14,963	40.5%
Other antihypertensives	3,318	9.0%
Antihypertensives (any of the above antihypertensives)	31,887	86.3%
Oral anticoagulants	4,449	12.0%
Vitamin K antagonists	1,129	3.1%
Other cardiac medications not mentioned above	3,340	9.0%
Other cardiac medications (any of the other cardiac medications)	7,900	21.4%
Lipid lowering therapy	32,117	86.9%
Baseline known risk of prolonged QT and torsades de pointes	17,693	47.9%
Baseline possible risk of prolonged QT and torsades de pointes	32,525	88.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	6,374	17.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.5	19.8
Mean number of emergency room encounters	0.7	1.9
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	7.8	16.5
Mean number of filled prescriptions	51.6	40.5
Mean number of generics dispensed	13.5	6.3
Mean number of unique drug classes dispensed	11.9	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bh. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	293	N/A
Demographic Characteristics		
Age (years)	53.7	10.8
Age		
0-40 years	35	11.9%
41-64 years	224	76.5%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	141	48.1%
Male	152	51.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	293	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	95	32.4%
No	12	4.1%
Unknown	186	63.5%
Year		
2022	190	64.8%
2023	103	35.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.8	1.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	174	59.4%
1-2	89	30.4%
3-4	22	7.5%
5+	*****	*****
Combined comorbidity score ⁴	1.3	2.0
Combined comorbidity score categories ⁴		
<0	21	7.2%
0	85	29.0%
1-2	138	47.1%
3-4	34	11.6%
5+	15	5.1%
Alcohol use or abuse	*****	*****

Table 1bh. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	155	52.9%
Tobacco use	28	9.6%
Arrhythmia	45	15.4%
Cerebrovascular disease/stroke/transient ischemic attack	13	4.4%
Chronic kidney disease	24	8.2%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	221	75.4%
Hypertensive disease	202	68.9%
Thyroid disease	39	13.3%
Ischemic heart disease/coronary artery disease/myocardial infarction	25	8.5%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	17	5.8%
Obstructive sleep apnea	63	21.5%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	82	28.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	43	14.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	64	21.8%
Biguanides (metformin, phenformin, etc.)	264	90.1%
SGLT2 inhibitors	88	30.0%
Sulfonylurea	101	34.5%
Thiazolidinedione	23	7.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	64	21.8%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	65	22.2%
Angiotensin-converting-enzyme (ACE) inhibitor	99	33.8%
Angiotensin ii receptor blockers (ARBs)	95	32.4%
Dihydropyridines	47	16.0%

Table 1bh. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	65	22.2%
Other antihypertensives	16	5.5%
Antihypertensives (any of the above antihypertensives)	203	69.3%
Oral anticoagulants	12	4.1%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	11	3.8%
Other cardiac medications (any of the other cardiac medications)	25	8.5%
Lipid lowering therapy	217	74.1%
Baseline known risk of prolonged QT and torsades de pointes	110	37.5%
Baseline possible risk of prolonged QT and torsades de pointes	203	69.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	29	9.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.2	14.8
Mean number of emergency room encounters	0.5	2.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.7	7.6
Mean number of filled prescriptions	32.8	27.9
Mean number of generics dispensed	9.7	5.7
Mean number of unique drug classes dispensed	8.4	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bi. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	5,398	N/A
Demographic Characteristics		
Age (years)	63.6	11.5
Age		
0-40 years	311	5.8%
41-64 years	2,168	40.2%
65-74 years	2,057	38.1%
75-84 years	761	14.1%
≥ 85 years	101	1.9%
Sex		
Female	3,142	58.2%
Male	2,256	41.8%
Race ²		
American Indian or Alaska Native	61	1.1%
Asian	93	1.7%
Black or African American	564	10.4%
Multi-racial	67	1.2%
Native Hawaiian or Other Pacific Islander	14	0.3%
Unknown	1,443	26.7%
White	3,156	58.5%
Hispanic origin		
Yes	224	4.1%
No	3,524	65.3%
Unknown	1,650	30.6%
Year		
2022	4,134	76.6%
2023	1,264	23.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	1,656	30.7%
1-2	1,905	35.3%
3-4	1,088	20.2%
5+	749	13.9%
Combined comorbidity score ⁴	2.8	2.8
Combined comorbidity score categories ⁴		
<0	242	4.5%
0	904	16.7%
1-2	1,835	34.0%
3-4	1,192	22.1%
5+	1,225	22.7%
Alcohol use or abuse	148	2.7%

Table 1bi. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	3,244	60.1%
Tobacco use	1,560	28.9%
Arrhythmia	1,464	27.1%
Cerebrovascular disease/stroke/transient ischemic attack	711	13.2%
Chronic kidney disease	1,211	22.4%
Chronic obstructive pulmonary disease	731	13.5%
Congenital heart disease	731	13.5%
Heart failure	851	15.8%
Hyperlipidemia	4,236	78.5%
Hypertensive disease	4,559	84.5%
Thyroid disease	1,177	21.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,414	26.2%
Left ventricular hypertrophy	358	6.6%
Peripheral artery disease	358	6.6%
Valvular/mitral valve disease	219	4.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	777	14.4%
Obstructive sleep apnea	1,538	28.5%
Hypertrophic cardiomyopathy	285	5.3%
Other cardiac disease	2,632	48.8%
Tachyarrhythmia day 0	71	1.3%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	93	1.7%
Medical Product Use		
Alpha-glucosidase inhibitors	25	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	719	13.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	72	1.3%
Insulin	2,061	38.2%
Biguanides (metformin, phenformin, etc.)	4,398	81.5%
SGLT2 inhibitors	1,424	26.4%
Sulfonylurea	1,829	33.9%
Thiazolidinedione	449	8.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	42	0.8%
Beta blockers	2,324	43.1%
Potassium channel blockers/openers	81	1.5%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	50	0.9%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	2,353	43.6%
Angiotensin-converting-enzyme (ACE) inhibitor	2,183	40.4%
Angiotensin ii receptor blockers (ARBs)	1,839	34.1%
Dihydropyridines	1,467	27.2%

Table 1bi. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	2,192	40.6%
Other antihypertensives	502	9.3%
Antihypertensives (any of the above antihypertensives)	4,525	83.8%
Oral anticoagulants	470	8.7%
Vitamin K antagonists	156	2.9%
Other cardiac medications not mentioned above	446	8.3%
Other cardiac medications (any of the other cardiac medications)	957	17.7%
Lipid lowering therapy	4,430	82.1%
Baseline known risk of prolonged QT and torsades de pointes	2,499	46.3%
Baseline possible risk of prolonged QT and torsades de pointes	4,689	86.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	823	15.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.3	22.5
Mean number of emergency room encounters	0.8	2.6
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.5	18.2
Mean number of filled prescriptions	51.0	41.2
Mean number of generics dispensed	13.5	6.6
Mean number of unique drug classes dispensed	11.9	5.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bj. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	71	N/A
Demographic Characteristics		
Age (years)	67.4	11.0
Age		
0-40 years	*****	*****
41-64 years	22	31.0%
65-74 years	29	40.8%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	28	39.4%
Male	43	60.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	11	15.5%
White	49	69.0%
Hispanic origin		
Yes	*****	*****
No	55	77.5%
Unknown	*****	*****
Year		
2022	54	76.1%
2023	17	23.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.9	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	16	22.5%
3-4	30	42.3%
5+	22	31.0%
Combined comorbidity score ⁴	5.3	3.1
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	12	16.9%
3-4	19	26.8%
5+	38	53.5%
Alcohol use or abuse	*****	*****

Table 1bj. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	46	64.8%
Tobacco use	32	45.1%
Arrhythmia	68	95.8%
Cerebrovascular disease/stroke/transient ischemic attack	17	23.9%
Chronic kidney disease	23	32.4%
Chronic obstructive pulmonary disease	15	21.1%
Congenital heart disease	15	21.1%
Heart failure	35	49.3%
Hyperlipidemia	62	87.3%
Hypertensive disease	69	97.2%
Thyroid disease	12	16.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	38	53.5%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	11	15.5%
Diseases of veins and lymphatics, and other diseases of circulatory system	23	32.4%
Obstructive sleep apnea	34	47.9%
Hypertrophic cardiomyopathy	16	22.5%
Other cardiac disease	59	83.1%
Tachyarrhythmia day 0	71	100.0%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	24	33.8%
Biguanides (metformin, phenformin, etc.)	50	70.4%
SGLT2 inhibitors	20	28.2%
Sulfonylurea	27	38.0%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	57	80.3%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	58	81.7%
Angiotensin-converting-enzyme (ACE) inhibitor	34	47.9%
Angiotensin ii receptor blockers (ARBs)	25	35.2%
Dihydropyridines	20	28.2%

Table 1bj. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	45	63.4%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	66	93.0%
Oral anticoagulants	37	52.1%
Vitamin K antagonists	11	15.5%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	48	67.6%
Lipid lowering therapy	62	87.3%
Baseline known risk of prolonged QT and torsades de pointes	39	54.9%
Baseline possible risk of prolonged QT and torsades de pointes	64	90.1%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	22	31.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	24.9	17.3
Mean number of emergency room encounters	1.8	3.5
Mean number of inpatient hospital encounters	0.5	0.8
Mean number of non-acute institutional encounters	0.2	0.7
Mean number of other ambulatory encounters	10.7	16.6
Mean number of filled prescriptions	54.9	33.0
Mean number of generics dispensed	14.6	5.3
Mean number of unique drug classes dispensed	13.1	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bk. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	77.2	10.4
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	0	0.0%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	4.3	2.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	0	0.0%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	6.5	2.9
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	*****	*****
3-4	0	0.0%
5+	*****	*****

Table 1bk. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	0	0.0%
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****

Table 1bk. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	42.0	26.9
Mean number of emergency room encounters	3.5	3.1
Mean number of inpatient hospital encounters	0.3	0.0
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	5.5	5.4
Mean number of filled prescriptions	44.8	16.3
Mean number of generics dispensed	12.0	4.0
Mean number of unique drug classes dispensed	11.5	3.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bl. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,443	N/A
Demographic Characteristics		
Age (years)	58.1	12.8
Age		
0-40 years	140	9.7%
41-64 years	852	59.0%
65-74 years	341	23.6%
75-84 years	93	6.4%
≥ 85 years	17	1.2%
Sex		
Female	856	59.3%
Male	587	40.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	1,443	100.0%
White	0	0.0%
Hispanic origin		
Yes	194	13.4%
No	0	0.0%
Unknown	1,249	86.6%
Year		
2022	1,029	71.3%
2023	414	28.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.4	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	673	46.6%
1-2	464	32.2%
3-4	188	13.0%
5+	118	8.2%
Combined comorbidity score ⁴	1.9	2.4
Combined comorbidity score categories ⁴		
<0	109	7.6%
0	341	23.6%
1-2	564	39.1%
3-4	257	17.8%
5+	172	11.9%
Alcohol use or abuse	22	1.5%

Table 1bl. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	855	59.3%
Tobacco use	295	20.4%
Arrhythmia	274	19.0%
Cerebrovascular disease/stroke/transient ischemic attack	118	8.2%
Chronic kidney disease	198	13.7%
Chronic obstructive pulmonary disease	115	8.0%
Congenital heart disease	115	8.0%
Heart failure	125	8.7%
Hyperlipidemia	1,043	72.3%
Hypertensive disease	1,117	77.4%
Thyroid disease	259	17.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	245	17.0%
Left ventricular hypertrophy	57	4.0%
Peripheral artery disease	57	4.0%
Valvular/mitral valve disease	34	2.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	124	8.6%
Obstructive sleep apnea	339	23.5%
Hypertrophic cardiomyopathy	60	4.2%
Other cardiac disease	527	36.5%
Tachyarrhythmia day 0	11	0.8%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	179	12.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	17	1.2%
Insulin	469	32.5%
Biguanides (metformin, phenformin, etc.)	1,222	84.7%
SGLT2 inhibitors	392	27.2%
Sulfonylurea	437	30.3%
Thiazolidinedione	103	7.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	480	33.3%
Potassium channel blockers/openers	13	0.9%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	486	33.7%
Angiotensin-converting-enzyme (ACE) inhibitor	570	39.5%
Angiotensin ii receptor blockers (ARBs)	460	31.9%
Dihydropyridines	311	21.6%

Table 1bl. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	460	31.9%
Other antihypertensives	91	6.3%
Antihypertensives (any of the above antihypertensives)	1,128	78.2%
Oral anticoagulants	79	5.5%
Vitamin K antagonists	20	1.4%
Other cardiac medications not mentioned above	77	5.3%
Other cardiac medications (any of the other cardiac medications)	164	11.4%
Lipid lowering therapy	1,097	76.0%
Baseline known risk of prolonged QT and torsades de pointes	634	43.9%
Baseline possible risk of prolonged QT and torsades de pointes	1,173	81.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	199	13.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.2	23.3
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.6	8.8
Mean number of filled prescriptions	42.3	35.4
Mean number of generics dispensed	12.2	6.5
Mean number of unique drug classes dispensed	10.7	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bm. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	61	N/A
Demographic Characteristics		
Age (years)	62.1	10.9
Age		
0-40 years	*****	*****
41-64 years	28	45.9%
65-74 years	20	32.8%
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	33	54.1%
Male	28	45.9%
Race ²		
American Indian or Alaska Native	61	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	26	42.6%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	2.0	2.3
Combined comorbidity score categories ⁴		
<0	*****	*****
0	12	19.7%
1-2	25	41.0%
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	*****	*****

Table 1bm. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	27	44.3%
Tobacco use	20	32.8%
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	40	65.6%
Hypertensive disease	45	73.8%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	11	18.0%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	18	29.5%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	30	49.2%
Biguanides (metformin, phenformin, etc.)	50	82.0%
SGLT2 inhibitors	17	27.9%
Sulfonylurea	15	24.6%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	22	36.1%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	22	36.1%
Angiotensin-converting-enzyme (ACE) inhibitor	29	47.5%
Angiotensin ii receptor blockers (ARBs)	16	26.2%
Dihydropyridines	17	27.9%

Table 1bm. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	21	34.4%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	49	80.3%
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	44	72.1%
Baseline known risk of prolonged QT and torsades de pointes	25	41.0%
Baseline possible risk of prolonged QT and torsades de pointes	50	82.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.0	15.1
Mean number of emergency room encounters	0.8	1.8
Mean number of inpatient hospital encounters	0.3	1.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	6.1	14.3
Mean number of filled prescriptions	58.4	49.8
Mean number of generics dispensed	12.5	7.3
Mean number of unique drug classes dispensed	11.0	6.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bn. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	93	N/A
Demographic Characteristics		
Age (years)	63.2	12.0
Age		
0-40 years	*****	*****
41-64 years	34	36.6%
65-74 years	31	33.3%
75-84 years	17	18.3%
≥ 85 years	*****	*****
Sex		
Female	59	63.4%
Male	34	36.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	93	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	79	84.9%
Unknown	14	15.1%
Year		
2022	74	79.6%
2023	19	20.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.4
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	31	33.3%
1-2	30	32.3%
3-4	12	12.9%
5+	20	21.5%
Combined comorbidity score ⁴	2.7	2.7
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	30	32.3%
3-4	19	20.4%
5+	21	22.6%
Alcohol use or abuse	*****	*****

Table 1bn. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	30	32.3%
Tobacco use	*****	*****
Arrhythmia	25	26.9%
Cerebrovascular disease/stroke/transient ischemic attack	17	18.3%
Chronic kidney disease	23	24.7%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	16	17.2%
Hyperlipidemia	70	75.3%
Hypertensive disease	77	82.8%
Thyroid disease	18	19.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	20	21.5%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	14	15.1%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	37	39.8%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	18	19.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	54	58.1%
Biguanides (metformin, phenformin, etc.)	68	73.1%
SGLT2 inhibitors	27	29.0%
Sulfonylurea	34	36.6%
Thiazolidinedione	12	12.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	45	48.4%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	47	50.5%
Angiotensin-converting-enzyme (ACE) inhibitor	33	35.5%
Angiotensin ii receptor blockers (ARBs)	39	41.9%
Dihydropyridines	31	33.3%

Table 1bn. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	34	36.6%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	76	81.7%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	13	14.0%
Lipid lowering therapy	82	88.2%
Baseline known risk of prolonged QT and torsades de pointes	33	35.5%
Baseline possible risk of prolonged QT and torsades de pointes	70	75.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.9	35.5
Mean number of emergency room encounters	0.5	1.0
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.4	11.0
Mean number of filled prescriptions	44.4	35.3
Mean number of generics dispensed	12.1	6.6
Mean number of unique drug classes dispensed	10.5	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bo. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	564	N/A
Demographic Characteristics		
Age (years)	61.8	11.0
Age		
0-40 years	39	6.9%
41-64 years	253	44.9%
65-74 years	227	40.2%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	365	64.7%
Male	199	35.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	564	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	510	90.4%
Unknown	*****	*****
Year		
2022	403	71.5%
2023	161	28.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.5	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	141	25.0%
1-2	178	31.6%
3-4	142	25.2%
5+	103	18.3%
Combined comorbidity score ⁴	3.3	3.0
Combined comorbidity score categories ⁴		
<0	23	4.1%
0	83	14.7%
1-2	164	29.1%
3-4	133	23.6%
5+	161	28.5%
Alcohol use or abuse	19	3.4%

Table 1bo. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	374	66.3%
Tobacco use	190	33.7%
Arrhythmia	147	26.1%
Cerebrovascular disease/stroke/transient ischemic attack	94	16.7%
Chronic kidney disease	164	29.1%
Chronic obstructive pulmonary disease	93	16.5%
Congenital heart disease	93	16.5%
Heart failure	129	22.9%
Hyperlipidemia	437	77.5%
Hypertensive disease	511	90.6%
Thyroid disease	71	12.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	141	25.0%
Left ventricular hypertrophy	65	11.5%
Peripheral artery disease	65	11.5%
Valvular/mitral valve disease	21	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	73	12.9%
Obstructive sleep apnea	156	27.7%
Hypertrophic cardiomyopathy	41	7.3%
Other cardiac disease	284	50.4%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	18	3.2%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	91	16.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	253	44.9%
Biguanides (metformin, phenformin, etc.)	445	78.9%
SGLT2 inhibitors	136	24.1%
Sulfonylurea	191	33.9%
Thiazolidinedione	35	6.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	267	47.3%
Potassium channel blockers/openers	11	2.0%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	269	47.7%
Angiotensin-converting-enzyme (ACE) inhibitor	198	35.1%
Angiotensin ii receptor blockers (ARBs)	239	42.4%
Dihydropyridines	254	45.0%

Table 1bo. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	288	51.1%
Other antihypertensives	90	16.0%
Antihypertensives (any of the above antihypertensives)	512	90.8%
Oral anticoagulants	56	9.9%
Vitamin K antagonists	18	3.2%
Other cardiac medications not mentioned above	55	9.8%
Other cardiac medications (any of the other cardiac medications)	107	19.0%
Lipid lowering therapy	478	84.8%
Baseline known risk of prolonged QT and torsades de pointes	258	45.7%
Baseline possible risk of prolonged QT and torsades de pointes	512	90.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	62	11.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.0	27.4
Mean number of emergency room encounters	1.5	5.8
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.8	15.3
Mean number of filled prescriptions	53.0	42.2
Mean number of generics dispensed	14.4	6.6
Mean number of unique drug classes dispensed	12.8	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bp. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	14	N/A
Demographic Characteristics		
Age (years)	67.4	10.0
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	14	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	14	100.0%
Unknown	0	0.0%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.7	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	3.4	2.6
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	0	0.0%

Table 1bp. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****

Table 1bp. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	*****	*****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.8	9.6
Mean number of emergency room encounters	0.6	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.5	4.2
Mean number of filled prescriptions	42.1	31.6
Mean number of generics dispensed	13.6	8.3
Mean number of unique drug classes dispensed	12.1	7.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bq. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	3,156	N/A
Demographic Characteristics		
Age (years)	66.8	10.4
Age		
0-40 years	97	3.1%
41-64 years	956	30.3%
65-74 years	1,426	45.2%
75-84 years	603	19.1%
≥ 85 years	74	2.3%
Sex		
Female	1,775	56.2%
Male	1,381	43.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	3,156	100.0%
Hispanic origin		
Yes	15	0.5%
No	2,830	89.7%
Unknown	311	9.9%
Year		
2022	2,528	80.1%
2023	628	19.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	739	23.4%
1-2	1,185	37.5%
3-4	731	23.2%
5+	501	15.9%
Combined comorbidity score ⁴	3.2	3.0
Combined comorbidity score categories ⁴		
<0	102	3.2%
0	435	13.8%
1-2	1,014	32.1%
3-4	755	23.9%
5+	850	26.9%
Alcohol use or abuse	99	3.1%

Table 1bq. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	1,903	60.3%
Tobacco use	1,021	32.4%
Arrhythmia	992	31.4%
Cerebrovascular disease/stroke/transient ischemic attack	475	15.1%
Chronic kidney disease	813	25.8%
Chronic obstructive pulmonary disease	507	16.1%
Congenital heart disease	507	16.1%
Heart failure	564	17.9%
Hyperlipidemia	2,594	82.2%
Hypertensive disease	2,767	87.7%
Thyroid disease	803	25.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	992	31.4%
Left ventricular hypertrophy	223	7.1%
Peripheral artery disease	223	7.1%
Valvular/mitral valve disease	161	5.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	565	17.9%
Obstructive sleep apnea	1,004	31.8%
Hypertrophic cardiomyopathy	173	5.5%
Other cardiac disease	1,738	55.1%
Tachyarrhythmia day 0	49	1.6%
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	66	2.1%
Medical Product Use		
Alpha-glucosidase inhibitors	17	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	414	13.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	45	1.4%
Insulin	1,224	38.8%
Biguanides (metformin, phenformin, etc.)	2,543	80.6%
SGLT2 inhibitors	832	26.4%
Sulfonylurea	1,136	36.0%
Thiazolidinedione	292	9.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	32	1.0%
Beta blockers	1,483	47.0%
Potassium channel blockers/openers	56	1.8%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	40	1.3%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	1,502	47.6%
Angiotensin-converting-enzyme (ACE) inhibitor	1,328	42.1%
Angiotensin ii receptor blockers (ARBs)	1,064	33.7%
Dihydropyridines	836	26.5%

Table 1bq. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	1,363	43.2%
Other antihypertensives	298	9.4%
Antihypertensives (any of the above antihypertensives)	2,705	85.7%
Oral anticoagulants	326	10.3%
Vitamin K antagonists	114	3.6%
Other cardiac medications not mentioned above	298	9.4%
Other cardiac medications (any of the other cardiac medications)	659	20.9%
Lipid lowering therapy	2,671	84.6%
Baseline known risk of prolonged QT and torsades de pointes	1,513	47.9%
Baseline possible risk of prolonged QT and torsades de pointes	2,818	89.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	534	16.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.7	20.9
Mean number of emergency room encounters	0.9	2.2
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	9.8	21.8
Mean number of filled prescriptions	54.8	43.4
Mean number of generics dispensed	14.0	6.5
Mean number of unique drug classes dispensed	12.3	5.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1br. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	67	N/A
Demographic Characteristics		
Age (years)	46.6	13.4
Age		
0-40 years	*****	*****
41-64 years	41	61.2%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	49	73.1%
Male	18	26.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	67	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	13	19.4%
No	35	52.2%
Unknown	19	28.4%
Year		
2022	37	55.2%
2023	30	44.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	45	67.2%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	2.2	2.2
Combined comorbidity score categories ⁴		
<0	*****	*****
0	11	16.4%
1-2	33	49.3%
3-4	14	20.9%
5+	*****	*****
Alcohol use or abuse	*****	*****

Table 1br. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	44	65.7%
Tobacco use	21	31.3%
Arrhythmia	12	17.9%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	40	59.7%
Hypertensive disease	30	44.8%
Thyroid disease	13	19.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	11	16.4%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	19	28.4%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	28	41.8%
Biguanides (metformin, phenformin, etc.)	59	88.1%
SGLT2 inhibitors	16	23.9%
Sulfonylurea	11	16.4%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	20	29.9%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	20	29.9%
Angiotensin-converting-enzyme (ACE) inhibitor	20	29.9%
Angiotensin ii receptor blockers (ARBs)	12	17.9%
Dihydropyridines	15	22.4%

Table 1br. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	19	28.4%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	43	64.2%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	46	68.7%
Baseline known risk of prolonged QT and torsades de pointes	30	44.8%
Baseline possible risk of prolonged QT and torsades de pointes	56	83.6%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.8	18.9
Mean number of emergency room encounters	1.0	2.6
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	11.1	18.4
Mean number of filled prescriptions	47.5	39.7
Mean number of generics dispensed	13.2	6.3
Mean number of unique drug classes dispensed	11.9	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bs. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	842	N/A
Demographic Characteristics		
Age (years)	52.0	10.4
Age		
0-40 years	136	16.2%
41-64 years	631	74.9%
65-74 years	64	7.6%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	579	68.8%
Male	263	31.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	38	4.5%
Multi-racial	18	2.1%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	676	80.3%
White	110	13.1%
Hispanic origin		
Yes	15	1.8%
No	58	6.9%
Unknown	769	91.3%
Year		
2022	74	8.8%
2023	768	91.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	539	64.0%
1-2	240	28.5%
3-4	49	5.8%
5+	14	1.7%
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	125	14.8%
0	244	29.0%
1-2	321	38.1%
3-4	100	11.9%
5+	52	6.2%
Alcohol use or abuse	*****	*****

Table 1bs. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	692	82.2%
Tobacco use	133	15.8%
Arrhythmia	175	20.8%
Cerebrovascular disease/stroke/transient ischemic attack	41	4.9%
Chronic kidney disease	53	6.3%
Chronic obstructive pulmonary disease	24	2.9%
Congenital heart disease	24	2.9%
Heart failure	52	6.2%
Hyperlipidemia	548	65.1%
Hypertensive disease	622	73.9%
Thyroid disease	199	23.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	99	11.8%
Left ventricular hypertrophy	26	3.1%
Peripheral artery disease	26	3.1%
Valvular/mitral valve disease	17	2.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	73	8.7%
Obstructive sleep apnea	291	34.6%
Hypertrophic cardiomyopathy	28	3.3%
Other cardiac disease	347	41.2%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	40	4.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	41	4.9%
Biguanides (metformin, phenformin, etc.)	750	89.1%
SGLT2 inhibitors	128	15.2%
Sulfonylurea	82	9.7%
Thiazolidinedione	21	2.5%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	244	29.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	246	29.2%
Angiotensin-converting-enzyme (ACE) inhibitor	230	27.3%
Angiotensin ii receptor blockers (ARBs)	269	31.9%
Dihydropyridines	170	20.2%

Table 1bs. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	286	34.0%
Other antihypertensives	42	5.0%
Antihypertensives (any of the above antihypertensives)	607	72.1%
Oral anticoagulants	41	4.9%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	26	3.1%
Other cardiac medications (any of the other cardiac medications)	70	8.3%
Lipid lowering therapy	452	53.7%
Baseline known risk of prolonged QT and torsades de pointes	427	50.7%
Baseline possible risk of prolonged QT and torsades de pointes	726	86.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	134	15.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.5	15.9
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.9	7.4
Mean number of filled prescriptions	37.0	28.8
Mean number of generics dispensed	12.2	6.8
Mean number of unique drug classes dispensed	11.0	6.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bt. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	49.1	12.4
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	*****	*****
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	0	0.0%
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	4.0	1.4
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	0	0.0%

Table 1bt. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	*****	*****
Tobacco use	0	0.0%
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	0	0.0%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	0	0.0%
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****

Table 1bt. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	*****	*****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.8	5.7
Mean number of emergency room encounters	1.0	0.0
Mean number of inpatient hospital encounters	0.4	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	10.0	4.1
Mean number of filled prescriptions	39.8	24.7
Mean number of generics dispensed	14.4	2.8
Mean number of unique drug classes dispensed	13.2	3.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bu. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.

Table 1bu. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	.	.
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.

Table 1bu. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1bv. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	676	N/A
Demographic Characteristics		
Age (years)	50.8	10.4
Age		
0-40 years	117	17.3%
41-64 years	529	78.3%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	473	70.0%
Male	203	30.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	676	100.0%
White	0	0.0%
Hispanic origin		
Yes	13	1.9%
No	0	0.0%
Unknown	663	98.1%
Year		
2022	64	9.5%
2023	612	90.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	455	67.3%
1-2	187	27.7%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.0	1.8
Combined comorbidity score categories ⁴		
<0	107	15.8%
0	209	30.9%
1-2	250	37.0%
3-4	75	11.1%
5+	35	5.2%
Alcohol use or abuse	*****	*****

Table 1bv. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	553	81.8%
Tobacco use	104	15.4%
Arrhythmia	135	20.0%
Cerebrovascular disease/stroke/transient ischemic attack	27	4.0%
Chronic kidney disease	37	5.5%
Chronic obstructive pulmonary disease	16	2.4%
Congenital heart disease	16	2.4%
Heart failure	37	5.5%
Hyperlipidemia	437	64.6%
Hypertensive disease	505	74.7%
Thyroid disease	161	23.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	71	10.5%
Left ventricular hypertrophy	22	3.3%
Peripheral artery disease	22	3.3%
Valvular/mitral valve disease	13	1.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	51	7.5%
Obstructive sleep apnea	215	31.8%
Hypertrophic cardiomyopathy	23	3.4%
Other cardiac disease	256	37.9%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	31	4.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	26	3.8%
Biguanides (metformin, phenformin, etc.)	612	90.5%
SGLT2 inhibitors	100	14.8%
Sulfonylurea	58	8.6%
Thiazolidinedione	12	1.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	188	27.8%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	190	28.1%
Angiotensin-converting-enzyme (ACE) inhibitor	191	28.3%
Angiotensin ii receptor blockers (ARBs)	213	31.5%
Dihydropyridines	136	20.1%

Table 1bv. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	221	32.7%
Other antihypertensives	30	4.4%
Antihypertensives (any of the above antihypertensives)	489	72.3%
Oral anticoagulants	29	4.3%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	21	3.1%
Other cardiac medications (any of the other cardiac medications)	51	7.5%
Lipid lowering therapy	349	51.6%
Baseline known risk of prolonged QT and torsades de pointes	360	53.3%
Baseline possible risk of prolonged QT and torsades de pointes	586	86.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	113	16.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.5	15.0
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	4.8	6.0
Mean number of filled prescriptions	35.1	25.1
Mean number of generics dispensed	12.0	6.5
Mean number of unique drug classes dispensed	10.8	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bw. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Alcohol use or abuse	.	.

Table 1bw. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.

Table 1bw. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1bx. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Alcohol use or abuse	.	.

Table 1bx. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.

Table 1bx. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1by. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	38	N/A
Demographic Characteristics		
Age (years)	56.3	9.4
Age		
0-40 years	*****	*****
41-64 years	24	63.2%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	38	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	14	36.8%
Unknown	24	63.2%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.9	1.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	20	52.6%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.3	1.9
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	15	39.5%
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	*****	*****

Table 1by. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	*****	*****
Hyperlipidemia	27	71.1%
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	11	28.9%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	13	34.2%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	32	84.2%
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	12	31.6%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	31.6%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	19	50.0%
Dihydropyridines	12	31.6%

Table 1by. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	17	44.7%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	20	52.6%
Baseline known risk of prolonged QT and torsades de pointes	13	34.2%
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.0	14.1
Mean number of emergency room encounters	0.6	1.3
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.7	4.7
Mean number of filled prescriptions	33.9	35.0
Mean number of generics dispensed	11.5	6.5
Mean number of unique drug classes dispensed	10.3	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bz. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Alcohol use or abuse	.	.

Table 1bz. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.

Table 1bz. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

N/A: Not applicable

Table 1ca. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	110	N/A
Demographic Characteristics		
Age (years)	58.5	10.1
Age		
0-40 years	*****	*****
41-64 years	64	58.2%
65-74 years	29	26.4%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	63	57.3%
Male	47	42.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	110	100.0%
Hispanic origin		
Yes	0	0.0%
No	41	37.3%
Unknown	69	62.7%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	53	48.2%
1-2	35	31.8%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.8	2.3
Combined comorbidity score categories ⁴		
<0	*****	*****
0	21	19.1%
1-2	49	44.5%
3-4	19	17.3%
5+	*****	*****
Alcohol use or abuse	*****	*****

Table 1ca. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	92	83.6%
Tobacco use	23	20.9%
Arrhythmia	27	24.5%
Cerebrovascular disease/stroke/transient ischemic attack	12	10.9%
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	13	11.8%
Hyperlipidemia	74	67.3%
Hypertensive disease	74	67.3%
Thyroid disease	25	22.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	25	22.7%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	15	13.6%
Obstructive sleep apnea	58	52.7%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	70	63.6%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	90	81.8%
SGLT2 inhibitors	20	18.2%
Sulfonylurea	17	15.5%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	39	35.5%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	39	35.5%
Angiotensin-converting-enzyme (ACE) inhibitor	29	26.4%
Angiotensin ii receptor blockers (ARBs)	33	30.0%
Dihydropyridines	18	16.4%

Table 1ca. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	42	38.2%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	75	68.2%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	16	14.5%
Lipid lowering therapy	72	65.5%
Baseline known risk of prolonged QT and torsades de pointes	47	42.7%
Baseline possible risk of prolonged QT and torsades de pointes	94	85.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	14	12.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.3	20.3
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.2	13.3
Mean number of filled prescriptions	47.6	38.3
Mean number of generics dispensed	13.7	7.7
Mean number of unique drug classes dispensed	12.1	6.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1cb. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	18	N/A
Demographic Characteristics		
Age (years)	49.6	9.0
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	18	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.8	2.2
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	*****	*****

Table 1cb. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****

Table 1cb. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	*****	*****
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.9	22.0
Mean number of emergency room encounters	0.9	1.6
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	5.3	10.7
Mean number of filled prescriptions	52.1	61.1
Mean number of generics dispensed	13.8	12.7
Mean number of unique drug classes dispensed	12.1	11.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1cc. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	366	N/A
Demographic Characteristics		
Age (years)	69.5	8.7
Age		
0-40 years	*****	*****
41-64 years	74	20.2%
65-74 years	185	50.5%
75-84 years	87	23.8%
≥ 85 years	*****	*****
Sex		
Female	173	47.3%
Male	193	52.7%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	40	10.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	63	17.2%
White	249	68.0%
Hispanic origin		
Yes	11	3.0%
No	276	75.4%
Unknown	79	21.6%
Year		
2022	219	59.8%
2023	147	40.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.8	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	68	18.6%
1-2	109	29.8%
3-4	107	29.2%
5+	82	22.4%
Combined comorbidity score ⁴	3.2	2.7
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	121	33.1%
3-4	82	22.4%
5+	103	28.1%
Alcohol use or abuse	*****	*****

Table 1cc. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	170	46.4%
Tobacco use	93	25.4%
Arrhythmia	102	27.9%
Cerebrovascular disease/stroke/transient ischemic attack	79	21.6%
Chronic kidney disease	110	30.1%
Chronic obstructive pulmonary disease	50	13.7%
Congenital heart disease	50	13.7%
Heart failure	70	19.1%
Hyperlipidemia	330	90.2%
Hypertensive disease	329	89.9%
Thyroid disease	90	24.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	125	34.2%
Left ventricular hypertrophy	26	7.1%
Peripheral artery disease	26	7.1%
Valvular/mitral valve disease	22	6.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	62	16.9%
Obstructive sleep apnea	94	25.7%
Hypertrophic cardiomyopathy	34	9.3%
Other cardiac disease	187	51.1%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	56	15.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	217	59.3%
Biguanides (metformin, phenformin, etc.)	293	80.1%
SGLT2 inhibitors	95	26.0%
Sulfonylurea	162	44.3%
Thiazolidinedione	54	14.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	173	47.3%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	174	47.5%
Angiotensin-converting-enzyme (ACE) inhibitor	179	48.9%
Angiotensin ii receptor blockers (ARBs)	137	37.4%
Dihydropyridines	107	29.2%

Table 1cc. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	132	36.1%
Other antihypertensives	37	10.1%
Antihypertensives (any of the above antihypertensives)	326	89.1%
Oral anticoagulants	30	8.2%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	30	8.2%
Other cardiac medications (any of the other cardiac medications)	63	17.2%
Lipid lowering therapy	332	90.7%
Baseline known risk of prolonged QT and torsades de pointes	147	40.2%
Baseline possible risk of prolonged QT and torsades de pointes	305	83.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	44	12.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.8	16.3
Mean number of emergency room encounters	0.8	1.6
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	4.7	8.0
Mean number of filled prescriptions	41.2	24.8
Mean number of generics dispensed	12.6	5.4
Mean number of unique drug classes dispensed	10.9	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1cd. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	65.9	6.1
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	*****	*****
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	0	0.0%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	7.3	0.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	0	0.0%
1-2	0	0.0%
3-4	0	0.0%
5+	*****	*****
Combined comorbidity score ⁴	8.0	2.1
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	0	0.0%
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	*****	*****

Table 1cd. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	0	0.0%
Dihydropyridines	*****	*****

Table 1cd. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Presence of Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	*****	*****
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	33.3	10.8
Mean number of emergency room encounters	2.8	0.9
Mean number of inpatient hospital encounters	1.3	1.2
Mean number of non-acute institutional encounters	0.5	0.5
Mean number of other ambulatory encounters	8.0	8.2
Mean number of filled prescriptions	56.3	16.4
Mean number of generics dispensed	12.8	4.1
Mean number of unique drug classes dispensed	11.0	4.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ce. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Presence of Hospitalized Tachyarrhythmia on Index Date in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹

This table was redacted due to small cell counts.

Table 1cf. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	63	N/A
Demographic Characteristics		
Age (years)	62.8	10.6
Age		
0-40 years	*****	*****
41-64 years	27	42.9%
65-74 years	22	34.9%
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	28	44.4%
Male	35	55.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	63	100.0%
White	0	0.0%
Hispanic origin		
Yes	11	17.5%
No	0	0.0%
Unknown	52	82.5%
Year		
2022	38	60.3%
2023	25	39.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	21	33.3%
1-2	20	31.7%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.9	2.0
Combined comorbidity score categories ⁴		
<0	*****	*****
0	12	19.0%
1-2	32	50.8%
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	0	0.0%

Table 1cf. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	30	47.6%
Tobacco use	11	17.5%
Arrhythmia	15	23.8%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	49	77.8%
Thyroid disease	14	22.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	17	27.0%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	18	28.6%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	30	47.6%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	36	57.1%
Biguanides (metformin, phenformin, etc.)	51	81.0%
SGLT2 inhibitors	17	27.0%
Sulfonylurea	26	41.3%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	26	41.3%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	27	42.9%
Angiotensin-converting-enzyme (ACE) inhibitor	37	58.7%
Angiotensin ii receptor blockers (ARBs)	15	23.8%
Dihydropyridines	12	19.0%

Table 1cf. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	16	25.4%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	52	82.5%
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	58	92.1%
Baseline known risk of prolonged QT and torsades de pointes	23	36.5%
Baseline possible risk of prolonged QT and torsades de pointes	48	76.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.0	11.8
Mean number of emergency room encounters	0.6	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.2	6.3
Mean number of filled prescriptions	36.1	25.5
Mean number of generics dispensed	11.6	5.9
Mean number of unique drug classes dispensed	10.2	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1cg. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	70.8	6.4
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	0	0.0%
Male	*****	*****
Race ²		
American Indian or Alaska Native	*****	*****
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	0	0.0%
Year		
2022	0	0.0%
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	0.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	0	0.0%
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	1.5	0.7
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Alcohol use or abuse	0	0.0%

Table 1cg. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	0	0.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	0	0.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	0	0.0%
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	0	0.0%
Dihydropyridines	*****	*****

Table 1cg. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	*****	*****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.5	3.5
Mean number of emergency room encounters	0.0	NaN
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	34.5	20.5
Mean number of generics dispensed	13.5	4.9
Mean number of unique drug classes dispensed	11.0	1.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1ch. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	74.8	6.8
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	3.2	3.2
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Alcohol use or abuse	0	0.0%

Table 1ch. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****

Table 1ch. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	*****	*****
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.4	27.7
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.3	1.0
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	7.8	14.2
Mean number of filled prescriptions	35.6	21.1
Mean number of generics dispensed	10.6	5.3
Mean number of unique drug classes dispensed	9.1	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1ci. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	40	N/A
Demographic Characteristics		
Age (years)	70.1	5.5
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	27	67.5%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	25	62.5%
Male	15	37.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	40	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	18	45.0%
2023	22	55.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.0	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	16	40.0%
5+	*****	*****
Combined comorbidity score ⁴	3.1	2.7
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	11	27.5%
3-4	11	27.5%
5+	*****	*****
Alcohol use or abuse	0	0.0%

Table 1ci. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	15	37.5%
Tobacco use	*****	*****
Arrhythmia	12	30.0%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	11	27.5%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	11	27.5%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	13	32.5%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	22	55.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	26	65.0%
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	13	32.5%
Sulfonylurea	16	40.0%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	24	60.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	24	60.0%
Angiotensin-converting-enzyme (ACE) inhibitor	15	37.5%
Angiotensin ii receptor blockers (ARBs)	16	40.0%
Dihydropyridines	21	52.5%

Table 1ci. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Diuretics	18	45.0%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	36	90.0%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	14	35.0%
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.2	23.3
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.9	4.0
Mean number of filled prescriptions	34.2	16.3
Mean number of generics dispensed	12.3	5.7
Mean number of unique drug classes dispensed	10.6	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1cj. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹

This table was redacted due to small cell counts.

Table 1ck. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	249	N/A
Demographic Characteristics		
Age (years)	71.1	8.2
Age		
0-40 years	*****	*****
41-64 years	42	16.9%
65-74 years	129	51.8%
75-84 years	66	26.5%
≥ 85 years	*****	*****
Sex		
Female	114	45.8%
Male	135	54.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	249	100.0%
Hispanic origin		
Yes	0	0.0%
No	231	92.8%
Unknown	18	7.2%
Year		
2022	155	62.2%
2023	94	37.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.1	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	35	14.1%
1-2	74	29.7%
3-4	75	30.1%
5+	65	26.1%
Combined comorbidity score ⁴	3.5	2.8
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	70	28.1%
3-4	60	24.1%
5+	83	33.3%
Alcohol use or abuse	*****	*****

Table 1ck. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	124	49.8%
Tobacco use	71	28.5%
Arrhythmia	73	29.3%
Cerebrovascular disease/stroke/transient ischemic attack	65	26.1%
Chronic kidney disease	86	34.5%
Chronic obstructive pulmonary disease	46	18.5%
Congenital heart disease	46	18.5%
Heart failure	53	21.3%
Hyperlipidemia	228	91.6%
Hypertensive disease	231	92.8%
Thyroid disease	65	26.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	92	36.9%
Left ventricular hypertrophy	23	9.2%
Peripheral artery disease	23	9.2%
Valvular/mitral valve disease	19	7.6%
Diseases of veins and lymphatics, and other diseases of circulatory system	47	18.9%
Obstructive sleep apnea	66	26.5%
Hypertrophic cardiomyopathy	25	10.0%
Other cardiac disease	130	52.2%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	*****	*****
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	34	13.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	150	60.2%
Biguanides (metformin, phenformin, etc.)	197	79.1%
SGLT2 inhibitors	62	24.9%
Sulfonylurea	114	45.8%
Thiazolidinedione	37	14.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	121	48.6%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	121	48.6%
Angiotensin-converting-enzyme (ACE) inhibitor	124	49.8%
Angiotensin ii receptor blockers (ARBs)	98	39.4%
Dihydropyridines	71	28.5%

Table 1ck. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Diuretics	95	38.2%
Other antihypertensives	25	10.0%
Antihypertensives (any of the above antihypertensives)	227	91.2%
Oral anticoagulants	23	9.2%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	20	8.0%
Other cardiac medications (any of the other cardiac medications)	45	18.1%
Lipid lowering therapy	224	90.0%
Baseline known risk of prolonged QT and torsades de pointes	105	42.2%
Baseline possible risk of prolonged QT and torsades de pointes	214	85.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	34	13.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.7	15.4
Mean number of emergency room encounters	0.9	1.7
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	5.0	8.6
Mean number of filled prescriptions	43.9	25.7
Mean number of generics dispensed	12.9	5.3
Mean number of unique drug classes dispensed	11.3	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1c. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	53.0	0.0
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.5	0.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	0.5	0.0
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Alcohol use or abuse	0	0.0%

Table 1c. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	0	0.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	0	0.0%
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	0	0.0%
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	0	0.0%
Angiotensin ii receptor blockers (ARBs)	*****	*****

Table 1c. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Dihydropyridines	0	0.0%
Diuretics	0	0.0%
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	0	0.0%
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.5	0.0
Mean number of emergency room encounters	0.5	0.0
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	19.5	0.0
Mean number of generics dispensed	8.0	0.0
Mean number of unique drug classes dispensed	7.5	0.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

NaN: Not a number

N/A: Not applicable

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Bydureon, Hospitalized Tachyarrhythmia</i>	1,328	1,328	*****	*****	*****	*****	385.12 (183.60, 807.85)	2,076	2,076	519.6
<i>Mounjaro, Hospitalized Tachyarrhythmia</i>	18,996	18,996	104	0.55 (0.44, 0.65)	2,211.1	807,588	470.36 (388.12, 570.04)	31,327	31,744	5,259.4
<i>Ozempic, Hospitalized Tachyarrhythmia</i>	117,721	117,721	811	0.69 (0.64, 0.74)	16,557.3	6,047,565	489.81 (457.24, 524.71)	175,147	175,667	42,414.4
<i>Rybelsus, Hospitalized Tachyarrhythmia</i>	34,260	34,260	186	0.54 (0.47, 0.62)	4,762.3	1,739,443	390.56 (338.28, 450.93)	50,164	51,248	12,889.0
<i>Saxenda, Hospitalized Tachyarrhythmia</i>	386	386	*****	*****	*****	*****	195.00 (27.47, 1,384.35)	587	587	195.2
<i>Trulicity, Hospitalized Tachyarrhythmia</i>	67,310	67,310	519	0.77 (0.70, 0.84)	10,086.5	3,684,093	514.55 (472.13, 560.78)	117,874	118,624	25,948.7
<i>Victoza, Hospitalized Tachyarrhythmia</i>	5,398	5,398	49	0.91 (0.65, 1.16)	763.4	278,815	641.90 (485.14, 849.32)	7,766	7,767	2,085.6
<i>Wegovy, Hospitalized Tachyarrhythmia</i>	842	842	*****	*****	*****	*****	132.90 (18.72, 943.47)	1,313	1,339	138.6
<i>Xultophy, Hospitalized Tachyarrhythmia</i>	366	366	*****	*****	*****	*****	343.68 (85.95, 1,374.23)	486	486	132.1
<i>Mounjaro, Atrial Fibrillation and Flutter</i>	18,996	18,996	66	0.35 (0.26, 0.43)	2,211.1	807,588	298.50 (234.51, 379.95)	31,327	31,744	5,259.4
<i>Bydureon, Atrial Fibrillation and Flutter</i>	1,328	1,328	*****	*****	*****	*****	275.09 (114.50, 660.92)	2,076	2,076	519.6
<i>Ozempic, Atrial Fibrillation and Flutter</i>	117,721	117,721	519	0.44 (0.40, 0.48)	16,557.3	6,047,565	313.46 (287.62, 341.62)	175,147	175,667	42,414.4
<i>Rybelsus, Atrial Fibrillation and Flutter</i>	34,260	34,260	129	0.38 (0.31, 0.44)	4,762.3	1,739,443	270.88 (227.94, 321.90)	50,164	51,248	12,889.0
<i>Wegovy, Atrial Fibrillation and Flutter</i>	842	842	*****	*****	*****	*****	132.90 (18.72, 943.47)	1,313	1,339	138.6

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Saxenda, Atrial Fibrillation and Flutter</i>	386	386	0	0.00 (0.00, 0.00)	51.3	18,731	0.00 (0.00, 0.00)	587	587	195.2
<i>Victoza, Atrial Fibrillation and Flutter</i>	5,398	5,398	29	0.54 (0.34, 0.73)	763.4	278,815	379.90 (264.00, 546.69)	7,766	7,767	2,085.6
<i>Trulicity, Atrial Fibrillation and Flutter</i>	67,310	67,310	363	0.54 (0.48, 0.59)	10,086.5	3,684,093	359.89 (324.70, 398.88)	117,874	118,624	25,948.7
<i>Xultophy, Atrial Fibrillation and Flutter</i>	366	366	*****	*****	*****	*****	171.84 (24.21, 1,219.96)	486	486	132.1
<i>Mounjaro, Sinus Tachycardia</i>	18,996	18,996	30	0.16 (0.10, 0.21)	2,211.1	807,588	135.68 (94.87, 194.06)	31,327	31,744	5,259.4
<i>Bydureon, Sinus Tachycardia</i>	1,328	1,328	*****	*****	*****	*****	55.02 (7.75, 390.59)	2,076	2,076	519.6
<i>Ozempic, Sinus Tachycardia</i>	117,721	117,721	182	0.15 (0.13, 0.18)	16,557.3	6,047,565	109.92 (95.06, 127.11)	175,147	175,667	42,414.4
<i>Rybelsus, Sinus Tachycardia</i>	34,260	34,260	47	0.14 (0.10, 0.18)	4,762.3	1,739,443	98.69 (74.15, 131.35)	50,164	51,248	12,889.0
<i>Wegovy, Sinus Tachycardia</i>	842	842	0	0.00 (0.00, 0.00)	75.2	27,484	0.00 (0.00, 0.00)	1,313	1,339	138.6
<i>Saxenda, Sinus Tachycardia</i>	386	386	*****	*****	*****	*****	195.00 (27.47, 1,384.35)	587	587	195.2
<i>Victoza, Sinus Tachycardia</i>	5,398	5,398	15	0.28 (0.14, 0.42)	763.4	278,815	196.50 (118.46, 325.95)	7,766	7,767	2,085.6
<i>Trulicity, Sinus Tachycardia</i>	67,310	67,310	109	0.16 (0.13, 0.19)	10,086.5	3,684,093	108.07 (89.57, 130.38)	117,874	118,624	25,948.7
<i>Xultophy, Sinus Tachycardia</i>	366	366	0	0.00 (0.00, 0.00)	58.2	21,255	0.00 (0.00, 0.00)	486	486	132.1
<i>Mounjaro, Supraventricular Tachycardia</i>	18,996	18,996	*****	*****	*****	*****	36.18 (18.09, 72.35)	31,327	31,744	5,259.4

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Bydureon, Supraventricular Tachycardia</i>	1,328	1,328	0	0.00 (0.00, 0.00)	181.8	66,388	0.00 (0.00, 0.00)	2,076	2,076	519.6
<i>Ozempic, Supraventricular Tachycardia</i>	117,721	117,721	73	0.06 (0.05, 0.08)	16,557.3	6,047,565	44.09 (35.05, 55.46)	175,147	175,667	42,414.4
<i>Rybelsus, Supraventricular Tachycardia</i>	34,260	34,260	16	0.05 (0.02, 0.07)	4,762.3	1,739,443	33.60 (20.58, 54.84)	50,164	51,248	12,889.0
<i>Wegovy, Supraventricular Tachycardia</i>	842	842	0	0.00 (0.00, 0.00)	75.2	27,484	0.00 (0.00, 0.00)	1,313	1,339	138.6
<i>Saxenda, Supraventricular Tachycardia</i>	386	386	*****	*****	*****	*****	195.00 (27.47, 1,384.35)	587	587	195.2
<i>Victoza, Supraventricular Tachycardia</i>	5,398	5,398	*****	*****	*****	*****	78.60 (35.31, 174.96)	7,766	7,767	2,085.6
<i>Trulicity, Supraventricular Tachycardia</i>	67,310	67,310	44	0.07 (0.05, 0.08)	10,086.5	3,684,093	43.62 (32.46, 58.62)	117,874	118,624	25,948.7
<i>Xultophy, Supraventricular Tachycardia</i>	366	366	0	0.00 (0.00, 0.00)	58.2	21,255	0.00 (0.00, 0.00)	486	486	132.1
<i>Mounjaro, Other Tachycardia</i>	18,996	18,996	*****	*****	*****	*****	22.61 (9.41, 54.33)	31,327	31,744	5,259.4
<i>Bydureon, Other Tachycardia</i>	1,328	1,328	*****	*****	*****	*****	110.03 (27.52, 439.98)	2,076	2,076	519.6
<i>Ozempic, Other Tachycardia</i>	117,721	117,721	55	0.05 (0.03, 0.06)	16,557.3	6,047,565	33.22 (25.50, 43.27)	175,147	175,667	42,414.4
<i>Rybelsus, Other Tachycardia</i>	34,260	34,260	*****	*****	*****	*****	12.60 (5.66, 28.04)	50,164	51,248	12,889.0
<i>Wegovy, Other Tachycardia</i>	842	842	0	0.00 (0.00, 0.00)	75.2	27,484	0.00 (0.00, 0.00)	1,313	1,339	138.6

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Saxenda, Other Tachycardia</i>	386	386	0	0.00 (0.00, 0.00)	51.3	18,731	0.00 (0.00, 0.00)	587	587	195.2
<i>Victoza, Other Trulicity, Other Tachycardia</i>	5,398	5,398	*****	*****	*****	*****	52.40 (19.67, 139.62)	7,766	7,767	2,085.6
<i>Xultophy, Other Tachycardia</i>	67,310	67,310	21	0.03 (0.02, 0.04)	10,086.5	3,684,093	20.82 (13.57, 31.93)	117,874	118,624	25,948.7
<i>Mounjaro, Cardiac Arrest</i>	366	366	*****	*****	*****	*****	171.84 (24.21, 1,219.96)	486	486	132.1
<i>Bydureon, Cardiac Arrest</i>	18,996	18,996	0	0.00 (0.00, 0.00)	2,211.1	807,588	0.00 (0.00, 0.00)	31,327	31,744	5,259.4
<i>Ozempic, Cardiac Arrest</i>	1,328	1,328	0	0.00 (0.00, 0.00)	181.8	66,388	0.00 (0.00, 0.00)	2,076	2,076	519.6
<i>Rybelsus, Cardiac Arrest</i>	117,721	117,721	18	0.02 (0.01, 0.02)	16,557.3	6,047,565	10.87 (6.85, 17.26)	175,147	175,667	42,414.4
<i>Wegovy, Cardiac Arrest</i>	34,260	34,260	*****	*****	*****	*****	4.20 (1.05, 16.79)	50,164	51,248	12,889.0
<i>Saxenda, Cardiac Arrest</i>	842	842	0	0.00 (0.00, 0.00)	75.2	27,484	0.00 (0.00, 0.00)	1,313	1,339	138.6
<i>Victoza, Cardiac Arrest</i>	386	386	0	0.00 (0.00, 0.00)	51.3	18,731	0.00 (0.00, 0.00)	587	587	195.2
<i>Trulicity, Cardiac Arrest</i>	5,398	5,398	*****	*****	*****	*****	39.30 (12.67, 121.86)	7,766	7,767	2,085.6
<i>Xultophy, Cardiac Arrest</i>	67,310	67,310	12	0.02 (0.01, 0.03)	10,086.5	3,684,093	11.90 (6.76, 20.95)	117,874	118,624	25,948.7
<i>Mounjaro, Ventricular Tachycardia</i>	366	366	0	0.00 (0.00, 0.00)	58.2	21,255	0.00 (0.00, 0.00)	486	486	132.1
<i>Bydureon, Ventricular Tachycardia</i>	18,996	18,996	0	0.00 (0.00, 0.00)	2,211.1	807,588	0.00 (0.00, 0.00)	31,327	31,744	5,259.4
<i>Ozempic, Ventricular Tachycardia</i>	1,328	1,328	0	0.00 (0.00, 0.00)	181.8	66,388	0.00 (0.00, 0.00)	2,076	2,076	519.6
<i>Rybelsus, Ventricular Tachycardia</i>	117,721	117,721	*****	*****	*****	*****	4.23 (2.02, 8.87)	175,147	175,667	42,414.4
<i>Wegovy, Ventricular Tachycardia</i>	34,260	34,260	0	0.00 (0.00, 0.00)	4,762.3	1,739,443	0.00 (0.00, 0.00)	50,164	51,248	12,889.0
<i>Saxenda, Ventricular Tachycardia</i>	842	842	0	0.00 (0.00, 0.00)	75.2	27,484	0.00 (0.00, 0.00)	1,313	1,339	138.6
<i>Victoza, Ventricular Tachycardia</i>	386	386	0	0.00 (0.00, 0.00)	51.3	18,731	0.00 (0.00, 0.00)	587	587	195.2

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Victoza, Ventricular Tachycardia</i>	5,398	5,398	0	0.00 (0.00, 0.00)	763.4	278,815	0.00 (0.00, 0.00)	7,766	7,767	2,085.6
<i>Trulicity, Ventricular Tachycardia</i>	67,310	67,310	*****	*****	*****	*****	3.97 (1.49, 10.57)	117,874	118,624	25,948.7
<i>Xultophy, Ventricular Tachycardia</i>	366	366	0	0.00 (0.00, 0.00)	58.2	21,255	0.00 (0.00, 0.00)	486	486	132.1
<i>Mounjaro, Ventricular Fibrillation and Flutter</i>	18,996	18,996	*****	*****	*****	*****	4.52 (0.64, 32.11)	31,327	31,744	5,259.4
<i>Bydureon, Ventricular Fibrillation and Flutter</i>	1,328	1,328	0	0.00 (0.00, 0.00)	181.8	66,388	0.00 (0.00, 0.00)	2,076	2,076	519.6
<i>Ozempic, Ventricular Fibrillation and Flutter</i>	117,721	117,721	*****	*****	*****	*****	2.42 (0.91, 6.44)	175,147	175,667	42,414.4
<i>Rybelsus, Ventricular Fibrillation and Flutter</i>	34,260	34,260	0	0.00 (0.00, 0.00)	4,762.3	1,739,443	0.00 (0.00, 0.00)	50,164	51,248	12,889.0
<i>Wegovy, Ventricular Fibrillation and Flutter</i>	842	842	0	0.00 (0.00, 0.00)	75.2	27,484	0.00 (0.00, 0.00)	1,313	1,339	138.6
<i>Saxenda, Ventricular Fibrillation and Flutter</i>	386	386	0	0.00 (0.00, 0.00)	51.3	18,731	0.00 (0.00, 0.00)	587	587	195.2
<i>Victoza, Ventricular Fibrillation and Flutter</i>	5,398	5,398	0	0.00 (0.00, 0.00)	763.4	278,815	0.00 (0.00, 0.00)	7,766	7,767	2,085.6
<i>Trulicity, Ventricular Fibrillation and Flutter</i>	67,310	67,310	*****	*****	*****	*****	4.96 (2.06, 11.91)	117,874	118,624	25,948.7
<i>Xultophy, Ventricular Fibrillation and Flutter</i>	366	366	0	0.00 (0.00, 0.00)	58.2	21,255	0.00 (0.00, 0.00)	486	486	132.1

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
Female	680	680	*****	*****	*****	*****	332.18 (107.13, 1,029.96)	1,076	1,076	267.9
Male	648	648	*****	*****	*****	*****	437.41 (164.17, 1,165.47)	1,000	1,000	251.7
Mounjaro, Hospitalized Tachyarrhythmia										
Female	10,895	10,895	*****	*****	*****	*****	380.04 (286.39, 504.30)	18,061	18,310	3,016.1
Male	8,101	8,101	*****	*****	*****	*****	590.71 (454.59, 767.57)	13,266	13,434	2,243.3
Ozempic, Hospitalized Tachyarrhythmia										
Female	65,903	65,903	*****	*****	*****	*****	473.38 (431.06, 519.86)	98,622	98,888	23,881.5
Male	51,818	51,818	*****	*****	*****	*****	510.63 (461.35, 565.17)	76,525	76,779	18,532.9
Rybelsus, Hospitalized Tachyarrhythmia										
Female	17,559	17,559	*****	*****	*****	*****	357.92 (289.73, 442.15)	25,583	26,078	6,636.7
Male	16,701	16,701	*****	*****	*****	*****	423.81 (348.38, 515.58)	24,581	25,170	6,252.3
Saxenda, Hospitalized Tachyarrhythmia										
Female	294	294	*****	*****	*****	*****	260.13 (36.64, 1,846.76)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Trulicity, Hospitalized Tachyarrhythmia										
Female	34,980	34,980	*****	*****	*****	*****	457.68 (403.08, 519.68)	61,294	61,669	13,523.9
Male	32,330	32,330	*****	*****	*****	*****	575.07 (511.61, 646.40)	56,580	56,955	12,424.8
Victoza, Hospitalized Tachyarrhythmia										
Female	3,142	3,142	*****	*****	*****	*****	568.65 (384.24, 841.57)	4,513	4,514	1,223.2
Male	2,256	2,256	*****	*****	*****	*****	741.39 (496.92, 1,106.11)	3,253	3,253	862.4
Wegovy, Hospitalized Tachyarrhythmia										
Female	579	579	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	909	95.7
Male	263	263	*****	*****	*****	*****	405.70 (57.15, 2,880.18)	419	430	42.9
Xultophy, Hospitalized Tachyarrhythmia										
Female	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	235	63.7
Male	193	193	*****	*****	*****	*****	688.44 (172.17, 2,752.74)	251	251	68.5
Mounjaro, Atrial Fibrillation and Flutter										
Female	10,895	10,895	*****	*****	*****	*****	205.85 (140.16, 302.34)	18,061	18,310	3,016.1
Male	8,101	8,101	*****	*****	*****	*****	421.93 (309.49, 575.22)	13,266	13,434	2,243.3

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Atrial Fibrillation and Flutter										
Female	680	680	*****	*****	*****	*****	332.18 (107.13, 1,029.96)	1,076	1,076	267.9
Male	648	648	*****	*****	*****	*****	218.71 (54.70, 874.50)	1,000	1,000	251.7
Ozempic, Atrial Fibrillation and Flutter										
Female	65,903	65,903	*****	*****	*****	*****	282.08 (249.86, 318.47)	98,622	98,888	23,881.5
Male	51,818	51,818	*****	*****	*****	*****	353.20 (312.62, 399.03)	76,525	76,779	18,532.9
Rybelsus, Atrial Fibrillation and Flutter										
Female	17,559	17,559	*****	*****	*****	*****	228.90 (175.74, 298.14)	25,583	26,078	6,636.7
Male	16,701	16,701	*****	*****	*****	*****	313.62 (249.72, 393.87)	24,581	25,170	6,252.3
Wegovy, Atrial Fibrillation and Flutter										
Female	579	579	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	909	95.7
Male	263	263	*****	*****	*****	*****	405.70 (57.15, 2,880.18)	419	430	42.9
Saxenda, Atrial Fibrillation and Flutter										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Atrial Fibrillation and Flutter										
Female	3,142	3,142	*****	*****	*****	*****	250.21 (138.56, 451.81)	4,513	4,514	1,223.2
Male	2,256	2,256	*****	*****	*****	*****	556.04 (350.33, 882.55)	3,253	3,253	862.4
Trulicity, Atrial Fibrillation and Flutter										
Female	34,980	34,980	*****	*****	*****	*****	301.92 (258.20, 353.04)	61,294	61,669	13,523.9
Male	32,330	32,330	*****	*****	*****	*****	421.58 (367.77, 483.27)	56,580	56,955	12,424.8
Xultophy, Atrial Fibrillation and Flutter										
Female	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	235	63.7
Male	193	193	*****	*****	*****	*****	344.22 (48.49, 2,443.72)	251	251	68.5
Mounjaro, Sinus Tachycardia										
Female	10,895	10,895	*****	*****	*****	*****	126.68 (77.61, 206.78)	18,061	18,310	3,016.1
Male	8,101	8,101	*****	*****	*****	*****	147.68 (87.46, 249.35)	13,266	13,434	2,243.3
Bydureon, Sinus Tachycardia										
Female	680	680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,076	1,076	267.9
Male	648	648	*****	*****	*****	*****	109.35 (15.40, 776.33)	1,000	1,000	251.7

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Ozempic, Sinus Tachycardia										
Female	65,903	65,903	*****	*****	*****	*****	127.53 (106.48, 152.75)	98,622	98,888	23,881.5
Male	51,818	51,818	*****	*****	*****	*****	87.61 (68.58, 111.94)	76,525	76,779	18,532.9
Rybelsus, Sinus Tachycardia										
Female	17,559	17,559	*****	*****	*****	*****	99.88 (66.95, 149.02)	25,583	26,078	6,636.7
Male	16,701	16,701	*****	*****	*****	*****	97.48 (64.78, 146.69)	24,581	25,170	6,252.3
Wegovy, Sinus Tachycardia										
Female	579	579	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	909	95.7
Male	263	263	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	419	430	42.9
Saxenda, Sinus Tachycardia										
Female	294	294	*****	*****	*****	*****	260.13 (36.64, 1,846.76)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Sinus Tachycardia										
Female	3,142	3,142	*****	*****	*****	*****	204.71 (106.51, 393.45)	4,513	4,514	1,223.2
Male	2,256	2,256	*****	*****	*****	*****	185.35 (83.27, 412.56)	3,253	3,253	862.4
Trulicity, Sinus Tachycardia										
Female	34,980	34,980	*****	*****	*****	*****	107.69 (82.88, 139.93)	61,294	61,669	13,523.9
Male	32,330	32,330	*****	*****	*****	*****	108.46 (82.86, 141.98)	56,580	56,955	12,424.8
Xultophy, Sinus Tachycardia										
Female	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	235	63.7
Male	193	193	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	251	251	68.5
Mounjaro, Supraventricular Tachycardia										
Female	10,895	10,895	*****	*****	*****	*****	39.59 (16.48, 95.11)	18,061	18,310	3,016.1
Male	8,101	8,101	*****	*****	*****	*****	31.64 (10.21, 98.12)	13,266	13,434	2,243.3
Bydureon, Supraventricular Tachycardia										
Female	680	680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,076	1,076	267.9
Male	648	648	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,000	1,000	251.7
Ozempic, Supraventricular Tachycardia										
Female	65,903	65,903	*****	*****	*****	*****	44.31 (32.63, 60.18)	98,622	98,888	23,881.5
Male	51,818	51,818	*****	*****	*****	*****	43.81 (30.98, 61.95)	76,525	76,779	18,532.9

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Rybelsus, Supraventricular Tachycardia										
Female	17,559	17,559	*****	*****	*****	*****	33.29 (16.65, 66.58)	25,583	26,078	6,636.7
Male	16,701	16,701	*****	*****	*****	*****	33.90 (16.96, 67.80)	24,581	25,170	6,252.3
Wegovy, Supraventricular Tachycardia										
Female	579	579	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	909	95.7
Male	263	263	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	419	430	42.9
Saxenda, Supraventricular Tachycardia										
Female	294	294	*****	*****	*****	*****	260.13 (36.64, 1,846.76)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Supraventricular Tachycardia										
Female	3,142	3,142	*****	*****	*****	*****	22.75 (3.20, 161.48)	4,513	4,514	1,223.2
Male	2,256	2,256	*****	*****	*****	*****	154.46 (64.29, 371.09)	3,253	3,253	862.4
Trulicity, Supraventricular Tachycardia										
Female	34,980	34,980	*****	*****	*****	*****	38.46 (24.81, 59.61)	61,294	61,669	13,523.9
Male	32,330	32,330	*****	*****	*****	*****	49.12 (32.92, 73.28)	56,580	56,955	12,424.8
Xultophy, Supraventricular Tachycardia										
Female	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	235	63.7
Male	193	193	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	251	251	68.5
Mounjaro, Other Tachycardia										
Female	10,895	10,895	*****	*****	*****	*****	15.83 (3.96, 63.32)	18,061	18,310	3,016.1
Male	8,101	8,101	*****	*****	*****	*****	31.64 (10.21, 98.12)	13,266	13,434	2,243.3
Bydureon, Other Tachycardia										
Female	680	680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,076	1,076	267.9
Male	648	648	*****	*****	*****	*****	218.71 (54.70, 874.50)	1,000	1,000	251.7
Ozempic, Other Tachycardia										
Female	65,903	65,903	*****	*****	*****	*****	36.75 (26.26, 51.43)	98,622	98,888	23,881.5
Male	51,818	51,818	*****	*****	*****	*****	28.75 (18.74, 44.09)	76,525	76,779	18,532.9
Rybelsus, Other Tachycardia										
Female	17,559	17,559	*****	*****	*****	*****	8.32 (2.08, 33.28)	25,583	26,078	6,636.7
Male	16,701	16,701	*****	*****	*****	*****	16.95 (6.36, 45.17)	24,581	25,170	6,252.3

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Wegovy, Other Tachycardia										
Female	579	579	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	909	95.7
Male	263	263	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	419	430	42.9
Saxenda, Other Tachycardia										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Other Tachycardia										
Female	3,142	3,142	*****	*****	*****	*****	45.49 (11.38, 181.90)	4,513	4,514	1,223.2
Male	2,256	2,256	*****	*****	*****	*****	61.78 (15.45, 247.04)	3,253	3,253	862.4
Trulicity, Other Tachycardia										
Female	34,980	34,980	*****	*****	*****	*****	23.08 (13.11, 40.63)	61,294	61,669	13,523.9
Male	32,330	32,330	*****	*****	*****	*****	18.42 (9.58, 35.40)	56,580	56,955	12,424.8
Xultophy, Other Tachycardia										
Female	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	235	63.7
Male	193	193	*****	*****	*****	*****	344.22 (48.49, 2,443.72)	251	251	68.5
Mounjaro, Cardiac Arrest										
Female	10,895	10,895	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,061	18,310	3,016.1
Male	8,101	8,101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,266	13,434	2,243.3
Bydureon, Cardiac Arrest										
Female	680	680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,076	1,076	267.9
Male	648	648	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,000	1,000	251.7
Ozempic, Cardiac Arrest										
Female	65,903	65,903	10	0.02 (0.01, 0.02)	*****	*****	10.81 (5.82, 20.09)	98,622	98,888	23,881.5
Male	51,818	51,818	*****	*****	*****	*****	10.95 (5.48, 21.90)	76,525	76,779	18,532.9
Rybelsus, Cardiac Arrest										
Female	17,559	17,559	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,583	26,078	6,636.7
Male	16,701	16,701	*****	*****	*****	*****	8.48 (2.12, 33.89)	24,581	25,170	6,252.3
Wegovy, Cardiac Arrest										
Female	579	579	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	909	95.7
Male	263	263	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	419	430	42.9

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Cardiac Arrest										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Cardiac Arrest										
Female	3,142	3,142	*****	*****	*****	*****	68.24 (22.01, 211.58)	4,513	4,514	1,223.2
Male	2,256	2,256	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,253	3,253	862.4
Trulicity, Cardiac Arrest										
Female	34,980	34,980	*****	*****	*****	*****	9.62 (4.00, 23.10)	61,294	61,669	13,523.9
Male	32,330	32,330	*****	*****	*****	*****	14.33 (6.83, 30.05)	56,580	56,955	12,424.8
Xultophy, Cardiac Arrest										
Female	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	235	63.7
Male	193	193	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	251	251	68.5
Mounjaro, Ventricular Tachycardia										
Female	10,895	10,895	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,061	18,310	3,016.1
Male	8,101	8,101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,266	13,434	2,243.3
Bydureon, Ventricular Tachycardia										
Female	680	680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,076	1,076	267.9
Male	648	648	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,000	1,000	251.7
Ozempic, Ventricular Tachycardia										
Female	65,903	65,903	*****	*****	*****	*****	4.32 (1.62, 11.52)	98,622	98,888	23,881.5
Male	51,818	51,818	*****	*****	*****	*****	4.11 (1.32, 12.73)	76,525	76,779	18,532.9
Rybelsus, Ventricular Tachycardia										
Female	17,559	17,559	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,583	26,078	6,636.7
Male	16,701	16,701	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24,581	25,170	6,252.3
Wegovy, Ventricular Tachycardia										
Female	579	579	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	909	95.7
Male	263	263	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	419	430	42.9
Saxenda, Ventricular Tachycardia										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Victoza, Ventricular Tachycardia										
Female	3,142	3,142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,513	4,514	1,223.2
Male	2,256	2,256	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,253	3,253	862.4
Trulicity, Ventricular Tachycardia										
Female	34,980	34,980	*****	*****	*****	*****	3.85 (0.96, 15.38)	61,294	61,669	13,523.9
Male	32,330	32,330	*****	*****	*****	*****	4.09 (1.02, 16.37)	56,580	56,955	12,424.8
Xultophy, Ventricular Tachycardia										
Female	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	235	63.7
Male	193	193	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	251	251	68.5
Mounjaro, Ventricular Fibrillation and Flutter										
Female	10,895	10,895	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,061	18,310	3,016.1
Male	8,101	8,101	*****	*****	*****	*****	10.55 (1.49, 74.89)	13,266	13,434	2,243.3
Bydureon, Ventricular Fibrillation and Flutter										
Female	680	680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,076	1,076	267.9
Male	648	648	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,000	1,000	251.7
Ozempic, Ventricular Fibrillation and Flutter										
Female	65,903	65,903	*****	*****	*****	*****	2.16 (0.54, 8.64)	98,622	98,888	23,881.5
Male	51,818	51,818	*****	*****	*****	*****	2.74 (0.68, 10.95)	76,525	76,779	18,532.9
Rybelsus, Ventricular Fibrillation and Flutter										
Female	17,559	17,559	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,583	26,078	6,636.7
Male	16,701	16,701	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24,581	25,170	6,252.3
Wegovy, Ventricular Fibrillation and Flutter										
Female	579	579	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	909	95.7
Male	263	263	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	419	430	42.9
Saxenda, Ventricular Fibrillation and Flutter										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Ventricular Fibrillation and Flutter										
Female	3,142	3,142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,513	4,514	1,223.2
Male	2,256	2,256	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,253	3,253	862.4

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

		Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Trulicity, Ventricular Fibrillation and Flutter									
Female	34,980	34,980	*****	*****	*****	3.85 (0.96, 15.38)	61,294	61,669	13,523.9
Male	32,330	32,330	*****	*****	*****	6.14 (1.98, 19.04)	56,580	56,955	12,424.8
Xultophy, Ventricular Fibrillation and Flutter									
Female	173	173	0	0.00 (0.00, 0.00)	*****	0.00 (0.00, 0.00)	235	235	63.7
Male	193	193	0	0.00 (0.00, 0.00)	*****	0.00 (0.00, 0.00)	251	251	68.5

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	109	109	37.1
41-64 years	500	500	*****	*****	*****	*****	468.21 (151.00, 1,451.75)	769	769	198.6
65-74 years	538	538	*****	*****	*****	*****	119.31 (16.81, 847.01)	894	894	211.1
75-84 years	196	196	*****	*****	*****	*****	798.45 (199.68, 3,192.63)	283	283	68.0
≥ 85 years	15	15	*****	*****	*****	*****	8,865.29 (1,248.75, 62,937.60)	21	21	4.7
Mounjaro, Hospitalized Tachyarrhythmia										
0-40 years	1,043	1,043	*****	*****	*****	*****	169.58 (42.41, 678.09)	1,758	1,780	285.5
41-64 years	9,324	9,324	*****	*****	*****	*****	350.79 (256.30, 480.12)	15,924	16,111	2,693.5
65-74 years	6,649	6,649	*****	*****	*****	*****	600.43 (449.74, 801.62)	10,639	10,803	1,776.1
75-84 years	1,885	1,885	*****	*****	*****	*****	728.21 (439.01, 1,207.92)	2,870	2,912	483.6
≥ 85 years	95	95	*****	*****	*****	*****	2,163.16 (540.99, 8,649.49)	136	138	20.7
Ozempic, Hospitalized Tachyarrhythmia										
0-40 years	5,541	5,541	*****	*****	*****	*****	255.11 (160.73, 404.91)	8,171	8,198	1,977.5
41-64 years	51,127	51,127	*****	*****	*****	*****	337.21 (297.06, 382.79)	77,645	77,898	18,933.0
65-74 years	44,620	44,620	*****	*****	*****	*****	528.51 (475.36, 587.60)	65,994	66,175	15,751.3
75-84 years	15,174	15,174	*****	*****	*****	*****	883.84 (766.11, 1,019.66)	21,564	21,621	5,310.9
≥ 85 years	1,259	1,259	*****	*****	*****	*****	1,445.15 (968.63, 2,156.09)	1,773	1,775	441.6
Rybelsus, Hospitalized Tachyarrhythmia										
0-40 years	1,136	1,136	*****	*****	*****	*****	348.27 (144.96, 836.74)	1,636	1,669	417.3
41-64 years	12,352	12,352	*****	*****	*****	*****	234.19 (171.78, 319.26)	18,198	18,642	4,923.5
65-74 years	13,749	13,749	*****	*****	*****	*****	334.19 (262.07, 426.17)	20,032	20,462	5,061.6
75-84 years	6,139	6,139	*****	*****	*****	*****	744.22 (581.38, 952.68)	8,974	9,138	2,180.7
≥ 85 years	884	884	*****	*****	*****	*****	1,090.40 (633.14, 1,877.89)	1,324	1,337	306.0
Saxenda, Hospitalized Tachyarrhythmia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	*****	*****	*****	*****	254.05 (35.79, 1,803.60)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Trulicity, Hospitalized Tachyarrhythmia										
0-40 years	2,438	2,438	*****	*****	*****	*****	293.86 (158.11, 546.17)	4,302	4,332	943.5
41-64 years	23,872	23,872	*****	*****	*****	*****	329.52 (275.53, 394.08)	43,318	43,638	9,651.0
65-74 years	27,508	27,508	*****	*****	*****	*****	512.49 (448.08, 586.15)	47,472	47,751	10,380.9
75-84 years	11,909	11,909	*****	*****	*****	*****	862.06 (734.58, 1,011.67)	20,038	20,149	4,424.0
≥ 85 years	1,583	1,583	*****	*****	*****	*****	1,248.13 (849.81, 1,833.14)	2,744	2,754	549.3
Victoza, Hospitalized Tachyarrhythmia										
0-40 years	311	311	*****	*****	*****	*****	240.98 (33.94, 1,710.78)	474	474	125.9
41-64 years	2,168	2,168	*****	*****	*****	*****	531.76 (325.77, 867.99)	3,204	3,205	876.4
65-74 years	2,057	2,057	*****	*****	*****	*****	432.00 (250.84, 743.99)	2,907	2,907	773.3
75-84 years	761	761	*****	*****	*****	*****	1,661.28 (1,046.67, 2,636.79)	1,045	1,045	272.6
≥ 85 years	101	101	*****	*****	*****	*****	855.59 (120.52, 6,074.09)	136	136	37.3
Wegovy, Hospitalized Tachyarrhythmia										
0-40 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	200	208	18.6
41-64 years	631	631	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	983	996	105.7
65-74 years	64	64	*****	*****	*****	*****	1,554.26 (218.93, 11,034.17)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Xultophy, Hospitalized Tachyarrhythmia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	70.7
75-84 years	87	87	*****	*****	*****	*****	1,466.57 (366.78, 5,864.15)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Atrial Fibrillation and Flutter										
0-40 years	1,043	1,043	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,758	1,780	285.5

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	9,324	9,324	*****	*****	*****	*****	206.88 (137.47, 311.32)	15,924	16,111	2,693.5
65-74 years	6,649	6,649	*****	*****	*****	*****	378.53 (263.05, 544.72)	10,639	10,803	1,776.1
75-84 years	1,885	1,885	*****	*****	*****	*****	631.11 (366.46, 1,086.91)	2,870	2,912	483.6
≥ 85 years	95	95	*****	*****	*****	*****	1,081.58 (152.35, 7,678.50)	136	138	20.7
Bydureon, Atrial Fibrillation and Flutter										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	109	109	37.1
41-64 years	500	500	*****	*****	*****	*****	468.21 (151.00, 1,451.75)	769	769	198.6
65-74 years	538	538	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	894	211.1
75-84 years	196	196	*****	*****	*****	*****	399.22 (56.23, 2,834.22)	283	283	68.0
≥ 85 years	15	15	*****	*****	*****	*****	8,865.29 (1,248.75, 62,937.60)	21	21	4.7
Ozempic, Atrial Fibrillation and Flutter										
0-40 years	5,541	5,541	*****	*****	*****	*****	28.35 (7.09, 113.34)	8,171	8,198	1,977.5
41-64 years	51,127	51,127	*****	*****	*****	*****	166.49 (139.00, 199.41)	77,645	77,898	18,933.0
65-74 years	44,620	44,620	*****	*****	*****	*****	355.43 (312.34, 404.47)	65,994	66,175	15,751.3
75-84 years	15,174	15,174	*****	*****	*****	*****	700.49 (596.58, 822.50)	21,564	21,621	5,310.9
≥ 85 years	1,259	1,259	*****	*****	*****	*****	1,204.29 (776.95, 1,866.68)	1,773	1,775	441.6
Rybelsus, Atrial Fibrillation and Flutter										
0-40 years	1,136	1,136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,636	1,669	417.3
41-64 years	12,352	12,352	*****	*****	*****	*****	128.80 (84.81, 195.62)	18,198	18,642	4,923.5
65-74 years	13,749	13,749	*****	*****	*****	*****	246.79 (185.98, 327.48)	20,032	20,462	5,061.6
75-84 years	6,139	6,139	*****	*****	*****	*****	567.03 (427.31, 752.43)	8,974	9,138	2,180.7
≥ 85 years	884	884	*****	*****	*****	*****	922.65 (510.96, 1,666.04)	1,324	1,337	306.0
Wegovy, Atrial Fibrillation and Flutter										
0-40 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	200	208	18.6
41-64 years	631	631	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	983	996	105.7
65-74 years	64	64	*****	*****	*****	*****	1,554.26 (218.93, 11,034.17)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Atrial Fibrillation and Flutter										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Atrial Fibrillation and Flutter										
0-40 years	311	311	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	474	474	125.9
41-64 years	2,168	2,168	*****	*****	*****	*****	199.41 (89.59, 443.87)	3,204	3,205	876.4
65-74 years	2,057	2,057	*****	*****	*****	*****	265.84 (132.95, 531.59)	2,907	2,907	773.3
75-84 years	761	761	*****	*****	*****	*****	1,292.10 (765.24, 2,181.70)	1,045	1,045	272.6
≥ 85 years	101	101	*****	*****	*****	*****	855.59 (120.52, 6,074.09)	136	136	37.3
Trulicity, Atrial Fibrillation and Flutter										
0-40 years	2,438	2,438	*****	*****	*****	*****	88.16 (28.43, 273.35)	4,302	4,332	943.5
41-64 years	23,872	23,872	*****	*****	*****	*****	162.01 (125.53, 209.11)	43,318	43,638	9,651.0
65-74 years	27,508	27,508	*****	*****	*****	*****	377.75 (323.05, 441.71)	47,472	47,751	10,380.9
75-84 years	11,909	11,909	*****	*****	*****	*****	689.65 (576.67, 824.77)	20,038	20,149	4,424.0
≥ 85 years	1,583	1,583	*****	*****	*****	*****	1,152.12 (772.22, 1,718.90)	2,744	2,754	549.3
Xultophy, Atrial Fibrillation and Flutter										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	70.7
75-84 years	87	87	*****	*****	*****	*****	733.29 (103.29, 5,205.84)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Sinus Tachycardia										
0-40 years	1,043	1,043	*****	*****	*****	*****	169.58 (42.41, 678.09)	1,758	1,780	285.5
41-64 years	9,324	9,324	*****	*****	*****	*****	134.92 (81.34, 223.80)	15,924	16,111	2,693.5
65-74 years	6,649	6,649	*****	*****	*****	*****	130.53 (70.23, 242.60)	10,639	10,803	1,776.1

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	1,885	1,885	*****	*****	*****	*****	97.09 (24.28, 388.24)	2,870	2,912	483.6
≥ 85 years	95	95	*****	*****	*****	*****	1,081.58 (152.35, 7,678.50)	136	138	20.7
Bydureon, Sinus Tachycardia										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	109	109	37.1
41-64 years	500	500	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	769	769	198.6
65-74 years	538	538	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	894	211.1
75-84 years	196	196	*****	*****	*****	*****	399.22 (56.23, 2,834.22)	283	283	68.0
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Sinus Tachycardia										
0-40 years	5,541	5,541	*****	*****	*****	*****	212.59 (128.16, 352.64)	8,171	8,198	1,977.5
41-64 years	51,127	51,127	*****	*****	*****	*****	119.93 (96.96, 148.34)	77,645	77,898	18,933.0
65-74 years	44,620	44,620	*****	*****	*****	*****	95.81 (74.70, 122.89)	65,994	66,175	15,751.3
75-84 years	15,174	15,174	*****	*****	*****	*****	94.03 (60.66, 145.74)	21,564	21,621	5,310.9
≥ 85 years	1,259	1,259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,773	1,775	441.6
Rybelsus, Sinus Tachycardia										
0-40 years	1,136	1,136	*****	*****	*****	*****	348.27 (144.96, 836.74)	1,636	1,669	417.3
41-64 years	12,352	12,352	*****	*****	*****	*****	99.53 (61.87, 160.10)	18,198	18,642	4,923.5
65-74 years	13,749	13,749	*****	*****	*****	*****	66.84 (38.81, 115.11)	20,032	20,462	5,061.6
75-84 years	6,139	6,139	*****	*****	*****	*****	141.76 (80.50, 249.61)	8,974	9,138	2,180.7
≥ 85 years	884	884	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,324	1,337	306.0
Wegovy, Sinus Tachycardia										
0-40 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	200	208	18.6
41-64 years	631	631	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	983	996	105.7
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Sinus Tachycardia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	*****	*****	*****	*****	254.05 (35.79, 1,803.60)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Sinus Tachycardia										
0-40 years	311	311	*****	*****	*****	*****	240.98 (33.94, 1,710.78)	474	474	125.9
41-64 years	2,168	2,168	*****	*****	*****	*****	265.88 (132.96, 531.66)	3,204	3,205	876.4
65-74 years	2,057	2,057	*****	*****	*****	*****	99.69 (32.15, 309.11)	2,907	2,907	773.3
75-84 years	761	761	*****	*****	*****	*****	276.88 (89.30, 858.50)	1,045	1,045	272.6
≥ 85 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	136	37.3
Trulicity, Sinus Tachycardia										
0-40 years	2,438	2,438	*****	*****	*****	*****	176.32 (79.21, 392.47)	4,302	4,332	943.5
41-64 years	23,872	23,872	*****	*****	*****	*****	131.81 (99.33, 174.91)	43,318	43,638	9,651.0
65-74 years	27,508	27,508	*****	*****	*****	*****	93.84 (68.56, 128.43)	47,472	47,751	10,380.9
75-84 years	11,909	11,909	*****	*****	*****	*****	91.95 (56.33, 150.10)	20,038	20,149	4,424.0
≥ 85 years	1,583	1,583	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,744	2,754	549.3
Xultophy, Sinus Tachycardia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	70.7
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Supraventricular Tachycardia										
0-40 years	1,043	1,043	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,758	1,780	285.5
41-64 years	9,324	9,324	*****	*****	*****	*****	26.98 (8.70, 83.67)	15,924	16,111	2,693.5

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	6,649	6,649	*****	*****	*****	*****	65.26 (27.16, 156.80)	10,639	10,803	1,776.1
75-84 years	1,885	1,885	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,870	2,912	483.6
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Supraventricular Tachycardia										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	109	109	37.1
41-64 years	500	500	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	769	769	198.6
65-74 years	538	538	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	894	211.1
75-84 years	196	196	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	283	283	68.0
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Supraventricular Tachycardia										
0-40 years	5,541	5,541	*****	*****	*****	*****	14.17 (2.00, 100.62)	8,171	8,198	1,977.5
41-64 years	51,127	51,127	*****	*****	*****	*****	25.40 (16.00, 40.31)	77,645	77,898	18,933.0
65-74 years	44,620	44,620	*****	*****	*****	*****	60.27 (44.03, 82.49)	65,994	66,175	15,751.3
75-84 years	15,174	15,174	*****	*****	*****	*****	65.82 (38.98, 111.13)	21,564	21,621	5,310.9
≥ 85 years	1,259	1,259	*****	*****	*****	*****	60.21 (8.48, 427.48)	1,773	1,775	441.6
Rybelsus, Supraventricular Tachycardia										
0-40 years	1,136	1,136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,636	1,669	417.3
41-64 years	12,352	12,352	*****	*****	*****	*****	23.42 (8.79, 62.40)	18,198	18,642	4,923.5
65-74 years	13,749	13,749	*****	*****	*****	*****	25.71 (10.70, 61.76)	20,032	20,462	5,061.6
75-84 years	6,139	6,139	*****	*****	*****	*****	59.07 (24.58, 141.91)	8,974	9,138	2,180.7
≥ 85 years	884	884	*****	*****	*****	*****	167.75 (41.95, 670.77)	1,324	1,337	306.0
Wegovy, Supraventricular Tachycardia										
0-40 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	200	208	18.6
41-64 years	631	631	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	983	996	105.7
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Supraventricular Tachycardia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	*****	*****	*****	*****	254.05 (35.79, 1,803.60)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Supraventricular Tachycardia										
0-40 years	311	311	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	474	474	125.9
41-64 years	2,168	2,168	*****	*****	*****	*****	66.47 (16.62, 265.78)	3,204	3,205	876.4
65-74 years	2,057	2,057	*****	*****	*****	*****	33.23 (4.68, 235.91)	2,907	2,907	773.3
75-84 years	761	761	*****	*****	*****	*****	276.88 (89.30, 858.50)	1,045	1,045	272.6
≥ 85 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	136	37.3
Trulicity, Supraventricular Tachycardia										
0-40 years	2,438	2,438	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,302	4,332	943.5
41-64 years	23,872	23,872	*****	*****	*****	*****	32.95 (18.71, 58.02)	43,318	43,638	9,651.0
65-74 years	27,508	27,508	*****	*****	*****	*****	40.90 (25.43, 65.80)	47,472	47,751	10,380.9
75-84 years	11,909	11,909	*****	*****	*****	*****	68.97 (39.17, 121.44)	20,038	20,149	4,424.0
≥ 85 years	1,583	1,583	*****	*****	*****	*****	144.01 (46.45, 446.54)	2,744	2,754	549.3
Xultophy, Supraventricular Tachycardia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	70.7
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Other Tachycardia										
0-40 years	1,043	1,043	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,758	1,780	285.5
41-64 years	9,324	9,324	*****	*****	*****	*****	8.99 (1.27, 63.86)	15,924	16,111	2,693.5

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	6,649	6,649	*****	*****	*****	*****	52.21 (19.60, 139.12)	10,639	10,803	1,776.1
75-84 years	1,885	1,885	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,870	2,912	483.6
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Other Tachycardia										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	109	109	37.1
41-64 years	500	500	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	769	769	198.6
65-74 years	538	538	*****	*****	*****	*****	119.31 (16.81, 847.01)	894	894	211.1
75-84 years	196	196	*****	*****	*****	*****	399.22 (56.23, 2,834.22)	283	283	68.0
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Other Tachycardia										
0-40 years	5,541	5,541	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,171	8,198	1,977.5
41-64 years	51,127	51,127	*****	*****	*****	*****	23.99 (14.91, 38.58)	77,645	77,898	18,933.0
65-74 years	44,620	44,620	*****	*****	*****	*****	38.63 (26.10, 57.18)	65,994	66,175	15,751.3
75-84 years	15,174	15,174	*****	*****	*****	*****	47.01 (25.30, 87.38)	21,564	21,621	5,310.9
≥ 85 years	1,259	1,259	*****	*****	*****	*****	180.64 (58.26, 560.11)	1,773	1,775	441.6
Rybelsus, Other Tachycardia										
0-40 years	1,136	1,136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,636	1,669	417.3
41-64 years	12,352	12,352	*****	*****	*****	*****	5.85 (0.82, 41.56)	18,198	18,642	4,923.5
65-74 years	13,749	13,749	*****	*****	*****	*****	5.14 (0.72, 36.50)	20,032	20,462	5,061.6
75-84 years	6,139	6,139	*****	*****	*****	*****	35.44 (11.43, 109.88)	8,974	9,138	2,180.7
≥ 85 years	884	884	*****	*****	*****	*****	83.88 (11.81, 595.47)	1,324	1,337	306.0
Wegovy, Other Tachycardia										
0-40 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	200	208	18.6
41-64 years	631	631	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	983	996	105.7
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Other Tachycardia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Other Tachycardia										
0-40 years	311	311	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	474	474	125.9
41-64 years	2,168	2,168	*****	*****	*****	*****	33.23 (4.68, 235.94)	3,204	3,205	876.4
65-74 years	2,057	2,057	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,907	2,907	773.3
75-84 years	761	761	*****	*****	*****	*****	276.88 (89.30, 858.50)	1,045	1,045	272.6
≥ 85 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	136	37.3
Trulicity, Other Tachycardia										
0-40 years	2,438	2,438	*****	*****	*****	*****	58.77 (14.70, 235.01)	4,302	4,332	943.5
41-64 years	23,872	23,872	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43,318	43,638	9,651.0
65-74 years	27,508	27,508	*****	*****	*****	*****	36.09 (21.76, 59.87)	47,472	47,751	10,380.9
75-84 years	11,909	11,909	*****	*****	*****	*****	22.99 (8.63, 61.25)	20,038	20,149	4,424.0
≥ 85 years	1,583	1,583	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,744	2,754	549.3
Xultophy, Other Tachycardia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	70.7
75-84 years	87	87	*****	*****	*****	*****	733.29 (103.29, 5,205.84)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Cardiac Arrest										
0-40 years	1,043	1,043	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,758	1,780	285.5
41-64 years	9,324	9,324	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15,924	16,111	2,693.5

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	6,649	6,649	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,639	10,803	1,776.1
75-84 years	1,885	1,885	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,870	2,912	483.6
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Cardiac Arrest										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	109	109	37.1
41-64 years	500	500	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	769	769	198.6
65-74 years	538	538	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	894	211.1
75-84 years	196	196	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	283	283	68.0
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Cardiac Arrest										
0-40 years	5,541	5,541	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,171	8,198	1,977.5
41-64 years	51,127	51,127	*****	*****	*****	*****	9.88 (4.71, 20.72)	77,645	77,898	18,933.0
65-74 years	44,620	44,620	*****	*****	*****	*****	10.82 (5.16, 22.69)	65,994	66,175	15,751.3
75-84 years	15,174	15,174	*****	*****	*****	*****	14.10 (4.55, 43.73)	21,564	21,621	5,310.9
≥ 85 years	1,259	1,259	*****	*****	*****	*****	60.21 (8.48, 427.48)	1,773	1,775	441.6
Rybelsus, Cardiac Arrest										
0-40 years	1,136	1,136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,636	1,669	417.3
41-64 years	12,352	12,352	*****	*****	*****	*****	5.85 (0.82, 41.56)	18,198	18,642	4,923.5
65-74 years	13,749	13,749	*****	*****	*****	*****	5.14 (0.72, 36.50)	20,032	20,462	5,061.6
75-84 years	6,139	6,139	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,974	9,138	2,180.7
≥ 85 years	884	884	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,324	1,337	306.0
Wegovy, Cardiac Arrest										
0-40 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	200	208	18.6
41-64 years	631	631	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	983	996	105.7
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Cardiac Arrest										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Cardiac Arrest										
0-40 years	311	311	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	474	474	125.9
41-64 years	2,168	2,168	*****	*****	*****	*****	33.23 (4.68, 235.94)	3,204	3,205	876.4
65-74 years	2,057	2,057	*****	*****	*****	*****	66.46 (16.62, 265.75)	2,907	2,907	773.3
75-84 years	761	761	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,045	1,045	272.6
≥ 85 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	136	37.3
Trulicity, Cardiac Arrest										
0-40 years	2,438	2,438	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,302	4,332	943.5
41-64 years	23,872	23,872	*****	*****	*****	*****	5.49 (1.37, 21.96)	43,318	43,638	9,651.0
65-74 years	27,508	27,508	*****	*****	*****	*****	9.62 (3.61, 25.64)	47,472	47,751	10,380.9
75-84 years	11,909	11,909	*****	*****	*****	*****	34.48 (15.49, 76.76)	20,038	20,149	4,424.0
≥ 85 years	1,583	1,583	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,744	2,754	549.3
Xultophy, Cardiac Arrest										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	70.7
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Ventricular Tachycardia										
0-40 years	1,043	1,043	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,758	1,780	285.5
41-64 years	9,324	9,324	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15,924	16,111	2,693.5
65-74 years	6,649	6,649	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,639	10,803	1,776.1

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	1,885	1,885	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,870	2,912	483.6
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Ventricular Tachycardia										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	109	109	37.1
41-64 years	500	500	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	769	769	198.6
65-74 years	538	538	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	894	211.1
75-84 years	196	196	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	283	283	68.0
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Ventricular Tachycardia										
0-40 years	5,541	5,541	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,171	8,198	1,977.5
41-64 years	51,127	51,127	*****	*****	*****	*****	1.41 (0.20, 10.02)	77,645	77,898	18,933.0
65-74 years	44,620	44,620	*****	*****	*****	*****	6.18 (2.32, 16.47)	65,994	66,175	15,751.3
75-84 years	15,174	15,174	*****	*****	*****	*****	9.40 (2.35, 37.60)	21,564	21,621	5,310.9
≥ 85 years	1,259	1,259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,773	1,775	441.6
Rybelsus, Ventricular Tachycardia										
0-40 years	1,136	1,136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,636	1,669	417.3
41-64 years	12,352	12,352	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,198	18,642	4,923.5
65-74 years	13,749	13,749	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20,032	20,462	5,061.6
75-84 years	6,139	6,139	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,974	9,138	2,180.7
≥ 85 years	884	884	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,324	1,337	306.0
Wegovy, Ventricular Tachycardia										
0-40 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	200	208	18.6
41-64 years	631	631	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	983	996	105.7
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Ventricular Tachycardia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricular Tachycardia										
0-40 years	311	311	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	474	474	125.9
41-64 years	2,168	2,168	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,204	3,205	876.4
65-74 years	2,057	2,057	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,907	2,907	773.3
75-84 years	761	761	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,045	1,045	272.6
≥ 85 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	136	37.3
Trulicity, Ventricular Tachycardia										
0-40 years	2,438	2,438	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,302	4,332	943.5
41-64 years	23,872	23,872	*****	*****	*****	*****	5.49 (1.37, 21.96)	43,318	43,638	9,651.0
65-74 years	27,508	27,508	*****	*****	*****	*****	2.41 (0.34, 17.08)	47,472	47,751	10,380.9
75-84 years	11,909	11,909	*****	*****	*****	*****	5.75 (0.81, 40.80)	20,038	20,149	4,424.0
≥ 85 years	1,583	1,583	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,744	2,754	549.3
Xultophy, Ventricular Tachycardia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	70.7
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Ventricular Fibrillation and Flutter										
0-40 years	1,043	1,043	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,758	1,780	285.5
41-64 years	9,324	9,324	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15,924	16,111	2,693.5

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	6,649	6,649	*****	*****	*****	*****	13.05 (1.84, 92.67)	10,639	10,803	1,776.1
75-84 years	1,885	1,885	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,870	2,912	483.6
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Ventricular Fibrillation and Flutter										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	109	109	37.1
41-64 years	500	500	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	769	769	198.6
65-74 years	538	538	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	894	894	211.1
75-84 years	196	196	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	283	283	68.0
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Ventricular Fibrillation and Flutter										
0-40 years	5,541	5,541	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,171	8,198	1,977.5
41-64 years	51,127	51,127	*****	*****	*****	*****	2.82 (0.71, 11.28)	77,645	77,898	18,933.0
65-74 years	44,620	44,620	*****	*****	*****	*****	3.09 (0.77, 12.36)	65,994	66,175	15,751.3
75-84 years	15,174	15,174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21,564	21,621	5,310.9
≥ 85 years	1,259	1,259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,773	1,775	441.6
Rybelsus, Ventricular Fibrillation and Flutter										
0-40 years	1,136	1,136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,636	1,669	417.3
41-64 years	12,352	12,352	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,198	18,642	4,923.5
65-74 years	13,749	13,749	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20,032	20,462	5,061.6
75-84 years	6,139	6,139	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,974	9,138	2,180.7
≥ 85 years	884	884	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,324	1,337	306.0
Wegovy, Ventricular Fibrillation and Flutter										
0-40 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	200	208	18.6
41-64 years	631	631	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	983	996	105.7
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Ventricular Fibrillation and Flutter										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricular Fibrillation and Flutter										
0-40 years	311	311	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	474	474	125.9
41-64 years	2,168	2,168	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,204	3,205	876.4
65-74 years	2,057	2,057	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,907	2,907	773.3
75-84 years	761	761	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,045	1,045	272.6
≥ 85 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	136	37.3
Trulicity, Ventricular Fibrillation and Flutter										
0-40 years	2,438	2,438	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,302	4,332	943.5
41-64 years	23,872	23,872	*****	*****	*****	*****	5.49 (1.37, 21.96)	43,318	43,638	9,651.0
65-74 years	27,508	27,508	*****	*****	*****	*****	4.81 (1.20, 19.24)	47,472	47,751	10,380.9
75-84 years	11,909	11,909	*****	*****	*****	*****	5.75 (0.81, 40.80)	20,038	20,149	4,424.0
≥ 85 years	1,583	1,583	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,744	2,754	549.3
Xultophy, Ventricular Fibrillation and Flutter										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	70.7
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
2022	1,080	1,080	*****	*****	*****	*****	319.31 (132.91, 767.17)	1,737	1,737	474.2
2023	248	248	*****	*****	*****	*****	794.45 (198.69, 3,176.65)	339	339	45.4
Mounjaro, Hospitalized Tachyarrhythmia										
2022	9,542	9,542	*****	*****	*****	*****	424.74 (324.49, 555.97)	16,463	16,650	3,684.1
2023	9,454	9,454	*****	*****	*****	*****	529.47 (402.39, 696.68)	14,864	15,094	1,575.2
Ozempic, Hospitalized Tachyarrhythmia										
2022	79,303	79,303	*****	*****	*****	*****	501.29 (463.63, 542.00)	124,233	124,545	36,586.1
2023	38,418	38,418	*****	*****	*****	*****	453.67 (392.17, 524.82)	50,914	51,122	5,828.3
Rybelsus, Hospitalized Tachyarrhythmia										
2022	25,319	25,319	*****	*****	*****	*****	367.42 (311.33, 433.61)	38,496	39,228	11,367.5
2023	8,941	8,941	*****	*****	*****	*****	483.21 (361.93, 645.12)	11,668	12,020	1,521.5
Saxenda, Hospitalized Tachyarrhythmia										
2022	333	333	*****	*****	*****	*****	216.38 (30.48, 1,536.15)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Trulicity, Hospitalized Tachyarrhythmia										
2022	53,098	53,098	*****	*****	*****	*****	510.89 (464.96, 561.35)	96,308	96,879	23,433.9
2023	14,212	14,212	*****	*****	*****	*****	533.82 (432.12, 659.45)	21,566	21,745	2,514.8
Victoza, Hospitalized Tachyarrhythmia										
2022	4,134	4,134	*****	*****	*****	*****	598.31 (433.50, 825.78)	6,121	6,122	1,841.9
2023	1,264	1,264	*****	*****	*****	*****	827.89 (470.16, 1,457.79)	1,645	1,645	243.7
Wegovy, Hospitalized Tachyarrhythmia										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	112	42.2
2023	768	768	*****	*****	*****	*****	148.13 (20.86, 1,051.60)	1,201	1,227	96.3
Kultophy, Hospitalized Tachyarrhythmia										
2022	219	219	*****	*****	*****	*****	261.75 (36.87, 1,858.27)	294	294	102.6
2023	147	147	*****	*****	*****	*****	500.27 (70.47, 3,551.61)	192	192	29.5
Mounjaro, Atrial Fibrillation and Flutter										
2022	9,542	9,542	*****	*****	*****	*****	280.49 (201.39, 390.66)	16,463	16,650	3,684.1
2023	9,454	9,454	*****	*****	*****	*****	321.83 (226.33, 457.63)	14,864	15,094	1,575.2

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Atrial Fibrillation and Flutter										
2022	1,080	1,080	*****	*****	*****	*****	191.59 (61.79, 594.04)	1,737	1,737	474.2
2023	248	248	*****	*****	*****	*****	794.45 (198.69, 3,176.65)	339	339	45.4
Ozempic, Atrial Fibrillation and Flutter										
2022	79,303	79,303	*****	*****	*****	*****	333.40 (302.95, 366.90)	124,233	124,545	36,586.1
2023	38,418	38,418	*****	*****	*****	*****	250.65 (206.04, 304.92)	50,914	51,122	5,828.3
Rybelsus, Atrial Fibrillation and Flutter										
2022	25,319	25,319	*****	*****	*****	*****	259.82 (213.36, 316.39)	38,496	39,228	11,367.5
2023	8,941	8,941	*****	*****	*****	*****	315.14 (220.34, 450.72)	11,668	12,020	1,521.5
Wegovy, Atrial Fibrillation and Flutter										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	112	42.2
2023	768	768	*****	*****	*****	*****	148.13 (20.86, 1,051.60)	1,201	1,227	96.3
Saxenda, Atrial Fibrillation and Flutter										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Atrial Fibrillation and Flutter										
2022	4,134	4,134	*****	*****	*****	*****	355.75 (234.24, 540.29)	6,121	6,122	1,841.9
2023	1,264	1,264	*****	*****	*****	*****	482.93 (230.23, 1,013.02)	1,645	1,645	243.7
Trulicity, Atrial Fibrillation and Flutter										
2022	53,098	53,098	*****	*****	*****	*****	364.58 (326.12, 407.59)	96,308	96,879	23,433.9
2023	14,212	14,212	*****	*****	*****	*****	335.19 (256.71, 437.65)	21,566	21,745	2,514.8
Xultophy, Atrial Fibrillation and Flutter										
2022	219	219	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	294	294	102.6
2023	147	147	*****	*****	*****	*****	500.27 (70.47, 3,551.61)	192	192	29.5
Mounjaro, Sinus Tachycardia										
2022	9,542	9,542	*****	*****	*****	*****	112.20 (66.45, 189.44)	16,463	16,650	3,684.1
2023	9,454	9,454	*****	*****	*****	*****	166.11 (101.76, 271.14)	14,864	15,094	1,575.2
Bydureon, Sinus Tachycardia										
2022	1,080	1,080	*****	*****	*****	*****	63.86 (9.00, 453.38)	1,737	1,737	474.2
2023	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	339	339	45.4

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Ozempic, Sinus Tachycardia										
2022	79,303	79,303	*****	*****	*****	*****	105.83 (89.29, 125.43)	124,233	124,545	36,586.1
2023	38,418	38,418	*****	*****	*****	*****	122.82 (92.82, 162.50)	50,914	51,122	5,828.3
Rybelsus, Sinus Tachycardia										
2022	25,319	25,319	*****	*****	*****	*****	94.48 (68.15, 130.98)	38,496	39,228	11,367.5
2023	8,941	8,941	*****	*****	*****	*****	115.55 (63.99, 208.65)	11,668	12,020	1,521.5
Wegovy, Sinus Tachycardia										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	112	42.2
2023	768	768	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,201	1,227	96.3
Saxenda, Sinus Tachycardia										
2022	333	333	*****	*****	*****	*****	216.38 (30.48, 1,536.15)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Sinus Tachycardia										
2022	4,134	4,134	*****	*****	*****	*****	161.71 (87.01, 300.54)	6,121	6,122	1,841.9
2023	1,264	1,264	*****	*****	*****	*****	344.95 (143.58, 828.77)	1,645	1,645	243.7
Trulicity, Sinus Tachycardia										
2022	53,098	53,098	*****	*****	*****	*****	101.47 (82.14, 125.35)	96,308	96,879	23,433.9
2023	14,212	14,212	*****	*****	*****	*****	142.76 (94.87, 214.84)	21,566	21,745	2,514.8
Xultophy, Sinus Tachycardia										
2022	219	219	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	294	294	102.6
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5
Mounjaro, Supraventricular Tachycardia										
2022	9,542	9,542	*****	*****	*****	*****	24.04 (7.75, 74.55)	16,463	16,650	3,684.1
2023	9,454	9,454	*****	*****	*****	*****	51.91 (21.61, 124.71)	14,864	15,094	1,575.2
Bydureon, Supraventricular Tachycardia										
2022	1,080	1,080	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,737	1,737	474.2
2023	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	339	339	45.4
Ozempic, Supraventricular Tachycardia										
2022	79,303	79,303	*****	*****	*****	*****	40.58 (30.84, 53.40)	124,233	124,545	36,586.1
2023	38,418	38,418	*****	*****	*****	*****	55.14 (36.31, 83.75)	50,914	51,122	5,828.3

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Rybelsus, Supraventricular Tachycardia										
2022	25,319	25,319	*****	*****	*****	*****	28.87 (15.99, 52.13)	38,496	39,228	11,367.5
2023	8,941	8,941	*****	*****	*****	*****	52.52 (21.86, 126.19)	11,668	12,020	1,521.5
Wegovy, Supraventricular Tachycardia										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	112	42.2
2023	768	768	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,201	1,227	96.3
Saxenda, Supraventricular Tachycardia										
2022	333	333	*****	*****	*****	*****	216.38 (30.48, 1,536.15)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Supraventricular Tachycardia										
2022	4,134	4,134	*****	*****	*****	*****	97.02 (43.59, 215.97)	6,121	6,122	1,841.9
2023	1,264	1,264	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,645	1,645	243.7
Trulicity, Supraventricular Tachycardia										
2022	53,098	53,098	*****	*****	*****	*****	43.66 (31.63, 60.25)	96,308	96,879	23,433.9
2023	14,212	14,212	*****	*****	*****	*****	43.45 (20.71, 91.14)	21,566	21,745	2,514.8
Kultophy, Supraventricular Tachycardia										
2022	219	219	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	294	294	102.6
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5
Mounjaro, Other Tachycardia										
2022	9,542	9,542	*****	*****	*****	*****	8.01 (1.13, 56.89)	16,463	16,650	3,684.1
2023	9,454	9,454	*****	*****	*****	*****	41.53 (15.59, 110.65)	14,864	15,094	1,575.2
Bydureon, Other Tachycardia										
2022	1,080	1,080	*****	*****	*****	*****	127.73 (31.94, 510.72)	1,737	1,737	474.2
2023	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	339	339	45.4
Ozempic, Other Tachycardia										
2022	79,303	79,303	*****	*****	*****	*****	29.44 (21.33, 40.63)	124,233	124,545	36,586.1
2023	38,418	38,418	*****	*****	*****	*****	45.12 (28.43, 71.61)	50,914	51,122	5,828.3
Rybelsus, Other Tachycardia										
2022	25,319	25,319	*****	*****	*****	*****	2.62 (0.37, 18.63)	38,496	39,228	11,367.5
2023	8,941	8,941	*****	*****	*****	*****	52.52 (21.86, 126.19)	11,668	12,020	1,521.5

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Wegovy, Other Tachycardia										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	112	42.2
2023	768	768	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,201	1,227	96.3
Saxenda, Other Tachycardia										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Other Tachycardia										
2022	4,134	4,134	*****	*****	*****	*****	48.51 (15.65, 150.42)	6,121	6,122	1,841.9
2023	1,264	1,264	*****	*****	*****	*****	68.99 (9.72, 489.79)	1,645	1,645	243.7
Trulicity, Other Tachycardia										
2022	53,098	53,098	*****	*****	*****	*****	18.88 (11.57, 30.81)	96,308	96,879	23,433.9
2023	14,212	14,212	*****	*****	*****	*****	31.04 (12.92, 74.57)	21,566	21,745	2,514.8
Kultophy, Other Tachycardia										
2022	219	219	*****	*****	*****	*****	261.75 (36.87, 1,858.27)	294	294	102.6
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5
Mounjaro, Cardiac Arrest										
2022	9,542	9,542	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,463	16,650	3,684.1
2023	9,454	9,454	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,864	15,094	1,575.2
Bydureon, Cardiac Arrest										
2022	1,080	1,080	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,737	1,737	474.2
2023	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	339	339	45.4
Ozempic, Cardiac Arrest										
2022	79,303	79,303	*****	*****	*****	*****	12.73 (7.80, 20.78)	124,233	124,545	36,586.1
2023	38,418	38,418	*****	*****	*****	*****	5.01 (1.25, 20.04)	50,914	51,122	5,828.3
Rybelsus, Cardiac Arrest										
2022	25,319	25,319	*****	*****	*****	*****	5.25 (1.31, 20.99)	38,496	39,228	11,367.5
2023	8,941	8,941	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,668	12,020	1,521.5
Wegovy, Cardiac Arrest										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	112	42.2
2023	768	768	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,201	1,227	96.3

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Cardiac Arrest										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Cardiac Arrest										
2022	4,134	4,134	*****	*****	*****	*****	48.51 (15.65, 150.42)	6,121	6,122	1,841.9
2023	1,264	1,264	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,645	1,645	243.7
Trulicity, Cardiac Arrest										
2022	53,098	53,098	*****	*****	*****	*****	12.98 (7.19, 23.44)	96,308	96,879	23,433.9
2023	14,212	14,212	*****	*****	*****	*****	6.21 (0.87, 44.07)	21,566	21,745	2,514.8
Xultophy, Cardiac Arrest										
2022	219	219	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	294	294	102.6
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5
Mounjaro, Ventricular Tachycardia										
2022	9,542	9,542	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,463	16,650	3,684.1
2023	9,454	9,454	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,864	15,094	1,575.2
Bydureon, Ventricular Tachycardia										
2022	1,080	1,080	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,737	1,737	474.2
2023	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	339	339	45.4
Ozempic, Ventricular Tachycardia										
2022	79,303	79,303	*****	*****	*****	*****	5.57 (2.66, 11.68)	124,233	124,545	36,586.1
2023	38,418	38,418	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	50,914	51,122	5,828.3
Rybelsus, Ventricular Tachycardia										
2022	25,319	25,319	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38,496	39,228	11,367.5
2023	8,941	8,941	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,668	12,020	1,521.5
Wegovy, Ventricular Tachycardia										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	112	42.2
2023	768	768	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,201	1,227	96.3
Saxenda, Ventricular Tachycardia										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Victoza, Ventricular Tachycardia										
2022	4,134	4,134	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,121	6,122	1,841.9
2023	1,264	1,264	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,645	1,645	243.7
Trulicity, Ventricular Tachycardia										
2022	53,098	53,098	*****	*****	*****	*****	4.72 (1.77, 12.57)	96,308	96,879	23,433.9
2023	14,212	14,212	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21,566	21,745	2,514.8
Xultophy, Ventricular Tachycardia										
2022	219	219	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	294	294	102.6
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5
Mounjaro, Ventricular Fibrillation and Flutter										
2022	9,542	9,542	*****	*****	*****	*****	8.01 (1.13, 56.89)	16,463	16,650	3,684.1
2023	9,454	9,454	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,864	15,094	1,575.2
Bydureon, Ventricular Fibrillation and Flutter										
2022	1,080	1,080	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,737	1,737	474.2
2023	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	339	339	45.4
Ozempic, Ventricular Fibrillation and Flutter										
2022	79,303	79,303	*****	*****	*****	*****	2.39 (0.77, 7.40)	124,233	124,545	36,586.1
2023	38,418	38,418	*****	*****	*****	*****	2.51 (0.35, 17.79)	50,914	51,122	5,828.3
Rybelsus, Ventricular Fibrillation and Flutter										
2022	25,319	25,319	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38,496	39,228	11,367.5
2023	8,941	8,941	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,668	12,020	1,521.5
Wegovy, Ventricular Fibrillation and Flutter										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	112	42.2
2023	768	768	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,201	1,227	96.3
Saxenda, Ventricular Fibrillation and Flutter										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Ventricular Fibrillation and Flutter										
2022	4,134	4,134	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,121	6,122	1,841.9
2023	1,264	1,264	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,645	1,645	243.7

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Trulicity, Ventricular Fibrillation and Flutter										
2022	53,098	53,098	*****	*****	*****	*****	4.72 (1.77, 12.57)	96,308	96,879	23,433.9
2023	14,212	14,212	*****	*****	*****	*****	6.21 (0.87, 44.07)	21,566	21,745	2,514.8
Xultophy, Ventricular Fibrillation and Flutter										
2022	219	219	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	294	294	102.6
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	*****	*****	*****	*****	441.50 (62.19, 3,134.33)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	247	247	*****	*****	*****	*****	289.65 (40.80, 2,056.33)	349	349	89.9
White	837	837	*****	*****	*****	*****	436.00 (181.47, 1,047.53)	1,340	1,340	319.1
Mounjaro, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,659	1,659	*****	*****	*****	*****	496.16 (258.16, 953.59)	2,513	2,557	469.1
Multi-racial	60	60	*****	*****	*****	*****	1,330.60 (187.43, 9,446.37)	112	113	23.5
Native Hawaiian or Other Pacific Islander	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	87	88	17.3
Unknown	8,068	8,068	*****	*****	*****	*****	232.06 (152.80, 352.44)	13,705	13,852	2,244.0
White	9,011	9,011	*****	*****	*****	*****	685.38 (544.02, 863.48)	14,692	14,915	2,468.6
Ozempic, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	828	828	*****	*****	*****	*****	1,147.80 (651.84, 2,021.12)	1,272	1,277	282.9
Asian	1,399	1,399	*****	*****	*****	*****	433.58 (225.59, 833.31)	2,127	2,131	490.0
Black or African American	9,900	9,900	*****	*****	*****	*****	523.13 (415.23, 659.06)	14,164	14,214	3,624.5
Multi-racial	818	818	*****	*****	*****	*****	371.98 (139.61, 991.13)	1,251	1,256	316.7
Native Hawaiian or Other Pacific Islander	335	335	*****	*****	*****	*****	392.87 (98.25, 1,570.90)	454	454	138.0
Unknown	45,728	45,728	*****	*****	*****	*****	238.57 (203.29, 279.97)	68,823	69,031	16,665.9
White	58,713	58,713	*****	*****	*****	*****	667.23 (614.28, 724.74)	87,056	87,304	20,896.4
Rybelsus, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	1,089	1,089	*****	*****	*****	*****	118.39 (29.61, 473.37)	1,657	1,686	388.0
Black or African American	3,424	3,424	*****	*****	*****	*****	413.73 (263.89, 648.63)	4,718	4,822	1,318.5
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	179	61.8
Unknown	12,876	12,876	*****	*****	*****	*****	214.94 (156.40, 295.39)	18,719	19,156	5,032.0
White	16,493	16,493	*****	*****	*****	*****	549.70 (461.94, 654.12)	24,518	25,014	5,982.0
Saxenda, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	*****	*****	*****	*****	218.33 (30.75, 1,550.02)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Trulicity, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	480	483	92.1
Asian	1,205	1,205	*****	*****	*****	*****	209.83 (78.75, 559.08)	2,050	2,058	440.1
Black or African American	6,463	6,463	*****	*****	*****	*****	493.15 (368.20, 660.50)	10,531	10,606	2,596.5
Multi-racial	293	293	*****	*****	*****	*****	396.36 (99.13, 1,584.88)	600	605	131.5
Native Hawaiian or Other Pacific Islander	248	248	*****	*****	*****	*****	509.49 (127.42, 2,037.20)	400	406	121.2
Unknown	21,889	21,889	*****	*****	*****	*****	328.94 (273.10, 396.19)	39,444	39,719	8,769.8
White	36,953	36,953	*****	*****	*****	*****	647.38 (583.42, 718.35)	64,369	64,747	13,797.4
Victoza, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	61	61	*****	*****	*****	*****	1,551.61 (218.56, 11,015.42)	84	84	23.8
Asian	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	36.0
Black or African American	564	564	*****	*****	*****	*****	537.90 (201.88, 1,433.22)	757	757	231.3

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,443	1,443	*****	*****	*****	*****	501.02 (269.57, 931.18)	2,084	2,085	578.4
White	3,156	3,156	*****	*****	*****	*****	739.64 (528.49, 1,035.15)	4,599	4,599	1,181.2
Wegovy, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	58	7.1
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	676	676	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,037	1,058	105.7
White	110	110	*****	*****	*****	*****	837.54 (117.97, 5,945.95)	192	195	22.2
Xultophy, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	24.0
White	249	249	*****	*****	*****	*****	512.42 (128.15, 2,048.92)	330	330	87.6
Mounjaro, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,659	1,659	*****	*****	*****	*****	385.90 (183.97, 809.48)	2,513	2,557	469.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiian or Other Pacific Islander	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	87	88	17.3
Unknown	8,068	8,068	*****	*****	*****	*****	126.58 (71.89, 222.89)	13,705	13,852	2,244.0
White	9,011	9,011	*****	*****	*****	*****	447.40 (336.15, 595.47)	14,692	14,915	2,468.6
Bydureon, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	247	247	*****	*****	*****	*****	289.65 (40.80, 2,056.33)	349	349	89.9
White	837	837	*****	*****	*****	*****	348.80 (130.91, 929.37)	1,340	1,340	319.1
Ozempic, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	828	828	*****	*****	*****	*****	860.85 (447.91, 1,654.50)	1,272	1,277	282.9
Asian	1,399	1,399	*****	*****	*****	*****	144.53 (46.61, 448.12)	2,127	2,131	490.0
Black or African American	9,900	9,900	*****	*****	*****	*****	261.56 (188.67, 362.61)	14,164	14,214	3,624.5
Multi-racial	818	818	*****	*****	*****	*****	185.99 (46.51, 743.69)	1,251	1,256	316.7
Native Hawaiian or Other Pacific Islander	335	335	*****	*****	*****	*****	392.87 (98.25, 1,570.90)	454	454	138.0
Unknown	45,728	45,728	*****	*****	*****	*****	135.19 (109.30, 167.21)	68,823	69,031	16,665.9
White	58,713	58,713	*****	*****	*****	*****	453.53 (410.25, 501.37)	87,056	87,304	20,896.4
Rybelsus, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,089	1,089	*****	*****	*****	*****	59.19 (8.34, 420.23)	1,657	1,686	388.0
Black or African American	3,424	3,424	*****	*****	*****	*****	239.53 (132.65, 432.52)	4,718	4,822	1,318.5
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	179	61.8

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown	12,876	12,876	*****	*****	*****	*****	113.13 (72.98, 175.35)	18,719	19,156	5,032.0
White	16,493	16,493	*****	*****	*****	*****	419.85 (344.08, 512.29)	24,518	25,014	5,982.0
Wegovy, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	58	7.1
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	676	676	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,037	1,058	105.7
White	110	110	*****	*****	*****	*****	837.54 (117.97, 5,945.95)	192	195	22.2
Saxenda, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	61	61	*****	*****	*****	*****	1,551.61 (218.56, 11,015.42)	84	84	23.8
Asian	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	36.0
Black or African American	564	564	*****	*****	*****	*****	268.95 (67.26, 1,075.41)	757	757	231.3
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,443	1,443	*****	*****	*****	*****	200.41 (75.22, 533.98)	2,084	2,085	578.4
White	3,156	3,156	*****	*****	*****	*****	478.59 (315.13, 726.85)	4,599	4,599	1,181.2

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Trulicity, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	480	483	92.1
Asian	1,205	1,205	*****	*****	*****	*****	157.37 (50.75, 487.95)	2,050	2,058	440.1
Black or African American	6,463	6,463	*****	*****	*****	*****	241.09 (158.75, 366.16)	10,531	10,606	2,596.5
Multi-racial	293	293	*****	*****	*****	*****	198.18 (27.92, 1,406.96)	600	605	131.5
Native Hawaiian or Other Pacific Islander	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,889	21,889	*****	*****	*****	*****	195.58 (153.66, 248.95)	39,444	39,719	8,769.8
White	36,953	36,953	*****	*****	*****	*****	494.20 (438.72, 556.68)	64,369	64,747	13,797.4
Xultophy, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	24.0
White	249	249	*****	*****	*****	*****	256.21 (36.09, 1,818.90)	330	330	87.6
Mounjaro, Sinus Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,659	1,659	*****	*****	*****	*****	110.26 (27.57, 440.87)	2,513	2,557	469.1
Multi-racial	60	60	*****	*****	*****	*****	1,330.60 (187.43, 9,446.37)	112	113	23.5
Native Hawaiian or Other Pacific Islander	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	87	88	17.3
Unknown	8,068	8,068	*****	*****	*****	*****	84.39 (42.20, 168.74)	13,705	13,852	2,244.0
White	9,011	9,011	*****	*****	*****	*****	180.87 (115.36, 283.56)	14,692	14,915	2,468.6
Bydureon, Sinus Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	*****	*****	*****	*****	441.50 (62.19, 3,134.33)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	247	247	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	349	349	89.9
White	837	837	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,340	1,340	319.1
Ozempic, Sinus Tachycardia										
American Indian or Alaska Native	828	828	*****	*****	*****	*****	191.30 (47.84, 764.92)	1,272	1,277	282.9
Asian	1,399	1,399	*****	*****	*****	*****	96.35 (24.10, 385.26)	2,127	2,131	490.0
Black or African American	9,900	9,900	*****	*****	*****	*****	174.38 (116.88, 260.16)	14,164	14,214	3,624.5
Multi-racial	818	818	*****	*****	*****	*****	93.00 (13.10, 660.21)	1,251	1,256	316.7
Native Hawaiian or Other Pacific Islander	335	335	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	454	454	138.0
Unknown	45,728	45,728	*****	*****	*****	*****	63.62 (46.66, 86.73)	68,823	69,031	16,665.9
White	58,713	58,713	*****	*****	*****	*****	134.16 (111.57, 161.32)	87,056	87,304	20,896.4
Rybelsus, Sinus Tachycardia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,089	1,089	*****	*****	*****	*****	59.19 (8.34, 420.23)	1,657	1,686	388.0
Black or African American	3,424	3,424	*****	*****	*****	*****	152.43 (72.67, 319.73)	4,718	4,822	1,318.5
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	179	61.8
Unknown	12,876	12,876	*****	*****	*****	*****	79.19 (46.90, 133.71)	18,719	19,156	5,032.0
White	16,493	16,493	*****	*****	*****	*****	108.21 (73.12, 160.14)	24,518	25,014	5,982.0
Wegovy, Sinus Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	58	7.1

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	676	676	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,037	1,058	105.7
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Sinus Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	*****	*****	*****	*****	218.33 (30.75, 1,550.02)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Sinus Tachycardia										
American Indian or Alaska Native	61	61	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23.8
Asian	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	36.0
Black or African American	564	564	*****	*****	*****	*****	268.95 (67.26, 1,075.41)	757	757	231.3
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,443	1,443	*****	*****	*****	*****	350.72 (167.20, 735.67)	2,084	2,085	578.4
White	3,156	3,156	*****	*****	*****	*****	130.52 (58.64, 290.54)	4,599	4,599	1,181.2
Trulicity, Sinus Tachycardia										
American Indian or Alaska Native	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	480	483	92.1
Asian	1,205	1,205	*****	*****	*****	*****	52.46 (7.39, 372.41)	2,050	2,058	440.1
Black or African American	6,463	6,463	*****	*****	*****	*****	197.26 (124.28, 313.09)	10,531	10,606	2,596.5
Multi-racial	293	293	*****	*****	*****	*****	198.18 (27.92, 1,406.96)	600	605	131.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiian or Other Pacific Islander	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,889	21,889	*****	*****	*****	*****	100.76 (71.99, 141.01)	39,444	39,719	8,769.8
White	36,953	36,953	*****	*****	*****	*****	100.30 (77.00, 130.64)	64,369	64,747	13,797.4
Xultophy, Sinus Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	24.0
White	249	249	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	330	87.6
Mounjaro, Supraventricular Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,659	1,659	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,513	2,557	469.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	87	88	17.3
Unknown	8,068	8,068	*****	*****	*****	*****	21.10 (5.28, 84.36)	13,705	13,852	2,244.0
White	9,011	9,011	*****	*****	*****	*****	57.12 (25.66, 127.13)	14,692	14,915	2,468.6
Bydureon, Supraventricular Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown	247	247	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	349	349	89.9
White	837	837	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,340	1,340	319.1
Ozempic, Supraventricular Tachycardia										
American Indian or Alaska Native	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,272	1,277	282.9
Asian	1,399	1,399	*****	*****	*****	*****	48.18 (6.79, 342.01)	2,127	2,131	490.0
Black or African American	9,900	9,900	*****	*****	*****	*****	58.13 (29.07, 116.23)	14,164	14,214	3,624.5
Multi-racial	818	818	*****	*****	*****	*****	93.00 (13.10, 660.21)	1,251	1,256	316.7
Native Hawaiian or Other Pacific Islander	335	335	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	454	454	138.0
Unknown	45,728	45,728	*****	*****	*****	*****	30.22 (19.27, 47.38)	68,823	69,031	16,665.9
White	58,713	58,713	*****	*****	*****	*****	52.24 (38.87, 70.20)	87,056	87,304	20,896.4
Rybelsus, Supraventricular Tachycardia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,089	1,089	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,657	1,686	388.0
Black or African American	3,424	3,424	*****	*****	*****	*****	21.78 (3.07, 154.59)	4,718	4,822	1,318.5
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	179	61.8
Unknown	12,876	12,876	*****	*****	*****	*****	16.97 (5.47, 52.61)	18,719	19,156	5,032.0
White	16,493	16,493	*****	*****	*****	*****	51.94 (29.50, 91.46)	24,518	25,014	5,982.0
Wegovy, Supraventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	58	7.1
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	676	676	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,037	1,058	105.7
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Supraventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	*****	*****	*****	*****	218.33 (30.75, 1,550.02)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Supraventricular Tachycardia										
American Indian or Alaska Native	61	61	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23.8
Asian	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	36.0
Black or African American	564	564	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	757	757	231.3
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,443	1,443	*****	*****	*****	*****	100.20 (25.06, 400.67)	2,084	2,085	578.4
White	3,156	3,156	*****	*****	*****	*****	87.02 (32.66, 231.85)	4,599	4,599	1,181.2
Trulicity, Supraventricular Tachycardia										
American Indian or Alaska Native	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	480	483	92.1
Asian	1,205	1,205	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,050	2,058	440.1
Black or African American	6,463	6,463	*****	*****	*****	*****	21.92 (5.48, 87.64)	10,531	10,606	2,596.5
Multi-racial	293	293	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	248	248	*****	*****	*****	*****	254.74 (35.88, 1,808.50)	400	406	121.2
Unknown	21,889	21,889	*****	*****	*****	*****	32.60 (18.05, 58.86)	39,444	39,719	8,769.8
White	36,953	36,953	*****	*****	*****	*****	54.71 (38.25, 78.25)	64,369	64,747	13,797.4
Xultophy, Supraventricular Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	24.0
White	249	249	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	330	87.6
Mounjaro, Other Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,659	1,659	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,513	2,557	469.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	87	88	17.3
Unknown	8,068	8,068	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,705	13,852	2,244.0
White	9,011	9,011	*****	*****	*****	*****	47.60 (19.81, 114.35)	14,692	14,915	2,468.6
Bydureon, Other Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	247	247	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	349	349	89.9
White	837	837	*****	*****	*****	*****	174.40 (43.62, 697.35)	1,340	1,340	319.1
Ozempic, Other Tachycardia										
American Indian or Alaska Native	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,272	1,277	282.9
Asian	1,399	1,399	*****	*****	*****	*****	96.35 (24.10, 385.26)	2,127	2,131	490.0
Black or African American	9,900	9,900	*****	*****	*****	*****	58.13 (29.07, 116.23)	14,164	14,214	3,624.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	818	818	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,251	1,256	316.7
Native Hawaiian or Other Pacific Islander	335	335	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	454	454	138.0
Unknown	45,728	45,728	*****	*****	*****	*****	11.13 (5.31, 23.35)	68,823	69,031	16,665.9
White	58,713	58,713	*****	*****	*****	*****	45.12 (32.83, 62.00)	87,056	87,304	20,896.4
Rybelsus, Other Tachycardia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,089	1,089	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,657	1,686	388.0
Black or African American	3,424	3,424	*****	*****	*****	*****	21.78 (3.07, 154.59)	4,718	4,822	1,318.5
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	179	61.8
Unknown	12,876	12,876	*****	*****	*****	*****	11.31 (2.83, 45.23)	18,719	19,156	5,032.0
White	16,493	16,493	*****	*****	*****	*****	12.98 (4.19, 40.26)	24,518	25,014	5,982.0
Wegovy, Other Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	58	7.1
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	676	676	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,037	1,058	105.7
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Other Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Other Tachycardia										
American Indian or Alaska Native	61	61	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23.8
Asian	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	36.0
Black or African American	564	564	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	757	757	231.3
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,443	1,443	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,084	2,085	578.4
White	3,156	3,156	*****	*****	*****	*****	87.02 (32.66, 231.85)	4,599	4,599	1,181.2
Trulicity, Other Tachycardia										
American Indian or Alaska Native	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	480	483	92.1
Asian	1,205	1,205	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,050	2,058	440.1
Black or African American	6,463	6,463	*****	*****	*****	*****	21.92 (5.48, 87.64)	10,531	10,606	2,596.5
Multi-racial	293	293	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,889	21,889	*****	*****	*****	*****	5.93 (1.48, 23.70)	39,444	39,719	8,769.8
White	36,953	36,953	*****	*****	*****	*****	31.00 (19.27, 49.87)	64,369	64,747	13,797.4
Xultophy, Other Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	24.0
White	249	249	*****	*****	*****	*****	256.21 (36.09, 1,818.90)	330	330	87.6
Mounjaro, Cardiac Arrest										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,659	1,659	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,513	2,557	469.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	87	88	17.3
Unknown	8,068	8,068	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,705	13,852	2,244.0
White	9,011	9,011	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,692	14,915	2,468.6
Bydureon, Cardiac Arrest										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	247	247	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	349	349	89.9
White	837	837	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,340	1,340	319.1
Ozempic, Cardiac Arrest										
American Indian or Alaska Native	828	828	*****	*****	*****	*****	95.65 (13.47, 679.05)	1,272	1,277	282.9
Asian	1,399	1,399	*****	*****	*****	*****	48.18 (6.79, 342.01)	2,127	2,131	490.0
Black or African American	9,900	9,900	*****	*****	*****	*****	7.27 (1.02, 51.58)	14,164	14,214	3,624.5
Multi-racial	818	818	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,251	1,256	316.7
Native Hawaiian or Other Pacific Islander	335	335	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	454	454	138.0
Unknown	45,728	45,728	*****	*****	*****	*****	4.77 (1.54, 14.79)	68,823	69,031	16,665.9
White	58,713	58,713	*****	*****	*****	*****	14.25 (8.09, 25.09)	87,056	87,304	20,896.4

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Rybelsus, Cardiac Arrest										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,089	1,089	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,657	1,686	388.0
Black or African American	3,424	3,424	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,718	4,822	1,318.5
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	179	61.8
Unknown	12,876	12,876	*****	*****	*****	*****	5.66 (0.80, 40.16)	18,719	19,156	5,032.0
White	16,493	16,493	*****	*****	*****	*****	4.33 (0.61, 30.73)	24,518	25,014	5,982.0
Wegovy, Cardiac Arrest										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	58	7.1
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	676	676	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,037	1,058	105.7
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Cardiac Arrest										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Cardiac Arrest										
American Indian or Alaska Native	61	61	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23.8

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	36.0
Black or African American	564	564	*****	*****	*****	*****	134.48 (18.94, 954.69)	757	757	231.3
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,443	1,443	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,084	2,085	578.4
White	3,156	3,156	*****	*****	*****	*****	43.51 (10.88, 173.97)	4,599	4,599	1,181.2
Trulicity, Cardiac Arrest										
American Indian or Alaska Native	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	480	483	92.1
Asian	1,205	1,205	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,050	2,058	440.1
Black or African American	6,463	6,463	*****	*****	*****	*****	10.96 (1.54, 77.80)	10,531	10,606	2,596.5
Multi-racial	293	293	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	248	248	*****	*****	*****	*****	254.74 (35.88, 1,808.50)	400	406	121.2
Unknown	21,889	21,889	*****	*****	*****	*****	2.96 (0.42, 21.04)	39,444	39,719	8,769.8
White	36,953	36,953	*****	*****	*****	*****	16.41 (8.54, 31.54)	64,369	64,747	13,797.4
Xultophy, Cardiac Arrest										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	24.0
White	249	249	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	330	87.6
Mounjaro, Ventricular Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,659	1,659	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,513	2,557	469.1

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	87	88	17.3
Unknown	8,068	8,068	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,705	13,852	2,244.0
White	9,011	9,011	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,692	14,915	2,468.6
Bydureon, Ventricular Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	247	247	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	349	349	89.9
White	837	837	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,340	1,340	319.1
Ozempic, Ventricular Tachycardia										
American Indian or Alaska Native	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,272	1,277	282.9
Asian	1,399	1,399	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,127	2,131	490.0
Black or African American	9,900	9,900	*****	*****	*****	*****	14.53 (3.63, 58.10)	14,164	14,214	3,624.5
Multi-racial	818	818	*****	*****	*****	*****	93.00 (13.10, 660.21)	1,251	1,256	316.7
Native Hawaiian or Other Pacific Islander	335	335	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	454	454	138.0
Unknown	45,728	45,728	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68,823	69,031	16,665.9
White	58,713	58,713	*****	*****	*****	*****	4.75 (1.78, 12.65)	87,056	87,304	20,896.4
Rybelsus, Ventricular Tachycardia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,089	1,089	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,657	1,686	388.0
Black or African American	3,424	3,424	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,718	4,822	1,318.5
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiian or Other Pacific Islander	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	179	61.8
Unknown	12,876	12,876	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,719	19,156	5,032.0
White	16,493	16,493	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24,518	25,014	5,982.0
Wegovy, Ventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	58	7.1
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	676	676	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,037	1,058	105.7
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Ventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Ventricular Tachycardia										
American Indian or Alaska Native	61	61	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23.8
Asian	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	36.0
Black or African American	564	564	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	757	757	231.3
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown	1,443	1,443	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,084	2,085	578.4
White	3,156	3,156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,599	4,599	1,181.2
Trulicity, Ventricular Tachycardia										
American Indian or Alaska Native	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	480	483	92.1
Asian	1,205	1,205	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,050	2,058	440.1
Black or African American	6,463	6,463	*****	*****	*****	*****	10.96 (1.54, 77.80)	10,531	10,606	2,596.5
Multi-racial	293	293	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,889	21,889	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39,444	39,719	8,769.8
White	36,953	36,953	*****	*****	*****	*****	5.47 (1.76, 16.96)	64,369	64,747	13,797.4
Xultophy, Ventricular Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	24.0
White	249	249	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	330	87.6
Mounjaro, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,659	1,659	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,513	2,557	469.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	87	88	17.3
Unknown	8,068	8,068	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,705	13,852	2,244.0
White	9,011	9,011	*****	*****	*****	*****	9.52 (1.34, 67.58)	14,692	14,915	2,468.6

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	247	247	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	349	349	89.9
White	837	837	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,340	1,340	319.1
Ozempic, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,272	1,277	282.9
Asian	1,399	1,399	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,127	2,131	490.0
Black or African American	9,900	9,900	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,164	14,214	3,624.5
Multi-racial	818	818	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,251	1,256	316.7
Native Hawaiian or Other Pacific Islander	335	335	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	454	454	138.0
Unknown	45,728	45,728	*****	*****	*****	*****	1.59 (0.22, 11.29)	68,823	69,031	16,665.9
White	58,713	58,713	*****	*****	*****	*****	3.56 (1.15, 11.04)	87,056	87,304	20,896.4
Rybelsus, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,089	1,089	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,657	1,686	388.0
Black or African American	3,424	3,424	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,718	4,822	1,318.5
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	179	61.8
Unknown	12,876	12,876	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,719	19,156	5,032.0
White	16,493	16,493	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24,518	25,014	5,982.0
Wegovy, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	58	7.1
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	676	676	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,037	1,058	105.7
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	61	61	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23.8
Asian	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	36.0
Black or African American	564	564	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	757	757	231.3
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,443	1,443	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,084	2,085	578.4
White	3,156	3,156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,599	4,599	1,181.2
Trulicity, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	480	483	92.1
Asian	1,205	1,205	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,050	2,058	440.1
Black or African American	6,463	6,463	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,531	10,606	2,596.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	293	293	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	248	248	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,889	21,889	*****	*****	*****	*****	5.93 (1.48, 23.70)	39,444	39,719	8,769.8
White	36,953	36,953	*****	*****	*****	*****	5.47 (1.76, 16.96)	64,369	64,747	13,797.4
Xultophy, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	24.0
White	249	249	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	330	87.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	601	601	*****	*****	*****	*****	729.41 (327.69, 1,623.59)	939	939	233.7
No evidence of Other cardiac	727	727	*****	*****	*****	*****	100.50 (14.16, 713.49)	1,137	1,137	285.9
Mounjaro, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	9,025	9,025	*****	*****	*****	*****	789.29 (635.67, 980.02)	14,782	14,983	2,495.5
No evidence of Other cardiac	9,971	9,971	*****	*****	*****	*****	187.69 (123.58, 285.05)	16,545	16,761	2,763.9
Ozempic, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	56,326	56,326	*****	*****	*****	*****	790.20 (730.48, 854.81)	83,553	83,817	20,122.5
No evidence of Other cardiac	61,395	61,395	*****	*****	*****	*****	217.59 (188.68, 250.94)	91,594	91,850	22,291.9
Rybelsus, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	13,847	13,847	*****	*****	*****	*****	742.09 (629.18, 875.27)	20,387	20,820	5,122.5
No evidence of Other cardiac	20,413	20,413	*****	*****	*****	*****	157.22 (117.38, 210.57)	29,777	30,428	7,766.5
Saxenda, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac	227	227	*****	*****	*****	*****	339.77 (47.86, 2,412.12)	348	348	112.9
Trulicity, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	31,574	31,574	*****	*****	*****	*****	817.43 (739.04, 904.13)	54,740	55,085	12,021.7
No evidence of Other cardiac	35,736	35,736	*****	*****	*****	*****	258.14 (218.86, 304.46)	63,134	63,539	13,926.9
Victoza, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	2,632	2,632	*****	*****	*****	*****	1,083.68 (794.90, 1,477.37)	3,746	3,746	1,007.5
No evidence of Other cardiac	2,766	2,766	*****	*****	*****	*****	228.29 (118.78, 438.75)	4,020	4,021	1,078.1
Wegovy, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	347	347	*****	*****	*****	*****	305.78 (43.07, 2,170.81)	566	583	58.5
No evidence of Other cardiac	495	495	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	747	756	80.1
Xultophy, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	187	187	*****	*****	*****	*****	665.85 (166.52, 2,662.41)	256	256	66.5
No evidence of Other cardiac	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	230	65.7
Mounjaro, Atrial Fibrillation and Flutter										

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Evidence of Other cardiac disease	9,025	9,025	*****	*****	*****	*****	558.28 (431.60, 722.14)	14,782	14,983	2,495.5
No evidence of Other cardiac	9,971	9,971	*****	*****	*****	*****	68.25 (34.13, 136.48)	16,545	16,761	2,763.9
Bydureon, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	601	601	*****	*****	*****	*****	486.27 (182.50, 1,295.65)	939	939	233.7
No evidence of Other cardiac	727	727	*****	*****	*****	*****	100.50 (14.16, 713.49)	1,137	1,137	285.9
Ozempic, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	56,326	56,326	*****	*****	*****	*****	566.61 (516.39, 621.71)	83,553	83,817	20,122.5
No evidence of Other cardiac	61,395	61,395	*****	*****	*****	*****	84.04 (66.82, 105.71)	91,594	91,850	22,291.9
Rybelsus, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	13,847	13,847	*****	*****	*****	*****	578.94 (480.25, 697.90)	20,387	20,820	5,122.5
No evidence of Other cardiac	20,413	20,413	*****	*****	*****	*****	66.38 (42.34, 104.07)	29,777	30,428	7,766.5
Wegovy, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	347	347	*****	*****	*****	*****	305.78 (43.07, 2,170.81)	566	583	58.5
No evidence of Other cardiac	495	495	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	747	756	80.1
Saxenda, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	2,632	2,632	*****	*****	*****	*****	704.39 (479.60, 1,034.55)	3,746	3,746	1,007.5
No evidence of Other cardiac	2,766	2,766	*****	*****	*****	*****	76.10 (24.54, 235.95)	4,020	4,021	1,078.1
Trulicity, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	31,574	31,574	*****	*****	*****	*****	627.13 (558.95, 703.63)	54,740	55,085	12,021.7
No evidence of Other cardiac	35,736	35,736	*****	*****	*****	*****	133.64 (106.25, 168.10)	63,134	63,539	13,926.9
Xultophy, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	187	187	*****	*****	*****	*****	332.92 (46.90, 2,363.53)	256	256	66.5
No evidence of Other cardiac	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	230	65.7
Mounjaro, Sinus Tachycardia										
Evidence of Other cardiac disease	9,025	9,025	*****	*****	*****	*****	154.01 (94.35, 251.39)	14,782	14,983	2,495.5

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
No evidence of Other cardiac	9,971	9,971	*****	*****	*****	*****	119.44 (70.74, 201.67)	16,545	16,761	2,763.9
Bydureon, Sinus Tachycardia										
Evidence of Other cardiac disease	601	601	*****	*****	*****	*****	121.57 (17.12, 863.05)	939	939	233.7
No evidence of Other cardiac	727	727	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,137	1,137	285.9
Ozempic, Sinus Tachycardia										
Evidence of Other cardiac disease	56,326	56,326	*****	*****	*****	*****	125.77 (103.28, 153.16)	83,553	83,817	20,122.5
No evidence of Other cardiac	61,395	61,395	*****	*****	*****	*****	95.56 (77.06, 118.49)	91,594	91,850	22,291.9
Rybelsus, Sinus Tachycardia										
Evidence of Other cardiac disease	13,847	13,847	*****	*****	*****	*****	126.31 (84.66, 188.45)	20,387	20,820	5,122.5
No evidence of Other cardiac	20,413	20,413	*****	*****	*****	*****	80.35 (53.40, 120.92)	29,777	30,428	7,766.5
Wegovy, Sinus Tachycardia										
Evidence of Other cardiac disease	347	347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	583	58.5
No evidence of Other cardiac	495	495	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	747	756	80.1
Saxenda, Sinus Tachycardia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac	227	227	*****	*****	*****	*****	339.77 (47.86, 2,412.12)	348	348	112.9
Victoza, Sinus Tachycardia										
Evidence of Other cardiac disease	2,632	2,632	*****	*****	*****	*****	243.83 (126.87, 468.62)	3,746	3,746	1,007.5
No evidence of Other cardiac	2,766	2,766	*****	*****	*****	*****	152.19 (68.37, 338.77)	4,020	4,021	1,078.1
Trulicity, Sinus Tachycardia										
Evidence of Other cardiac disease	31,574	31,574	*****	*****	*****	*****	127.59 (98.85, 164.68)	54,740	55,085	12,021.7
No evidence of Other cardiac	35,736	35,736	*****	*****	*****	*****	91.54 (69.38, 120.78)	63,134	63,539	13,926.9
Xultophy, Sinus Tachycardia										
Evidence of Other cardiac disease	187	187	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	256	256	66.5
No evidence of Other cardiac	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	230	65.7
Mounjaro, Supraventricular Tachycardia										
Evidence of Other cardiac disease	9,025	9,025	*****	*****	*****	*****	77.00 (38.51, 153.98)	14,782	14,983	2,495.5
No evidence of Other cardiac	9,971	9,971	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,545	16,761	2,763.9

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Supraventricular Tachycardia										
Evidence of Other cardiac disease	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	939	233.7
No evidence of Other cardiac	727	727	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,137	1,137	285.9
Ozempic, Supraventricular Tachycardia										
Evidence of Other cardiac disease	56,326	56,326	*****	*****	*****	*****	64.79 (49.24, 85.25)	83,553	83,817	20,122.5
No evidence of Other cardiac	61,395	61,395	*****	*****	*****	*****	25.33 (16.68, 38.47)	91,594	91,850	22,291.9
Rybelsus, Supraventricular Tachycardia										
Evidence of Other cardiac disease	13,847	13,847	*****	*****	*****	*****	57.89 (32.06, 104.54)	20,387	20,820	5,122.5
No evidence of Other cardiac	20,413	20,413	*****	*****	*****	*****	17.47 (7.27, 41.97)	29,777	30,428	7,766.5
Wegovy, Supraventricular Tachycardia										
Evidence of Other cardiac disease	347	347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	583	58.5
No evidence of Other cardiac	495	495	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	747	756	80.1
Saxenda, Supraventricular Tachycardia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac	227	227	*****	*****	*****	*****	339.77 (47.86, 2,412.12)	348	348	112.9
Victoza, Supraventricular Tachycardia										
Evidence of Other cardiac disease	2,632	2,632	*****	*****	*****	*****	162.55 (73.03, 361.82)	3,746	3,746	1,007.5
No evidence of Other cardiac	2,766	2,766	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,020	4,021	1,078.1
Trulicity, Supraventricular Tachycardia										
Evidence of Other cardiac disease	31,574	31,574	*****	*****	*****	*****	62.71 (43.58, 90.25)	54,740	55,085	12,021.7
No evidence of Other cardiac	35,736	35,736	*****	*****	*****	*****	27.46 (16.56, 45.55)	63,134	63,539	13,926.9
Xultophy, Supraventricular Tachycardia										
Evidence of Other cardiac disease	187	187	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	256	256	66.5
No evidence of Other cardiac	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	230	65.7
Mounjaro, Other Tachycardia										
Evidence of Other cardiac disease	9,025	9,025	*****	*****	*****	*****	38.50 (14.45, 102.59)	14,782	14,983	2,495.5
No evidence of Other cardiac	9,971	9,971	*****	*****	*****	*****	8.53 (1.20, 60.57)	16,545	16,761	2,763.9
Bydureon, Other Tachycardia										

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Evidence of Other cardiac disease	601	601	*****	*****	*****	*****	243.14 (60.81, 972.19)	939	939	233.7
No evidence of Other cardiac	727	727	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,137	1,137	285.9
Ozempic, Other Tachycardia										
Evidence of Other cardiac disease	56,326	56,326	*****	*****	*****	*****	49.55 (36.20, 67.81)	83,553	83,817	20,122.5
No evidence of Other cardiac	61,395	61,395	*****	*****	*****	*****	18.42 (11.28, 30.07)	91,594	91,850	22,291.9
Rybelsus, Other Tachycardia										
Evidence of Other cardiac disease	13,847	13,847	*****	*****	*****	*****	21.05 (7.90, 56.09)	20,387	20,820	5,122.5
No evidence of Other cardiac	20,413	20,413	*****	*****	*****	*****	6.99 (1.75, 27.94)	29,777	30,428	7,766.5
Wegovy, Other Tachycardia										
Evidence of Other cardiac disease	347	347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	583	58.5
No evidence of Other cardiac	495	495	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	747	756	80.1
Saxenda, Other Tachycardia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Other Tachycardia										
Evidence of Other cardiac disease	2,632	2,632	*****	*****	*****	*****	81.28 (26.21, 252.01)	3,746	3,746	1,007.5
No evidence of Other cardiac	2,766	2,766	*****	*****	*****	*****	25.37 (3.57, 180.08)	4,020	4,021	1,078.1
Trulicity, Other Tachycardia										
Evidence of Other cardiac disease	31,574	31,574	*****	*****	*****	*****	30.28 (17.93, 51.12)	54,740	55,085	12,021.7
No evidence of Other cardiac	35,736	35,736	*****	*****	*****	*****	12.82 (6.11, 26.88)	63,134	63,539	13,926.9
Xultophy, Other Tachycardia										
Evidence of Other cardiac disease	187	187	*****	*****	*****	*****	332.92 (46.90, 2,363.53)	256	256	66.5
No evidence of Other cardiac	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	230	65.7
Mounjaro, Cardiac Arrest										
Evidence of Other cardiac disease	9,025	9,025	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,782	14,983	2,495.5
No evidence of Other cardiac	9,971	9,971	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,545	16,761	2,763.9
Bydureon, Cardiac Arrest										
Evidence of Other cardiac disease	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	939	233.7

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
No evidence of Other cardiac	727	727	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,137	1,137	285.9
Ozempic, Cardiac Arrest										
Evidence of Other cardiac disease	56,326	56,326	*****	*****	*****	*****	15.25 (8.66, 26.84)	83,553	83,817	20,122.5
No evidence of Other cardiac	61,395	61,395	*****	*****	*****	*****	6.91 (3.10, 15.38)	91,594	91,850	22,291.9
Rybelsus, Cardiac Arrest										
Evidence of Other cardiac disease	13,847	13,847	*****	*****	*****	*****	10.53 (2.63, 42.09)	20,387	20,820	5,122.5
No evidence of Other cardiac	20,413	20,413	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29,777	30,428	7,766.5
Wegovy, Cardiac Arrest										
Evidence of Other cardiac disease	347	347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	583	58.5
No evidence of Other cardiac	495	495	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	747	756	80.1
Saxenda, Cardiac Arrest										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Cardiac Arrest										
Evidence of Other cardiac disease	2,632	2,632	*****	*****	*****	*****	81.28 (26.21, 252.01)	3,746	3,746	1,007.5
No evidence of Other cardiac	2,766	2,766	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,020	4,021	1,078.1
Trulicity, Cardiac Arrest										
Evidence of Other cardiac disease	31,574	31,574	*****	*****	*****	*****	19.46 (10.13, 37.41)	54,740	55,085	12,021.7
No evidence of Other cardiac	35,736	35,736	*****	*****	*****	*****	5.49 (1.77, 17.03)	63,134	63,539	13,926.9
Xultophy, Cardiac Arrest										
Evidence of Other cardiac disease	187	187	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	256	256	66.5
No evidence of Other cardiac	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	230	65.7
Mounjaro, Ventricular Tachycardia										
Evidence of Other cardiac disease	9,025	9,025	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,782	14,983	2,495.5
No evidence of Other cardiac	9,971	9,971	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,545	16,761	2,763.9
Bydureon, Ventricular Tachycardia										
Evidence of Other cardiac disease	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	939	233.7
No evidence of Other cardiac	727	727	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,137	1,137	285.9

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Ozempic, Ventricular Tachycardia										
Evidence of Other cardiac disease	56,326	56,326	*****	*****	*****	*****	6.35 (2.64, 15.26)	83,553	83,817	20,122.5
No evidence of Other cardiac	61,395	61,395	*****	*****	*****	*****	2.30 (0.58, 9.21)	91,594	91,850	22,291.9
Rybelsus, Ventricular Tachycardia										
Evidence of Other cardiac disease	13,847	13,847	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20,387	20,820	5,122.5
No evidence of Other cardiac	20,413	20,413	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29,777	30,428	7,766.5
Wegovy, Ventricular Tachycardia										
Evidence of Other cardiac disease	347	347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	583	58.5
No evidence of Other cardiac	495	495	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	747	756	80.1
Saxenda, Ventricular Tachycardia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Ventricular Tachycardia										
Evidence of Other cardiac disease	2,632	2,632	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,746	3,746	1,007.5
No evidence of Other cardiac	2,766	2,766	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,020	4,021	1,078.1
Trulicity, Ventricular Tachycardia										
Evidence of Other cardiac disease	31,574	31,574	*****	*****	*****	*****	8.65 (3.25, 23.05)	54,740	55,085	12,021.7
No evidence of Other cardiac	35,736	35,736	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	63,134	63,539	13,926.9
Xultophy, Ventricular Tachycardia										
Evidence of Other cardiac disease	187	187	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	256	256	66.5
No evidence of Other cardiac	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	230	65.7
Mounjaro, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	9,025	9,025	*****	*****	*****	*****	9.63 (1.36, 68.33)	14,782	14,983	2,495.5
No evidence of Other cardiac	9,971	9,971	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,545	16,761	2,763.9
Bydureon, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	939	233.7
No evidence of Other cardiac	727	727	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,137	1,137	285.9
Ozempic, Ventricular Fibrillation and Flutter										

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Evidence of Other cardiac disease	56,326	56,326	*****	*****	*****	*****	5.08 (1.91, 13.54)	83,553	83,817	20,122.5
No evidence of Other cardiac	61,395	61,395	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	91,594	91,850	22,291.9
Rybelsus, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	13,847	13,847	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20,387	20,820	5,122.5
No evidence of Other cardiac	20,413	20,413	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29,777	30,428	7,766.5
Wegovy, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	347	347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	583	58.5
No evidence of Other cardiac	495	495	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	747	756	80.1
Saxenda, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	2,632	2,632	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,746	3,746	1,007.5
No evidence of Other cardiac	2,766	2,766	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,020	4,021	1,078.1
Trulicity, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	31,574	31,574	*****	*****	*****	*****	8.65 (3.25, 23.05)	54,740	55,085	12,021.7
No evidence of Other cardiac	35,736	35,736	*****	*****	*****	*****	1.83 (0.26, 13.00)	63,134	63,539	13,926.9
Xultophy, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	187	187	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	256	256	66.5
No evidence of Other cardiac	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	230	65.7

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	*****	*****	*****	*****	6,190.68 (872.01, 43,949.65)	16	16	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	6.5
41-64 years	119	119	*****	*****	*****	*****	613.66 (86.44, 4,356.57)	161	161	42.5
65-74 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	131	131	30.1
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	252	252	*****	*****	*****	*****	621.44 (155.42, 2,484.84)	405	405	99.0
65-74 years	389	389	*****	*****	*****	*****	166.89 (23.51, 1,184.79)	656	656	152.2
75-84 years	150	150	*****	*****	*****	*****	534.54 (75.29, 3,794.86)	218	218	49.9
≥ 85 years	12	12	*****	*****	*****	*****	12,215.72 (1,720.69, 86,723.38)	16	16	3.9
Mounjaro, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	74	13.5
41-64 years	678	678	*****	*****	*****	*****	789.90 (354.87, 1,758.25)	1,081	1,092	199.4
65-74 years	754	754	*****	*****	*****	*****	367.66 (118.58, 1,139.99)	1,110	1,136	210.2
75-84 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	240	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	*****	*****	*****	*****	7,305.00 (1,028.97, 51,860.58)	20	20	3.7
41-64 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	1.6
65-74 years	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	862	862	*****	*****	*****	*****	104.42 (14.71, 741.33)	1,430	1,447	232.9
41-64 years	6,131	6,131	*****	*****	*****	*****	177.20 (102.89, 305.18)	10,529	10,640	1,735.1
65-74 years	905	905	*****	*****	*****	*****	688.85 (328.40, 1,444.96)	1,481	1,496	233.9
75-84 years	*****	*****	*****	*****	*****	*****	616.77 (86.88, 4,378.64)	252	256	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	116	116	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	216	218	33.2
41-64 years	2,416	2,416	*****	*****	*****	*****	690.28 (445.34, 1,069.96)	4,137	4,201	726.0
65-74 years	4,885	4,885	*****	*****	*****	*****	631.74 (455.69, 875.80)	7,894	8,015	1,302.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	1,519	1,519	*****	*****	*****	*****	827.47 (490.06, 1,397.17)	2,339	2,373	390.3
≥ 85 years	75	75	*****	*****	*****	*****	2,828.11 (707.28, 11,308.30)	106	108	16.6
Ozempic, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	*****	*****	*****	*****	1,156.22 (433.94, 3,080.70)	409	411	89.4
65-74 years	362	362	*****	*****	*****	*****	652.27 (210.37, 2,022.45)	567	570	120.8
75-84 years	166	166	*****	*****	*****	*****	2,505.14 (1,042.69, 6,018.78)	240	240	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	*****	*****	*****	*****	2,051.39 (513.03, 8,202.57)	111	111	29.8
41-64 years	363	363	*****	*****	*****	*****	186.69 (26.30, 1,325.34)	566	566	138.9
65-74 years	658	658	*****	*****	*****	*****	410.00 (153.88, 1,092.43)	985	988	218.0
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	*****	*****	*****	*****	2,728.80 (682.45, 10,911.22)	80	80	16.7
<i>Black or African American</i>										
0-40 years	315	315	*****	*****	*****	*****	497.24 (124.36, 1,988.25)	436	438	111.5
41-64 years	3,829	3,829	*****	*****	*****	*****	589.35 (414.47, 838.03)	5,642	5,669	1,411.3
65-74 years	4,535	4,535	*****	*****	*****	*****	469.62 (328.35, 671.67)	6,402	6,417	1,655.4
75-84 years	1,119	1,119	*****	*****	*****	*****	568.06 (295.57, 1,091.78)	1,544	1,549	409.2
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	119	119	*****	*****	*****	*****	689.02 (97.05, 4,891.59)	172	173	42.9
41-64 years	624	624	*****	*****	*****	*****	122.08 (17.20, 866.65)	954	958	241.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	*****	*****	*****	*****	1,037.05 (146.08, 7,362.38)	108	108	30.3
75-84 years	*****	*****	*****	*****	*****	*****	6,852.72 (965.26, 48,649.70)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	4.2
41-64 years	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	24.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	247	247	77.6
75-84 years	82	82	*****	*****	*****	*****	1,652.71 (413.33, 6,608.45)	101	101	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,065	4,065	*****	*****	*****	*****	157.40 (78.71, 314.74)	5,922	5,939	1,438.6
41-64 years	31,892	31,892	*****	*****	*****	*****	211.17 (172.33, 258.76)	48,462	48,612	11,773.7
65-74 years	7,803	7,803	*****	*****	*****	*****	298.95 (212.53, 420.51)	11,619	11,654	2,756.5
75-84 years	1,823	1,823	*****	*****	*****	*****	633.65 (388.19, 1,034.32)	2,622	2,628	648.1
≥ 85 years	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	198	198	49.1
<i>White</i>										
0-40 years	931	931	*****	*****	*****	*****	386.65 (160.93, 928.95)	1,486	1,493	343.0
41-64 years	14,102	14,102	*****	*****	*****	*****	551.17 (456.83, 664.99)	21,520	21,590	5,254.4
65-74 years	31,009	31,009	*****	*****	*****	*****	595.90 (529.02, 671.25)	46,066	46,191	10,892.7
75-84 years	11,726	11,726	*****	*****	*****	*****	943.25 (805.85, 1,104.08)	16,655	16,700	4,074.3
≥ 85 years	945	945	*****	*****	*****	*****	1,760.13 (1,158.95, 2,673.15)	1,329	1,330	332.0
Rybelsus, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	285	294	67.4
65-74 years	525	525	*****	*****	*****	*****	128.43 (18.09, 911.75)	760	771	187.7
75-84 years	292	292	*****	*****	*****	*****	214.36 (30.19, 1,521.82)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	89	89	*****	*****	*****	*****	2,855.75 (921.02, 8,854.62)	128	132	29.8
41-64 years	995	995	*****	*****	*****	*****	154.85 (38.73, 619.17)	1,416	1,448	395.1
65-74 years	1,694	1,694	*****	*****	*****	*****	471.43 (261.07, 851.27)	2,312	2,366	653.1
75-84 years	570	570	*****	*****	*****	*****	264.34 (66.11, 1,056.97)	755	766	211.8
≥ 85 years	76	76	*****	*****	*****	*****	944.77 (133.08, 6,707.27)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	27	8.5
65-74 years	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	85	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	776	776	*****	*****	*****	*****	100.62 (14.17, 714.35)	1,109	1,130	291.8
41-64 years	7,993	7,993	*****	*****	*****	*****	191.64 (124.95, 293.93)	11,630	11,924	3,223.3
65-74 years	3,052	3,052	*****	*****	*****	*****	256.31 (141.94, 462.83)	4,422	4,519	1,128.2
75-84 years	904	904	*****	*****	*****	*****	245.29 (79.11, 760.56)	1,326	1,348	332.8
≥ 85 years	151	151	*****	*****	*****	*****	938.70 (234.76, 3,753.45)	232	235	55.8
<i>White</i>										
0-40 years	209	209	*****	*****	*****	*****	399.05 (56.21, 2,832.98)	303	309	70.2
41-64 years	3,018	3,018	*****	*****	*****	*****	395.94 (246.14, 636.91)	4,617	4,717	1,160.9
65-74 years	8,362	8,362	*****	*****	*****	*****	353.49 (261.23, 478.32)	12,388	12,650	3,039.0
75-84 years	4,328	4,328	*****	*****	*****	*****	960.65 (741.00, 1,245.40)	6,355	6,476	1,517.1
≥ 85 years	576	576	*****	*****	*****	*****	1,343.23 (722.72, 2,496.48)	855	862	194.8
Saxenda, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	*****	*****	*****	*****	274.85 (38.72, 1,951.26)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Trulicity, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	176	178	39.0
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	222	222	*****	*****	*****	*****	325.83 (45.90, 2,313.14)	367	367	84.8
65-74 years	571	571	*****	*****	*****	*****	211.49 (52.89, 845.67)	974	979	208.2
75-84 years	297	297	*****	*****	*****	*****	212.37 (29.91, 1,507.66)	495	497	105.0
≥ 85 years	69	69	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	21.9
<i>Black or African American</i>										
0-40 years	220	220	*****	*****	*****	*****	329.20 (46.37, 2,337.12)	378	379	84.3
41-64 years	2,128	2,128	*****	*****	*****	*****	538.18 (329.70, 878.48)	3,624	3,655	841.7
65-74 years	2,967	2,967	*****	*****	*****	*****	284.28 (161.45, 500.58)	4,743	4,776	1,206.9
75-84 years	1,029	1,029	*****	*****	*****	*****	878.44 (510.07, 1,512.86)	1,599	1,608	418.8
≥ 85 years	119	119	*****	*****	*****	*****	2,037.09 (656.99, 6,316.27)	187	188	44.8
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	224	224	*****	*****	*****	*****	519.08 (129.82, 2,075.56)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	*****	*****	*****	*****	2,269.34 (567.54, 9,074.04)	90	90	30.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.7
<i>Unknown</i>										
0-40 years	1,585	1,585	*****	*****	*****	*****	413.81 (215.31, 795.31)	2,738	2,759	633.3
41-64 years	13,656	13,656	*****	*****	*****	*****	213.35 (159.81, 284.84)	25,130	25,321	5,601.4
65-74 years	4,908	4,908	*****	*****	*****	*****	466.11 (334.66, 649.19)	8,602	8,649	1,869.7
75-84 years	1,540	1,540	*****	*****	*****	*****	801.80 (505.16, 1,272.62)	2,644	2,659	596.2
≥ 85 years	200	200	*****	*****	*****	*****	1,173.18 (378.37, 3,637.60)	330	331	69.2
<i>White</i>										
0-40 years	539	539	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,002	1,009	186.9
41-64 years	7,502	7,502	*****	*****	*****	*****	499.59 (383.56, 650.71)	13,487	13,577	2,965.5
65-74 years	18,807	18,807	*****	*****	*****	*****	576.51 (494.70, 671.86)	32,684	32,873	6,984.2
75-84 years	8,928	8,928	*****	*****	*****	*****	888.64 (740.79, 1,066.01)	15,125	15,209	3,254.4
≥ 85 years	1,177	1,177	*****	*****	*****	*****	1,291.37 (833.13, 2,001.65)	2,071	2,079	406.4
Victoza, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
41-64 years	28	28	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	12.8
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	*****	*****	*****	*****	10,495.69 (1,478.41, 74,512.33)	11	11	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	9.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24	24	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	253	253	*****	*****	*****	*****	911.08 (293.84, 2,824.91)	345	345	101.9
65-74 years	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	304	304	97.7
75-84 years	*****	*****	*****	*****	*****	*****	2,209.62 (311.24, 15,686.81)	43	43	15.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	*****	*****	*****	*****	528.43 (74.43, 3,751.49)	201	201	55.5
41-64 years	852	852	*****	*****	*****	*****	412.58 (171.73, 991.26)	1,273	1,274	357.0
65-74 years	341	341	*****	*****	*****	*****	644.18 (207.76, 1,997.37)	466	466	126.9
75-84 years	93	93	*****	*****	*****	*****	932.47 (131.35, 6,619.94)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	97	97	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	166	166	41.3
41-64 years	956	956	*****	*****	*****	*****	597.53 (298.82, 1,194.85)	1,433	1,433	369.8
65-74 years	1,426	1,426	*****	*****	*****	*****	467.23 (251.39, 868.37)	2,057	2,057	527.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	603	603	*****	*****	*****	*****	1,690.19 (1,018.95, 2,803.62)	845	845	215.7
≥ 85 years	74	74	*****	*****	*****	*****	1,149.67 (161.94, 8,161.88)	98	98	27.5
Wegovy, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	4.7
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	117	117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	169	175	14.9
41-64 years	529	529	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	813	826	85.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	49	50	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	*****	*****	*****	*****	4,217.67 (594.09, 29,942.60)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Xultophy, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	163	163	50.3
75-84 years	66	66	*****	*****	*****	*****	1,956.35 (489.27, 7,822.53)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	4.6
Mounjaro, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	74	13.5
41-64 years	678	678	*****	*****	*****	*****	658.25 (273.98, 1,581.49)	1,081	1,092	199.4
65-74 years	754	754	*****	*****	*****	*****	245.11 (61.30, 980.08)	1,110	1,136	210.2
75-84 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	240	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	1.6
65-74 years	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	862	862	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,430	1,447	232.9
41-64 years	6,131	6,131	*****	*****	*****	*****	95.42 (45.49, 200.15)	10,529	10,640	1,735.1
65-74 years	905	905	*****	*****	*****	*****	393.63 (147.73, 1,048.81)	1,481	1,496	233.9
75-84 years	*****	*****	*****	*****	*****	*****	616.77 (86.88, 4,378.64)	252	256	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	116	116	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	216	218	33.2
41-64 years	2,416	2,416	*****	*****	*****	*****	379.66 (210.25, 685.55)	4,137	4,201	726.0
65-74 years	4,885	4,885	*****	*****	*****	*****	403.61 (268.21, 607.37)	7,894	8,015	1,302.6
75-84 years	1,519	1,519	*****	*****	*****	*****	709.26 (402.79, 1,248.90)	2,339	2,373	390.3
≥ 85 years	75	75	*****	*****	*****	*****	1,414.05 (199.18, 10,038.83)	106	108	16.6
Bydureon, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	6.5
41-64 years	119	119	*****	*****	*****	*****	613.66 (86.44, 4,356.57)	161	161	42.5
65-74 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	131	131	30.1
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	252	252	*****	*****	*****	*****	621.44 (155.42, 2,484.84)	405	405	99.0
65-74 years	389	389	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	656	656	152.2
75-84 years	150	150	*****	*****	*****	*****	534.54 (75.29, 3,794.86)	218	218	49.9
≥ 85 years	12	12	*****	*****	*****	*****	12,215.72 (1,720.69, 86,723.38)	16	16	3.9
Ozempic, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	*****	*****	*****	*****	578.11 (144.58, 2,311.60)	409	411	89.4
65-74 years	362	362	*****	*****	*****	*****	434.85 (108.75, 1,738.75)	567	570	120.8
75-84 years	166	166	*****	*****	*****	*****	2,505.14 (1,042.69, 6,018.78)	240	240	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	*****	*****	*****	*****	1,025.70 (144.48, 7,281.74)	111	111	29.8
41-64 years	363	363	*****	*****	*****	*****	186.69 (26.30, 1,325.34)	566	566	138.9
65-74 years	658	658	*****	*****	*****	*****	102.50 (14.44, 727.68)	985	988	218.0
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	315	315	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	436	438	111.5
41-64 years	3,829	3,829	*****	*****	*****	*****	266.16 (157.63, 449.41)	5,642	5,669	1,411.3
65-74 years	4,535	4,535	*****	*****	*****	*****	250.46 (153.44, 408.84)	6,402	6,417	1,655.4
75-84 years	1,119	1,119	*****	*****	*****	*****	378.71 (170.14, 842.97)	1,544	1,549	409.2
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	172	173	42.9
41-64 years	624	624	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	954	958	241.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	*****	*****	*****	*****	1,037.05 (146.08, 7,362.38)	108	108	30.3
75-84 years	*****	*****	*****	*****	*****	*****	6,852.72 (965.26, 48,649.70)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	24.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	247	247	77.6
75-84 years	82	82	*****	*****	*****	*****	1,652.71 (413.33, 6,608.45)	101	101	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,065	4,065	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,922	5,939	1,438.6
41-64 years	31,892	31,892	*****	*****	*****	*****	108.99 (82.13, 144.63)	48,462	48,612	11,773.7
65-74 years	7,803	7,803	*****	*****	*****	*****	199.30 (131.23, 302.68)	11,619	11,654	2,756.5
75-84 years	1,823	1,823	*****	*****	*****	*****	594.05 (358.13, 985.39)	2,622	2,628	648.1
≥ 85 years	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	198	198	49.1
<i>White</i>										
0-40 years	931	931	*****	*****	*****	*****	77.33 (10.89, 548.99)	1,486	1,493	343.0
41-64 years	14,102	14,102	*****	*****	*****	*****	268.00 (204.74, 350.80)	21,520	21,590	5,254.4
65-74 years	31,009	31,009	*****	*****	*****	*****	413.39 (358.33, 476.92)	46,066	46,191	10,892.7
75-84 years	11,726	11,726	*****	*****	*****	*****	730.26 (610.62, 873.34)	16,655	16,700	4,074.3
≥ 85 years	945	945	*****	*****	*****	*****	1,600.11 (1,032.32, 2,480.21)	1,329	1,330	332.0
Rybelsus, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	285	294	67.4
65-74 years	525	525	*****	*****	*****	*****	128.43 (18.09, 911.75)	760	771	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	89	89	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	128	132	29.8
41-64 years	995	995	*****	*****	*****	*****	77.42 (10.91, 549.66)	1,416	1,448	395.1
65-74 years	1,694	1,694	*****	*****	*****	*****	385.71 (200.69, 741.32)	2,312	2,366	653.1
75-84 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	755	766	211.8
≥ 85 years	76	76	*****	*****	*****	*****	944.77 (133.08, 6,707.27)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	27	8.5
65-74 years	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	85	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	776	776	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,109	1,130	291.8

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	7,993	7,993	*****	*****	*****	*****	100.38 (55.59, 181.27)	11,630	11,924	3,223.3
65-74 years	3,052	3,052	*****	*****	*****	*****	116.51 (48.49, 279.91)	4,422	4,519	1,128.2
75-84 years	904	904	*****	*****	*****	*****	245.29 (79.11, 760.56)	1,326	1,348	332.8
≥ 85 years	151	151	*****	*****	*****	*****	469.35 (66.11, 3,332.09)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	3,018	3,018	*****	*****	*****	*****	232.90 (125.31, 432.87)	4,617	4,717	1,160.9
65-74 years	8,362	8,362	*****	*****	*****	*****	277.74 (197.45, 390.68)	12,388	12,650	3,039.0
75-84 years	4,328	4,328	*****	*****	*****	*****	758.41 (566.25, 1,015.77)	6,355	6,476	1,517.1
≥ 85 years	576	576	*****	*****	*****	*****	1,208.90 (629.00, 2,323.44)	855	862	194.8
Wegovy, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	4.7
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	117	117	0	0.00 (0.00, 0.00)	9.4	3,417	0.00 (0.00, 0.00)	169	175	14.9
41-64 years	529	529	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	813	826	85.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	49	50	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	*****	*****	*****	*****	29,942.60)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
41-64 years	28	28	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	12.8
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	*****	*****	*****	*****	10,495.69 (1,478.41, 74,512.33)	11	11	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24	24	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	253	253	*****	*****	*****	*****	303.69 (42.78, 2,156.01)	345	345	101.9
65-74 years	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	304	304	97.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
							2,209.62 (311.24, 15,686.81)			
75-84 years	*****	*****	*****	*****	*****	*****	15,686.81)	43	43	15.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	852	852	*****	*****	*****	*****	82.52 (11.62, 585.81)	1,273	1,274	357.0
65-74 years	341	341	*****	*****	*****	*****	429.45 (107.40, 1,717.19)	466	466	126.9
75-84 years	93	93	*****	*****	*****	*****	932.47 (131.35, 6,619.94)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	97	97	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	166	166	41.3
41-64 years	956	956	*****	*****	*****	*****	298.77 (112.13, 796.05)	1,433	1,433	369.8
65-74 years	1,426	1,426	*****	*****	*****	*****	280.34 (125.94, 624.00)	2,057	2,057	527.0
							1,239.47 (686.41, 2,238.15)			
75-84 years	603	603	*****	*****	*****	*****	2,238.15)	845	845	215.7
≥ 85 years	74	74	*****	*****	*****	*****	1,149.67 (161.94, 8,161.88)	98	98	27.5
Trulicity, Atrial Fibrillation and Flutter										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	176	178	39.0
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	222	222	*****	*****	*****	*****	325.83 (45.90, 2,313.14)	367	367	84.8
65-74 years	571	571	*****	*****	*****	*****	105.75 (14.90, 750.73)	974	979	208.2
75-84 years	297	297	*****	*****	*****	*****	212.37 (29.91, 1,507.66)	495	497	105.0
≥ 85 years	69	69	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	21.9
<i>Black or African American</i>										
0-40 years	220	220	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	378	379	84.3
41-64 years	2,128	2,128	*****	*****	*****	*****	269.09 (134.57, 538.08)	3,624	3,655	841.7
65-74 years	2,967	2,967	*****	*****	*****	*****	142.14 (63.86, 316.40)	4,743	4,776	1,206.9
75-84 years	1,029	1,029	*****	*****	*****	*****	405.44 (182.14, 902.46)	1,599	1,608	418.8
≥ 85 years	119	119	*****	*****	*****	*****	1,358.06 (339.64, 5,430.25)	187	188	44.8
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	224	224	*****	*****	*****	*****	259.54 (36.56, 1,842.56)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.7
<i>Unknown</i>										
0-40 years	1,585	1,585	*****	*****	*****	*****	137.94 (44.49, 427.69)	2,738	2,759	633.3
41-64 years	13,656	13,656	*****	*****	*****	*****	102.04 (67.19, 154.97)	25,130	25,321	5,601.4
65-74 years	4,908	4,908	*****	*****	*****	*****	306.30 (203.54, 460.94)	8,602	8,649	1,869.7
75-84 years	1,540	1,540	*****	*****	*****	*****	712.71 (436.62, 1,163.37)	2,644	2,659	596.2
≥ 85 years	200	200	*****	*****	*****	*****	782.12 (195.60, 3,127.34)	330	331	69.2
<i>White</i>										
0-40 years	539	539	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,002	1,009	186.9
41-64 years	7,502	7,502	*****	*****	*****	*****	245.25 (168.19, 357.63)	13,487	13,577	2,965.5
65-74 years	18,807	18,807	*****	*****	*****	*****	446.44 (375.18, 531.25)	32,684	32,873	6,984.2
75-84 years	8,928	8,928	*****	*****	*****	*****	743.09 (608.99, 906.71)	15,125	15,209	3,254.4
≥ 85 years	1,177	1,177	*****	*****	*****	*****	1,291.37 (833.13, 2,001.65)	2,071	2,079	406.4
Xultophy, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	163	163	50.3
75-84 years	66	66	*****	*****	*****	*****	978.17 (137.78, 6,944.37)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	4.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	74	13.5
41-64 years	678	678	*****	*****	*****	*****	131.65 (18.54, 934.63)	1,081	1,092	199.4
65-74 years	754	754	*****	*****	*****	*****	122.55 (17.26, 870.06)	1,110	1,136	210.2
75-84 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	240	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	*****	*****	*****	*****	7,305.00 (1,028.97, 51,860.58)	20	20	3.7
41-64 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	1.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	862	862	*****	*****	*****	*****	104.42 (14.71, 741.33)	1,430	1,447	232.9
41-64 years	6,131	6,131	*****	*****	*****	*****	68.15 (28.37, 163.74)	10,529	10,640	1,735.1
65-74 years	905	905	*****	*****	*****	*****	196.82 (49.22, 786.97)	1,481	1,496	233.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	252	256	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	116	116	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	216	218	33.2
41-64 years	2,416	2,416	*****	*****	*****	*****	310.63 (161.62, 597.01)	4,137	4,201	726.0
65-74 years	4,885	4,885	*****	*****	*****	*****	122.84 (58.56, 257.67)	7,894	8,015	1,302.6
75-84 years	1,519	1,519	*****	*****	*****	*****	118.21 (29.56, 472.67)	2,339	2,373	390.3
≥ 85 years	75	75	*****	*****	*****	*****	1,414.05 (199.18, 10,038.83)	106	108	16.6
Bydureon, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	*****	*****	*****	*****	6,190.68 (872.01, 43,949.65)	16	16	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	0.0	10	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	6.5
41-64 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	42.5
65-74 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	131	131	30.1
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	252	252	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	405	405	99.0
65-74 years	389	389	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	656	656	152.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	150	150	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	218	218	49.9
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	*****	*****	*****	*****	289.06 (40.72, 2,052.10)	409	411	89.4
65-74 years	362	362	*****	*****	*****	*****	217.42 (30.63, 1,543.56)	567	570	120.8
75-84 years	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	*****	*****	*****	*****	1,025.70 (144.48, 7,281.74)	111	111	29.8
41-64 years	363	363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	566	138.9
65-74 years	658	658	*****	*****	*****	*****	102.50 (14.44, 727.68)	985	988	218.0
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	315	315	*****	*****	*****	*****	497.24 (124.36, 1,988.25)	436	438	111.5
41-64 years	3,829	3,829	*****	*****	*****	*****	228.14 (129.56, 401.72)	5,642	5,669	1,411.3
65-74 years	4,535	4,535	*****	*****	*****	*****	140.89 (73.30, 270.77)	6,402	6,417	1,655.4
75-84 years	1,119	1,119	*****	*****	*****	*****	63.12 (8.89, 448.09)	1,544	1,549	409.2
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	119	119	*****	*****	*****	*****	689.02 (97.05, 4,891.59)	172	173	42.9
41-64 years	624	624	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	954	958	241.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	4.2
41-64 years	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	24.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	247	247	77.6
75-84 years	82	82	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	101	101	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,065	4,065	*****	*****	*****	*****	137.72 (65.66, 288.89)	5,922	5,939	1,438.6
41-64 years	31,892	31,892	*****	*****	*****	*****	63.58 (43.90, 92.08)	48,462	48,612	11,773.7
65-74 years	7,803	7,803	*****	*****	*****	*****	36.24 (13.60, 96.55)	11,619	11,654	2,756.5
75-84 years	1,823	1,823	*****	*****	*****	*****	39.60 (5.58, 281.16)	2,622	2,628	648.1
≥ 85 years	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	198	198	49.1
<i>White</i>										
0-40 years	931	931	*****	*****	*****	*****	309.32 (116.09, 824.16)	1,486	1,493	343.0
41-64 years	14,102	14,102	*****	*****	*****	*****	222.49 (165.57, 298.98)	21,520	21,590	5,254.4
65-74 years	31,009	31,009	*****	*****	*****	*****	103.35 (77.65, 137.55)	46,066	46,191	10,892.7
75-84 years	11,726	11,726	*****	*****	*****	*****	109.54 (69.01, 173.86)	16,655	16,700	4,074.3
≥ 85 years	945	945	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,329	1,330	332.0
Rybelsus, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	285	294	67.4
65-74 years	525	525	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	760	771	187.7
75-84 years	292	292	*****	*****	*****	*****	214.36 (30.19, 1,521.82)	457	465	98.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>							2,855.75 (921.02, 8,854.62)	128	132	29.8
0-40 years	89	89	*****	*****	*****	*****	77.42 (10.91, 549.66)	1,416	1,448	395.1
41-64 years	995	995	*****	*****	*****	*****	85.71 (21.44, 342.73)	2,312	2,366	653.1
65-74 years	1,694	1,694	*****	*****	*****	*****	132.17 (18.62, 938.31)	755	766	211.8
75-84 years	570	570	*****	*****	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>							0.00 (0.00, 0.00)	38	38	9.5
0-40 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>							0.00 (0.00, 0.00)	*****	*****	0.8
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	27	8.5
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	85	32.6
65-74 years	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>							100.62 (14.17, 714.35)	1,109	1,130	291.8
0-40 years	776	776	*****	*****	*****	*****	82.13 (42.73, 157.85)	11,630	11,924	3,223.3
41-64 years	7,993	7,993	*****	*****	*****	*****	93.20 (34.98, 248.34)	4,422	4,519	1,128.2
65-74 years	3,052	3,052	*****	*****	*****	*****	0.00 (0.00, 0.00)	1,326	1,348	332.8
75-84 years	904	904	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
<i>White</i>							399.05 (56.21, 2,832.98)	303	309	70.2
0-40 years	209	209	*****	*****	*****	*****	163.03 (77.72, 341.98)	4,617	4,717	1,160.9
41-64 years	3,018	3,018	*****	*****	*****	*****				

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	8,362	8,362	*****	*****	*****	*****	58.91 (28.09, 123.58)	12,388	12,650	3,039.0
75-84 years	4,328	4,328	*****	*****	*****	*****	168.53 (90.68, 313.23)	6,355	6,476	1,517.1
≥ 85 years	576	576	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	855	862	194.8
Wegovy, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	4.7
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	117	117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	169	175	14.9
41-64 years	529	529	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	813	826	85.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	49	50	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	*****	*****	*****	*****	274.85 (38.72, 1,951.26)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
41-64 years	28	28	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	12.8
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24	24	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	253	253	*****	*****	*****	*****	303.69 (42.78, 2,156.01)	345	345	101.9
65-74 years	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	304	304	97.7
75-84 years	*****	*****	*****	*****	*****	*****	15,686.81)	43	43	15.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	*****	*****	*****	*****	528.43 (74.43, 3,751.49)	201	201	55.5
41-64 years	852	852	*****	*****	*****	*****	330.07 (123.88, 879.44)	1,273	1,274	357.0
65-74 years	341	341	*****	*****	*****	*****	214.73 (30.25, 1,524.41)	466	466	126.9
75-84 years	93	93	*****	*****	*****	*****	932.47 (131.35, 6,619.94)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	97	97	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	166	166	41.3
41-64 years	956	956	*****	*****	*****	*****	224.08 (72.27, 694.78)	1,433	1,433	369.8
65-74 years	1,426	1,426	*****	*****	*****	*****	93.45 (23.37, 373.65)	2,057	2,057	527.0
75-84 years	603	603	*****	*****	*****	*****	112.68 (15.87, 799.95)	845	845	215.7
≥ 85 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	27.5
Trulicity, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	176	178	39.0
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	222	222	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	367	367	84.8
65-74 years	571	571	*****	*****	*****	*****	105.75 (14.90, 750.73)	974	979	208.2
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	69	69	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	21.9
<i>Black or African American</i>										
0-40 years	220	220	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	378	379	84.3
41-64 years	2,128	2,128	*****	*****	*****	*****	235.45 (112.25, 493.90)	3,624	3,655	841.7
65-74 years	2,967	2,967	*****	*****	*****	*****	142.14 (63.86, 316.40)	4,743	4,776	1,206.9
75-84 years	1,029	1,029	*****	*****	*****	*****	337.86 (140.63, 811.74)	1,599	1,608	418.8
≥ 85 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	187	188	44.8
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	224	224	*****	*****	*****	*****	259.54 (36.56, 1,842.56)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.7
<i>Unknown</i>										
0-40 years	1,585	1,585	*****	*****	*****	*****	275.87 (123.94, 614.07)	2,738	2,759	633.3
41-64 years	13,656	13,656	*****	*****	*****	*****	88.12 (56.21, 138.16)	25,130	25,321	5,601.4
65-74 years	4,908	4,908	*****	*****	*****	*****	119.86 (62.36, 230.36)	8,602	8,649	1,869.7
75-84 years	1,540	1,540	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,644	2,659	596.2
≥ 85 years	200	200	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	331	69.2
<i>White</i>										
0-40 years	539	539	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,002	1,009	186.9
41-64 years	7,502	7,502	*****	*****	*****	*****	190.75 (124.37, 292.56)	13,487	13,577	2,965.5
65-74 years	18,807	18,807	*****	*****	*****	*****	80.85 (53.73, 121.67)	32,684	32,873	6,984.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	8,928	8,928	*****	*****	*****	*****	84.27 (46.67, 152.16)	15,125	15,209	3,254.4
≥ 85 years	1,177	1,177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,071	2,079	406.4
Xultophy, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	163	163	50.3
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	4.6
Mounjaro, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	74	13.5
41-64 years	678	678	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,081	1,092	199.4
65-74 years	754	754	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,110	1,136	210.2
75-84 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	240	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	1.6
65-74 years	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	862	862	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,430	1,447	232.9
41-64 years	6,131	6,131	*****	*****	*****	*****	13.63 (1.92, 96.77)	10,529	10,640	1,735.1
65-74 years	905	905	*****	*****	*****	*****	98.41 (13.86, 698.63)	1,481	1,496	233.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	252	256	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	116	116	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	216	218	33.2
41-64 years	2,416	2,416	*****	*****	*****	*****	69.03 (17.26, 276.01)	4,137	4,201	726.0
65-74 years	4,885	4,885	*****	*****	*****	*****	70.19 (26.34, 187.03)	7,894	8,015	1,302.6
75-84 years	1,519	1,519	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,339	2,373	390.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	6.5
41-64 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	42.5
65-74 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	131	131	30.1
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	252	252	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	405	405	99.0
65-74 years	389	389	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	656	656	152.2
75-84 years	150	150	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	218	218	49.9
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	362	362	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	567	570	120.8
75-84 years	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	363	363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	566	138.9
65-74 years	658	658	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	985	988	218.0
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	*****	*****	*****	*****	1,364.40 (192.19, 9,686.33)	80	80	16.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
0-40 years	315	315	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	436	438	111.5
41-64 years	3,829	3,829	*****	*****	*****	*****	19.01 (2.68, 134.97)	5,642	5,669	1,411.3
65-74 years	4,535	4,535	*****	*****	*****	*****	62.62 (23.50, 166.84)	6,402	6,417	1,655.4
75-84 years	1,119	1,119	*****	*****	*****	*****	189.35 (61.07, 587.12)	1,544	1,549	409.2
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	172	173	42.9
41-64 years	624	624	*****	*****	*****	*****	122.08 (17.20, 866.65)	954	958	241.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	4.2
41-64 years	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	24.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	247	247	77.6
75-84 years	82	82	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	101	101	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,065	4,065	*****	*****	*****	*****	19.67 (2.77, 139.68)	5,922	5,939	1,438.6
41-64 years	31,892	31,892	*****	*****	*****	*****	24.98 (13.83, 45.10)	48,462	48,612	11,773.7
65-74 years	7,803	7,803	*****	*****	*****	*****	63.41 (30.23, 133.02)	11,619	11,654	2,756.5
75-84 years	1,823	1,823	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,622	2,628	648.1
≥ 85 years	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	198	198	49.1
<i>White</i>										
0-40 years	931	931	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,486	1,493	343.0
41-64 years	14,102	14,102	*****	*****	*****	*****	25.28 (10.52, 60.74)	21,520	21,590	5,254.4
65-74 years	31,009	31,009	*****	*****	*****	*****	61.57 (42.51, 89.17)	46,066	46,191	10,892.7
75-84 years	11,726	11,726	*****	*****	*****	*****	66.94 (37.07, 120.88)	16,655	16,700	4,074.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	945	945	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,329	1,330	332.0
Rybelsus, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	285	294	67.4
65-74 years	525	525	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	760	771	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	89	89	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	128	132	29.8
41-64 years	995	995	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,416	1,448	395.1
65-74 years	1,694	1,694	*****	*****	*****	*****	42.86 (6.04, 304.26)	2,312	2,366	653.1
75-84 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	755	766	211.8
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	27	8.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	85	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	776	776	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,109	1,130	291.8
41-64 years	7,993	7,993	*****	*****	*****	*****	18.25 (4.56, 72.98)	11,630	11,924	3,223.3
65-74 years	3,052	3,052	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,422	4,519	1,128.2
75-84 years	904	904	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,326	1,348	332.8
≥ 85 years	151	151	*****	*****	*****	*****	469.35 (66.11, 3,332.09)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	3,018	3,018	*****	*****	*****	*****	46.58 (11.65, 186.26)	4,617	4,717	1,160.9
65-74 years	8,362	8,362	*****	*****	*****	*****	33.67 (12.64, 89.70)	12,388	12,650	3,039.0
75-84 years	4,328	4,328	*****	*****	*****	*****	84.27 (35.07, 202.46)	6,355	6,476	1,517.1
≥ 85 years	576	576	*****	*****	*****	*****	134.32 (18.92, 953.60)	855	862	194.8
Wegovy, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	4.7
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	117	117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	169	175	14.9
41-64 years	529	529	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	813	826	85.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	49	50	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	*****	*****	*****	*****	274.85 (38.72, 1,951.26)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
41-64 years	28	28	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	12.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	9.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24	24	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	253	253	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	345	345	101.9
65-74 years	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	304	304	97.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	15.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	852	852	*****	*****	*****	*****	82.52 (11.62, 585.81)	1,273	1,274	357.0
65-74 years	341	341	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	466	466	126.9
75-84 years	93	93	*****	*****	*****	*****	932.47 (131.35, 6,619.94)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	97	97	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	166	166	41.3
41-64 years	956	956	*****	*****	*****	*****	74.69 (10.52, 530.26)	1,433	1,433	369.8
65-74 years	1,426	1,426	*****	*****	*****	*****	46.72 (6.58, 331.70)	2,057	2,057	527.0
75-84 years	603	603	*****	*****	*****	*****	225.36 (56.36, 901.11)	845	845	215.7
≥ 85 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	27.5
Trulicity, Supraventricular Tachycardia										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	176	178	39.0
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	222	222	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	367	367	84.8
65-74 years	571	571	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	974	979	208.2
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	69	69	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	21.9
<i>Black or African American</i>										
0-40 years	220	220	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	378	379	84.3
41-64 years	2,128	2,128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,624	3,655	841.7
65-74 years	2,967	2,967	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,743	4,776	1,206.9
75-84 years	1,029	1,029	*****	*****	*****	*****	67.57 (9.52, 479.72)	1,599	1,608	418.8
≥ 85 years	119	119	*****	*****	*****	*****	679.03 (95.65, 4,820.65)	187	188	44.8
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	224	224	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	62	62	*****	*****	*****	*****	1,134.67 (159.83, 8,055.39)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.7
<i>Unknown</i>										
0-40 years	1,585	1,585	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,738	2,759	633.3
41-64 years	13,656	13,656	*****	*****	*****	*****	18.55 (6.96, 49.43)	25,130	25,321	5,601.4
65-74 years	4,908	4,908	*****	*****	*****	*****	66.59 (27.72, 159.98)	8,602	8,649	1,869.7
75-84 years	1,540	1,540	*****	*****	*****	*****	44.54 (6.27, 316.23)	2,644	2,659	596.2
≥ 85 years	200	200	*****	*****	*****	*****	391.06 (55.08, 2,776.26)	330	331	69.2
<i>White</i>										
0-40 years	539	539	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,002	1,009	186.9
41-64 years	7,502	7,502	*****	*****	*****	*****	72.67 (36.34, 145.31)	13,487	13,577	2,965.5
65-74 years	18,807	18,807	*****	*****	*****	*****	42.18 (23.96, 74.28)	32,684	32,873	6,984.2
75-84 years	8,928	8,928	*****	*****	*****	*****	68.95 (35.87, 132.51)	15,125	15,209	3,254.4
≥ 85 years	1,177	1,177	*****	*****	*****	*****	64.57 (9.09, 458.39)	2,071	2,079	406.4
Xultophy, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	163	163	50.3
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	4.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	74	13.5
41-64 years	678	678	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,081	1,092	199.4
65-74 years	754	754	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,110	1,136	210.2
75-84 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	240	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	1.6
65-74 years	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	862	862	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,430	1,447	232.9
41-64 years	6,131	6,131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,529	10,640	1,735.1
65-74 years	905	905	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,481	1,496	233.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	252	256	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	116	116	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	216	218	33.2
41-64 years	2,416	2,416	*****	*****	*****	*****	34.51 (4.86, 245.03)	4,137	4,201	726.0
65-74 years	4,885	4,885	*****	*****	*****	*****	70.19 (26.34, 187.03)	7,894	8,015	1,302.6
75-84 years	1,519	1,519	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,339	2,373	390.3
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	0.0	10	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	6.5
41-64 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	42.5
65-74 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	131	131	30.1
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	252	252	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	405	405	99.0
65-74 years	389	389	*****	*****	*****	*****	166.89 (23.51, 1,184.79)	656	656	152.2
75-84 years	150	150	*****	*****	*****	*****	534.54 (75.29, 3,794.86)	218	218	49.9
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Other Tachycardia										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	362	362	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	567	570	120.8
75-84 years	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	363	363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	566	138.9
65-74 years	658	658	*****	*****	*****	*****	205.00 (51.27, 819.70)	985	988	218.0
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	315	315	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	436	438	111.5
41-64 years	3,829	3,829	*****	*****	*****	*****	95.06 (39.56, 228.38)	5,642	5,669	1,411.3
65-74 years	4,535	4,535	*****	*****	*****	*****	46.96 (15.15, 145.61)	6,402	6,417	1,655.4
75-84 years	1,119	1,119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,544	1,549	409.2
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	172	173	42.9
41-64 years	624	624	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	954	958	241.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	4.2
41-64 years	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	24.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	247	247	77.6
75-84 years	82	82	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	101	101	31.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,065	4,065	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,922	5,939	1,438.6
41-64 years	31,892	31,892	*****	*****	*****	*****	11.35 (4.73, 27.28)	48,462	48,612	11,773.7
65-74 years	7,803	7,803	*****	*****	*****	*****	18.12 (4.53, 72.45)	11,619	11,654	2,756.5
75-84 years	1,823	1,823	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,622	2,628	648.1
≥ 85 years	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	198	198	49.1
<i>White</i>										
0-40 years	931	931	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,486	1,493	343.0
41-64 years	14,102	14,102	*****	*****	*****	*****	35.40 (16.87, 74.25)	21,520	21,590	5,254.4
65-74 years	31,009	31,009	*****	*****	*****	*****	39.58 (24.94, 62.82)	46,066	46,191	10,892.7
75-84 years	11,726	11,726	*****	*****	*****	*****	60.85 (32.74, 113.10)	16,655	16,700	4,074.3
≥ 85 years	945	945	*****	*****	*****	*****	240.02 (77.41, 744.21)	1,329	1,330	332.0
Rybelsus, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	285	294	67.4
65-74 years	525	525	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	760	771	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	89	89	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	128	132	29.8
41-64 years	995	995	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,416	1,448	395.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	1,694	1,694	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,312	2,366	653.1
75-84 years	570	570	*****	*****	*****	*****	132.17 (18.62, 938.31)	755	766	211.8
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	27	8.5
65-74 years	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	85	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	776	776	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,109	1,130	291.8
41-64 years	7,993	7,993	*****	*****	*****	*****	9.13 (1.29, 64.79)	11,630	11,924	3,223.3
65-74 years	3,052	3,052	*****	*****	*****	*****	23.30 (3.28, 165.42)	4,422	4,519	1,128.2
75-84 years	904	904	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,326	1,348	332.8
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	3,018	3,018	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,617	4,717	1,160.9
65-74 years	8,362	8,362	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12,388	12,650	3,039.0
75-84 years	4,328	4,328	*****	*****	*****	*****	33.71 (8.43, 134.78)	6,355	6,476	1,517.1
≥ 85 years	576	576	*****	*****	*****	*****	134.32 (18.92, 953.60)	855	862	194.8

Wegovy, Other Tachycardia

American Indian or Alaska Native

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	4.7
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Unknown</i>										
0-40 years	117	117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	169	175	14.9
41-64 years	529	529	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	813	826	85.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	49	50	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	28	28	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	12.8
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24	24	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	253	253	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	345	345	101.9
65-74 years	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	304	304	97.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	15.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	852	852	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,273	1,274	357.0
65-74 years	341	341	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	466	466	126.9
75-84 years	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	97	97	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	166	166	41.3
41-64 years	956	956	*****	*****	*****	*****	74.69 (10.52, 530.26)	1,433	1,433	369.8
65-74 years	1,426	1,426	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,057	2,057	527.0
75-84 years	603	603	*****	*****	*****	*****	338.04 (109.02, 1,048.13)	845	845	215.7
≥ 85 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	27.5
Trulicity, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	176	178	39.0
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	0.9	326	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	222	222	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	367	367	84.8
65-74 years	571	571	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	974	979	208.2
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	69	69	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	21.9
<i>Black or African American</i>										
0-40 years	220	220	*****	*****	*****	*****	329.20 (46.37, 2,337.12)	378	379	84.3
41-64 years	2,128	2,128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,624	3,655	841.7
65-74 years	2,967	2,967	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,743	4,776	1,206.9
75-84 years	1,029	1,029	*****	*****	*****	*****	67.57 (9.52, 479.72)	1,599	1,608	418.8

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	187	188	44.8
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	224	224	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.7
<i>Unknown</i>										
0-40 years	1,585	1,585	*****	*****	*****	*****	45.98 (6.48, 326.42)	2,738	2,759	633.3
41-64 years	13,656	13,656	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,130	25,321	5,601.4
65-74 years	4,908	4,908	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,602	8,649	1,869.7
75-84 years	1,540	1,540	*****	*****	*****	*****	44.54 (6.27, 316.23)	2,644	2,659	596.2
≥ 85 years	200	200	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	331	69.2
<i>White</i>										
0-40 years	539	539	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,002	1,009	186.9
41-64 years	7,502	7,502	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,487	13,577	2,965.5
65-74 years	18,807	18,807	*****	*****	*****	*****	52.73 (31.79, 87.47)	32,684	32,873	6,984.2
75-84 years	8,928	8,928	*****	*****	*****	*****	15.32 (3.83, 61.26)	15,125	15,209	3,254.4
≥ 85 years	1,177	1,177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,071	2,079	406.4
Kultophy, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	163	163	50.3
75-84 years	66	66	*****	*****	*****	*****	978.17 (137.78, 6,944.37)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	4.6
Mounjaro, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	74	13.5
41-64 years	678	678	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,081	1,092	199.4
65-74 years	754	754	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,110	1,136	210.2
75-84 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	240	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	1.6
65-74 years	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	862	862	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,430	1,447	232.9
41-64 years	6,131	6,131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,529	10,640	1,735.1
65-74 years	905	905	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,481	1,496	233.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	252	256	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	116	116	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	216	218	33.2
41-64 years	2,416	2,416	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,137	4,201	726.0
65-74 years	4,885	4,885	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,894	8,015	1,302.6
75-84 years	1,519	1,519	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,339	2,373	390.3
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	4.3
41-64 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	6.5
41-64 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	42.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	131	131	30.1
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	252	252	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	405	405	99.0
65-74 years	389	389	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	656	656	152.2
75-84 years	150	150	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	218	218	49.9
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	*****	*****	*****	*****	289.06 (40.72, 2,052.10)	409	411	89.4
65-74 years	362	362	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	567	570	120.8
75-84 years	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	363	363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	566	138.9
65-74 years	658	658	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	985	988	218.0
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	*****	*****	*****	*****	1,364.40 (192.19, 9,686.33)	80	80	16.7
<i>Black or African American</i>										
0-40 years	315	315	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	436	438	111.5
41-64 years	3,829	3,829	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,642	5,669	1,411.3
65-74 years	4,535	4,535	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,402	6,417	1,655.4
75-84 years	1,119	1,119	*****	*****	*****	*****	63.12 (8.89, 448.09)	1,544	1,549	409.2
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
0-40 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	172	173	42.9
41-64 years	624	624	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	954	958	241.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	4.2
41-64 years	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	24.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	247	247	77.6
75-84 years	82	82	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	101	101	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,065	4,065	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,922	5,939	1,438.6
41-64 years	31,892	31,892	*****	*****	*****	*****	6.81 (2.20, 21.12)	48,462	48,612	11,773.7
65-74 years	7,803	7,803	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,619	11,654	2,756.5
75-84 years	1,823	1,823	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,622	2,628	648.1
≥ 85 years	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	198	198	49.1
<i>White</i>										
0-40 years	931	931	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,486	1,493	343.0
41-64 years	14,102	14,102	*****	*****	*****	*****	15.17 (4.89, 47.04)	21,520	21,590	5,254.4
65-74 years	31,009	31,009	*****	*****	*****	*****	15.39 (7.34, 32.29)	46,066	46,191	10,892.7
75-84 years	11,726	11,726	*****	*****	*****	*****	12.17 (3.04, 48.67)	16,655	16,700	4,074.3
≥ 85 years	945	945	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,329	1,330	332.0
Rybelsus, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	285	294	67.4
65-74 years	525	525	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	760	771	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	89	89	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	128	132	29.8
41-64 years	995	995	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,416	1,448	395.1
65-74 years	1,694	1,694	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,312	2,366	653.1
75-84 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	755	766	211.8
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	27	8.5
65-74 years	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	85	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	776	776	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,109	1,130	291.8
41-64 years	7,993	7,993	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,630	11,924	3,223.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	3,052	3,052	*****	*****	*****	*****	23.30 (3.28, 165.42)	4,422	4,519	1,128.2
75-84 years	904	904	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,326	1,348	332.8
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	3,018	3,018	*****	*****	*****	*****	23.29 (3.28, 165.35)	4,617	4,717	1,160.9
65-74 years	8,362	8,362	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12,388	12,650	3,039.0
75-84 years	4,328	4,328	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,355	6,476	1,517.1
≥ 85 years	576	576	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	855	862	194.8
Wegovy, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	4.7
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiian or Other Pacific Islander										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	117	117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	169	175	14.9
41-64 years	529	529	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	813	826	85.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	49	50	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Cardiac Arrest										
American Indian or Alaska Native										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
41-64 years	28	28	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	12.8
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24	24	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	253	253	*****	*****	*****	*****	303.69 (42.78, 2,156.01)	345	345	101.9
65-74 years	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	304	304	97.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	15.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	852	852	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,273	1,274	357.0
65-74 years	341	341	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	466	466	126.9
75-84 years	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	97	97	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	166	166	41.3
41-64 years	956	956	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,433	1,433	369.8
65-74 years	1,426	1,426	*****	*****	*****	*****	93.45 (23.37, 373.65)	2,057	2,057	527.0
75-84 years	603	603	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	845	845	215.7
≥ 85 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	27.5
Trulicity, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	176	178	39.0
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	222	222	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	367	367	84.8
65-74 years	571	571	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	974	979	208.2
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	69	69	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	21.9
<i>Black or African American</i>										
0-40 years	220	220	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	378	379	84.3
41-64 years	2,128	2,128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,624	3,655	841.7
65-74 years	2,967	2,967	*****	*****	*****	*****	23.69 (3.34, 168.19)	4,743	4,776	1,206.9
75-84 years	1,029	1,029	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,599	1,608	418.8
≥ 85 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	187	188	44.8
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	224	224	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	*****	*****	*****	*****	8,055.39)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.7
<i>Unknown</i>										
0-40 years	1,585	1,585	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,738	2,759	633.3
41-64 years	13,656	13,656	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,130	25,321	5,601.4
65-74 years	4,908	4,908	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,602	8,649	1,869.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	1,540	1,540	*****	*****	*****	*****	44.54 (6.27, 316.23)	2,644	2,659	596.2
≥ 85 years	200	200	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	331	69.2
<i>White</i>										
0-40 years	539	539	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,002	1,009	186.9
41-64 years	7,502	7,502	*****	*****	*****	*****	18.17 (4.54, 72.64)	13,487	13,577	2,965.5
65-74 years	18,807	18,807	*****	*****	*****	*****	10.55 (3.40, 32.70)	32,684	32,873	6,984.2
75-84 years	8,928	8,928	*****	*****	*****	*****	30.64 (11.50, 81.65)	15,125	15,209	3,254.4
≥ 85 years	1,177	1,177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,071	2,079	406.4
Xultophy, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	163	163	50.3
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	4.6
Mounjaro, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	74	13.5
41-64 years	678	678	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,081	1,092	199.4
65-74 years	754	754	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,110	1,136	210.2
75-84 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	240	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	1.6
65-74 years	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	862	862	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,430	1,447	232.9
41-64 years	6,131	6,131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,529	10,640	1,735.1
65-74 years	905	905	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,481	1,496	233.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	252	256	40.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	116	116	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	216	218	33.2
41-64 years	2,416	2,416	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,137	4,201	726.0
65-74 years	4,885	4,885	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,894	8,015	1,302.6
75-84 years	1,519	1,519	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,339	2,373	390.3
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	6.5
41-64 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	42.5
65-74 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	131	131	30.1
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	252	252	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	405	405	99.0
65-74 years	389	389	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	656	656	152.2
75-84 years	150	150	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	218	218	49.9
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	362	362	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	567	570	120.8
75-84 years	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	363	363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	566	138.9
65-74 years	658	658	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	985	988	218.0
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	315	315	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	436	438	111.5
41-64 years	3,829	3,829	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,642	5,669	1,411.3
65-74 years	4,535	4,535	*****	*****	*****	*****	31.31 (7.83, 125.19)	6,402	6,417	1,655.4
75-84 years	1,119	1,119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,544	1,549	409.2
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	172	173	42.9
41-64 years	624	624	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	954	958	241.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	*****	*****	*****	*****	6,852.72 (965.26, 48,649.70)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	24.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	247	247	77.6
75-84 years	82	82	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	101	101	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,065	4,065	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,922	5,939	1,438.6
41-64 years	31,892	31,892	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	48,462	48,612	11,773.7
65-74 years	7,803	7,803	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,619	11,654	2,756.5
75-84 years	1,823	1,823	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,622	2,628	648.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	198	198	49.1
<i>White</i>										
0-40 years	931	931	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,486	1,493	343.0
41-64 years	14,102	14,102	*****	*****	*****	*****	5.06 (0.71, 35.90)	21,520	21,590	5,254.4
65-74 years	31,009	31,009	*****	*****	*****	*****	4.40 (1.10, 17.58)	46,066	46,191	10,892.7
75-84 years	11,726	11,726	*****	*****	*****	*****	6.09 (0.86, 43.20)	16,655	16,700	4,074.3
≥ 85 years	945	945	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,329	1,330	332.0
Rybelsus, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	285	294	67.4
65-74 years	525	525	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	760	771	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	89	89	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	128	132	29.8
41-64 years	995	995	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,416	1,448	395.1
65-74 years	1,694	1,694	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,312	2,366	653.1
75-84 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	755	766	211.8
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	27	8.5
65-74 years	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	85	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	776	776	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,109	1,130	291.8
41-64 years	7,993	7,993	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,630	11,924	3,223.3
65-74 years	3,052	3,052	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,422	4,519	1,128.2
75-84 years	904	904	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,326	1,348	332.8
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	3,018	3,018	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,617	4,717	1,160.9
65-74 years	8,362	8,362	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12,388	12,650	3,039.0
75-84 years	4,328	4,328	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,355	6,476	1,517.1
≥ 85 years	576	576	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	855	862	194.8
Wegovy, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	4.7
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	117	117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	169	175	14.9
41-64 years	529	529	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	813	826	85.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	49	50	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
41-64 years	28	28	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	12.8
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	5.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24	24	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	253	253	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	345	345	101.9
65-74 years	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	304	304	97.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	15.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	852	852	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,273	1,274	357.0
65-74 years	341	341	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	466	466	126.9
75-84 years	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	97	97	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	166	166	41.3
41-64 years	956	956	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,433	1,433	369.8
65-74 years	1,426	1,426	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,057	2,057	527.0
75-84 years	603	603	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	845	845	215.7
≥ 85 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	27.5
Trulicity, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	176	178	39.0
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	222	222	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	367	367	84.8
65-74 years	571	571	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	974	979	208.2
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	69	69	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	21.9
<i>Black or African American</i>										
0-40 years	220	220	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	378	379	84.3
41-64 years	2,128	2,128	*****	*****	*****	*****	33.64 (4.74, 238.80)	3,624	3,655	841.7
65-74 years	2,967	2,967	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,743	4,776	1,206.9
75-84 years	1,029	1,029	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,599	1,608	418.8
≥ 85 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	187	188	44.8
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	224	224	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.7
<i>Unknown</i>										
0-40 years	1,585	1,585	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,738	2,759	633.3
41-64 years	13,656	13,656	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,130	25,321	5,601.4
65-74 years	4,908	4,908	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,602	8,649	1,869.7
75-84 years	1,540	1,540	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,644	2,659	596.2
≥ 85 years	200	200	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	331	69.2
<i>White</i>										
0-40 years	539	539	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,002	1,009	186.9
41-64 years	7,502	7,502	*****	*****	*****	*****	9.08 (1.28, 64.49)	13,487	13,577	2,965.5
65-74 years	18,807	18,807	*****	*****	*****	*****	3.52 (0.50, 24.96)	32,684	32,873	6,984.2
75-84 years	8,928	8,928	*****	*****	*****	*****	7.66 (1.08, 54.39)	15,125	15,209	3,254.4
≥ 85 years	1,177	1,177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,071	2,079	406.4
Xultophy, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	163	163	50.3
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	4.6
Mounjaro, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	74	13.5
41-64 years	678	678	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,081	1,092	199.4
65-74 years	754	754	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,110	1,136	210.2
75-84 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	240	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	1.6
65-74 years	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	862	862	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,430	1,447	232.9
41-64 years	6,131	6,131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,529	10,640	1,735.1
65-74 years	905	905	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,481	1,496	233.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	252	256	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	116	116	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	216	218	33.2
41-64 years	2,416	2,416	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,137	4,201	726.0
65-74 years	4,885	4,885	*****	*****	*****	*****	17.55 (2.47, 124.58)	7,894	8,015	1,302.6
75-84 years	1,519	1,519	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,339	2,373	390.3
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	0.0	10	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	6.5
41-64 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	42.5
65-74 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	131	131	30.1
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	252	252	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	405	405	99.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	389	389	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	656	656	152.2
75-84 years	150	150	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	218	218	49.9
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	362	362	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	567	570	120.8
75-84 years	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	240	240	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	363	363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	566	138.9
65-74 years	658	658	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	985	988	218.0
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	315	315	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	436	438	111.5
41-64 years	3,829	3,829	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,642	5,669	1,411.3
65-74 years	4,535	4,535	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,402	6,417	1,655.4
75-84 years	1,119	1,119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,544	1,549	409.2
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	172	173	42.9
41-64 years	624	624	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	954	958	241.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	4.2
41-64 years	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	24.2
65-74 years	185	185	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	247	247	77.6
75-84 years	82	82	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	101	101	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown										
0-40 years	4,065	4,065	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,922	5,939	1,438.6
41-64 years	31,892	31,892	*****	*****	*****	*****	2.27 (0.32, 16.12)	48,462	48,612	11,773.7
65-74 years	7,803	7,803	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,619	11,654	2,756.5
75-84 years	1,823	1,823	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,622	2,628	648.1
≥ 85 years	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	198	198	49.1
White										
0-40 years	931	931	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,486	1,493	343.0
41-64 years	14,102	14,102	*****	*****	*****	*****	5.06 (0.71, 35.90)	21,520	21,590	5,254.4
65-74 years	31,009	31,009	*****	*****	*****	*****	4.40 (1.10, 17.58)	46,066	46,191	10,892.7
75-84 years	11,726	11,726	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,655	16,700	4,074.3
≥ 85 years	945	945	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,329	1,330	332.0
Rybelsus, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Asian										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	174	174	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	285	294	67.4
65-74 years	525	525	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	760	771	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	89	89	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	128	132	29.8
41-64 years	995	995	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,416	1,448	395.1
65-74 years	1,694	1,694	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,312	2,366	653.1
75-84 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	755	766	211.8
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	27	8.5
65-74 years	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	85	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	776	776	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,109	1,130	291.8
41-64 years	7,993	7,993	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,630	11,924	3,223.3
65-74 years	3,052	3,052	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,422	4,519	1,128.2
75-84 years	904	904	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,326	1,348	332.8
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	3,018	3,018	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,617	4,717	1,160.9
65-74 years	8,362	8,362	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12,388	12,650	3,039.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	4,328	4,328	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,355	6,476	1,517.1
≥ 85 years	576	576	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	855	862	194.8
Wegovy, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	24	24	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	4.7
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	117	117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	169	175	14.9
41-64 years	529	529	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	813	826	85.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	49	50	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	0.1	28	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	0.9	328	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	0.4	137	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
41-64 years	28	28	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	12.8
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11	11	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	24	24	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	253	253	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	345	345	101.9
65-74 years	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	304	304	97.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	15.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	852	852	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,273	1,274	357.0
65-74 years	341	341	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	466	466	126.9
75-84 years	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	97	97	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	166	166	41.3
41-64 years	956	956	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,433	1,433	369.8
65-74 years	1,426	1,426	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,057	2,057	527.0
75-84 years	603	603	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	845	845	215.7
≥ 85 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	27.5
Trulicity, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	101	101	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	176	178	39.0
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	222	222	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	367	367	84.8
65-74 years	571	571	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	974	979	208.2
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	69	69	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	21.9
<i>Black or African American</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	220	220	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	378	379	84.3
41-64 years	2,128	2,128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,624	3,655	841.7
65-74 years	2,967	2,967	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,743	4,776	1,206.9
75-84 years	1,029	1,029	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,599	1,608	418.8
≥ 85 years	119	119	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	187	188	44.8
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	224	224	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.7
<i>Unknown</i>										
0-40 years	1,585	1,585	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,738	2,759	633.3
41-64 years	13,656	13,656	*****	*****	*****	*****	4.64 (0.65, 32.93)	25,130	25,321	5,601.4
65-74 years	4,908	4,908	*****	*****	*****	*****	13.32 (1.88, 94.55)	8,602	8,649	1,869.7
75-84 years	1,540	1,540	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,644	2,659	596.2
≥ 85 years	200	200	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	330	331	69.2
<i>White</i>										
0-40 years	539	539	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,002	1,009	186.9
41-64 years	7,502	7,502	*****	*****	*****	*****	9.08 (1.28, 64.49)	13,487	13,577	2,965.5
65-74 years	18,807	18,807	*****	*****	*****	*****	3.52 (0.50, 24.96)	32,684	32,873	6,984.2
75-84 years	8,928	8,928	*****	*****	*****	*****	7.66 (1.08, 54.39)	15,125	15,209	3,254.4
≥ 85 years	1,177	1,177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,071	2,079	406.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Xultophy, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	38	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	163	163	50.3
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	4.6

NaN: Not a number

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	*****	*****	*****	*****	549.66 (77.42, 3,902.23)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	264	264	80.2
2023	66	66	*****	*****	*****	*****	1,535.95 (216.35, 10,904.24)	85	85	9.7
<i>White</i>										
2022	726	726	*****	*****	*****	*****	388.62 (145.85, 1,035.45)	1,184	1,184	297.3
2023	111	111	*****	*****	*****	*****	851.20 (119.90, 6,042.95)	156	156	21.7
Mounjaro, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	640	640	*****	*****	*****	*****	523.79 (196.58, 1,395.61)	986	1,005	275.6
2023	1,019	1,019	*****	*****	*****	*****	476.07 (198.15, 1,143.79)	1,527	1,552	193.5
<i>Multi-racial</i>										
2022	34	34	*****	*****	*****	*****	2,174.11 (306.24, 15,434.70)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	61	62	6.7
<i>Unknown</i>										
2022	4,067	4,067	*****	*****	*****	*****	262.98 (158.54, 436.22)	7,443	7,520	1,701.3
2023	4,001	4,001	*****	*****	*****	*****	185.37 (88.37, 388.84)	6,262	6,332	542.7
<i>White</i>										
2022	4,689	4,689	*****	*****	*****	*****	568.22 (403.96, 799.27)	7,793	7,882	1,648.4
2023	4,322	4,322	*****	*****	*****	*****	830.24 (606.60, 1,136.34)	6,899	7,033	820.2
Ozempic, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	697	697	*****	*****	*****	*****	1,197.33 (663.07, 2,162.04)	1,102	1,104	260.9
2023	131	131	*****	*****	*****	*****	788.88 (111.12, 5,600.50)	170	173	22.1
<i>Asian</i>										
2022	1,026	1,026	*****	*****	*****	*****	305.82 (127.29, 734.76)	1,609	1,611	424.8
2023	373	373	*****	*****	*****	*****	907.40 (340.56, 2,417.72)	518	520	65.1
<i>Black or African American</i>										
2022	6,083	6,083	*****	*****	*****	*****	531.12 (402.55, 700.77)	9,127	9,155	2,937.4
2023	3,817	3,817	*****	*****	*****	*****	505.81 (333.05, 768.19)	5,037	5,059	687.1
<i>Multi-racial</i>										
2022	408	408	*****	*****	*****	*****	302.84 (75.74, 1,210.90)	691	693	254.3
2023	410	410	*****	*****	*****	*****	482.05 (120.56, 1,927.50)	560	563	62.4

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	*****	*****	*****	*****	681.69 (170.48, 2,725.77)	229	229	106.1
2023	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	225	225	31.9
<i>Unknown</i>										
2022	27,644	27,644	*****	*****	*****	*****	249.37 (207.88, 299.15)	45,287	45,401	14,495.0
2023	18,084	18,084	*****	*****	*****	*****	207.84 (148.50, 290.87)	23,536	23,630	2,171.0
<i>White</i>										
2022	43,289	43,289	*****	*****	*****	*****	670.30 (610.76, 735.64)	66,188	66,352	18,107.6
2023	15,424	15,424	*****	*****	*****	*****	655.92 (547.63, 785.62)	20,868	20,952	2,788.7
Rybelsus, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	*****	*****	*****	*****	133.60 (33.41, 534.21)	1,445	1,471	355.0
2023	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	212	215	32.9
<i>Black or African American</i>										
2022	2,347	2,347	*****	*****	*****	*****	413.43 (244.85, 698.07)	3,346	3,409	1,111.7
2023	1,077	1,077	*****	*****	*****	*****	414.56 (172.55, 996.00)	1,372	1,413	206.9
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	59	59	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	81	13.4
<i>Unknown</i>										
2022	8,927	8,927	*****	*****	*****	*****	192.85 (132.25, 281.21)	13,675	13,954	4,502.8
2023	3,949	3,949	*****	*****	*****	*****	299.02 (165.59, 539.94)	5,044	5,202	529.2

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
2022	12,878	12,878	*****	*****	*****	*****	515.11 (422.15, 628.53)	19,666	20,021	5,257.6
2023	3,615	3,615	*****	*****	*****	*****	702.14 (490.93, 1,004.24)	4,852	4,993	724.4
Saxenda, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	*****	*****	*****	*****	238.82 (33.64, 1,695.46)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Trulicity, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	5.3

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
2022	1,048	1,048	*****	*****	*****	*****	233.36 (87.58, 621.79)	1,828	1,834	408.5
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	224	31.7
<i>Black or African American</i>										
2022	4,913	4,913	*****	*****	*****	*****	506.95 (367.30, 699.68)	8,260	8,321	2,276.8
2023	1,550	1,550	*****	*****	*****	*****	438.02 (219.05, 875.87)	2,271	2,285	319.7
<i>Multi-racial</i>										
2022	190	190	*****	*****	*****	*****	525.65 (131.46, 2,101.84)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	*****	*****	*****	*****	740.95 (185.30, 2,962.71)	246	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,460	15,460	*****	*****	*****	*****	308.91 (249.44, 382.57)	29,714	29,907	7,872.3
2023	6,429	6,429	*****	*****	*****	*****	412.04 (282.57, 600.83)	9,730	9,812	897.5
<i>White</i>										
2022	31,108	31,108	*****	*****	*****	*****	639.03 (571.09, 715.06)	55,394	55,694	12,574.8
2023	5,845	5,845	*****	*****	*****	*****	702.03 (533.53, 923.73)	8,975	9,053	1,222.5
Victoza, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	*****	*****	*****	*****	1,641.57 (231.23, 11,654.06)	78	78	22.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.2
<i>Black or African American</i>										
2022	403	403	*****	*****	*****	*****	529.58 (170.80, 1,642.03)	556	556	196.8
2023	161	161	*****	*****	*****	*****	564.53 (79.52, 4,007.77)	201	201	34.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,029	1,029	*****	*****	*****	*****	377.35 (169.53, 839.95)	1,558	1,559	516.0
2023	414	414	*****	*****	*****	*****	985.50 (369.87, 2,625.81)	526	526	62.3
<i>White</i>										
2022	2,528	2,528	*****	*****	*****	*****	710.37 (487.15, 1,035.86)	3,769	3,769	1,045.6
2023	628	628	*****	*****	*****	*****	879.42 (419.25, 1,844.71)	830	830	135.6
Wegovy, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	51	53	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown										
2022	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	35.5
2023	612	612	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	960	70.2
White										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	*****	*****	*****	*****	876.74 (123.50, 6,224.27)	185	188	18.4
Xultophy, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
Black or African American										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
Multi-racial										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
Native Hawaiian or Other Pacific Islander										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
White										
2022	155	155	*****	*****	*****	*****	371.87 (52.38, 2,640.02)	209	209	68.3
2023	94	94	*****	*****	*****	*****	823.75 (116.03, 5,848.06)	121	121	19.3
Mounjaro, Atrial Fibrillation and Flutter										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	640	640	*****	*****	*****	*****	392.84 (126.70, 1,218.05)	986	1,005	275.6
2023	1,019	1,019	*****	*****	*****	*****	380.86 (142.94, 1,014.77)	1,527	1,552	193.5
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	61	62	6.7
<i>Unknown</i>										
2022	4,067	4,067	*****	*****	*****	*****	122.72 (58.51, 257.43)	7,443	7,520	1,701.3
2023	4,001	4,001	*****	*****	*****	*****	132.41 (55.11, 318.12)	6,262	6,332	542.7
<i>White</i>										
2022	4,689	4,689	*****	*****	*****	*****	430.47 (290.87, 637.07)	7,793	7,882	1,648.4
2023	4,322	4,322	*****	*****	*****	*****	468.34 (308.38, 711.28)	6,899	7,033	820.2
Bydureon, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	264	264	80.2
2023	66	66	*****	*****	*****	*****	1,535.95 (216.35, 10,904.24)	85	85	9.7
<i>White</i>										
2022	726	726	*****	*****	*****	*****	291.46 (94.00, 903.72)	1,184	1,184	297.3
2023	111	111	*****	*****	*****	*****	851.20 (119.90, 6,042.95)	156	156	21.7
Ozempic, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	697	697	*****	*****	*****	*****	870.78 (435.47, 1,741.25)	1,102	1,104	260.9
2023	131	131	*****	*****	*****	*****	788.88 (111.12, 5,600.50)	170	173	22.1
<i>Asian</i>										
2022	1,026	1,026	*****	*****	*****	*****	122.33 (30.59, 489.14)	1,609	1,611	424.8
2023	373	373	*****	*****	*****	*****	226.85 (31.95, 1,610.48)	518	520	65.1
<i>Black or African American</i>										
2022	6,083	6,083	*****	*****	*****	*****	276.18 (188.05, 405.64)	9,127	9,155	2,937.4
2023	3,817	3,817	*****	*****	*****	*****	229.92 (123.71, 427.31)	5,037	5,059	687.1
<i>Multi-racial</i>										
2022	408	408	*****	*****	*****	*****	151.42 (21.33, 1,074.96)	691	693	254.3
2023	410	410	*****	*****	*****	*****	241.03 (33.95, 1,711.12)	560	563	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	*****	*****	*****	*****	681.69 (170.48, 2,725.77)	229	229	106.1

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	225	225	31.9
<i>Unknown</i>										
2022	27,644	27,644	*****	*****	*****	*****	146.19 (115.26, 185.41)	45,287	45,401	14,495.0
2023	18,084	18,084	*****	*****	*****	*****	103.92 (64.60, 167.16)	23,536	23,630	2,171.0
<i>White</i>										
2022	43,289	43,289	*****	*****	*****	*****	471.02 (421.55, 526.30)	66,188	66,352	18,107.6
2023	15,424	15,424	*****	*****	*****	*****	389.10 (307.84, 491.82)	20,868	20,952	2,788.7
Rybelsus, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	*****	*****	*****	*****	66.80 (9.41, 474.24)	1,445	1,471	355.0
2023	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	212	215	32.9
<i>Black or African American</i>										
2022	2,347	2,347	*****	*****	*****	*****	236.25 (118.14, 472.40)	3,346	3,409	1,111.7
2023	1,077	1,077	*****	*****	*****	*****	248.73 (80.22, 771.23)	1,372	1,413	206.9
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	59	59	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	81	13.4
<i>Unknown</i>										
2022	8,927	8,927	*****	*****	*****	*****	99.99 (59.22, 168.84)	13,675	13,954	4,502.8
2023	3,949	3,949	*****	*****	*****	*****	163.10 (73.27, 363.04)	5,044	5,202	529.2
<i>White</i>										
2022	12,878	12,878	*****	*****	*****	*****	403.59 (322.33, 505.34)	19,666	20,021	5,257.6
2023	3,615	3,615	*****	*****	*****	*****	491.50 (320.46, 753.83)	4,852	4,993	724.4

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Wegovy, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	51	53	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	35.5
2023	612	612	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	960	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	*****	*****	*****	*****	876.74 (123.50, 6,224.27)	185	188	18.4
Saxenda, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	*****	*****	*****	*****	1,641.57 (231.23, 11,654.06)	78	78	22.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.2
<i>Black or African American</i>										
2022	403	403	*****	*****	*****	*****	176.53 (24.87, 1,253.22)	556	556	196.8
2023	161	161	*****	*****	*****	*****	564.53 (79.52, 4,007.77)	201	201	34.5
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,029	1,029	*****	*****	*****	*****	125.78 (31.46, 502.95)	1,558	1,559	516.0
2023	414	414	*****	*****	*****	*****	492.75 (123.23, 1,970.28)	526	526	62.3
<i>White</i>										
2022	2,528	2,528	*****	*****	*****	*****	473.58 (298.37, 751.67)	3,769	3,769	1,045.6
2023	628	628	*****	*****	*****	*****	502.53 (188.60, 1,338.96)	830	830	135.6
Trulicity, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	5.3
<i>Asian</i>										
2022	1,048	1,048	*****	*****	*****	*****	175.02 (56.45, 542.68)	1,828	1,834	408.5
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	224	31.7
<i>Black or African American</i>										
2022	4,913	4,913	*****	*****	*****	*****	260.32 (166.05, 408.13)	8,260	8,321	2,276.8
2023	1,550	1,550	*****	*****	*****	*****	164.26 (52.97, 509.30)	2,271	2,285	319.7
<i>Multi-racial</i>										
2022	190	190	*****	*****	*****	*****	262.83 (37.02, 1,865.89)	426	430	114.0
2023	103	103	*****	*****	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	246	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,460	15,460	*****	*****	*****	*****	180.20 (136.19, 238.43)	29,714	29,907	7,872.3
2023	6,429	6,429	*****	*****	*****	*****	259.43 (161.28, 417.32)	9,730	9,812	897.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
2022	31,108	31,108	*****	*****	*****	*****	498.19 (438.64, 565.84)	55,394	55,694	12,574.8
2023	5,845	5,845	*****	*****	*****	*****	468.02 (334.41, 655.00)	8,975	9,053	1,222.5
Xultophy, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	155	155	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	209	209	68.3
2023	94	94	*****	*****	*****	*****	823.75 (116.03, 5,848.06)	121	121	19.3
Mounjaro, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	640	640	*****	*****	*****	*****	130.95 (18.44, 929.63)	986	1,005	275.6
2023	1,019	1,019	*****	*****	*****	*****	95.21 (13.41, 675.95)	1,527	1,552	193.5
<i>Multi-racial</i>										
2022	34	34	*****	*****	*****	*****	2,174.11 (306.24, 15,434.70)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	61	62	6.7
<i>Unknown</i>										
2022	4,067	4,067	*****	*****	*****	*****	122.72 (58.51, 257.43)	7,443	7,520	1,701.3
2023	4,001	4,001	*****	*****	*****	*****	26.48 (3.73, 188.00)	6,262	6,332	542.7
<i>White</i>										
2022	4,689	4,689	*****	*****	*****	*****	86.09 (35.83, 206.85)	7,793	7,882	1,648.4
2023	4,322	4,322	*****	*****	*****	*****	298.03 (176.51, 503.23)	6,899	7,033	820.2
Bydureon, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	*****	*****	*****	*****	549.66 (77.42, 3,902.23)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	264	264	80.2
2023	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	85	85	9.7
<i>White</i>										
2022	726	726	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,184	1,184	297.3
2023	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	156	156	21.7
Ozempic, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	697	697	*****	*****	*****	*****	217.70 (54.44, 870.47)	1,102	1,104	260.9
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,026	1,026	*****	*****	*****	*****	61.16 (8.62, 434.23)	1,609	1,611	424.8
2023	373	373	*****	*****	*****	*****	226.85 (31.95, 1,610.48)	518	520	65.1
<i>Black or African American</i>										
2022	6,083	6,083	*****	*****	*****	*****	191.20 (120.47, 303.48)	9,127	9,155	2,937.4
2023	3,817	3,817	*****	*****	*****	*****	137.95 (61.97, 307.06)	5,037	5,059	687.1
<i>Multi-racial</i>										
2022	408	408	*****	*****	*****	*****	151.42 (21.33, 1,074.96)	691	693	254.3
2023	410	410	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	560	563	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	225	225	31.9

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Unknown</i>										
2022	27,644	27,644	*****	*****	*****	*****	68.79 (48.65, 97.28)	45,287	45,401	14,495.0
2023	18,084	18,084	*****	*****	*****	*****	48.90 (24.46, 97.79)	23,536	23,630	2,171.0
<i>White</i>										
2022	43,289	43,289	*****	*****	*****	*****	119.27 (95.66, 148.69)	66,188	66,352	18,107.6
2023	15,424	15,424	*****	*****	*****	*****	188.99 (135.04, 264.50)	20,868	20,952	2,788.7
Rybelsus, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	*****	*****	*****	*****	66.80 (9.41, 474.24)	1,445	1,471	355.0
2023	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	212	215	32.9
<i>Black or African American</i>										
2022	2,347	2,347	*****	*****	*****	*****	177.18 (79.60, 394.40)	3,346	3,409	1,111.7
2023	1,077	1,077	*****	*****	*****	*****	82.91 (11.68, 588.62)	1,372	1,413	206.9
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	59	59	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	81	13.4
<i>Unknown</i>										
2022	8,927	8,927	*****	*****	*****	*****	78.57 (43.51, 141.87)	13,675	13,954	4,502.8
2023	3,949	3,949	*****	*****	*****	*****	81.55 (26.30, 252.86)	5,044	5,202	529.2
<i>White</i>										
2022	12,878	12,878	*****	*****	*****	*****	95.59 (60.22, 151.72)	19,666	20,021	5,257.6
2023	3,615	3,615	*****	*****	*****	*****	163.83 (78.10, 343.66)	4,852	4,993	724.4
Wegovy, Sinus Tachycardia										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	51	53	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	35.5
2023	612	612	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	960	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4

Saxenda, Sinus Tachycardia

<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	*****	*****	*****	*****	238.82 (33.64, 1,695.46)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	78	78	22.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.2
<i>Black or African American</i>										
2022	403	403	*****	*****	*****	*****	353.05 (88.30, 1,411.69)	556	556	196.8
2023	161	161	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	34.5
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,029	1,029	*****	*****	*****	*****	314.46 (130.88, 755.51)	1,558	1,559	516.0
2023	414	414	*****	*****	*****	*****	492.75 (123.23, 1,970.28)	526	526	62.3
<i>White</i>										
2022	2,528	2,528	*****	*****	*****	*****	78.93 (25.46, 244.73)	3,769	3,769	1,045.6
2023	628	628	*****	*****	*****	*****	376.90 (121.55, 1,168.62)	830	830	135.6
Trulicity, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	5.3
<i>Asian</i>										
2022	1,048	1,048	*****	*****	*****	*****	58.34 (8.22, 414.18)	1,828	1,834	408.5
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	224	31.7
<i>Black or African American</i>										
2022	4,913	4,913	*****	*****	*****	*****	191.82 (113.60, 323.88)	8,260	8,321	2,276.8
2023	1,550	1,550	*****	*****	*****	*****	219.01 (82.20, 583.54)	2,271	2,285	319.7
<i>Multi-racial</i>										
2022	190	190	*****	*****	*****	*****	262.83 (37.02, 1,865.89)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	246	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,460	15,460	*****	*****	*****	*****	91.94 (62.12, 136.06)	29,714	29,907	7,872.3
2023	6,429	6,429	*****	*****	*****	*****	137.35 (71.46, 263.97)	9,730	9,812	897.5
<i>White</i>										
2022	31,108	31,108	*****	*****	*****	*****	94.59 (70.63, 126.69)	55,394	55,694	12,574.8
2023	5,845	5,845	*****	*****	*****	*****	137.65 (74.06, 255.84)	8,975	9,053	1,222.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Xultophy, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	155	155	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	209	209	68.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	640	640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	986	1,005	275.6
2023	1,019	1,019	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,527	1,552	193.5
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	61	62	6.7
<i>Unknown</i>										
2022	4,067	4,067	*****	*****	*****	*****	17.53 (2.47, 124.46)	7,443	7,520	1,701.3
2023	4,001	4,001	*****	*****	*****	*****	26.48 (3.73, 188.00)	6,262	6,332	542.7
<i>White</i>										
2022	4,689	4,689	*****	*****	*****	*****	34.44 (8.61, 137.70)	7,793	7,882	1,648.4
2023	4,322	4,322	*****	*****	*****	*****	85.15 (31.96, 226.89)	6,899	7,033	820.2
Bydureon, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	264	264	80.2
2023	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	85	85	9.7
<i>White</i>										
2022	726	726	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,184	1,184	297.3
2023	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	156	156	21.7
Ozempic, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	697	697	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,102	1,104	260.9
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,026	1,026	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,609	1,611	424.8
2023	373	373	*****	*****	*****	*****	226.85 (31.95, 1,610.48)	518	520	65.1
<i>Black or African American</i>										
2022	6,083	6,083	*****	*****	*****	*****	42.49 (15.95, 113.21)	9,127	9,155	2,937.4
2023	3,817	3,817	*****	*****	*****	*****	91.97 (34.52, 245.04)	5,037	5,059	687.1
<i>Multi-racial</i>										
2022	408	408	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	691	693	254.3
2023	410	410	*****	*****	*****	*****	241.03 (33.95, 1,711.12)	560	563	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	225	225	31.9
<i>Unknown</i>										
2022	27,644	27,644	*****	*****	*****	*****	27.95 (16.23, 48.13)	45,287	45,401	14,495.0
2023	18,084	18,084	*****	*****	*****	*****	36.68 (16.48, 81.64)	23,536	23,630	2,171.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Rybelsus, Supraventricular Tachycardia										
<i>White</i>										
2022	43,289	43,289	*****	*****	*****	*****	51.33 (36.68, 71.84)	66,188	66,352	18,107.6
2023	15,424	15,424	*****	*****	*****	*****	55.59 (29.91, 103.31)	20,868	20,952	2,788.7
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	212	215	32.9
<i>Black or African American</i>										
2022	2,347	2,347	*****	*****	*****	*****	29.53 (4.16, 209.65)	3,346	3,409	1,111.7
2023	1,077	1,077	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,372	1,413	206.9
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	59	59	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	81	13.4
<i>Unknown</i>										
2022	8,927	8,927	*****	*****	*****	*****	14.28 (3.57, 57.12)	13,675	13,954	4,502.8
2023	3,949	3,949	*****	*****	*****	*****	27.18 (3.83, 192.98)	5,044	5,202	529.2
<i>White</i>										
2022	12,878	12,878	*****	*****	*****	*****	42.48 (21.25, 84.95)	19,666	20,021	5,257.6
2023	3,615	3,615	*****	*****	*****	*****	93.62 (35.14, 249.44)	4,852	4,993	724.4
Wegovy, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	51	53	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	35.5
2023	612	612	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	960	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	*****	*****	*****	*****	238.82 (33.64, 1,695.46)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	78	78	22.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.2
<i>Black or African American</i>										
2022	403	403	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	556	556	196.8
2023	161	161	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	34.5
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Unknown</i>										
2022	1,029	1,029	*****	*****	*****	*****	125.78 (31.46, 502.95)	1,558	1,559	516.0
2023	414	414	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	62.3
<i>White</i>										
2022	2,528	2,528	*****	*****	*****	*****	105.24 (39.50, 280.41)	3,769	3,769	1,045.6
2023	628	628	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	830	830	135.6
Trulicity, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	5.3
<i>Asian</i>										
2022	1,048	1,048	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,828	1,834	408.5
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	224	31.7
<i>Black or African American</i>										
2022	4,913	4,913	*****	*****	*****	*****	13.70 (1.93, 97.27)	8,260	8,321	2,276.8
2023	1,550	1,550	*****	*****	*****	*****	54.75 (7.71, 388.70)	2,271	2,285	319.7
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	*****	*****	*****	*****	370.47 (52.18, 2,630.11)	246	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,460	15,460	*****	*****	*****	*****	36.78 (19.79, 68.35)	29,714	29,907	7,872.3
2023	6,429	6,429	*****	*****	*****	*****	15.26 (2.15, 108.34)	9,730	9,812	897.5
<i>White</i>										
2022	31,108	31,108	*****	*****	*****	*****	52.55 (35.51, 77.77)	55,394	55,694	12,574.8
2023	5,845	5,845	*****	*****	*****	*****	68.83 (28.65, 165.36)	8,975	9,053	1,222.5
Xultophy, Supraventricular Tachycardia										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	155	155	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	209	209	68.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	640	640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	986	1,005	275.6
2023	1,019	1,019	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,527	1,552	193.5
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	61	62	6.7
<i>Unknown</i>										
2022	4,067	4,067	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,443	7,520	1,701.3
2023	4,001	4,001	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,262	6,332	542.7
<i>White</i>										
2022	4,689	4,689	*****	*****	*****	*****	17.22 (2.43, 122.24)	7,793	7,882	1,648.4
2023	4,322	4,322	*****	*****	*****	*****	85.15 (31.96, 226.89)	6,899	7,033	820.2
Bydureon, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	264	264	80.2
2023	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	85	85	9.7
<i>White</i>										
2022	726	726	*****	*****	*****	*****	194.31 (48.59, 776.95)	1,184	1,184	297.3
2023	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	156	156	21.7
Ozempic, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	697	697	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,102	1,104	260.9
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,026	1,026	*****	*****	*****	*****	61.16 (8.62, 434.23)	1,609	1,611	424.8
2023	373	373	*****	*****	*****	*****	226.85 (31.95, 1,610.48)	518	520	65.1
<i>Black or African American</i>										
2022	6,083	6,083	*****	*****	*****	*****	42.49 (15.95, 113.21)	9,127	9,155	2,937.4
2023	3,817	3,817	*****	*****	*****	*****	91.97 (34.52, 245.04)	5,037	5,059	687.1
<i>Multi-racial</i>										
2022	408	408	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	691	693	254.3
2023	410	410	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	560	563	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	225	225	31.9
<i>Unknown</i>										
2022	27,644	27,644	*****	*****	*****	*****	10.75 (4.47, 25.82)	45,287	45,401	14,495.0
2023	18,084	18,084	*****	*****	*****	*****	12.23 (3.06, 48.88)	23,536	23,630	2,171.0
<i>White</i>										
2022	43,289	43,289	*****	*****	*****	*****	40.76 (27.95, 59.44)	66,188	66,352	18,107.6
2023	15,424	15,424	*****	*****	*****	*****	61.15 (33.86, 110.41)	20,868	20,952	2,788.7

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Rybelsus, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	212	215	32.9
<i>Black or African American</i>										
2022	2,347	2,347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,346	3,409	1,111.7
2023	1,077	1,077	*****	*****	*****	*****	82.91 (11.68, 588.62)	1,372	1,413	206.9
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	59	59	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	81	13.4
<i>Unknown</i>										
2022	8,927	8,927	*****	*****	*****	*****	7.14 (1.01, 50.71)	13,675	13,954	4,502.8
2023	3,949	3,949	*****	*****	*****	*****	27.18 (3.83, 192.98)	5,044	5,202	529.2
<i>White</i>										
2022	12,878	12,878	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,666	20,021	5,257.6
2023	3,615	3,615	*****	*****	*****	*****	70.21 (22.65, 217.71)	4,852	4,993	724.4
Wegovy, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	51	53	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	35.5
2023	612	612	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	960	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	78	78	22.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.2
<i>Black or African American</i>										
2022	403	403	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	556	556	196.8
2023	161	161	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	34.5
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,029	1,029	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,558	1,559	516.0
2023	414	414	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	62.3

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
2022	2,528	2,528	*****	*****	*****	*****	78.93 (25.46, 244.73)	3,769	3,769	1,045.6
2023	628	628	*****	*****	*****	*****	125.63 (17.70, 891.90)	830	830	135.6
Trulicity, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	5.3
<i>Asian</i>										
2022	1,048	1,048	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,828	1,834	408.5
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	224	31.7
<i>Black or African American</i>										
2022	4,913	4,913	*****	*****	*****	*****	27.40 (6.85, 109.57)	8,260	8,321	2,276.8
2023	1,550	1,550	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,271	2,285	319.7
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	246	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,460	15,460	*****	*****	*****	*****	7.36 (1.84, 29.41)	29,714	29,907	7,872.3
2023	6,429	6,429	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,730	9,812	897.5
<i>White</i>										
2022	31,108	31,108	*****	*****	*****	*****	25.22 (14.33, 44.42)	55,394	55,694	12,574.8
2023	5,845	5,845	*****	*****	*****	*****	68.83 (28.65, 165.36)	8,975	9,053	1,222.5
Xultophy, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	155	155	*****	*****	*****	*****	371.87 (52.38, 2,640.02)	209	209	68.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	640	640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	986	1,005	275.6
2023	1,019	1,019	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,527	1,552	193.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	61	62	6.7
<i>Unknown</i>										
2022	4,067	4,067	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,443	7,520	1,701.3
2023	4,001	4,001	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,262	6,332	542.7
<i>White</i>										
2022	4,689	4,689	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,793	7,882	1,648.4
2023	4,322	4,322	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,899	7,033	820.2
Bydureon, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Unknown</i>										
2022	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	264	264	80.2
2023	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	85	85	9.7
<i>White</i>										
2022	726	726	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,184	1,184	297.3
2023	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	156	156	21.7
Ozempic, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	697	697	*****	*****	*****	*****	108.85 (15.33, 772.75)	1,102	1,104	260.9
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,026	1,026	*****	*****	*****	*****	61.16 (8.62, 434.23)	1,609	1,611	424.8
2023	373	373	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	518	520	65.1
<i>Black or African American</i>										
2022	6,083	6,083	*****	*****	*****	*****	10.62 (1.50, 75.41)	9,127	9,155	2,937.4
2023	3,817	3,817	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,037	5,059	687.1
<i>Multi-racial</i>										
2022	408	408	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	691	693	254.3
2023	410	410	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	560	563	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	225	225	31.9
<i>Unknown</i>										
2022	27,644	27,644	*****	*****	*****	*****	4.30 (1.08, 17.19)	45,287	45,401	14,495.0
2023	18,084	18,084	*****	*****	*****	*****	6.11 (0.86, 43.40)	23,536	23,630	2,171.0
<i>White</i>										
2022	43,289	43,289	*****	*****	*****	*****	16.61 (9.20, 29.99)	66,188	66,352	18,107.6
2023	15,424	15,424	*****	*****	*****	*****	5.56 (0.78, 39.46)	20,868	20,952	2,788.7
Rybelsus, Cardiac Arrest										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	212	215	32.9
<i>Black or African American</i>										
2022	2,347	2,347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,346	3,409	1,111.7
2023	1,077	1,077	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,372	1,413	206.9
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	59	59	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	81	13.4
<i>Unknown</i>										
2022	8,927	8,927	*****	*****	*****	*****	7.14 (1.01, 50.71)	13,675	13,954	4,502.8
2023	3,949	3,949	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,044	5,202	529.2
<i>White</i>										
2022	12,878	12,878	*****	*****	*****	*****	5.31 (0.75, 37.70)	19,666	20,021	5,257.6
2023	3,615	3,615	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,852	4,993	724.4

Wegovy, Cardiac Arrest

<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	51	53	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	35.5
2023	612	612	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	960	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	78	78	22.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.2
<i>Black or African American</i>										
2022	403	403	*****	*****	*****	*****	176.53 (24.87, 1,253.22)	556	556	196.8
2023	161	161	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	34.5
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,029	1,029	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,558	1,559	516.0
2023	414	414	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	62.3
<i>White</i>										
2022	2,528	2,528	*****	*****	*****	*****	52.62 (13.16, 210.40)	3,769	3,769	1,045.6
2023	628	628	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	830	830	135.6

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Trulicity, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	5.3
<i>Asian</i>										
2022	1,048	1,048	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,828	1,834	408.5
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	224	31.7
<i>Black or African American</i>										
2022	4,913	4,913	*****	*****	*****	*****	13.70 (1.93, 97.27)	8,260	8,321	2,276.8
2023	1,550	1,550	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,271	2,285	319.7
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	*****	*****	*****	*****	370.47 (52.18, 2,630.11)	246	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,460	15,460	*****	*****	*****	*****	3.68 (0.52, 26.11)	29,714	29,907	7,872.3
2023	6,429	6,429	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,730	9,812	897.5
<i>White</i>										
2022	31,108	31,108	*****	*****	*****	*****	16.82 (8.41, 33.63)	55,394	55,694	12,574.8
2023	5,845	5,845	*****	*****	*****	*****	13.77 (1.94, 97.72)	8,975	9,053	1,222.5
Xultophy, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	155	155	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	209	209	68.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	640	640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	986	1,005	275.6
2023	1,019	1,019	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,527	1,552	193.5
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	61	62	6.7
<i>Unknown</i>										
2022	4,067	4,067	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,443	7,520	1,701.3
2023	4,001	4,001	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,262	6,332	542.7
<i>White</i>										
2022	4,689	4,689	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,793	7,882	1,648.4
2023	4,322	4,322	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,899	7,033	820.2
Bydureon, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	264	264	80.2
2023	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	85	85	9.7

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
2022	726	726	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,184	1,184	297.3
2023	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	156	156	21.7
Ozempic, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	697	697	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,102	1,104	260.9
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,026	1,026	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,609	1,611	424.8
2023	373	373	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	518	520	65.1
<i>Black or African American</i>										
2022	6,083	6,083	*****	*****	*****	*****	21.24 (5.31, 84.95)	9,127	9,155	2,937.4
2023	3,817	3,817	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,037	5,059	687.1
<i>Multi-racial</i>										
2022	408	408	*****	*****	*****	*****	151.42 (21.33, 1,074.96)	691	693	254.3
2023	410	410	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	560	563	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	225	225	31.9
<i>Unknown</i>										
2022	27,644	27,644	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45,287	45,401	14,495.0
2023	18,084	18,084	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23,536	23,630	2,171.0
<i>White</i>										
2022	43,289	43,289	*****	*****	*****	*****	6.04 (2.27, 16.09)	66,188	66,352	18,107.6
2023	15,424	15,424	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20,868	20,952	2,788.7
Rybelsus, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	212	215	32.9
<i>Black or African American</i>										
2022	2,347	2,347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,346	3,409	1,111.7
2023	1,077	1,077	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,372	1,413	206.9
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	59	59	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	81	13.4
<i>Unknown</i>										
2022	8,927	8,927	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,675	13,954	4,502.8
2023	3,949	3,949	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,044	5,202	529.2
<i>White</i>										
2022	12,878	12,878	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,666	20,021	5,257.6
2023	3,615	3,615	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,852	4,993	724.4
Wegovy, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	51	53	4.8

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	35.5
2023	612	612	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	960	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	78	78	22.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.2
<i>Black or African American</i>										
2022	403	403	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	556	556	196.8
2023	161	161	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	34.5
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,029	1,029	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,558	1,559	516.0
2023	414	414	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	62.3
<i>White</i>										
2022	2,528	2,528	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,769	3,769	1,045.6
2023	628	628	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	830	830	135.6
Trulicity, Ventricular Tachycardia										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	5.3
<i>Asian</i>										
2022	1,048	1,048	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,828	1,834	408.5
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	224	31.7
<i>Black or African American</i>										
2022	4,913	4,913	*****	*****	*****	*****	13.70 (1.93, 97.27)	8,260	8,321	2,276.8
2023	1,550	1,550	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,271	2,285	319.7
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	246	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,460	15,460	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29,714	29,907	7,872.3
2023	6,429	6,429	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,730	9,812	897.5
<i>White</i>										
2022	31,108	31,108	*****	*****	*****	*****	6.31 (2.03, 19.55)	55,394	55,694	12,574.8
2023	5,845	5,845	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,975	9,053	1,222.5
Xultophy, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	155	155	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	209	209	68.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	640	640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	986	1,005	275.6
2023	1,019	1,019	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,527	1,552	193.5
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	61	62	6.7
<i>Unknown</i>										
2022	4,067	4,067	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,443	7,520	1,701.3
2023	4,001	4,001	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,262	6,332	542.7
<i>White</i>										
2022	4,689	4,689	*****	*****	*****	*****	17.22 (2.43, 122.24)	7,793	7,882	1,648.4
2023	4,322	4,322	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,899	7,033	820.2
Bydureon, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	264	264	80.2
2023	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	85	85	9.7
<i>White</i>										
2022	726	726	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,184	1,184	297.3
2023	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	156	156	21.7

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Ozempic, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	697	697	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,102	1,104	260.9
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,026	1,026	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,609	1,611	424.8
2023	373	373	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	518	520	65.1
<i>Black or African American</i>										
2022	6,083	6,083	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,127	9,155	2,937.4
2023	3,817	3,817	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,037	5,059	687.1
<i>Multi-racial</i>										
2022	408	408	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	691	693	254.3
2023	410	410	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	560	563	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	225	225	31.9
<i>Unknown</i>										
2022	27,644	27,644	*****	*****	*****	*****	2.15 (0.30, 15.26)	45,287	45,401	14,495.0
2023	18,084	18,084	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23,536	23,630	2,171.0
<i>White</i>										
2022	43,289	43,289	*****	*****	*****	*****	3.02 (0.76, 12.07)	66,188	66,352	18,107.6
2023	15,424	15,424	*****	*****	*****	*****	5.56 (0.78, 39.46)	20,868	20,952	2,788.7
Rybelsus, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	166	166	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	212	215	32.9

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	2,347	2,347	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,346	3,409	1,111.7
2023	1,077	1,077	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,372	1,413	206.9
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	59	59	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	81	13.4
<i>Unknown</i>										
2022	8,927	8,927	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,675	13,954	4,502.8
2023	3,949	3,949	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,044	5,202	529.2
<i>White</i>										
2022	12,878	12,878	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,666	20,021	5,257.6
2023	3,615	3,615	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,852	4,993	724.4
Wegovy, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	51	53	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	98	98	35.5
2023	612	612	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	939	960	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	78	78	22.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
Asian										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.2
Black or African American										
2022	403	403	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	556	556	196.8
2023	161	161	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	34.5
Multi-racial										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
Native Hawaiian or Other Pacific Islander										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
Unknown										
2022	1,029	1,029	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,558	1,559	516.0
2023	414	414	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	62.3
White										
2022	2,528	2,528	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,769	3,769	1,045.6
2023	628	628	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	830	830	135.6
Trulicity, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	40	40	5.3

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
2022	1,048	1,048	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,828	1,834	408.5
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	224	31.7
<i>Black or African American</i>										
2022	4,913	4,913	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,260	8,321	2,276.8
2023	1,550	1,550	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,271	2,285	319.7
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	246	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,460	15,460	*****	*****	*****	*****	7.36 (1.84, 29.41)	29,714	29,907	7,872.3
2023	6,429	6,429	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,730	9,812	897.5
<i>White</i>										
2022	31,108	31,108	*****	*****	*****	*****	4.20 (1.05, 16.81)	55,394	55,694	12,574.8
2023	5,845	5,845	*****	*****	*****	*****	13.77 (1.94, 97.72)	8,975	9,053	1,222.5
Xultophy, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	155	155	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	209	209	68.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3

NaN: Not a number

Table 10. Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes	Number of Episodes by Episode Length													
		0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	727	54.7%	239	18.0%	226	17.0%	116	8.7%	20	1.5%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,996	11,010	58.0%	4,471	23.5%	2,222	11.7%	1,184	6.2%	109	0.6%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	54,897	46.6%	31,021	26.4%	18,987	16.1%	11,008	9.4%	1,791	1.5%	17	0.0%	0	0.0%
<i>Rybelsus</i>	34,260	19,874	58.0%	5,674	16.6%	5,265	15.4%	2,873	8.4%	*****	1.7%	*****	0.0%	0	0.0%
<i>Saxenda</i>	386	225	58.3%	72	18.7%	53	13.7%	*****	8.5%	*****	0.8%	0	0.0%	0	0.0%
<i>Trulicity</i>	67,310	32,272	47.9%	14,271	21.2%	11,730	17.4%	7,575	11.3%	1,450	2.2%	12	0.0%	0	0.0%
<i>Victoza</i>	5,398	2,738	50.7%	1,230	22.8%	853	15.8%	490	9.1%	*****	1.6%	*****	0.0%	0	0.0%
<i>Wegovy</i>	842	561	66.6%	195	23.2%	75	8.9%	11	1.3%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	366	162	44.3%	66	18.0%	86	23.5%	*****	11.7%	*****	2.5%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 10. Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

		Distribution of At-Risk Time in Days, by Episode						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
	Total Number of Episodes							
Bydureon	1,328	1	28	29	71	345	50.0	40.4
Mounjaro	18,996	1	28	28	54	345	42.5	31.6
Ozempic	117,721	1	28	38	66	384	51.4	40.5
Rybelsus	34,260	1	30	30	62	381	50.8	41.6
Saxenda	386	3	30	30	59	278	48.5	36.9
Trulicity	67,310	1	28	37	78	384	54.7	44.6
Victoza	5,398	1	30	30	67	370	51.7	42.4
Wegovy	842	1	19	28	46	165	32.6	21.4
Xultophy	366	1	30	37	90	302	58.1	45.8

Table 11. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to End of Exposure Episode by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes Censored due to End of Exposure Episode ¹		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	1,063	581	54.7%	186	17.5%	193	18.2%	88	8.3%	15	1.4%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,996	13,264	7,829	59.0%	3,058	23.1%	1,565	11.8%	776	5.9%	36	0.3%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	85,764	38,482	44.9%	22,621	26.4%	15,249	17.8%	8,378	9.8%	*****	1.2%	*****	0.0%	0	0.0%
<i>Rybelsus</i>	34,260	27,088	16,163	59.7%	4,194	15.5%	4,307	15.9%	2,106	7.8%	318	1.2%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	322	193	59.9%	60	18.6%	44	13.7%	*****	7.5%	*****	0.3%	0	0.0%	0	0.0%
<i>Trulicity</i>	67,310	52,725	25,225	47.8%	10,894	20.7%	9,751	18.5%	5,995	11.4%	860	1.6%	0	0.0%	0	0.0%
<i>Victoza</i>	5,398	4,099	2,031	49.5%	964	23.5%	681	16.6%	367	9.0%	56	1.4%	0	0.0%	0	0.0%
<i>Wegovy</i>	842	403	266	66.0%	104	25.8%	*****	7.4%	*****	0.7%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	366	241	108	44.8%	41	17.0%	62	25.7%	*****	9.1%	*****	3.3%	0	0.0%	0	0.0%

¹Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 11. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

			Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	1,063	1	28	30	76	239	51.5	37.9
<i>Mounjaro</i>	18,996	13,264	1	28	28	54	345	44.0	27.9
<i>Ozempic</i>	117,721	85,764	1	28	42	70	384	54.2	37.4
<i>Rybelsus</i>	34,260	27,088	1	30	30	60	338	51.2	37.6
<i>Saxenda</i>	386	322	6	30	30	59	187	47.8	31.2
<i>Trulicity</i>	67,310	52,725	1	28	41	80	345	55.7	40.6
<i>Victoza</i>	5,398	4,099	1	30	31	71	303	53.9	39.6
<i>Wegovy</i>	842	403	2	28	28	49	165	37.7	17.6
<i>Xultophy</i>	366	241	3	30	38	90	242	61.0	44.9

¹Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Hospitalized Tachyarrhythmia</i>	1,328	*****	*****	71.4%	*****	14.3%	0	0.0%	*****	14.3%	0	0.0%	0	0.0%	0	0.0%
<i>Hospitalized Tachyarrhythmia</i>	18,996	104	67	64.4%	23	22.1%	*****	10.6%	*****	2.9%	0	0.0%	0	0.0%	0	0.0%
<i>Hospitalized Tachyarrhythmia</i>	117,721	811	445	54.9%	213	26.3%	83	10.2%	*****	7.4%	*****	1.2%	0	0.0%	0	0.0%
<i>Hospitalized Tachyarrhythmia</i>	34,260	186	110	59.1%	46	24.7%	*****	10.8%	*****	5.4%	0	0.0%	0	0.0%	0	0.0%
<i>Hospitalized Tachyarrhythmia</i>	386	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Hospitalized Tachyarrhythmia</i>	67,310	519	320	61.7%	102	19.7%	50	9.6%	*****	7.9%	*****	1.2%	0	0.0%	0	0.0%
<i>Hospitalized Tachyarrhythmia</i>	5,398	49	29	59.2%	*****	16.3%	*****	8.2%	*****	16.3%	0	0.0%	0	0.0%	0	0.0%

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Wegovy, Hospitalized Tachyarrhythmia</i>	842	*****	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro, Hospitalized Tachyarrhythmia</i>	366	*****	0	0.0%	*****	50.0%	0	0.0%	*****	50.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro, Atrial Fibrillation and Flutter</i>	18,996	66	44	66.7%	*****	21.2%	*****	10.6%	*****	1.5%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Atrial Fibrillation and Flutter</i>	1,328	*****	*****	80.0%	*****	20.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic, Atrial Fibrillation and Flutter</i>	117,721	519	294	56.6%	126	24.3%	48	9.2%	*****	8.3%	*****	1.5%	0	0.0%	0	0.0%
<i>Rybelsus, Atrial Fibrillation and Flutter</i>	34,260	129	76	58.9%	29	22.5%	*****	11.6%	*****	7.0%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Atrial Fibrillation and Flutter</i>	842	*****	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Saxenda, Atrial Fibrillation and Flutter</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza, Atrial Fibrillation and Flutter</i>	5,398	29	16	55.2%	*****	20.7%	*****	10.3%	*****	13.8%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity, Atrial Fibrillation and Flutter</i>	67,310	363	242	66.7%	68	18.7%	32	8.8%	*****	5.0%	*****	0.8%	0	0.0%	0	0.0%
<i>Xultophy, Atrial Fibrillation and Flutter</i>	366	*****	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro, Sinus Tachycardia</i>	18,996	30	18	60.0%	*****	26.7%	*****	6.7%	*****	6.7%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Sinus Tachycardia</i>	1,328	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic, Sinus Tachycardia</i>	117,721	182	97	53.3%	58	31.9%	17	9.3%	*****	4.9%	*****	0.5%	0	0.0%	0	0.0%
<i>Rybelsus, Sinus Tachycardia</i>	34,260	47	26	55.3%	15	31.9%	*****	8.5%	*****	4.3%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Sinus Tachycardia</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Sinus Tachycardia</i>	386	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Victoza, Sinus Tachycardia</i>	5,398	15	*****	80.0%	*****	13.3%	0	0.0%	*****	6.7%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity, Sinus Tachycardia</i>	67,310	109	53	48.6%	23	21.1%	16	14.7%	*****	14.7%	*****	0.9%	0	0.0%	0	0.0%
<i>Xultophy, Sinus Tachycardia</i>	366	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Mounjaro, Supraventricular Tachycardia</i>	18,996	*****	*****	62.5%	*****	12.5%	*****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Supraventricular Tachycardia</i>	1,328	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic, Supraventricular Tachycardia</i>	117,721	73	37	50.7%	25	34.2%	*****	13.7%	0	0.0%	*****	1.4%	0	0.0%	0	0.0%
<i>Rybelsus, Supraventricular Tachycardia</i>	34,260	16	*****	56.3%	*****	18.8%	*****	12.5%	*****	12.5%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Supraventricular Tachycardia</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Saxenda, Supraventricular Tachycardia</i>	386	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Victoza, Supraventricular Tachycardia</i>	5,398	*****	*****	50.0%	0	0.0%	0	0.0%	*****	50.0%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity, Supraventricular Tachycardia</i>	67,310	44	27	61.4%	*****	22.7%	*****	9.1%	*****	6.8%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy, Supraventricular Tachycardia</i>	366	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Other Tachycardia</i>	18,996	*****	*****	80.0%	0	0.0%	*****	20.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Other Tachycardia</i>	1,328	*****	*****	50.0%	0	0.0%	0	0.0%	*****	50.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic, Other Tachycardia</i>	117,721	55	29	52.7%	12	21.8%	*****	10.9%	*****	14.5%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus, Other Tachycardia</i>	34,260	*****	*****	66.7%	*****	16.7%	0	0.0%	*****	16.7%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Other Tachycardia</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Saxenda, Other Tachycardia</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza, Other Tachycardia</i>	5,398	*****	*****	75.0%	0	0.0%	*****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity, Other Tachycardia</i>	67,310	21	11	52.4%	*****	23.8%	0	0.0%	*****	19.0%	*****	4.8%	0	0.0%	0	0.0%
<i>Xultophy, Other Tachycardia</i>	366	*****	0	0.0%	0	0.0%	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro, Cardiac Arrest</i>	18,996	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Bydureon, Cardiac Arrest</i>	1,328	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic, Cardiac Arrest</i>	117,721	18	*****	44.4%	*****	22.2%	*****	16.7%	*****	16.7%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus, Cardiac Arrest</i>	34,260	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Cardiac Arrest</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Cardiac Arrest</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza, Cardiac Arrest</i>	5,398	*****	0	0.0%	*****	33.3%	0	0.0%	*****	66.7%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity, Cardiac Arrest</i>	67,310	12	*****	41.7%	*****	25.0%	*****	16.7%	*****	8.3%	*****	8.3%	0	0.0%	0	0.0%

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episode s	Percent of Total Episodes	Number of Episode s	Percent of Total Episodes	Number of Episode s	Percent of Total Episodes	Number of Episode s	Percent of Total Episodes	Number of Episode s	Percent of Total Episodes	Number of Episode s	Percent of Total Episodes	Number of Episode s	Percent of Total Episodes
<i>Xultophy, Cardiac Arrest</i>	366	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Mounjaro, Ventricular Tachycardia</i>	18,996	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Bydureon, Ventricular Tachycardia</i>	1,328	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic, Ventricular Tachycardia</i>	117,721	*****	*****	42.9%	*****	42.9%	*****	14.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus, Ventricular Tachycardia</i>	34,260	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Wegovy, Ventricular Tachycardia</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Ventricular Tachycardia</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza, Ventricular Tachycardia</i>	5,398	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes		Number of Episodes		Number of Episodes		Number of Episodes		Number of Episodes		Number of Episodes		Number of Episodes	
			Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes	Percent of Total Episodes
<i>Trulicity, Ventricular Tachycardia</i>	67,310	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy, Ventricular Tachycardia</i>	366	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Mounjaro, Ventricular Fibrillation and Flutter</i>	18,996	*****	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Ventricular Fibrillation and Flutter</i>	1,328	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic, Ventricular Fibrillation and Flutter</i>	117,721	*****	*****	75.0%	*****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus, Ventricular Fibrillation and Flutter</i>	34,260	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Wegovy, Ventricular Fibrillation and Flutter</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Ventricular Fibrillation and Flutter</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza, Ventricular Fibrillation and Flutter</i>	5,398	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity, Ventricular Fibrillation and Flutter</i>	67,310	*****	*****	60.0%	*****	40.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy, Ventricular Fibrillation and Flutter</i>	366	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to occurrence of request-defined event.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Censored due to Occurrence of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon, Hospitalized Tachyarrhythmia</i>	1,328	*****	3	11	20	34	95	29.1	30.6
<i>Mounjaro, Hospitalized Tachyarrhythmia</i>	18,996	104	1	9	20	36	167	29.3	30.0
<i>Ozempic, Hospitalized Tachyarrhythmia</i>	117,721	811	1	12	26	52	355	38.5	39.3
<i>Rybelsus, Hospitalized Tachyarrhythmia</i>	34,260	186	1	12	27	48	171	35.5	33.8
<i>Saxenda, Hospitalized Tachyarrhythmia</i>	386	*****	5	5	5	5	5	5.0	NaN
<i>Trulicity, Hospitalized Tachyarrhythmia</i>	67,310	519	1	9	22	47	327	36.4	41.5
<i>Victoza, Hospitalized Tachyarrhythmia</i>	5,398	49	1	11	23	55	175	43.1	47.8
<i>Wegovy, Hospitalized Tachyarrhythmia</i>	842	*****	35	35	35	35	35	35.0	NaN
<i>Xultophy, Hospitalized Tachyarrhythmia</i>	366	*****	39	39	78	117	117	78.0	55.2
<i>Mounjaro, Atrial Fibrillation and Flutter</i>	18,996	66	1	9	19	39	120	27.2	24.9
<i>Bydureon, Atrial Fibrillation and Flutter</i>	1,328	*****	3	11	18	20	34	17.2	11.5
<i>Ozempic, Atrial Fibrillation and Flutter</i>	117,721	519	1	12	25	52	262	38.8	40.6
<i>Rybelsus, Atrial Fibrillation and Flutter</i>	34,260	129	1	14	25	50	171	38.7	37.4
<i>Wegovy, Atrial Fibrillation and Flutter</i>	842	*****	35	35	35	35	35	35.0	NaN
<i>Saxenda, Atrial Fibrillation and Flutter</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Atrial Fibrillation and Flutter</i>	5,398	29	1	11	23	55	156	41.6	43.6
<i>Trulicity, Atrial Fibrillation and Flutter</i>	67,310	363	1	9	21	42	327	32.0	38.0
<i>Xultophy, Atrial Fibrillation and Flutter</i>	366	*****	39	39	39	39	39	39.0	NaN
<i>Mounjaro, Sinus Tachycardia</i>	18,996	30	2	10	25	35	167	33.3	39.3
<i>Bydureon, Sinus Tachycardia</i>	1,328	*****	23	23	23	23	23	23.0	NaN
<i>Ozempic, Sinus Tachycardia</i>	117,721	182	2	13	28	50	355	36.7	37.9
<i>Rybelsus, Sinus Tachycardia</i>	34,260	47	1	12	27	45	166	33.5	29.8
<i>Wegovy, Sinus Tachycardia</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Sinus Tachycardia</i>	386	*****	5	5	5	5	5	5.0	NaN
<i>Victoza, Sinus Tachycardia</i>	5,398	15	3	10	13	26	114	24.2	28.1
<i>Trulicity, Sinus Tachycardia</i>	67,310	109	1	12	32	73	226	47.2	46.3
<i>Xultophy, Sinus Tachycardia</i>	366	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro, Supraventricular Tachycardia</i>	18,996	*****	5	13	25	56	87	34.8	30.6

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Censored due to Occurrence of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon, Supraventricular Tachycardia</i>	1,328	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic, Supraventricular Tachycardia</i>	117,721	73	1	12	30	52	190	35.1	29.5
<i>Rybelsus, Supraventricular Tachycardia</i>	34,260	16	2	17	25	61	171	46.6	51.5
<i>Wegovy, Supraventricular Tachycardia</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Supraventricular Tachycardia</i>	386	*****	5	5	5	5	5	5.0	NaN
<i>Victoza, Supraventricular Tachycardia</i>	5,398	*****	1	7	66	139	175	75.5	78.4
<i>Trulicity, Supraventricular Tachycardia</i>	67,310	44	1	5	21	46	151	30.9	33.1
<i>Xultophy, Supraventricular Tachycardia</i>	366	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro, Other Tachycardia</i>	18,996	*****	8	8	15	19	76	25.2	28.8
<i>Bydureon, Other Tachycardia</i>	1,328	*****	18	18	57	95	95	56.5	54.4
<i>Ozempic, Other Tachycardia</i>	117,721	55	1	9	28	62	156	41.8	38.2
<i>Rybelsus, Other Tachycardia</i>	34,260	*****	1	6	28	41	166	45.0	61.1
<i>Wegovy, Other Tachycardia</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Other Tachycardia</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Other Tachycardia</i>	5,398	*****	1	5	13	49	81	26.8	36.7
<i>Trulicity, Other Tachycardia</i>	67,310	21	4	14	26	60	195	47.6	50.7
<i>Xultophy, Other Tachycardia</i>	366	*****	117	117	117	117	117	117.0	NaN
<i>Mounjaro, Cardiac Arrest</i>	18,996	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Bydureon, Cardiac Arrest</i>	1,328	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic, Cardiac Arrest</i>	117,721	18	5	7	35	81	166	47.7	44.8
<i>Rybelsus, Cardiac Arrest</i>	34,260	*****	3	3	11	19	19	11.0	11.3
<i>Wegovy, Cardiac Arrest</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Cardiac Arrest</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Cardiac Arrest</i>	5,398	*****	40	40	134	143	143	105.7	57.0
<i>Trulicity, Cardiac Arrest</i>	67,310	12	2	14	50	66	193	54.6	53.9
<i>Xultophy, Cardiac Arrest</i>	366	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro, Ventricular Tachycardia</i>	18,996	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Bydureon, Ventricular Tachycardia</i>	1,328	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Censored due to Occurrence of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Ozempic, Ventricular Tachycardia</i>	117,721	*****	2	4	35	52	72	32.4	24.9
<i>Rybelsus, Ventricular Tachycardia</i>	34,260	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Wegovy, Ventricular Tachycardia</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Ventricular Tachycardia</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Ventricular Tachycardia</i>	5,398	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity, Ventricular Tachycardia</i>	67,310	*****	1	2	5	13	19	7.3	8.1
<i>Xultophy, Ventricular Tachycardia</i>	366	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Flutter</i>	18,996	*****	34	34	34	34	34	34.0	NaN
<i>Bydureon, Ventricular Fibrillation and Flutter</i>	1,328	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic, Ventricular Fibrillation and Flutter</i>	117,721	*****	8	13	23	43	58	27.8	21.6
<i>Rybelsus, Ventricular Fibrillation and Flutter</i>	34,260	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Wegovy, Ventricular Fibrillation and Flutter</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Ventricular Fibrillation and Flutter</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Ventricular Fibrillation and Flutter</i>	5,398	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity, Ventricular Fibrillation and Flutter</i>	67,310	*****	2	25	26	39	58	30.0	20.6
<i>Xultophy, Ventricular Fibrillation and Flutter</i>	366	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Represents episodes censored due to occurrence of request-defined event.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 13. Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length															
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days			
	Total Number of Episodes	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	156	88	56.4%	32	20.5%	23	14.7%	*****	7.7%	*****	0.6%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,996	1,299	877	67.5%	247	19.0%	124	9.5%	*****	3.6%	*****	0.3%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	10,242	5,771	56.3%	2,624	25.6%	1,041	10.2%	707	6.9%	99	1.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus</i>	34,260	2,668	1,606	60.2%	520	19.5%	303	11.4%	218	8.2%	21	0.8%	0	0.0%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	37	22	59.5%	*****	24.3%	*****	10.8%	*****	5.4%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity</i>	67,310	6,965	4,121	59.2%	1,486	21.3%	734	10.5%	549	7.9%	75	1.1%	0	0.0%	0	0.0%	0	0.0%
<i>Victoza</i>	5,398	760	471	62.0%	148	19.5%	76	10.0%	*****	8.3%	*****	0.3%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy</i>	842	41	*****	82.9%	*****	14.6%	*****	2.4%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	366	48	25	52.1%	11	22.9%	*****	12.5%	*****	12.5%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

¹Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 13. Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes	Total Number of- Episodes Censored due to Occurrence of User-Defined Censoring Criteria ¹	Distribution of At-Risk Time in Days, by Episode						
			Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	156	1	12	27	56	345	39.0	41.0
<i>Mounjaro</i>	18,996	1,299	1	10	20	41	242	29.5	29.7
<i>Ozempic</i>	117,721	10,242	1	12	26	50	357	37.3	37.5
<i>Rybelsus</i>	34,260	2,668	1	12	25	52	330	38.1	38.4
<i>Saxenda</i>	386	37	3	11	29	51	167	35.6	35.7
<i>Trulicity</i>	67,310	6,965	1	11	24	51	338	37.5	39.7
<i>Victoza</i>	5,398	760	1	10	23	48	274	35.6	36.7
<i>Wegovy</i>	842	41	1	7	17	27	64	19.0	14.9
<i>Xultophy</i>	366	48	1	16	28	61	171	42.4	41.2

¹Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 14. Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Evidence of Death by Episode Length															
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days			
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,996	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	32	22	68.8%	*****	15.6%	*****	6.3%	*****	9.4%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus</i>	34,260	*****	*****	66.7%	*****	33.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity</i>	67,310	50	33	66.0%	*****	14.0%	*****	10.0%	*****	8.0%	*****	2.0%	0	0.0%	0	0.0%	0	0.0%
<i>Victoza</i>	5,398	8	*****	75.0%	*****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Xultophy</i>	366	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 14. Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes Censored due to Evidence of Death ¹		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	*****	8	8	8	8	8	8.0	NaN
<i>Mounjaro</i>	18,996	*****	8	8	12	16	16	12.0	5.7
<i>Ozempic</i>	117,721	32	4	15	22	37	166	33.9	35.2
<i>Rybelsus</i>	34,260	*****	19	19	24	50	53	31.5	15.7
<i>Saxenda</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity</i>	67,310	50	1	7	18	58	193	36.1	42.4
<i>Victoza</i>	5,398	8	4	4	13	31	40	17.5	17.2
<i>Wegovy</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Xultophy</i>	366	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

NaN: Not a number

Table 15. Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Disenrollment by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon Mounjaro</i>	1,328	193	96	49.7%	34	17.6%	24	12.4%	*****	15.0%	*****	5.2%	0	0.0%	0	0.0%
	18,996	1,586	938	59.1%	377	23.8%	167	10.5%	*****	6.4%	*****	0.1%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	12,121	5,360	44.2%	2,894	23.9%	1,817	15.0%	1,690	13.9%	*****	3.0%	*****	0.0%	0	0.0%
<i>Rybelsus</i>	34,260	4,408	1,970	44.7%	930	21.1%	647	14.7%	694	15.7%	167	3.8%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	*****	*****	75.0%	*****	12.5%	0	0.0%	*****	12.5%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity</i>	67,310	9,753	3,887	39.9%	2,318	23.8%	1,495	15.3%	1,647	16.9%	406	4.2%	0	0.0%	0	0.0%
<i>Victoza</i>	5,398	724	305	42.1%	195	26.9%	94	13.0%	99	13.7%	31	4.3%	0	0.0%	0	0.0%
<i>Wegovy</i>	842	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	366	44	12	27.3%	*****	22.7%	*****	18.2%	*****	20.5%	*****	11.4%	0	0.0%	0	0.0%

¹Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 15. Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes Censored due to Disenrollment ¹		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	193	1	13	31	76	233	54.0	54.4
<i>Mounjaro</i>	18,996	1,586	1	16	26	48	190	35.9	31.1
<i>Ozempic</i>	117,721	12,121	1	19	39	72	384	52.8	47.9
<i>Rybelsus</i>	34,260	4,408	1	18	39	79	263	55.8	51.0
<i>Saxenda</i>	386	*****	9	16	27	33	128	35.9	38.2
<i>Trulicity</i>	67,310	9,753	1	19	44	80	292	58.5	51.9
<i>Victoza</i>	5,398	724	1	18	39	73	249	55.6	52.6
<i>Wegovy</i>	842	*****	2	2	12	22	25	12.7	8.9
<i>Xultophy</i>	366	44	3	29	60	120	228	77.0	64.2

¹Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 16. Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to End of Data by Episode Length															
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days			
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	286	143	50.0%	53	18.5%	31	10.8%	45	15.7%	14	4.9%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,996	5,789	3,100	53.5%	1,486	25.7%	687	11.9%	446	7.7%	70	1.2%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	32,444	15,292	47.1%	8,321	25.6%	4,348	13.4%	3,480	10.7%	989	3.0%	14	0.0%	0	0.0%	0	0.0%
<i>Rybelsus</i>	34,260	8,452	3,838	45.4%	1,791	21.2%	1,252	14.8%	1,185	14.0%	*****	4.5%	*****	0.1%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	29	12	41.4%	*****	10.3%	*****	17.2%	*****	24.1%	*****	6.9%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity</i>	67,310	16,372	6,322	38.6%	3,957	24.2%	2,608	15.9%	2,570	15.7%	903	5.5%	12	0.1%	0	0.0%	0	0.0%
<i>Victoza</i>	5,398	1,197	500	41.8%	298	24.9%	187	15.6%	154	12.9%	*****	4.8%	*****	0.1%	0	0.0%	0	0.0%
<i>Wegovy</i>	842	409	267	65.3%	89	21.8%	*****	10.8%	*****	2.2%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	366	122	43	35.2%	24	19.7%	26	21.3%	*****	19.7%	*****	4.1%	0	0.0%	0	0.0%	0	0.0%

¹Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 16. Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

			Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	286	1	15	31	78	320	54.6	56.4
<i>Mounjaro</i>	18,996	5,789	1	15	28	53	310	40.6	38.3
<i>Ozempic</i>	117,721	32,444	1	17	33	65	384	49.2	49.8
<i>Rybelsus</i>	34,260	8,452	1	18	37	77	381	56.4	56.3
<i>Saxenda</i>	386	29	3	15	59	97	278	71.3	71.6
<i>Trulicity</i>	67,310	16,372	1	20	45	81	384	61.8	59.1
<i>Victoza</i>	5,398	1,197	1	18	40	76	370	57.2	56.8
<i>Wegovy</i>	842	409	1	11	23	43	119	29.2	24.2
<i>Xultophy</i>	366	122	2	22	52	90	302	63.6	54.2

¹Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 17. Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to End of Study Period by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Study Period ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Mounjaro</i>	18,996	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic</i>	117,721	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Rybelsus</i>	34,260	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity</i>	67,310	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza</i>	5,398	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Wegovy</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Xultophy</i>	366	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

NaN: Not a number

Table 17. Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

			Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to End of Study Period ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro</i>	18,996	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic</i>	117,721	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Rybelsus</i>	34,260	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity</i>	67,310	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza</i>	5,398	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Wegovy</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Xultophy</i>	366	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

NaN: Not a number

Table 18. Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

	Total Number of Episodes	Number of Episodes by Observable Time													
		0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	170	12.8%	137	10.3%	132	9.9%	457	34.4%	414	31.2%	18	1.4%	0	0.0%
<i>Mounjaro</i>	18,996	3,533	18.6%	3,508	18.5%	2,953	15.5%	6,105	32.1%	2,897	15.3%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	17,037	14.5%	16,630	14.1%	15,099	12.8%	34,152	29.0%	33,903	28.8%	900	0.8%	0	0.0%
<i>Rybelsus</i>	34,260	4,270	12.5%	4,325	12.6%	4,168	12.2%	10,835	31.6%	10,400	30.4%	262	0.8%	0	0.0%
<i>Saxenda</i>	386	18	4.7%	22	5.7%	22	5.7%	125	32.4%	*****	51.0%	*****	0.5%	0	0.0%
<i>Trulicity</i>	67,310	7,452	11.1%	8,165	12.1%	8,212	12.2%	21,801	32.4%	21,072	31.3%	608	0.9%	0	0.0%
<i>Victoza</i>	5,398	590	10.9%	685	12.7%	645	11.9%	1,746	32.3%	1,670	30.9%	62	1.1%	0	0.0%
<i>Wegovy</i>	842	286	34.0%	241	28.6%	192	22.8%	82	9.7%	41	4.9%	0	0.0%	0	0.0%
<i>Xultophy</i>	366	45	12.3%	40	10.9%	61	16.7%	125	34.2%	*****	24.9%	*****	1.1%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 18. Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

		Distribution of Observable Time in Days, by Episode						
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	1	66	136	206	384	142.9	92.3
<i>Mounjaro</i>	18,996	1	41	86	147	359	101.1	74.0
<i>Ozempic</i>	117,721	1	53	114	199	410	131.6	93.2
<i>Rybelsus</i>	34,260	1	60	125	201	384	137.4	91.8
<i>Saxenda</i>	386	3	115	187	256	372	184.7	87.0
<i>Trulicity</i>	67,310	1	65	130	205	389	140.8	91.3
<i>Victoza</i>	5,398	1	64	130	205	412	141.1	92.4
<i>Wegovy</i>	842	1	23	49	75	363	60.1	61.7
<i>Xultophy</i>	366	2	65	112	191	381	131.9	91.9

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 19. Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

			Number of Episodes Censored due to Evidence of Death by Observable Time													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death ²	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	*****	*****	25.0%	*****	12.5%	*****	12.5%	*****	37.5%	*****	12.5%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,996	16	*****	25.0%	*****	43.8%	*****	12.5%	*****	12.5%	*****	6.3%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	297	50	16.8%	41	13.8%	49	16.5%	116	39.1%	41	13.8%	0	0.0%	0	0.0%
<i>Rybelsus</i>	34,260	105	11	10.5%	21	20.0%	17	16.2%	*****	44.8%	*****	8.6%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity</i>	67,310	372	67	18.0%	61	16.4%	71	19.1%	129	34.7%	44	11.8%	0	0.0%	0	0.0%
<i>Victoza</i>	5,398	26	*****	19.2%	*****	38.5%	*****	7.7%	*****	26.9%	*****	7.7%	0	0.0%	0	0.0%
<i>Wegovy</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Xultophy</i>	366	*****	0	0.0%	0	0.0%	*****	50.0%	*****	50.0%	0	0.0%	0	0.0%	0	0.0%

NaN: Not a number

Table 19. Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

			Distribution of Observable Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death ²	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	*****	8	43	88	156	360	117.6	112.7
<i>Mounjaro</i>	18,996	16	8	29	42	76	245	66.6	65.1
<i>Ozempic</i>	117,721	297	4	48	93	149	363	106.3	73.4
<i>Rybelsus</i>	34,260	105	8	50	96	127	260	97.7	57.2
<i>Saxenda</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity</i>	67,310	372	1	46	86	143	345	98.9	68.7
<i>Victoza</i>	5,398	26	4	40	60	129	220	79.0	57.5
<i>Wegovy</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Xultophy</i>	366	*****	84	84	131	178	178	131.0	66.5

NaN: Not a number

Table 20. Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

			Number of Episodes Censored due to Disenrollment by Observable Time													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment ²	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	745	104	14.0%	82	11.0%	82	11.0%	297	39.9%	180	24.2%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,996	4,007	1,004	25.1%	985	24.6%	809	20.2%	1,092	27.3%	117	2.9%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	44,735	5,638	12.6%	5,710	12.8%	6,684	14.9%	16,824	37.6%	9,809	21.9%	70	0.2%	0	0.0%
<i>Rybelsus</i>	34,260	14,754	2,031	13.8%	*****	13.6%	2,018	13.7%	5,441	36.9%	3,262	22.1%	*****	0.0%	0	0.0%
<i>Saxenda</i>	386	29	*****	20.7%	*****	17.2%	*****	3.4%	*****	31.0%	*****	27.6%	0	0.0%	0	0.0%
<i>Trulicity</i>	67,310	33,651	*****	12.5%	4,589	13.6%	4,536	13.5%	12,784	38.0%	7,543	22.4%	*****	0.0%	0	0.0%
<i>Victoza</i>	5,398	2,667	*****	12.3%	381	14.3%	328	12.3%	1,014	38.0%	610	22.9%	*****	0.2%	0	0.0%
<i>Wegovy</i>	842	15	*****	46.7%	*****	20.0%	*****	26.7%	*****	6.7%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	366	128	12	9.4%	21	16.4%	24	18.8%	47	36.7%	24	18.8%	0	0.0%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 20. Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

	Total Number of Episodes Censored due to Disenrollment ²		Distribution of Observable Time in Days, by Episode						
	Total Number of Episodes		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	745	1	61	129	180	360	122.0	70.5
<i>Mounjaro</i>	18,996	4,007	1	30	61	102	328	71.4	50.9
<i>Ozempic</i>	117,721	44,735	1	60	111	174	410	117.2	69.1
<i>Rybelsus</i>	34,260	14,754	1	55	111	174	372	115.3	68.7
<i>Saxenda</i>	386	29	9	39	113	213	318	123.9	96.5
<i>Trulicity</i>	67,310	33,651	1	59	115	174	389	117.1	68.2
<i>Victoza</i>	5,398	2,667	1	58	117	174	412	119.0	70.3
<i>Wegovy</i>	842	15	2	12	31	75	94	40.7	31.6
<i>Xultophy</i>	366	128	3	60	103	168	233	112.9	65.7

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

Table 21. Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

			Number of Episodes Censored due to End of Data by Observable Time													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data ²	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	1,254	154	12.3%	126	10.0%	121	9.6%	433	34.5%	402	32.1%	18	1.4%	0	0.0%
<i>Mounjaro</i>	18,996	18,157	3,317	18.3%	3,317	18.3%	2,800	15.4%	5,865	32.3%	2,858	15.7%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,721	111,491	16,016	14.4%	15,662	14.0%	14,139	12.7%	32,019	28.7%	32,755	29.4%	900	0.8%	0	0.0%
<i>Rybelsus</i>	34,260	32,345	3,928	12.1%	4,027	12.5%	3,894	12.0%	10,190	31.5%	10,044	31.1%	262	0.8%	0	0.0%
<i>Saxenda</i>	386	362	12	3.3%	17	4.7%	21	5.8%	116	32.0%	*****	53.6%	*****	0.6%	0	0.0%
<i>Trulicity</i>	67,310	63,249	6,755	10.7%	7,511	11.9%	7,630	12.1%	20,408	32.3%	20,337	32.2%	608	1.0%	0	0.0%
<i>Victoza</i>	5,398	5,069	531	10.5%	623	12.3%	601	11.9%	1,634	32.2%	1,618	31.9%	62	1.2%	0	0.0%
<i>Wegovy</i>	842	834	282	33.8%	239	28.7%	190	22.8%	82	9.8%	41	4.9%	0	0.0%	0	0.0%
<i>Xultophy</i>	366	352	45	12.8%	38	10.8%	58	16.5%	119	33.8%	*****	25.0%	*****	1.1%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 21. Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

			Distribution of Observable Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data ²	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	1,254	1	67	138	207	384	145.2	92.7
<i>Mounjaro</i>	18,996	18,157	1	41	86	149	359	102.4	74.5
<i>Ozempic</i>	117,721	111,491	1	53	115	200	410	132.9	94.0
<i>Rybelsus</i>	34,260	32,345	1	61	128	204	384	139.3	92.5
<i>Saxenda</i>	386	362	3	124	194	261	372	190.7	84.4
<i>Trulicity</i>	67,310	63,249	1	67	132	206	389	143.0	91.9
<i>Victoza</i>	5,398	5,069	1	66	132	207	412	143.6	93.0
<i>Wegovy</i>	842	834	1	23	49	75	363	60.4	61.8
<i>Xultophy</i>	366	352	2	65	111	191	381	131.8	92.9

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 22. Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

			Number of Episodes Censored due to End of Study Period by Observable Time													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Study Period ²	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,328	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Mounjaro</i>	18,996	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic</i>	117,721	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Rybelsus</i>	34,260	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity</i>	67,310	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza</i>	5,398	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Wegovy</i>	842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Xultophy</i>	366	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

NaN: Not a number

Table 22. Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

			Distribution of Observable Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to End of Study Period ²	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,328	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro</i>	18,996	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic</i>	117,721	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Rybelsus</i>	34,260	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity</i>	67,310	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza</i>	5,398	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Wegovy</i>	842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Xultophy</i>	366	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence.

²Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 23a. Full Code Distribution of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	11	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23b. Total Code Counts of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	96
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	11
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23c. Full Code Distribution of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	901	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	40	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23d. Total Code Counts of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,002
Inpatientencounter	Inpatient Encounter	RX	N/A	242
Ozempic	Ozempic	RX	N/A	87
Trulicity	Trulicity	RX	N/A	40
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23e. Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,000	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	526	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	283	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	65	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Encounter For Elective Termination Of Pregnancy	PX	C4	*****	IP
Z33.2	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	DX	10		AV
S0199	Mifepristone, Oral, 200 Mg	PX	HC	*****	AV
S0190	Complete Or Unspecified Spontaneous Abortion Without Complication	PX	HC		AV
O03.9	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****	ED
O00.201	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED

Table 23e. Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.0	Blighted Ovum And Nonhydatidiform Mole	DX	10	*****	AV

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23f. Total Code Counts of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,505
Inpatientencounter	Inpatient Encounter	RX	N/A	2,113
Trulicity	Trulicity	RX	N/A	526
Mounjaro	Mounjaro	RX	N/A	283
Rybelsus	Rybelsus	RX	N/A	207
Victoza	Victoza	RX	N/A	65
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O02.0	Blighted Ovum And Nonhydatidiform Mole	DX	10	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23g. Full Code Distribution of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,681	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	88	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23h. Total Code Counts of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,797
Inpatientencounter	Inpatient Encounter	RX	N/A	545
Ozempic	Ozempic	RX	N/A	281
Trulicity	Trulicity	RX	N/A	88
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	*****
	Oophorectomy And/Or Salpingectomy)			
O02.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23i. Full Code Distribution of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A:Not Applicable

Table 23j. Total Code Counts of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23k. Full Code Distribution of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,666	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	398	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	117	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Wegovy	Wegovy	RX	N/A	*****	N/A
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23I. Total Code Counts of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,982
Inpatientencounter	Inpatient Encounter	RX	N/A	1,627
Ozempic	Ozempic	RX	N/A	398
Mounjaro	Mounjaro	RX	N/A	117
Rybelsus	Rybelsus	RX	N/A	92
Victoza	Victoza	RX	N/A	34
Bydureonbcise	Bydureon Bcise	RX	N/A	13
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23m. Full Code Distribution of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	464	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	95	N/A
Ozempic	Ozempic	RX	N/A	93	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	38	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	27	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through
N/A:Not Applicable

Table 23n. Total Code Counts of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	502
Inpatientencounter	Inpatient Encounter	RX	N/A	133
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	27
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A:Not Applicable

Table 23o. Full Code Distribution of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A:Not Applicable

Table 23p. Total Code Counts of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23q. Full Code Distribution of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23r. Total Code Counts of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23s. Full Code Distribution of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	901	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	40	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23t. Total Code Counts of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,002
Inpatientencounter	Inpatient Encounter	RX	N/A	242
Ozempic	Ozempic	RX	N/A	87
Trulicity	Trulicity	RX	N/A	40
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23u. Full Code Distribution of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	11	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23v. Total Code Counts of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	96
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	11
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A:Not Applicable

Table 23w. Full Code Distribution of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,000	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	526	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	283	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	65	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Encounter For Elective Termination Of Pregnancy	PX	C4	*****	IP
Z33.2	Medically Induced Abortion By Oral Ingestion Of Medication Including All	DX	10		AV
S0199	Associated Services And Supplies (E.G.,	PX	HC	*****	AV
S0190	Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC		AV
O03.9	Mifepristone, Oral, 200 Mg Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED

Table 23w. Full Code Distribution of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****	AV

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23x. Total Code Counts of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,505
Inpatientencounter	Inpatient Encounter	RX	N/A	2,113
Trulicity	Trulicity	RX	N/A	526
Mounjaro	Mounjaro	RX	N/A	283
Rybelsus	Rybelsus	RX	N/A	207
Victoza	Victoza	RX	N/A	65
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O02.0	Blighted Ovum And Nonhydatidiform Mole	DX	10	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23y. Full Code Distribution of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,681	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	88	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23z. Total Code Counts of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,797
Inpatientencounter	Inpatient Encounter	RX	N/A	545
Ozempic	Ozempic	RX	N/A	281
Trulicity	Trulicity	RX	N/A	88
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	*****
	Oophorectomy And/Or Salpingectomy)			
O02.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23aa. Full Code Distribution of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ab. Total Code Counts of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ac. Full Code Distribution of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ad. Total Code Counts of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ae. Full Code Distribution of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	464	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	95	N/A
Ozempic	Ozempic	RX	N/A	93	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	38	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	27	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	OA
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		ED
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23af. Total Code Counts of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	502
Inpatientencounter	Inpatient Encounter	RX	N/A	133
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	27
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23ag. Full Code Distribution of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,666	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	398	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	117	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ah. Total Code Counts of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,982
Inpatientencounter	Inpatient Encounter	RX	N/A	1,627
Ozempic	Ozempic	RX	N/A	398
Mounjaro	Mounjaro	RX	N/A	117
Rybelsus	Rybelsus	RX	N/A	92
Victoza	Victoza	RX	N/A	34
Bydureonbcise	Bydureon Bcise	RX	N/A	13
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23ai. Full Code Distribution of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23aj. Total Code Counts of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	40
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ak. Full Code Distribution of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	901	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	40	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23a. Total Code Counts of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,002
Inpatientencounter	Inpatient Encounter	RX	N/A	242
Ozempic	Ozempic	RX	N/A	87
Trulicity	Trulicity	RX	N/A	40
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23am. Full Code Distribution of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	11	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23an. Total Code Counts of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	96
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	11
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ao. Full Code Distribution of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,000	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	526	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	283	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	65	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Encounter For Elective Termination Of Pregnancy	PX	C4	*****	IP
Z33.2	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	DX	10		AV
S0199	Mifepristone, Oral, 200 Mg	PX	HC	*****	AV
S0190	Complete Or Unspecified Spontaneous Abortion Without Complication	PX	HC		AV
O03.9	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****	ED
O00.201		DX	10		ED

Table 23ao. Full Code Distribution of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****	AV

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ap. Total Code Counts of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,505
Inpatientencounter	Inpatient Encounter	RX	N/A	2,113
Trulicity	Trulicity	RX	N/A	526
Mounjaro	Mounjaro	RX	N/A	283
Rybelsus	Rybelsus	RX	N/A	207
Victoza	Victoza	RX	N/A	65
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23aq. Full Code Distribution of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,681	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	88	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ar. Total Code Counts of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,797
Inpatientencounter	Inpatient Encounter	RX	N/A	545
Ozempic	Ozempic	RX	N/A	281
Trulicity	Trulicity	RX	N/A	88
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	*****
	Oophorectomy And/Or Salpingectomy)			
O02.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23as. Full Code Distribution of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23at. Total Code Counts of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23au. Full Code Distribution of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23av. Total Code Counts of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23aw. Full Code Distribution of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	464	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	95	N/A
Ozempic	Ozempic	RX	N/A	93	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	38	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	27	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		ED
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ax. Total Code Counts of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	502
Inpatientencounter	Inpatient Encounter	RX	N/A	133
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	27
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23ay. Full Code Distribution of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,666	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	398	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	117	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23az. Total Code Counts of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,982
Inpatientencounter	Inpatient Encounter	RX	N/A	1,627
Ozempic	Ozempic	RX	N/A	398
Mounjaro	Mounjaro	RX	N/A	117
Rybelsus	Rybelsus	RX	N/A	92
Victoza	Victoza	RX	N/A	34
Bydureonbcise	Bydureon Bcise	RX	N/A	13
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23ba. Full Code Distribution of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bb. Total Code Counts of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	40
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bc. Full Code Distribution of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	901	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	40	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bd. Total Code Counts of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,002
Inpatientencounter	Inpatient Encounter	RX	N/A	242
Ozempic	Ozempic	RX	N/A	87
Trulicity	Trulicity	RX	N/A	40
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23be. Full Code Distribution of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	11	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bf. Total Code Counts of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	96
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	11
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bg. Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,000	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	526	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	283	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	65	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Encounter For Elective Termination Of Pregnancy	PX	C4	*****	IP
Z33.2	Medically Induced Abortion By Oral Ingestion Of Medication Including All	DX	10		AV
S0199	Associated Services And Supplies (E.G.,	PX	HC	*****	AV
S0190	Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC		AV
O03.9	Mifepristone, Oral, 200 Mg Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV

Table 23bg. Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****	ED
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****	AV

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bh. Total Code Counts of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,505
Inpatientencounter	Inpatient Encounter	RX	N/A	2,113
Trulicity	Trulicity	RX	N/A	526
Mounjaro	Mounjaro	RX	N/A	283
Rybelsus	Rybelsus	RX	N/A	207
Victoza	Victoza	RX	N/A	65
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bi. Full Code Distribution of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,681	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	88	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bj. Total Code Counts of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,797
Inpatientencounter	Inpatient Encounter	RX	N/A	545
Ozempic	Ozempic	RX	N/A	281
Trulicity	Trulicity	RX	N/A	88
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	*****
	Oophorectomy And/Or Salpingectomy)			
O02.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bk. Full Code Distribution of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 23bl. Total Code Counts of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bm. Full Code Distribution of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bn. Total Code Counts of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bo. Full Code Distribution of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	464	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	95	N/A
Ozempic	Ozempic	RX	N/A	93	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	38	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	27	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bp. Total Code Counts of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	502
Inpatientencounter	Inpatient Encounter	RX	N/A	133
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	27
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bq. Full Code Distribution of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,666	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	398	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	117	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Wegovy	Wegovy	RX	N/A	*****	N/A
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23br. Total Code Counts of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,982
Inpatientencounter	Inpatient Encounter	RX	N/A	1,627
Ozempic	Ozempic	RX	N/A	398
Mounjaro	Mounjaro	RX	N/A	117
Rybelsus	Rybelsus	RX	N/A	92
Victoza	Victoza	RX	N/A	34
Bydureonbcise	Bydureon Bcise	RX	N/A	13
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bs. Full Code Distribution of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bt. Total Code Counts of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	40
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bu. Full Code Distribution of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	901	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	40	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bv. Total Code Counts of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,002
Inpatientencounter	Inpatient Encounter	RX	N/A	242
Ozempic	Ozempic	RX	N/A	87
Trulicity	Trulicity	RX	N/A	40
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bw. Full Code Distribution of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	11	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bx. Total Code Counts of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	96
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	11
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23by. Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,000	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	526	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	283	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	65	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Encounter For Elective Termination Of Pregnancy	PX	C4	*****	IP
Z33.2	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	DX	10		AV
S0199	Mifepristone, Oral, 200 Mg	PX	HC	*****	AV
S0190	Complete Or Unspecified Spontaneous Abortion Without Complication	PX	HC		AV
O03.9	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****	ED
O00.201		DX	10		ED

Table 23by. Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****	AV

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23bz. Total Code Counts of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,505
Inpatientencounter	Inpatient Encounter	RX	N/A	2,113
Trulicity	Trulicity	RX	N/A	526
Mounjaro	Mounjaro	RX	N/A	283
Rybelsus	Rybelsus	RX	N/A	207
Victoza	Victoza	RX	N/A	65
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ca. Full Code Distribution of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,681	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	88	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cb. Total Code Counts of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,797
Inpatientencounter	Inpatient Encounter	RX	N/A	545
Ozempic	Ozempic	RX	N/A	281
Trulicity	Trulicity	RX	N/A	88
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	3
Bydureonbcise	Bydureon Bcise	RX	N/A	2
Xultophy10036	Xultophy 100/3.6	RX	N/A	2
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	1
	Oophorectomy And/Or Salpingectomy)			
O02.1	Missed Abortion	DX	10	1

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cc. Full Code Distribution of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cd. Total Code Counts of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ce. Full Code Distribution of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cf. Total Code Counts of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cg. Full Code Distribution of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	464	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	95	N/A
Ozempic	Ozempic	RX	N/A	93	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	38	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	27	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ch. Total Code Counts of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	502
Inpatientencounter	Inpatient Encounter	RX	N/A	133
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	27
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ci. Full Code Distribution of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,666	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	398	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	117	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cj. Total Code Counts of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,982
Inpatientencounter	Inpatient Encounter	RX	N/A	1,627
Ozempic	Ozempic	RX	N/A	398
Mounjaro	Mounjaro	RX	N/A	117
Rybelsus	Rybelsus	RX	N/A	92
Victoza	Victoza	RX	N/A	34
Bydureonbcise	Bydureon Bcise	RX	N/A	13
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ck. Full Code Distribution of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cl. Total Code Counts of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	40
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cm. Full Code Distribution of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	901	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	40	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cn. Total Code Counts of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,002
Inpatientencounter	Inpatient Encounter	RX	N/A	242
Ozempic	Ozempic	RX	N/A	87
Trulicity	Trulicity	RX	N/A	40
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23co. Full Code Distribution of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	11	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cp. Total Code Counts of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	96
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	11
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cq. Full Code Distribution of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,000	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	526	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	283	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	65	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Encounter For Elective Termination Of Pregnancy	PX	C4	*****	IP
Z33.2	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	DX	10		AV
S0199	Mifepristone, Oral, 200 Mg	PX	HC	*****	AV
S0190	Complete Or Unspecified Spontaneous Abortion Without Complication	PX	HC		AV
O03.9	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pregnancy, First Trimester	DX	10	*****	ED
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED

Table 23cq. Full Code Distribution of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****	AV

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cr. Total Code Counts of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,505
Inpatientencounter	Inpatient Encounter	RX	N/A	2,113
Trulicity	Trulicity	RX	N/A	526
Mounjaro	Mounjaro	RX	N/A	283
Rybelsus	Rybelsus	RX	N/A	207
Victoza	Victoza	RX	N/A	65
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cs. Full Code Distribution of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,681	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	88	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ct. Total Code Counts of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,797
Inpatientencounter	Inpatient Encounter	RX	N/A	545
Ozempic	Ozempic	RX	N/A	281
Trulicity	Trulicity	RX	N/A	88
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	*****
	Oophorectomy And/Or Salpingectomy)			
O02.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cu. Full Code Distribution of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cv. Total Code Counts of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cw. Full Code Distribution of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cx. Total Code Counts of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cy. Full Code Distribution of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	464	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	95	N/A
Ozempic	Ozempic	RX	N/A	93	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	38	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	27	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23cz. Total Code Counts of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	502
Inpatientencounter	Inpatient Encounter	RX	N/A	133
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	27
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23da. Full Code Distribution of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,666	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	398	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	117	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23db. Total Code Counts of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,982
Inpatientencounter	Inpatient Encounter	RX	N/A	1,627
Ozempic	Ozempic	RX	N/A	398
Mounjaro	Mounjaro	RX	N/A	117
Rybelsus	Rybelsus	RX	N/A	92
Victoza	Victoza	RX	N/A	34
Bydureonbcise	Bydureon Bcise	RX	N/A	13
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dc. Full Code Distribution of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dd. Total Code Counts of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	40
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23de. Full Code Distribution of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	901	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	40	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23df. Total Code Counts of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,002
Inpatientencounter	Inpatient Encounter	RX	N/A	242
Ozempic	Ozempic	RX	N/A	87
Trulicity	Trulicity	RX	N/A	40
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dg. Full Code Distribution of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	11	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dh. Total Code Counts of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	96
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	11
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23di. Full Code Distribution of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,000	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	526	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	283	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	65	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Encounter For Elective Termination Of Pregnancy	PX	C4	*****	IP
Z33.2	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G.,	DX	10		AV
S0199	Patient Counseling, Office Visits,	PX	HC	*****	AV
S0190	Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC		AV
O03.9	Mifepristone, Oral, 200 Mg Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV

Table 23di. Full Code Distribution of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****	ED
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****	AV

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dj. Total Code Counts of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,505
Inpatientencounter	Inpatient Encounter	RX	N/A	2,113
Trulicity	Trulicity	RX	N/A	526
Mounjaro	Mounjaro	RX	N/A	283
Rybelsus	Rybelsus	RX	N/A	207
Victoza	Victoza	RX	N/A	65
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dk. Full Code Distribution of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,681	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	88	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dl. Total Code Counts of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,797
Inpatientencounter	Inpatient Encounter	RX	N/A	545
Ozempic	Ozempic	RX	N/A	281
Trulicity	Trulicity	RX	N/A	88
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	*****
	Oophorectomy And/Or Salpingectomy)			
O02.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dm. Full Code Distribution of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dn. Total Code Counts of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23do. Full Code Distribution of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dp. Total Code Counts of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dq. Full Code Distribution of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	464	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	95	N/A
Ozempic	Ozempic	RX	N/A	93	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	38	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	27	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dr. Total Code Counts of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	502
Inpatientencounter	Inpatient Encounter	RX	N/A	133
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	27
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ds. Full Code Distribution of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,666	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	398	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	117	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dt. Total Code Counts of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,982
Inpatientencounter	Inpatient Encounter	RX	N/A	1,627
Ozempic	Ozempic	RX	N/A	398
Mounjaro	Mounjaro	RX	N/A	117
Rybelsus	Rybelsus	RX	N/A	92
Victoza	Victoza	RX	N/A	34
Bydureonbcise	Bydureon Bcise	RX	N/A	13
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23du. Full Code Distribution of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dv. Total Code Counts of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	40
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dw. Full Code Distribution of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	901	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	40	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dx. Total Code Counts of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,002
Inpatientencounter	Inpatient Encounter	RX	N/A	242
Ozempic	Ozempic	RX	N/A	87
Trulicity	Trulicity	RX	N/A	40
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dy. Full Code Distribution of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	11	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23dz. Total Code Counts of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	96
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	11
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ea. Full Code Distribution of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,000	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	526	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	283	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	65	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Encounter For Elective Termination Of Pregnancy	PX	C4	*****	IP
Z33.2	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	DX	10		AV
S0199	Mifepristone, Oral, 200 Mg	PX	HC	*****	AV
S0190	Complete Or Unspecified Spontaneous Abortion Without Complication	PX	HC		AV
O03.9	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****	ED
O00.201	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.111	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****	AV

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 23eb. Total Code Counts of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,505
Inpatientencounter	Inpatient Encounter	RX	N/A	2,113
Trulicity	Trulicity	RX	N/A	526
Mounjaro	Mounjaro	RX	N/A	283
Rybelsus	Rybelsus	RX	N/A	207
Victoza	Victoza	RX	N/A	65
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O02.0	Blighted Ovum And Nonhydatidiform	DX	10	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ec. Full Code Distribution of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,681	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	88	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
O02.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ed. Total Code Counts of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,797
Inpatientencounter	Inpatient Encounter	RX	N/A	545
Ozempic	Ozempic	RX	N/A	281
Trulicity	Trulicity	RX	N/A	88
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
	Laparoscopy, Surgical; With Removal Of			
58661	Adnexal Structures (Partial Or Total	PX	C4	*****
	Oophorectomy And/Or Salpingectomy)			
O02.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ee. Full Code Distribution of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ef. Total Code Counts of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23eg. Full Code Distribution of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23eh. Total Code Counts of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	21
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ei. Full Code Distribution of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	464	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	95	N/A
Ozempic	Ozempic	RX	N/A	93	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	38	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	27	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		ED
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ej. Total Code Counts of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	502
Inpatientencounter	Inpatient Encounter	RX	N/A	133
Ozempic	Ozempic	RX	N/A	93
Trulicity	Trulicity	RX	N/A	27
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23ek. Full Code Distribution of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,666	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	398	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	117	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23el. Total Code Counts of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,982
Inpatientencounter	Inpatient Encounter	RX	N/A	1,627
Ozempic	Ozempic	RX	N/A	398
Mounjaro	Mounjaro	RX	N/A	117
Rybelsus	Rybelsus	RX	N/A	92
Victoza	Victoza	RX	N/A	34
Bydureonbcise	Bydureon Bcise	RX	N/A	13
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O24.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O24.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O24.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23em. Full Code Distribution of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 23en. Total Code Counts of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	40
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 24. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia		Mounjaro, Hospitalized Tachyarrhythmia		Ozempic, Hospitalized Tachyarrhythmia		Rybelsus, Hospitalized Tachyarrhythmia		Saxenda, Hospitalized Tachyarrhythmia	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements										
Enrolled at any point during the query period	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A
Had required coverage type (medical and/or drug coverage)	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183
Enrolled during specified age range	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435
Had requestable medical charts	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0
Met demographic requirements (sex, race, and Hispanic origin)	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428
Members with a valid index event										
Had any cohort-defining claim during the query period	28,331	63,995,494	111,549	63,912,276	759,923	63,263,902	144,832	63,878,993	35,314	63,988,511
Claim recorded during specified age range	28,331	0	111,549	0	759,923	0	144,832	0	35,314	0
Episode defining index claim recorded during the query period	25,705	2,626	111,549	0	732,176	27,747	138,261	6,571	34,747	567
Members with required pre-index history										
Had sufficient pre-index continuous enrollment	21,407	4,298	85,913	25,636	577,425	154,751	109,675	28,586	29,118	5,629
Met inclusion and exclusion criteria ¹	1,328	20,079	18,996	66,917	117,721	459,704	34,260	75,415	386	28,732
Evidence of gestational diabetes	N/A	*****	N/A	115	N/A	701	N/A	52	N/A	100
Evidence of insulin with no evidence of any anti-diabetic drug	N/A	1,656	N/A	4,483	N/A	39,740	N/A	3,364	N/A	182
Evidence of other secondary diabetes illness	N/A	1,751	N/A	3,897	N/A	34,029	N/A	5,946	N/A	108
Evidence of pregnancy	N/A	35	N/A	532	N/A	2,621	N/A	214	N/A	542
Evidence of short-acting GLP-1 receptor agonist	N/A	104	N/A	562	N/A	2,155	N/A	314	N/A	*****
Evidence of type 1 diabetes	N/A	1,236	N/A	3,308	N/A	26,508	N/A	3,138	N/A	188
Evidence of washout	N/A	19,689	N/A	54,323	N/A	398,929	N/A	66,865	N/A	21,063
No evidence of inclusion criteria	N/A	3,737	N/A	36,260	N/A	207,285	N/A	24,601	N/A	27,984
Met event incidence criteria	1,328	0	18,996	0	117,721	0	34,260	0	386	0
Members with required post-index follow-up										
Had sufficient post-index continuous enrollment	1,328	0	18,996	0	117,721	0	34,260	0	386	0

Table 24. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon, Hospitalized Tachyarrhythmia		Mounjaro, Hospitalized Tachyarrhythmia		Ozempic, Hospitalized Tachyarrhythmia		Rybelsus, Hospitalized Tachyarrhythmia		Saxenda, Hospitalized Tachyarrhythmia	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Had minimum days' supply on index date	1,328	0	18,996	0	117,721	0	34,260	0	386	0
Had index episode of at least required length	1,328	0	18,996	0	117,721	0	34,260	0	386	0
Had index episode longer than blackout period	1,328	0	18,996	0	117,721	0	34,260	0	386	0
Did not have an event during blackout period	1,328	0	18,996	0	117,721	0	34,260	0	386	0
Final cohort										
Number of members	1,328	N/A	18,996	N/A	117,721	N/A	34,260	N/A	386	N/A
Number of episodes	1,328	N/A	18,996	N/A	117,721	N/A	34,260	N/A	386	N/A

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 25. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
(Continued)

	Trulicity, Hospitalized Tachyarrhythmia		Victoza, Hospitalized Tachyarrhythmia		Wegovy, Hospitalized Tachyarrhythmia		Xultophy, Hospitalized Tachyarrhythmia		Mounjaro, Atrial Fibrillation and Flutter	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements										
Enrolled at any point during the query period	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A
Had required coverage type (medical and/or drug coverage)	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183
Enrolled during specified age range	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435
Had requestable medical charts	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0
Met demographic requirements (sex, race, and Hispanic origin)	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428
Members with a valid index event										
Had any cohort-defining claim during the query period	600,556	63,423,269	130,989	63,892,836	75,900	63,947,925	7,954	64,015,871	111,549	63,912,276
Claim recorded during specified age range	600,556	0	130,989	0	75,900	0	7,954	0	111,549	0
Episode defining index claim recorded during the query period	563,759	36,797	119,663	11,326	75,220	680	7,348	606	111,549	0
Members with required pre-index history										
Had sufficient pre-index continuous enrollment	439,194	124,565	96,267	23,396	63,144	12,076	6,067	1,281	85,913	25,636
Met inclusion and exclusion criteria ¹	67,310	371,884	5,398	90,869	842	62,302	366	5,701	18,996	66,917
Evidence of gestational diabetes	N/A	159	N/A	28	N/A	216	N/A	0	N/A	115
Evidence of insulin with no evidence of any anti-diabetic drug	N/A	41,097	N/A	11,935	N/A	365	N/A	491	N/A	4,483
Evidence of other secondary diabetes illness	N/A	35,989	N/A	7,729	N/A	175	N/A	531	N/A	3,897
Evidence of pregnancy	N/A	732	N/A	187	N/A	1,168	N/A	*****	N/A	532
Evidence of short-acting GLP-1 receptor	N/A	1,446	N/A	245	N/A	*****	N/A	101	N/A	562
Evidence of type 1 diabetes	N/A	25,028	N/A	6,049	N/A	419	N/A	476	N/A	3,308
Evidence of washout	N/A	354,726	N/A	87,843	N/A	34,794	N/A	5,590	N/A	54,323
No evidence of inclusion criteria	N/A	92,962	N/A	26,549	N/A	60,678	N/A	1,376	N/A	36,260
Met event incidence criteria	67,310	0	5,398	0	842	0	366	0	18,996	0
Members with required post-index follow-up										
Had sufficient post-index continuous enrollment	67,310	0	5,398	0	842	0	366	0	18,996	0
Had minimum days' supply on index date	67,310	0	5,398	0	842	0	366	0	18,996	0
Had index episode of at least required length	67,310	0	5,398	0	842	0	366	0	18,996	0
Had index episode longer than blackout period	67,310	0	5,398	0	842	0	366	0	18,996	0
Did not have an event during blackout period	67,310	0	5,398	0	842	0	366	0	18,996	0
Final cohort										
Number of members	67,310	N/A	5,398	N/A	842	N/A	366	N/A	18,996	N/A
Number of episodes	67,310	N/A	5,398	N/A	842	N/A	366	N/A	18,996	N/A

**Table 25. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
(Continued)**

	Trulicity, Hospitalized Tachyarrhythmia		Victoza, Hospitalized Tachyarrhythmia		Wegovy, Hospitalized Tachyarrhythmia		Xultophy, Hospitalized Tachyarrhythmia		Mounjaro, Atrial Fibrillation and Flutter	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 28, 2023)

Masked DP ID	DP Start Date	DP End Date ¹
DP01	07/01/2017	05/31/2023
DP02	07/01/2017	05/31/2023
DP03	01/01/2000	10/31/2022
DP04	01/01/2017	03/31/2023
DP05	01/01/2010	12/31/2022
DP06	01/01/2017	04/30/2023
DP07	07/01/2017	06/30/2023

¹DP End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. Generic and Brand Names of Medical Products Used to Define Exposures or Exposure Washout in this Request

Generic Name	Brand Name
Mounjaro (tirzepatide)	
tirzepatide	Mounjaro
Bydureon, Bydureon BCISE (exenatide synthetic)	
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
Ozempic (semaglutide)	
semaglutide	Ozempic
Rybelsus (semaglutide)	
semaglutide	Rybelsus
Wegovy (semaglutide)	
semaglutide	Wegovy
Saxenda (liraglutide)	
liraglutide	Saxenda
Victoza (liraglutide)	
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
Trulicity (dulaglutide)	
dulaglutide	Trulicity
Xultophy (insulin degludec/liraglutide)	
insulin degludec/liraglutide	Xultophy 100/3.6

Appendix C. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Tachyarrhythmia in this Request

Code	Description	Code Category	Code Type
Atrial Fibrillation and Flutter			
I48	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
I48.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM
Sinus Tachycardia			
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
Supraventricular Tachycardia			
I47.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
I47.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
I49.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
I49.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
I49.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
Other Tachycardia			
I47	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
I49	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
I49.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.49	Other premature depolarization	Diagnosis	ICD-10-CM
I49.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
Cardiac Arrest			
I46	Cardiac arrest	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
Ventricular Fibrillation and Flutter			
I49.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
I49.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
I49.02	Ventricular flutter	Diagnosis	ICD-10-CM
Ventricular Tachycardia			
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Type 2 Diabetes Mellitus			
E11	Type 2 diabetes mellitus	Diagnosis	ICD-10-CM
E11.0	Type 2 diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.1	Type 2 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.2	Type 2 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.3	Type 2 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E11.31	Type 2 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.32	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.33	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.34	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.35	Type 2 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.352	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.353	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.354	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.355	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.4	Type 2 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.5	Type 2 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.6	Type 2 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E11.61	Type 2 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.62	Type 2 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.63	Type 2 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
Type 1 Diabetes Mellitus			
E10	Type 1 diabetes mellitus	Diagnosis	ICD-10-CM
E10.1	Type 1 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.2	Type 1 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.3	Type 1 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E10.31	Type 1 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.32	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema. unspecified eve	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema. right eve	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema. left eve	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema. bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema. unspecified eve	Diagnosis	ICD-10-CM
E10.33	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema. right eve	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema. left eve	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema. bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema. unspecified eve	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema. right eve	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema. left eve	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema. bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema. unspecified eve	Diagnosis	ICD-10-CM
E10.34	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema. right eve	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema. left eve	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema. bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema. unspecified eve	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema. right eve	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema. left eve	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema. bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema. unspecified eve	Diagnosis	ICD-10-CM
E10.35	Type 1 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eve	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eve	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eve	Diagnosis	ICD-10-CM
E10.352	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula. right eve	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula. left eve	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula. bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula. unspecified eve	Diagnosis	ICD-10-CM
E10.353	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula. right eve	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula. left eve	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula. bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula. unspecified eve	Diagnosis	ICD-10-CM
E10.354	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment. right eve	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment. left eve	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment. bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment. unspecified eve	Diagnosis	ICD-10-CM
E10.355	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.4	Type 1 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.5	Type 1 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.6	Type 1 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E10.61	Type 1 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.62	Type 1 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.63	Type 1 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.64	Type 1 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
Gestational Diabetes			

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O24.4	Gestational diabetes mellitus	Diagnosis	ICD-10-CM
O24.41	Gestational diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
O24.410	Gestational diabetes mellitus in pregnancy, diet controlled	Diagnosis	ICD-10-CM
O24.414	Gestational diabetes mellitus in pregnancy, insulin controlled	Diagnosis	ICD-10-CM
O24.415	Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.419	Gestational diabetes mellitus in pregnancy, unspecified control	Diagnosis	ICD-10-CM
O24.42	Gestational diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM
O24.424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
O24.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
O24.43	Gestational diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.430	Gestational diabetes mellitus in the puerperium, diet controlled	Diagnosis	ICD-10-CM
O24.434	Gestational diabetes mellitus in the puerperium, insulin controlled	Diagnosis	ICD-10-CM
O24.435	Gestational diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.439	Gestational diabetes mellitus in the puerperium, unspecified control	Diagnosis	ICD-10-CM
Other Secondary Diabetes Illnesses			
E08	Diabetes mellitus due to underlying condition	Diagnosis	ICD-10-CM
E08.0	Diabetes mellitus due to underlying condition with hyperosmolarity	Diagnosis	ICD-10-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.1	Diabetes mellitus due to underlying condition with ketoacidosis	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.2	Diabetes mellitus due to underlying condition with kidney complications	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.3	Diabetes mellitus due to underlying condition with ophthalmic complications	Diagnosis	ICD-10-CM
E08.31	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.32	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema. right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema. left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema. bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema. unspecified eye	Diagnosis	ICD-10-CM
E08.33	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema. right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema. left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema. bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema. unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema. right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema. left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema. bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema. unspecified eye	Diagnosis	ICD-10-CM
E08.34	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema. right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema. left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema. bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema. unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema. right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema. left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema. bilateral	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.35	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.352	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.353	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.354	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.355	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.4	Diabetes mellitus due to underlying condition with neurological complications	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.5	Diabetes mellitus due to underlying condition with circulatory complications	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.6	Diabetes mellitus due to underlying condition with other specified complications	Diagnosis	ICD-10-CM
E08.61	Diabetes mellitus due to underlying condition with diabetic arthropathy	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.62	Diabetes mellitus due to underlying condition with skin complications	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E08.63	Diabetes mellitus due to underlying condition with oral complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.64	Diabetes mellitus due to underlying condition with hypoglycemia	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E13	Other specified diabetes mellitus	Diagnosis	ICD-10-CM
E13.0	Other specified diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.1	Other specified diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.2	Other specified diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.3	Other specified diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E13.31	Other specified diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.32	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.33	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.34	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.35	Other specified diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.352	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.353	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.354	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.355	Other specified diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E13.37	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment. right eye	Diagnosis	ICD-10-CM
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment. left eye	Diagnosis	ICD-10-CM
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment. bilateral	Diagnosis	ICD-10-CM
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment. unspecified eye	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.4	Other specified diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.5	Other specified diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.6	Other specified diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E13.61	Other specified diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.62	Other specified diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.63	Other specified diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.64	Other specified diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Pregnancy			
O00	Ectopic pregnancy	Diagnosis	ICD-10-CM
O0000	Abdominal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0001	Abdominal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00101	Right tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00102	Left tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00109	Unspecified tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00111	Right tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00112	Left tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
000119	Unspecified tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
000201	Right ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
000202	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
000209	Unspecified ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
000211	Right ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
000212	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
000219	Unspecified ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
0008	Other ectopic pregnancy	Diagnosis	ICD-10-CM
00080	Other ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
00081	Other ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
0009	Ectopic pregnancy, unspecified	Diagnosis	ICD-10-CM
00090	Unspecified ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
00091	Unspecified ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
001	Hydatidiform mole	Diagnosis	ICD-10-CM
001.0	Classical hydatidiform mole	Diagnosis	ICD-10-CM
001.1	Incomplete and partial hydatidiform mole	Diagnosis	ICD-10-CM
001.9	Hydatidiform mole, unspecified	Diagnosis	ICD-10-CM
002.0	Blighted ovum and nonhydatidiform mole	Diagnosis	ICD-10-CM
002.1	Missed abortion	Diagnosis	ICD-10-CM
00289	Other abnormal products of conception	Diagnosis	ICD-10-CM
0029	Abnormal products of conception, unspecified	Diagnosis	ICD-10-CM
003	Spontaneous abortion	Diagnosis	ICD-10-CM
003.0	Genital tract and pelvic infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.1	Delayed or excessive hemorrhage following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.2	Embolism following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.3	Other and unspecified complications following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.30	Unspecified complication following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.31	Shock following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.32	Renal failure following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.33	Metabolic disorder following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.34	Damage to pelvic organs following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.35	Other venous complications following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.36	Cardiac arrest following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.37	Sepsis following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.38	Urinary tract infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.39	Incomplete spontaneous abortion with other complications	Diagnosis	ICD-10-CM
003.4	Incomplete spontaneous abortion without complication	Diagnosis	ICD-10-CM
003.5	Genital tract and pelvic infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.6	Delayed or excessive hemorrhage following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.7	Embolism following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.8	Other and unspecified complications following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.80	Unspecified complication following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.81	Shock following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.82	Renal failure following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.83	Metabolic disorder following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.84	Damage to pelvic organs following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.85	Other venous complications following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
003.86	Cardiac arrest following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.87	Sepsis following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.88	Urinary tract infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.89	Complete or unspecified spontaneous abortion with other complications	Diagnosis	ICD-10-CM
003.9	Complete or unspecified spontaneous abortion without complication	Diagnosis	ICD-10-CM
004.5	Genital tract and pelvic infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.6	Delayed or excessive hemorrhage following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.7	Embolism following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.80	(Induced) termination of pregnancy with unspecified complications	Diagnosis	ICD-10-CM
004.81	Shock following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.82	Renal failure following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.83	Metabolic disorder following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.84	Damage to pelvic organs following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.85	Other venous complications following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.86	Cardiac arrest following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.87	Sepsis following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.88	Urinary tract infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.89	(Induced) termination of pregnancy with other complications	Diagnosis	ICD-10-CM
007.30	Failed attempted termination of pregnancy with unspecified complications	Diagnosis	ICD-10-CM
007.35	Other venous complications following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
007.36	Cardiac arrest following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
007.38	Urinary tract infection following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
007.39	Failed attempted termination of pregnancy with other complications	Diagnosis	ICD-10-CM
0080	Genital tract and pelvic infection following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0081	Delayed or excessive hemorrhage following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0082	Embolism following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0083	Shock following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0084	Renal failure following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0085	Metabolic disorders following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0086	Damage to pelvic organs and tissues following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0087	Other venous complications following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
00881	Cardiac arrest following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
00882	Sepsis following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
00883	Urinary tract infection following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
00889	Other complications following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0089	Unspecified complication following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
010.02	Pre-existing essential hypertension complicating childbirth	Diagnosis	ICD-10-CM
010.12	Pre-existing hypertensive heart disease complicating childbirth	Diagnosis	ICD-10-CM
010.22	Pre-existing hypertensive chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
010.32	Pre-existing hypertensive heart and chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
010.42	Pre-existing secondary hypertension complicating childbirth	Diagnosis	ICD-10-CM
010.92	Unspecified pre-existing hypertension complicating childbirth	Diagnosis	ICD-10-CM
011.4	Pre-existing hypertension with pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
012.04	Gestational edema, complicating childbirth	Diagnosis	ICD-10-CM
012.14	Gestational proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
012.24	Gestational edema with proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
013.4	Gestational [pregnancy-induced] hypertension without significant proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
014.04	Mild to moderate pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
014.14	Severe pre-eclampsia complicating childbirth	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
O14.24	HELLP syndrome, complicating childbirth	Diagnosis	ICD-10-CM
O14.94	Unspecified pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
O16.4	Unspecified maternal hypertension, complicating childbirth	Diagnosis	ICD-10-CM
O24	Diabetes mellitus in pregnancy, childbirth, and the puerperium	Diagnosis	ICD-10-CM
O24.0	Pre-existing type 1 diabetes mellitus, in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O24.01	Pre-existing type 1 diabetes mellitus, in pregnancy	Diagnosis	ICD-10-CM
O24.011	Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24.012	Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.013	Pre-existing type 1 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24.019	Pre-existing type 1 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.02	Pre-existing type 1 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
O24.03	Pre-existing type 1 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
O24.1	Pre-existing type 2 diabetes mellitus, in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O24.11	Pre-existing type 2 diabetes mellitus, in pregnancy	Diagnosis	ICD-10-CM
O24.111	Pre-existing type 2 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24.112	Pre-existing type 2 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.113	Pre-existing type 2 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24.119	Pre-existing type 2 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.12	Pre-existing type 2 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
O24.13	Pre-existing type 2 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
O24.3	Unspecified pre-existing diabetes mellitus in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O24.31	Unspecified pre-existing diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
O24.311	Unspecified pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24.312	Unspecified pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.313	Unspecified pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24.319	Unspecified pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.32	Unspecified pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.33	Unspecified pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM
O24.424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
O24.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
O24.8	Other pre-existing diabetes mellitus in pregnancy, childbirth, and the puerperium	Diagnosis	ICD-10-CM
O24.81	Other pre-existing diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
O24.811	Other pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24.812	Other pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.813	Other pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24.819	Other pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.82	Other pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.83	Other pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.9	Unspecified diabetes mellitus in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O24.91	Unspecified diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
O24.911	Unspecified diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24.912	Unspecified diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.913	Unspecified diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24.919	Unspecified diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.92	Unspecified diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.93	Unspecified diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O25.2	Malnutrition in childbirth	Diagnosis	ICD-10-CM
O26.62	Liver and biliary tract disorders in childbirth	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O26.72	Subluxation of symphysis (pubis) in childbirth	Diagnosis	ICD-10-CM
O31.00X0	Papraceous fetus, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.00X1	Papraceous fetus, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.00X2	Papraceous fetus, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.00X3	Papraceous fetus, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.00X4	Papraceous fetus, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.00X5	Papraceous fetus, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.00X9	Papraceous fetus, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.02X0	Papraceous fetus, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.02X1	Papraceous fetus, second trimester, fetus 1	Diagnosis	ICD-10-CM
O31.02X2	Papraceous fetus, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.02X3	Papraceous fetus, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.02X4	Papraceous fetus, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.02X5	Papraceous fetus, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.02X9	Papraceous fetus, second trimester, other fetus	Diagnosis	ICD-10-CM
O31.03X0	Papraceous fetus, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.03X1	Papraceous fetus, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.03X2	Papraceous fetus, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.03X3	Papraceous fetus, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.03X4	Papraceous fetus, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.03X5	Papraceous fetus, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.03X9	Papraceous fetus, third trimester, other fetus	Diagnosis	ICD-10-CM
O31.1	Continuing pregnancy after spontaneous abortion of one fetus or more	Diagnosis	ICD-10-CM
O31.10	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester	Diagnosis	ICD-10-CM
O31.10X0	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.10X1	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.10X2	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.10X3	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.10X4	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.10X5	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.10X9	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.11	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester	Diagnosis	ICD-10-CM
O31.11X0	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.11X1	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 1	Diagnosis	ICD-10-CM
O31.11X2	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 2	Diagnosis	ICD-10-CM
O31.11X3	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 3	Diagnosis	ICD-10-CM
O31.11X4	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 4	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O31.11X5	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 5	Diagnosis	ICD-10-CM
O31.11X9	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, other fetus	Diagnosis	ICD-10-CM
O31.12	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester	Diagnosis	ICD-10-CM
O31.12X0	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.12X1	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 1	Diagnosis	ICD-10-CM
O31.12X2	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.12X3	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.12X4	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.12X5	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.12X9	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
O31.13	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester	Diagnosis	ICD-10-CM
O31.13X0	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.13X1	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.13X2	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.13X3	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.13X4	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.13X5	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.13X9	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, other fetus	Diagnosis	ICD-10-CM
O31.2	Continuing pregnancy after intrauterine death of one fetus or more	Diagnosis	ICD-10-CM
O31.20	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester	Diagnosis	ICD-10-CM
O31.20X0	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.20X1	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.20X2	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.20X3	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.20X4	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.20X5	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.20X9	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, other fetus	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O31.22	Continuing pregnancy after intrauterine death of one fetus or more, second trimester	Diagnosis	ICD-10-CM
O31.22X0	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.22X1	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 1	Diagnosis	ICD-10-CM
O31.22X2	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.22X3	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.22X4	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.22X5	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.22X9	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
O31.23	Continuing pregnancy after intrauterine death of one fetus or more, third trimester	Diagnosis	ICD-10-CM
O31.23X0	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.23X1	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.23X2	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.23X3	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.23X4	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.23X5	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.23X9	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, other fetus	Diagnosis	ICD-10-CM
O36.4	Maternal care for intrauterine death	Diagnosis	ICD-10-CM
O36.4XX0	Maternal care for intrauterine death, not applicable or unspecified	Diagnosis	ICD-10-CM
O36.4XX1	Maternal care for intrauterine death, fetus 1	Diagnosis	ICD-10-CM
O36.4XX2	Maternal care for intrauterine death, fetus 2	Diagnosis	ICD-10-CM
O36.4XX3	Maternal care for intrauterine death, fetus 3	Diagnosis	ICD-10-CM
O36.4XX4	Maternal care for intrauterine death, fetus 4	Diagnosis	ICD-10-CM
O36.4XX5	Maternal care for intrauterine death, fetus 5	Diagnosis	ICD-10-CM
O36.4XX9	Maternal care for intrauterine death, other fetus	Diagnosis	ICD-10-CM
O48.0	Post-term pregnancy	Diagnosis	ICD-10-CM
O48.1	Prolonged pregnancy	Diagnosis	ICD-10-CM
O60.12X0	Preterm labor second trimester with preterm delivery second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.12X1	Preterm labor second trimester with preterm delivery second trimester, fetus 1	Diagnosis	ICD-10-CM
O60.12X2	Preterm labor second trimester with preterm delivery second trimester, fetus 2	Diagnosis	ICD-10-CM
O60.12X3	Preterm labor second trimester with preterm delivery second trimester, fetus 3	Diagnosis	ICD-10-CM
O60.12X4	Preterm labor second trimester with preterm delivery second trimester, fetus 4	Diagnosis	ICD-10-CM
O60.12X5	Preterm labor second trimester with preterm delivery second trimester, fetus 5	Diagnosis	ICD-10-CM
O60.12X9	Preterm labor second trimester with preterm delivery second trimester, other fetus	Diagnosis	ICD-10-CM
O60.13X0	Preterm labor second trimester with preterm delivery third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.13X1	Preterm labor second trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.13X2	Preterm labor second trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.13X3	Preterm labor second trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.13X4	Preterm labor second trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.13X5	Preterm labor second trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O60.13X9	Preterm labor second trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O60.14X0	Preterm labor third trimester with preterm delivery third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.14X1	Preterm labor third trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.14X2	Preterm labor third trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.14X3	Preterm labor third trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.14X4	Preterm labor third trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.14X5	Preterm labor third trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O60.14X9	Preterm labor third trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O60.22X0	Term delivery with preterm labor, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.22X1	Term delivery with preterm labor, second trimester, fetus 1	Diagnosis	ICD-10-CM
O60.22X2	Term delivery with preterm labor, second trimester, fetus 2	Diagnosis	ICD-10-CM
O60.22X3	Term delivery with preterm labor, second trimester, fetus 3	Diagnosis	ICD-10-CM
O60.22X4	Term delivery with preterm labor, second trimester, fetus 4	Diagnosis	ICD-10-CM
O60.22X5	Term delivery with preterm labor, second trimester, fetus 5	Diagnosis	ICD-10-CM
O60.22X9	Term delivery with preterm labor, second trimester, other fetus	Diagnosis	ICD-10-CM
O60.23X0	Term delivery with preterm labor, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.23X1	Term delivery with preterm labor, third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.23X2	Term delivery with preterm labor, third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.23X3	Term delivery with preterm labor, third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.23X4	Term delivery with preterm labor, third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.23X5	Term delivery with preterm labor, third trimester, fetus 5	Diagnosis	ICD-10-CM
O60.23X9	Term delivery with preterm labor, third trimester, other fetus	Diagnosis	ICD-10-CM
O63.2	Delayed delivery of second twin, triplet, etc.	Diagnosis	ICD-10-CM
O67.0	Intrapartum hemorrhage with coagulation defect	Diagnosis	ICD-10-CM
O67.8	Other intrapartum hemorrhage	Diagnosis	ICD-10-CM
O67.9	Intrapartum hemorrhage, unspecified	Diagnosis	ICD-10-CM
O68	Labor and delivery complicated by abnormality of fetal acid-base balance	Diagnosis	ICD-10-CM
O69.0XX0	Labor and delivery complicated by prolapse of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.0XX1	Labor and delivery complicated by prolapse of cord, fetus 1	Diagnosis	ICD-10-CM
O69.0XX2	Labor and delivery complicated by prolapse of cord, fetus 2	Diagnosis	ICD-10-CM
O69.0XX3	Labor and delivery complicated by prolapse of cord, fetus 3	Diagnosis	ICD-10-CM
O69.0XX4	Labor and delivery complicated by prolapse of cord, fetus 4	Diagnosis	ICD-10-CM
O69.0XX5	Labor and delivery complicated by prolapse of cord, fetus 5	Diagnosis	ICD-10-CM
O69.0XX9	Labor and delivery complicated by prolapse of cord, other fetus	Diagnosis	ICD-10-CM
O69.1XX0	Labor and delivery complicated by cord around neck, with compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.1XX1	Labor and delivery complicated by cord around neck, with compression, fetus 1	Diagnosis	ICD-10-CM
O69.1XX2	Labor and delivery complicated by cord around neck, with compression, fetus 2	Diagnosis	ICD-10-CM
O69.1XX3	Labor and delivery complicated by cord around neck, with compression, fetus 3	Diagnosis	ICD-10-CM
O69.1XX4	Labor and delivery complicated by cord around neck, with compression, fetus 4	Diagnosis	ICD-10-CM
O69.1XX5	Labor and delivery complicated by cord around neck, with compression, fetus 5	Diagnosis	ICD-10-CM
O69.1XX9	Labor and delivery complicated by cord around neck, with compression, other fetus	Diagnosis	ICD-10-CM
O69.2XX0	Labor and delivery complicated by other cord entanglement, with compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.2XX1	Labor and delivery complicated by other cord entanglement, with compression, fetus 1	Diagnosis	ICD-10-CM
O69.2XX2	Labor and delivery complicated by other cord entanglement, with compression, fetus 2	Diagnosis	ICD-10-CM
O69.2XX3	Labor and delivery complicated by other cord entanglement, with compression, fetus 3	Diagnosis	ICD-10-CM
O69.2XX4	Labor and delivery complicated by other cord entanglement, with compression, fetus 4	Diagnosis	ICD-10-CM
O69.2XX5	Labor and delivery complicated by other cord entanglement, with compression, fetus 5	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O69.2XX9	Labor and delivery complicated by other cord entanglement, with compression, other	Diagnosis	ICD-10-CM
O69.3XX0	Labor and delivery complicated by short cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.3XX1	Labor and delivery complicated by short cord, fetus 1	Diagnosis	ICD-10-CM
O69.3XX2	Labor and delivery complicated by short cord, fetus 2	Diagnosis	ICD-10-CM
O69.3XX3	Labor and delivery complicated by short cord, fetus 3	Diagnosis	ICD-10-CM
O69.3XX4	Labor and delivery complicated by short cord, fetus 4	Diagnosis	ICD-10-CM
O69.3XX5	Labor and delivery complicated by short cord, fetus 5	Diagnosis	ICD-10-CM
O69.3XX9	Labor and delivery complicated by short cord, other fetus	Diagnosis	ICD-10-CM
O69.4XX0	Labor and delivery complicated by vasa previa, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.4XX1	Labor and delivery complicated by vasa previa, fetus 1	Diagnosis	ICD-10-CM
O69.4XX2	Labor and delivery complicated by vasa previa, fetus 2	Diagnosis	ICD-10-CM
O69.4XX3	Labor and delivery complicated by vasa previa, fetus 3	Diagnosis	ICD-10-CM
O69.4XX4	Labor and delivery complicated by vasa previa, fetus 4	Diagnosis	ICD-10-CM
O69.4XX5	Labor and delivery complicated by vasa previa, fetus 5	Diagnosis	ICD-10-CM
O69.4XX9	Labor and delivery complicated by vasa previa, other fetus	Diagnosis	ICD-10-CM
O69.5XX0	Labor and delivery complicated by vascular lesion of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.5XX1	Labor and delivery complicated by vascular lesion of cord, fetus 1	Diagnosis	ICD-10-CM
O69.5XX2	Labor and delivery complicated by vascular lesion of cord, fetus 2	Diagnosis	ICD-10-CM
O69.5XX3	Labor and delivery complicated by vascular lesion of cord, fetus 3	Diagnosis	ICD-10-CM
O69.5XX4	Labor and delivery complicated by vascular lesion of cord, fetus 4	Diagnosis	ICD-10-CM
O69.5XX5	Labor and delivery complicated by vascular lesion of cord, fetus 5	Diagnosis	ICD-10-CM
O69.5XX9	Labor and delivery complicated by vascular lesion of cord, other fetus	Diagnosis	ICD-10-CM
O69.81X0	Labor and delivery complicated by cord around neck, without compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.81X1	Labor and delivery complicated by cord around neck, without compression, fetus 1	Diagnosis	ICD-10-CM
O69.81X2	Labor and delivery complicated by cord around neck, without compression, fetus 2	Diagnosis	ICD-10-CM
O69.81X3	Labor and delivery complicated by cord around neck, without compression, fetus 3	Diagnosis	ICD-10-CM
O69.81X4	Labor and delivery complicated by cord around neck, without compression, fetus 4	Diagnosis	ICD-10-CM
O69.81X5	Labor and delivery complicated by cord around neck, without compression, fetus 5	Diagnosis	ICD-10-CM
O69.81X9	Labor and delivery complicated by cord around neck, without compression, other fetus	Diagnosis	ICD-10-CM
O69.82X0	Labor and delivery complicated by other cord entanglement, without compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.82X1	Labor and delivery complicated by other cord entanglement, without compression, fetus 1	Diagnosis	ICD-10-CM
O69.82X2	Labor and delivery complicated by other cord entanglement, without compression, fetus 2	Diagnosis	ICD-10-CM
O69.82X3	Labor and delivery complicated by other cord entanglement, without compression, fetus 3	Diagnosis	ICD-10-CM
O69.82X4	Labor and delivery complicated by other cord entanglement, without compression, fetus 4	Diagnosis	ICD-10-CM
O69.82X5	Labor and delivery complicated by other cord entanglement, without compression, fetus 5	Diagnosis	ICD-10-CM
O69.82X9	Labor and delivery complicated by other cord entanglement, without compression, other fetus	Diagnosis	ICD-10-CM
O69.89X0	Labor and delivery complicated by other cord complications, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.89X1	Labor and delivery complicated by other cord complications, fetus 1	Diagnosis	ICD-10-CM
O69.89X2	Labor and delivery complicated by other cord complications, fetus 2	Diagnosis	ICD-10-CM
O69.89X3	Labor and delivery complicated by other cord complications, fetus 3	Diagnosis	ICD-10-CM
O69.89X4	Labor and delivery complicated by other cord complications, fetus 4	Diagnosis	ICD-10-CM
O69.89X5	Labor and delivery complicated by other cord complications, fetus 5	Diagnosis	ICD-10-CM
O69.89X9	Labor and delivery complicated by other cord complications, other fetus	Diagnosis	ICD-10-CM
O69.9XX0	Labor and delivery complicated by cord complication, unspecified, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.9XX1	Labor and delivery complicated by cord complication, unspecified, fetus 1	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O69.9XX2	Labor and delivery complicated by cord complication, unspecified, fetus 2	Diagnosis	ICD-10-CM
O69.9XX3	Labor and delivery complicated by cord complication, unspecified, fetus 3	Diagnosis	ICD-10-CM
O69.9XX4	Labor and delivery complicated by cord complication, unspecified, fetus 4	Diagnosis	ICD-10-CM
O69.9XX5	Labor and delivery complicated by cord complication, unspecified, fetus 5	Diagnosis	ICD-10-CM
O69.9XX9	Labor and delivery complicated by cord complication, unspecified, other fetus	Diagnosis	ICD-10-CM
O70.0	First degree perineal laceration during delivery	Diagnosis	ICD-10-CM
O70.1	Second degree perineal laceration during delivery	Diagnosis	ICD-10-CM
O70.20	Third degree perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CM
O70.21	Third degree perineal laceration during delivery, IIIa	Diagnosis	ICD-10-CM
O70.22	Third degree perineal laceration during delivery, IIIb	Diagnosis	ICD-10-CM
O70.23	Third degree perineal laceration during delivery, IIIc	Diagnosis	ICD-10-CM
O70.3	Fourth degree perineal laceration during delivery	Diagnosis	ICD-10-CM
O70.4	Anal sphincter tear complicating delivery, not associated with third degree laceration	Diagnosis	ICD-10-CM
O70.9	Perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CM
O74.0	Aspiration pneumonitis due to anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.1	Other pulmonary complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.2	Cardiac complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.3	Central nervous system complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.4	Toxic reaction to local anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.5	Spinal and epidural anesthesia-induced headache during labor and delivery	Diagnosis	ICD-10-CM
O74.6	Other complications of spinal and epidural anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.7	Failed or difficult intubation for anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.8	Other complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.9	Complication of anesthesia during labor and delivery, unspecified	Diagnosis	ICD-10-CM
O75.0	Maternal distress during labor and delivery	Diagnosis	ICD-10-CM
O75.1	Shock during or following labor and delivery	Diagnosis	ICD-10-CM
O75.5	Delayed delivery after artificial rupture of membranes	Diagnosis	ICD-10-CM
O75.81	Maternal exhaustion complicating labor and delivery	Diagnosis	ICD-10-CM
O75.82	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation. with delivery by (planned) cesarean section	Diagnosis	ICD-10-CM
O75.89	Other specified complications of labor and delivery	Diagnosis	ICD-10-CM
O75.9	Complication of labor and delivery, unspecified	Diagnosis	ICD-10-CM
O76	Abnormality in fetal heart rate and rhythm complicating labor and delivery	Diagnosis	ICD-10-CM
O77.0	Labor and delivery complicated by meconium in amniotic fluid	Diagnosis	ICD-10-CM
O77.8	Labor and delivery complicated by other evidence of fetal stress	Diagnosis	ICD-10-CM
O77.9	Labor and delivery complicated by fetal stress, unspecified	Diagnosis	ICD-10-CM
O80	Encounter for full-term uncomplicated delivery	Diagnosis	ICD-10-CM
O82	Encounter for cesarean delivery without indication	Diagnosis	ICD-10-CM
O88.02	Air embolism in childbirth	Diagnosis	ICD-10-CM
O88.12	Amniotic fluid embolism in childbirth	Diagnosis	ICD-10-CM
O88.22	Thromboembolism in childbirth	Diagnosis	ICD-10-CM
O88.32	Pyemic and septic embolism in childbirth	Diagnosis	ICD-10-CM
O88.82	Other embolism in childbirth	Diagnosis	ICD-10-CM
O98.02	Tuberculosis complicating childbirth	Diagnosis	ICD-10-CM
O98.12	Syphilis complicating childbirth	Diagnosis	ICD-10-CM
O98.22	Gonorrhea complicating childbirth	Diagnosis	ICD-10-CM
O98.32	Other infections with a predominantly sexual mode of transmission complicating childbirth	Diagnosis	ICD-10-CM
O98.42	Viral hepatitis complicating childbirth	Diagnosis	ICD-10-CM
O98.52	Other viral diseases complicating childbirth	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O98.62	Protozoal diseases complicating childbirth	Diagnosis	ICD-10-CM
O98.72	Human immunodeficiency virus [HIV] disease complicating childbirth	Diagnosis	ICD-10-CM
O98.82	Other maternal infectious and parasitic diseases complicating childbirth	Diagnosis	ICD-10-CM
O98.92	Unspecified maternal infectious and parasitic disease complicating childbirth	Diagnosis	ICD-10-CM
O99.02	Anemia complicating childbirth	Diagnosis	ICD-10-CM
O99.12	Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating childbirth	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.284	Endocrine, nutritional and metabolic diseases complicating childbirth	Diagnosis	ICD-10-CM
O99.314	Alcohol use complicating childbirth	Diagnosis	ICD-10-CM
O99.324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.344	Other mental disorders complicating childbirth	Diagnosis	ICD-10-CM
O99.354	Diseases of the nervous system complicating childbirth	Diagnosis	ICD-10-CM
O99.42	Diseases of the circulatory system complicating childbirth	Diagnosis	ICD-10-CM
O99.52	Diseases of the respiratory system complicating childbirth	Diagnosis	ICD-10-CM
O99.62	Diseases of the digestive system complicating childbirth	Diagnosis	ICD-10-CM
O99.72	Diseases of the skin and subcutaneous tissue complicating childbirth	Diagnosis	ICD-10-CM
O99.814	Abnormal glucose complicating childbirth	Diagnosis	ICD-10-CM
O99.824	Streptococcus B carrier state complicating childbirth	Diagnosis	ICD-10-CM
O99.834	Other infection carrier state complicating childbirth	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O9A.12	Malignant neoplasm complicating childbirth	Diagnosis	ICD-10-CM
O9A.22	Injury, poisoning and certain other consequences of external causes complicating childbirth	Diagnosis	ICD-10-CM
O9A.32	Physical abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A.42	Sexual abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A.52	Psychological abuse complicating childbirth	Diagnosis	ICD-10-CM
P03.0	Newborn affected by breech delivery and extraction	Diagnosis	ICD-10-CM
P03.2	Newborn affected by forceps delivery	Diagnosis	ICD-10-CM
P03.3	Newborn affected by delivery by vacuum extractor [ventouse]	Diagnosis	ICD-10-CM
P03.4	Newborn affected by Cesarean delivery	Diagnosis	ICD-10-CM
P03.5	Newborn affected by precipitate delivery	Diagnosis	ICD-10-CM
P07.00	Extremely low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P07.01	Extremely low birth weight newborn, less than 500 grams	Diagnosis	ICD-10-CM
P07.02	Extremely low birth weight newborn, 500-749 grams	Diagnosis	ICD-10-CM
P07.03	Extremely low birth weight newborn, 750-999 grams	Diagnosis	ICD-10-CM
P07.10	Other low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P07.14	Other low birth weight newborn, 1000-1249 grams	Diagnosis	ICD-10-CM
P07.15	Other low birth weight newborn, 1250-1499 grams	Diagnosis	ICD-10-CM
P07.16	Other low birth weight newborn, 1500-1749 grams	Diagnosis	ICD-10-CM
P07.17	Other low birth weight newborn, 1750-1999 grams	Diagnosis	ICD-10-CM
P07.18	Other low birth weight newborn, 2000-2499 grams	Diagnosis	ICD-10-CM
P07.20	Extreme immaturity of newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P07.21	Extreme immaturity of newborn, gestational age less than 23 completed weeks	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
P07.22	Extreme immaturity of newborn, gestational age 23 completed weeks	Diagnosis	ICD-10-CM
P07.23	Extreme immaturity of newborn, gestational age 24 completed weeks	Diagnosis	ICD-10-CM
P07.24	Extreme immaturity of newborn, gestational age 25 completed weeks	Diagnosis	ICD-10-CM
P07.25	Extreme immaturity of newborn, gestational age 26 completed weeks	Diagnosis	ICD-10-CM
P07.26	Extreme immaturity of newborn, gestational age 27 completed weeks	Diagnosis	ICD-10-CM
P07.30	Preterm newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P07.31	Preterm newborn, gestational age 28 completed weeks	Diagnosis	ICD-10-CM
P07.32	Preterm newborn, gestational age 29 completed weeks	Diagnosis	ICD-10-CM
P07.33	Preterm newborn, gestational age 30 completed weeks	Diagnosis	ICD-10-CM
P07.34	Preterm newborn, gestational age 31 completed weeks	Diagnosis	ICD-10-CM
P07.35	Preterm newborn, gestational age 32 completed weeks	Diagnosis	ICD-10-CM
P07.36	Preterm newborn, gestational age 33 completed weeks	Diagnosis	ICD-10-CM
P07.37	Preterm newborn, gestational age 34 completed weeks	Diagnosis	ICD-10-CM
P07.38	Preterm newborn, gestational age 35 completed weeks	Diagnosis	ICD-10-CM
P07.39	Preterm newborn, gestational age 36 completed weeks	Diagnosis	ICD-10-CM
P08.21	Post-term newborn	Diagnosis	ICD-10-CM
P08.22	Prolonged gestation of newborn	Diagnosis	ICD-10-CM
P95	Stillbirth	Diagnosis	ICD-10-CM
Z33.2	Encounter for elective termination of pregnancy	Diagnosis	ICD-10-CM
Z37.0	Single live birth	Diagnosis	ICD-10-CM
Z37.1	Single stillbirth	Diagnosis	ICD-10-CM
Z37.2	Twins, both liveborn	Diagnosis	ICD-10-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z37.4	Twins, both stillborn	Diagnosis	ICD-10-CM
Z37.50	Multiple births, unspecified, all liveborn	Diagnosis	ICD-10-CM
Z37.51	Triplets, all liveborn	Diagnosis	ICD-10-CM
Z37.52	Quadruplets, all liveborn	Diagnosis	ICD-10-CM
Z37.53	Quintuplets, all liveborn	Diagnosis	ICD-10-CM
Z37.54	Sextuplets, all liveborn	Diagnosis	ICD-10-CM
Z37.59	Other multiple births, all liveborn	Diagnosis	ICD-10-CM
Z37.6	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.60	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z37.60	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z37.61	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z37.61	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z37.62	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z37.62	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z37.63	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.63	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.64	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.64	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.69	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.69	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.7	Other multiple births, all stillborn	Diagnosis	ICD-10-CM
Z37.9	Outcome of delivery, unspecified	Diagnosis	ICD-10-CM
Z38.00	Single liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.01	Single liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.1	Single liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.2	Single liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Z38.30	Twin liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.31	Twin liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.4	Twin liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.5	Twin liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z38.61	Triplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.62	Triplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.63	Quadruplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.64	Quadruplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.65	Quintuplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.66	Quintuplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.68	Other multiple liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.69	Other multiple liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.7	Other multiple liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.8	Other multiple liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3A.20	20 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.21	21 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.22	22 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.23	23 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.24	24 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.25	25 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.26	26 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.27	27 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.28	28 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.29	29 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.30	30 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.31	31 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.32	32 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.33	33 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.34	34 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.35	35 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.36	36 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.37	37 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.38	38 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.39	39 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.40	40 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.41	41 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.42	42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.49	Greater than 42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
0W8NXZZ	Division of Female Perineum, External Approach	Procedure	ICD-10-PCS
10900ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Open Approach	Procedure	ICD-10-PCS
10903ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
10904ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
10907ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10908ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10A00ZZ	Abortion of Products of Conception, Open Approach	Procedure	ICD-10-PCS
10A03ZZ	Abortion of Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
10A04ZZ	Abortion of Products of Conception, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
10A07Z6	Abortion of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZW	Abortion of Products of Conception, Laminaria, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZX	Abortion of Products of Conception, Abortifacient, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A08ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10D00Z0	Extraction of Products of Conception, High, Open Approach	Procedure	ICD-10-PCS
10D00Z1	Extraction of Products of Conception, Low, Open Approach	Procedure	ICD-10-PCS
10D00Z2	Extraction of Products of Conception, Extraperitoneal, Open Approach	Procedure	ICD-10-PCS
10D07Z3	Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z4	Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z5	Extraction of Products of Conception, High Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z6	Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z7	Extraction of Products of Conception, Internal Version, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z8	Extraction of Products of Conception, Other, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D17Z9	Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D18Z9	Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10D27ZZ	Extraction of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10D28ZZ	Extraction of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
10E0XZZ	Delivery of Products of Conception, External Approach	Procedure	ICD-10-PCS
10S07ZZ	Reposition Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10T20ZZ	Resection of products of conception, ectopic, open approach	Procedure	ICD-10-PCS
10T23ZZ	Resection of products of conception, ectopic, percutaneous approach	Procedure	ICD-10-PCS
10T24ZZ	Resection of products of conception, ectopic, percutaneous endoscopic approach	Procedure	ICD-10-PCS
10T27ZZ	Resection of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10T28ZZ	Resection of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
58661	Laparoscopy, surgical; with removal of adnexal structures (partial or total oophorectomy and/or salpingectomy)	Procedure	CPT-4
58673	Laparoscopy, surgical; with salpingostomy (salpingoneostomy)	Procedure	CPT-4
58700	Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)	Procedure	CPT-4
58770	Salpingostomy (salpingoneostomy)	Procedure	CPT-4
59100	Surgical treatment of ectopic pregnancy: tubal or ovarian, requiring salpingectomy and/or oophorectomy, abdominal or vaginal approach	Procedure	CPT-4
59830	TREATMENT OF SEPTIC ABORTION, COMPLETED SURGICALLY	Procedure	CPT-4
59840	INDUCED ABORTION, BY DILATION AND CURETTAGE	Procedure	CPT-4
59841	INDUCED ABORTION, BY DILATION AND EVACUATION	Procedure	CPT-4
59850	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS	Procedure	CPT-4
59851	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH DILATION AND CURETTAGE AND/OR EVACUATION	Procedure	CPT-4
59852	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH	Procedure	CPT-4
59855	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES	Procedure	CPT-4
59856	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH DILATION AND CURETTAGE AND/OR EVACUATION	Procedure	CPT-4
59857	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH HYSTEROTOMY	Procedure	CPT-4
59870	Evacuation and curettage of uterus for hydatidiform mole	Procedure	CPT-4
01964	ANESTHESIA FOR ABORTION PROCEDURES	Procedure	CPT-4
01965	Anesthesia for incomplete or missed abortion procedures	Procedure	CPT-4
01966	Anesthesia for induced abortion procedures	Procedure	CPT-4

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
59120	Surgical treatment of ectopic pregnancy; tubal or ovarian, requiring salpingectomy and/or oophorectomy, abdominal or vaginal approach	Procedure	CPT-4
59121	Surgical treatment of ectopic pregnancy; tubal or ovarian, without salpingectomy and/or oophorectomy	Procedure	CPT-4
59125	Surgical Treatment Of Ectopic Pregnancy	Procedure	CPT-4
59126	Surgical Treatment Of Ectopic Pregnancy	Procedure	CPT-4
59130	Surgical treatment of ectopic pregnancy; abdominal pregnancy	Procedure	CPT-4
59135	Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy requiring total hysterectomy	Procedure	CPT-4
59136	Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy with partial resection of uterus	Procedure	CPT-4
59140	Surgical treatment of ectopic pregnancy; cervical, with evacuation	Procedure	CPT-4
59150	Laparoscopic treatment of ectopic pregnancy; without salpingectomy and/or oophorectomy	Procedure	CPT-4
59151	Laparoscopic treatment of ectopic pregnancy; with salpingectomy and/or oophorectomy	Procedure	CPT-4
59400	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care	Procedure	CPT-4
59409	Vaginal delivery only (with or without episiotomy and/or forceps);	Procedure	CPT-4
59410	Vaginal delivery only (with or without episiotomy and/or forceps); including postpartum care	Procedure	CPT-4
59510	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care	Procedure	CPT-4
59514	Cesarean delivery only;	Procedure	CPT-4
59515	Cesarean delivery only; including postpartum care	Procedure	CPT-4
59610	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery	Procedure	CPT-4
59612	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps);	Procedure	CPT-4
59614	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps); including postpartum care	Procedure	CPT-4
59618	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery	Procedure	CPT-4
59620	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery;	Procedure	CPT-4
59622	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery; including postpartum care	Procedure	CPT-4
59812	Treatment of incomplete abortion, any trimester, completed surgically	Procedure	CPT-4
59820	Treatment of missed abortion, completed surgically; first trimester	Procedure	CPT-4
59821	Treatment of missed abortion, completed surgically; second trimester	Procedure	CPT-4
S0190	Mifepristone, oral, 200 mg	Procedure	HCPCS
S0191	Misoprostol, oral, 200 mcg	Procedure	HCPCS
S0199	Medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by HCG, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs	Procedure	HCPCS
S2260	Induced abortion, 17 to 24 weeks	Procedure	HCPCS
S2265	Induced abortion, 25 to 28 weeks	Procedure	HCPCS
S2266	Induced abortion, 29 to 31 weeks	Procedure	HCPCS
S2267	Induced abortion, 32 weeks or greater	Procedure	HCPCS

Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name
Short-Acting Glucagon-Like Peptide-1 Receptor Agonists (SA GLP-1 RAs)	
exenatide	Byetta
lixisenatide	Adlyxin
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
Insulin	
insulin aspart	insulin aspart U-100
insulin aspart	Novolog FlexPen U-100 Insulin
insulin aspart	Novolog PenFill U-100 Insulin
insulin aspart	Novolog U-100 Insulin aspart
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
insulin aspart (niacinamide)	Fiasp U-100 Insulin
insulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insuln
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100
insulin degludec	insulin degludec
insulin degludec	Tresiba FlexTouch U-100
insulin degludec	Tresiba FlexTouch U-200
insulin degludec	Tresiba U-100 Insulin
insulin detemir	Levemir FlexPen
insulin detemir	Levemir FlexTouch U-100 Insuln
insulin detemir	Levemir U-100 Insulin
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin
insulin glargine,human recombinant analog	Basaglar Tempo Pen(U-100)Insln
insulin glargine,human recombinant analog	insulin glargine
insulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin
insulin glargine,human recombinant analog	Lantus U-100 Insulin
insulin glargine,human recombinant analog	Semglee Pen U-100 Insulin
insulin glargine,human recombinant analog	Semglee U-100 Insulin
insulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
insulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
insulin glargine-yfgn	insulin glargine-yfgn
insulin glargine-yfgn	Semglee(insulin glargine-yfgn)
insulin glargine-yfgn	Semglee(insulin glarg-yfgn)Pen
insulin glulisine	Apidra SoloStar U-100 Insulin
insulin glulisine	Apidra U-100 Insulin
insulin lispro	Admelog SoloStar U-100 Insulin
insulin lispro	Admelog U-100 Insulin lispro
insulin lispro	Humalog Junior KwikPen U-100
insulin lispro	Humalog KwikPen Insulin
insulin lispro	Humalog Tempo Pen(U-100)Insuln
insulin lispro	Humalog U-100 Insulin
insulin lispro	insulin lispro
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln
insulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
insulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
insulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
insulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insuln
insulin lispro-aabc	Lyumjev U-100 Insulin
insulin NPH human isophane	Humulin N NPH Insulin KwikPen
insulin NPH human isophane	Humulin N NPH U-100 Insulin

Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name
insulin NPH human isophane	Novolin N FlexPen
insulin NPH human isophane	Novolin N NPH U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
insulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
insulin regular, human	Afrezza
insulin regular, human	Humulin R Regular U-100 Insulin
insulin regular, human	Humulin R U-500 (Conc) Insulin
insulin regular, human	Humulin R U-500 (Conc) Kwikpen
insulin regular, human	Novolin R FlexPen
insulin regular, human	Novolin R Regular U-100 Insulin
insulin regular, human in 0.9 % sodium chloride	Myxredlin
Oral Antidiabetics	
acarbose	acarbose
acarbose	Precose
alogliptin benzoate	alogliptin
alogliptin benzoate	Nesina
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
alogliptin benzoate/pioglitazone HCl	Oseni
bromocriptine mesylate	Cycloset
canagliflozin	Invokana
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/metformin HCl	Xigduo XR
dapagliflozin propanediol/saxagliptin HCl	Qtern
empagliflozin	Jardiance
empagliflozin/linagliptin	Glyxambi
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/metformin HCl	Segluromet
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	glipizide
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide/metformin HCl	glipizide-metformin
glyburide	glyburide
glyburide,micronized	glyburide micronized
glyburide,micronized	Glynase
glyburide/metformin HCl	glyburide-metformin
linagliptin	Tradjenta
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glumetza
metformin HCl	metformin
metformin HCl	Riomet

Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name
metformin HCl	Riomet ER
mifepristone	Korlym
miglitol	miglitol
nateglinide	nateglinide
pioglitazone HCl	Actos
pioglitazone HCl	pioglitazone
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	pioglitazone-metformin
repaglinide	repaglinide
repaglinide/metformin HCl	repaglinide-metformin
saxagliptin HCl	Onglyza
saxagliptin HCl/metformin HCl	Kombiglyze XR
sitagliptin phosphate	Januvia
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
Non-Oral Antidiabetics	
pramlintide acetate	SymlinPen 60
pramlintide acetate	SymlinPen 120

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
Alcohol Use or Abuse			
F10	Alcohol related disorders	Diagnosis	ICD-10-CM
F10.1	Alcohol abuse	Diagnosis	ICD-10-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.12	Alcohol abuse with intoxication	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.15	Alcohol abuse with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.18	Alcohol abuse with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.2	Alcohol dependence	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.22	Alcohol dependence with intoxication	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.23	Alcohol dependence with withdrawal	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.25	Alcohol dependence with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.28	Alcohol dependence with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.9	Alcohol use, unspecified	Diagnosis	ICD-10-CM
F10.92	Alcohol use, unspecified with intoxication	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.95	Alcohol use, unspecified with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.98	Alcohol use, unspecified with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.2	Alcoholic gastritis	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
T51	Toxic effect of alcohol	Diagnosis	ICD-10-CM
T51.0	Toxic effect of ethanol	Diagnosis	ICD-10-CM
T51.0X	Toxic effect of ethanol	Diagnosis	ICD-10-CM
T51.0X1	Toxic effect of ethanol, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T51.0X1D	Toxic effect of ethanol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.0X1S	Toxic effect of ethanol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.0X2	Toxic effect of ethanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.0X2D	Toxic effect of ethanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X2S	Toxic effect of ethanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.0X3	Toxic effect of ethanol, assault	Diagnosis	ICD-10-CM
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.0X3D	Toxic effect of ethanol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X3S	Toxic effect of ethanol, assault, sequela	Diagnosis	ICD-10-CM
T51.0X4	Toxic effect of ethanol, undetermined	Diagnosis	ICD-10-CM
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.0X4D	Toxic effect of ethanol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X4S	Toxic effect of ethanol, undetermined, sequela	Diagnosis	ICD-10-CM
T51.8	Toxic effect of other alcohols	Diagnosis	ICD-10-CM
T51.8X	Toxic effect of other alcohols	Diagnosis	ICD-10-CM
T51.8X1	Toxic effect of other alcohols, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.8X1A	Toxic effect of other alcohols, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.8X1D	Toxic effect of other alcohols, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.8X1S	Toxic effect of other alcohols, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.8X2	Toxic effect of other alcohols, intentional self-harm	Diagnosis	ICD-10-CM
T51.8X2A	Toxic effect of other alcohols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.8X2D	Toxic effect of other alcohols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X2S	Toxic effect of other alcohols, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.8X3	Toxic effect of other alcohols, assault	Diagnosis	ICD-10-CM
T51.8X3A	Toxic effect of other alcohols, assault, initial encounter	Diagnosis	ICD-10-CM
T51.8X3D	Toxic effect of other alcohols, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X3S	Toxic effect of other alcohols, assault, sequela	Diagnosis	ICD-10-CM
T51.8X4	Toxic effect of other alcohols, undetermined	Diagnosis	ICD-10-CM
T51.8X4A	Toxic effect of other alcohols, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.8X4D	Toxic effect of other alcohols, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X4S	Toxic effect of other alcohols, undetermined, sequela	Diagnosis	ICD-10-CM
T51.9	Toxic effect of unspecified alcohol	Diagnosis	ICD-10-CM
T51.91	Toxic effect of unspecified alcohol, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.91XA	Toxic effect of unspecified alcohol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.91XD	Toxic effect of unspecified alcohol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.91XS	Toxic effect of unspecified alcohol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.92	Toxic effect of unspecified alcohol, intentional self-harm	Diagnosis	ICD-10-CM
T51.92XA	Toxic effect of unspecified alcohol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.92XD	Toxic effect of unspecified alcohol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.92XS	Toxic effect of unspecified alcohol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.93	Toxic effect of unspecified alcohol, assault	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T51.93XA	Toxic effect of unspecified alcohol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.93XD	Toxic effect of unspecified alcohol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.93XS	Toxic effect of unspecified alcohol, assault, sequela	Diagnosis	ICD-10-CM
T51.94	Toxic effect of unspecified alcohol, undetermined	Diagnosis	ICD-10-CM
T51.94XA	Toxic effect of unspecified alcohol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.94XD	Toxic effect of unspecified alcohol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.94XS	Toxic effect of unspecified alcohol, undetermined, sequela	Diagnosis	ICD-10-CM
Z71.4	Alcohol abuse counseling and surveillance	Diagnosis	ICD-10-CM
Obesity			
Z68.3	Body mass index [BMI] 30-39, adult	Diagnosis	ICD-10-CM
Z68.4	Body mass index [BMI] 40 or greater, adult	Diagnosis	ICD-10-CM
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index [BMI] 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index [BMI] 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index [BMI] 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index [BMI] 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index [BMI] 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index [BMI] 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index [BMI] 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index [BMI] 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index [BMI] 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index [BMI] 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index [BMI] 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index [BMI] 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index [BMI] 50.0-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index [BMI] 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index [BMI] 70 or greater, adult	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
Z98.84	Bariatric surgery status	Diagnosis	ICD-10-CM
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
Tobacco Use			
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.21	Nicotine dependence, cigarettes	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.22	Nicotine dependence, chewing tobacco	Diagnosis	ICD-10-CM
F17.220	Nicotine dependence, chewing tobacco, uncomplicated	Diagnosis	ICD-10-CM
F17.221	Nicotine dependence, chewing tobacco, in remission	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.29	Nicotine dependence, other tobacco product	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
T65.21	Toxic effect of chewing tobacco	Diagnosis	ICD-10-CM
T65.211	Toxic effect of chewing tobacco, accidental (unintentional)	Diagnosis	ICD-10-CM
T65.211A	Toxic effect of chewing tobacco, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.211D	Toxic effect of chewing tobacco, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.211S	Toxic effect of chewing tobacco, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.212	Toxic effect of chewing tobacco, intentional self-harm	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.212D	Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.212S	Toxic effect of chewing tobacco, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.213	Toxic effect of chewing tobacco, assault	Diagnosis	ICD-10-CM
T65.213A	Toxic effect of chewing tobacco, assault, initial encounter	Diagnosis	ICD-10-CM
T65.213D	Toxic effect of chewing tobacco, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.213S	Toxic effect of chewing tobacco, assault, sequela	Diagnosis	ICD-10-CM
T65.214	Toxic effect of chewing tobacco, undetermined	Diagnosis	ICD-10-CM
T65.214A	Toxic effect of chewing tobacco, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.214D	Toxic effect of chewing tobacco, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.214S	Toxic effect of chewing tobacco, undetermined, sequela	Diagnosis	ICD-10-CM
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.221D	Toxic effect of tobacco cigarettes, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.221S	Toxic effect of tobacco cigarettes, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.222D	Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.222S	Toxic effect of tobacco cigarettes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.223D	Toxic effect of tobacco cigarettes, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.223S	Toxic effect of tobacco cigarettes, assault, sequela	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.224D	Toxic effect of tobacco cigarettes, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.224S	Toxic effect of tobacco cigarettes, undetermined, sequela	Diagnosis	ICD-10-CM
T65.291A	Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.291D	Toxic effect of other tobacco and nicotine, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.291S	Toxic effect of other tobacco and nicotine, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.292D	Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.292S	Toxic effect of other tobacco and nicotine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.293A	Toxic effect of other tobacco and nicotine, assault, initial encounter	Diagnosis	ICD-10-CM
T65.293D	Toxic effect of other tobacco and nicotine, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.293S	Toxic effect of other tobacco and nicotine, assault, sequela	Diagnosis	ICD-10-CM
T65.294A	Toxic effect of other tobacco and nicotine, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.294D	Toxic effect of other tobacco and nicotine, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.294S	Toxic effect of other tobacco and nicotine, undetermined, sequela	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z72.0	Tobacco use	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
1032F	Current tobacco smoker or currently exposed to secondhand smoke (asthma)	Procedure	HCPCS
1034F	Current tobacco smoker (cad, cap, copd, pv) (dm)	Procedure	HCPCS
1035F	Current smokeless tobacco user (eg, chew, snuff) (pv)	Procedure	HCPCS
4000F	Tobacco use cessation intervention, counseling (copd, cap, cad, asthma) (dm) (pv)	Procedure	HCPCS
4001F	Tobacco use cessation intervention, pharmacologic therapy (copd, cad, cap, pv, asthma) (dm) (pv)	Procedure	HCPCS
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (pv, cad)	Procedure	HCPCS
99406	Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes	Procedure	HCPCS
99407	Smoking and tobacco use intensive counseling, greater than 10 minutes	Procedure	HCPCS
C9801	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
C9802	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
D1320	Tobacco counseling for the control and prevention of oral disease	Procedure	HCPCS
G0375	SMOKING AND TOBACCO USE CESSATION COUNSELING VISIT; INTERMEDIATE, GREATER THAN 3 MINUTES UP TO 10 MINUTES	Procedure	HCPCS
G0376	SMOKING AND TOBACCO USE CESSATION COUNSELING VISIT; INTENSIVE, GREATER THAN 10 MINUTES	Procedure	HCPCS
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G8093	Newly diagnosed chronic obstructive pulmonary disease (copd) patient documented to have received smoking cessation intervention, within 3 months of diagnosis	Procedure	HCPCS
G8094	Newly diagnosed chronic obstructive pulmonary disease (copd) patient not documented to have received smoking cessation intervention, within 3 months of diagnosis	Procedure	HCPCS
G8402	Tobacco (smoke) use cessation intervention, counseling	Procedure	HCPCS
G8403	Tobacco (smoke) use cessation intervention not counseled	Procedure	HCPCS
G8453	Tobacco use cessation intervention, counseling	Procedure	HCPCS
G8454	Tobacco use cessation intervention not counseled, reason not specified	Procedure	HCPCS
G8455	Current tobacco smoker	Procedure	HCPCS
G8456	Current smokeless tobacco user	Procedure	HCPCS
G8686	Currently a tobacco smoker or current exposure to secondhand smoke	Procedure	HCPCS
G8688	Currently a smokeless tobacco user (eg, chew, snuff) and no exposure to secondhand smoke	Procedure	HCPCS
G8690	Current tobacco smoker or current exposure to secondhand smoke	Procedure	HCPCS
G8692	Current smokeless tobacco user (eg, chew, snuff) and no exposure to secondhand smoke	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) âdemo project code only	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of q	Procedure	HCPCS
G9645	Patients who did not abstain from smoking prior to anesthesia on the day of surgery or procedure	Procedure	HCPCS
G9792	Most recent tobacco status is not tobacco free	Procedure	HCPCS
G9902	Patient screened for tobacco use and identified as a tobacco user	Procedure	HCPCS
G9906	Patient identified as a tobacco user received tobacco cessation intervention (counseling and/or pharmacotherapy)	Procedure	HCPCS
G9908	Patient identified as tobacco user did not receive tobacco cessation intervention (counseling and/or pharmacotherapy), reason not given	Procedure	HCPCS
G9909	Documentation of medical reason(s) for not providing tobacco cessation intervention if identified as a tobacco user (eg, limited life expectancy, other medical reason)	Procedure	HCPCS
S4990	Nicotine patches, legend	Procedure	HCPCS
S4991	Nicotine patches, non-legend	Procedure	HCPCS
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
Arrhythmia			
I44	Atrioventricular and left bundle-branch block	Diagnosis	ICD-10-CM
I44.0	Atrioventricular block, first degree	Diagnosis	ICD-10-CM
I44.1	Atrioventricular block, second degree	Diagnosis	ICD-10-CM
I44.2	Atrioventricular block, complete	Diagnosis	ICD-10-CM
I44.3	Other and unspecified atrioventricular block	Diagnosis	ICD-10-CM
I44.30	Unspecified atrioventricular block	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I44.39	Other atrioventricular block	Diagnosis	ICD-10-CM
I44.4	Left anterior fascicular block	Diagnosis	ICD-10-CM
I44.5	Left posterior fascicular block	Diagnosis	ICD-10-CM
I44.6	Other and unspecified fascicular block	Diagnosis	ICD-10-CM
I44.60	Unspecified fascicular block	Diagnosis	ICD-10-CM
I44.69	Other fascicular block	Diagnosis	ICD-10-CM
I44.7	Left bundle-branch block, unspecified	Diagnosis	ICD-10-CM
I45	Other conduction disorders	Diagnosis	ICD-10-CM
I45.0	Right fascicular block	Diagnosis	ICD-10-CM
I45.1	Other and unspecified right bundle-branch block	Diagnosis	ICD-10-CM
I45.10	Unspecified right bundle-branch block	Diagnosis	ICD-10-CM
I45.19	Other right bundle-branch block	Diagnosis	ICD-10-CM
I45.2	Bifascicular block	Diagnosis	ICD-10-CM
I45.3	Trifascicular block	Diagnosis	ICD-10-CM
I45.4	Nonspecific intraventricular block	Diagnosis	ICD-10-CM
I45.5	Other specified heart block	Diagnosis	ICD-10-CM
I45.6	Pre-excitation syndrome	Diagnosis	ICD-10-CM
I45.8	Other specified conduction disorders	Diagnosis	ICD-10-CM
I45.89	Other specified conduction disorders	Diagnosis	ICD-10-CM
I45.9	Conduction disorder, unspecified	Diagnosis	ICD-10-CM
I46	Cardiac arrest	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I47	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
I47.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
I48	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
I48.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I49	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
I49.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
I49.02	Ventricular flutter	Diagnosis	ICD-10-CM
I49.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
I49.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
I49.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
I49.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.49	Other premature depolarization	Diagnosis	ICD-10-CM
I49.5	Sick sinus syndrome	Diagnosis	ICD-10-CM
I49.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
R00	Abnormalities of heart beat	Diagnosis	ICD-10-CM
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
R00.1	Bradycardia, unspecified	Diagnosis	ICD-10-CM
R00.2	Palpitations	Diagnosis	ICD-10-CM
R00.8	Other abnormalities of heart beat	Diagnosis	ICD-10-CM
R00.9	Unspecified abnormalities of heart beat	Diagnosis	ICD-10-CM
Cerebrovascular Disease/Stroke/Transient Ischemic Attack			
G43.5	Persistent migraine aura without cerebral infarction	Diagnosis	ICD-10-CM
G43.50	Persistent migraine aura without cerebral infarction, not intractable	Diagnosis	ICD-10-CM
G43.501	Persistent migraine aura without cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.509	Persistent migraine aura without cerebral infarction, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.51	Persistent migraine aura without cerebral infarction, intractable	Diagnosis	ICD-10-CM
G43.511	Persistent migraine aura without cerebral infarction, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.519	Persistent migraine aura without cerebral infarction, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.6	Persistent migraine aura with cerebral infarction	Diagnosis	ICD-10-CM
G43.60	Persistent migraine aura with cerebral infarction, not intractable	Diagnosis	ICD-10-CM
G43.601	Persistent migraine aura with cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.609	Persistent migraine aura with cerebral infarction, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.61	Persistent migraine aura with cerebral infarction, intractable	Diagnosis	ICD-10-CM
G43.611	Persistent migraine aura with cerebral infarction, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.619	Persistent migraine aura with cerebral infarction, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G45	Transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.4	Transient global amnesia	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
I60	Nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.0	Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.1	Nontraumatic subarachnoid hemorrhage from middle cerebral artery	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.3	Nontraumatic subarachnoid hemorrhage from posterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.5	Nontraumatic subarachnoid hemorrhage from vertebral artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61	Nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62	Other and unspecified nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I62.0	Nontraumatic subdural hemorrhage	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.03	Nontraumatic chronic subdural hemorrhage	Diagnosis	ICD-10-CM
I62.1	Nontraumatic extradural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63	Cerebral infarction	Diagnosis	ICD-10-CM
I63.0	Cerebral infarction due to thrombosis of precerebral arteries	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.01	Cerebral infarction due to thrombosis of vertebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.03	Cerebral infarction due to thrombosis of carotid artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.1	Cerebral infarction due to embolism of precerebral arteries	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.11	Cerebral infarction due to embolism of vertebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.13	Cerebral infarction due to embolism of carotid artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.2	Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.21	Cerebral infarction due to unspecified occlusion or stenosis of vertebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.23	Cerebral infarction due to unspecified occlusion or stenosis of carotid arteries	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.3	Cerebral infarction due to thrombosis of cerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.31	Cerebral infarction due to thrombosis of middle cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.32	Cerebral infarction due to thrombosis of anterior cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.33	Cerebral infarction due to thrombosis of posterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.34	Cerebral infarction due to thrombosis of cerebellar artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.4	Cerebral infarction due to embolism of cerebral arteries	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.41	Cerebral infarction due to embolism of middle cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.42	Cerebral infarction due to embolism of anterior cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.43	Cerebral infarction due to embolism of posterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.44	Cerebral infarction due to embolism of cerebellar artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.5	Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.51	Cerebral infarction due to unspecified occlusion or stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.52	Cerebral infarction due to unspecified occlusion or stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.53	Cerebral infarction due to unspecified occlusion or stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.54	Cerebral infarction due to unspecified occlusion or stenosis of cerebellar artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I65	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
I65.0	Occlusion and stenosis of vertebral artery	Diagnosis	ICD-10-CM
I65.01	Occlusion and stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I65.02	Occlusion and stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I65.03	Occlusion and stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I65.09	Occlusion and stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I65.1	Occlusion and stenosis of basilar artery	Diagnosis	ICD-10-CM
I65.2	Occlusion and stenosis of carotid artery	Diagnosis	ICD-10-CM
I65.21	Occlusion and stenosis of right carotid artery	Diagnosis	ICD-10-CM
I65.22	Occlusion and stenosis of left carotid artery	Diagnosis	ICD-10-CM
I65.23	Occlusion and stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I65.29	Occlusion and stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I65.8	Occlusion and stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I65.9	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I66	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
I66.0	Occlusion and stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.1	Occlusion and stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.2	Occlusion and stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67	Other cerebrovascular diseases	Diagnosis	ICD-10-CM
I67.0	Dissection of cerebral arteries, nonruptured	Diagnosis	ICD-10-CM
I67.1	Cerebral aneurysm, nonruptured	Diagnosis	ICD-10-CM
I67.2	Cerebral atherosclerosis	Diagnosis	ICD-10-CM
I67.3	Progressive vascular leukoencephalopathy	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
I67.5	Moyamoya disease	Diagnosis	ICD-10-CM
I67.7	Cerebral arteritis, not elsewhere classified	Diagnosis	ICD-10-CM
I67.8	Other specified cerebrovascular diseases	Diagnosis	ICD-10-CM
I67.81	Acute cerebrovascular insufficiency	Diagnosis	ICD-10-CM
I67.82	Cerebral ischemia	Diagnosis	ICD-10-CM
I67.83	Posterior reversible encephalopathy syndrome	Diagnosis	ICD-10-CM
I67.84	Cerebral vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.85	Hereditary cerebrovascular diseases	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I67.850	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	Diagnosis	ICD-10-CM
I67.858	Other hereditary cerebrovascular disease	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I67.9	Cerebrovascular disease, unspecified	Diagnosis	ICD-10-CM
I68	Cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
I68.0	Cerebral amyloid angiopathy	Diagnosis	ICD-10-CM
I68.2	Cerebral arteritis in other diseases classified elsewhere	Diagnosis	ICD-10-CM
I68.8	Other cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
I69	Sequelae of cerebrovascular disease	Diagnosis	ICD-10-CM
I69.0	Sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.00	Unspecified sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.01	Cognitive deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.010	Attention and concentration deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.011	Memory deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.012	Visuospatial deficit and spatial neglect following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.013	Psychomotor deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.014	Frontal lobe and executive function deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.015	Cognitive social or emotional deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.018	Other symptoms and signs involving cognitive functions following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.019	Unspecified symptoms and signs involving cognitive functions following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.02	Speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.020	Aphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.021	Dysphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.022	Dysarthria following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.023	Fluency disorder following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.028	Other speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.03	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.031	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.032	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.033	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.034	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.04	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.041	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.042	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.043	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.044	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.05	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.051	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.052	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.053	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.054	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.06	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.061	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.062	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.063	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.064	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.065	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage, bilateral	Diagnosis	ICD-10-CM
I69.069	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.09	Other sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.090	Apraxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.091	Dysphagia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.092	Facial weakness following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.093	Ataxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.098	Other sequelae following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.1	Sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.10	Unspecified sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.11	Cognitive deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.110	Attention and concentration deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.111	Memory deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.112	Visuospatial deficit and spatial neglect following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.113	Psychomotor deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.114	Frontal lobe and executive function deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.115	Cognitive social or emotional deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.118	Other symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.119	Unspecified symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.12	Speech and language deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.120	Aphasia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.121	Dysphasia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.122	Dysarthria following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.123	Fluency disorder following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.128	Other speech and language deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.13	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.131	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.132	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.133	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.134	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.14	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.141	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.142	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.143	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.144	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.149	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.15	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.151	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.152	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.153	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.154	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.16	Other paralytic syndrome following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.161	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.162	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.163	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.164	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.165	Other paralytic syndrome following nontraumatic intracerebral hemorrhage, bilateral	Diagnosis	ICD-10-CM
I69.169	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.19	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.190	Apraxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.191	Dysphagia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.192	Facial weakness following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.193	Ataxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.198	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.2	Sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.20	Unspecified sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.21	Cognitive deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.210	Attention and concentration deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.211	Memory deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.212	Visuospatial deficit and spatial neglect following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.213	Psychomotor deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.214	Frontal lobe and executive function deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.215	Cognitive social or emotional deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.218	Other symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.219	Unspecified symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.22	Speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.220	Aphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.221	Dysphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.222	Dysarthria following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.223	Fluency disorder following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.228	Other speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.23	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.231	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.232	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.233	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.234	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.24	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.241	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.242	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.243	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.244	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.249	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.25	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.26	Other paralytic syndrome following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.261	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.262	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.263	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.264	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.265	Other paralytic syndrome following other nontraumatic intracranial hemorrhage, bilateral	Diagnosis	ICD-10-CM
I69.269	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.29	Other sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.290	Apraxia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.291	Dysphagia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.292	Facial weakness following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.293	Ataxia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.298	Other sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.3	Sequelae of cerebral infarction	Diagnosis	ICD-10-CM
I69.30	Unspecified sequelae of cerebral infarction	Diagnosis	ICD-10-CM
I69.31	Cognitive deficits following cerebral infarction	Diagnosis	ICD-10-CM
I69.310	Attention and concentration deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.311	Memory deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.312	Visuospatial deficit and spatial neglect following cerebral infarction	Diagnosis	ICD-10-CM
I69.313	Psychomotor deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.314	Frontal lobe and executive function deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.315	Cognitive social or emotional deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.318	Other symptoms and signs involving cognitive functions following cerebral infarction	Diagnosis	ICD-10-CM
I69.319	Unspecified symptoms and signs involving cognitive functions following cerebral infarction	Diagnosis	ICD-10-CM
I69.32	Speech and language deficits following cerebral infarction	Diagnosis	ICD-10-CM
I69.320	Aphasia following cerebral infarction	Diagnosis	ICD-10-CM
I69.321	Dysphasia following cerebral infarction	Diagnosis	ICD-10-CM
I69.322	Dysarthria following cerebral infarction	Diagnosis	ICD-10-CM
I69.323	Fluency disorder following cerebral infarction	Diagnosis	ICD-10-CM
I69.328	Other speech and language deficits following cerebral infarction	Diagnosis	ICD-10-CM
I69.33	Monoplegia of upper limb following cerebral infarction	Diagnosis	ICD-10-CM
I69.331	Monoplegia of upper limb following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
I69.332	Monoplegia of upper limb following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
I69.333	Monoplegia of upper limb following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.334	Monoplegia of upper limb following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.339	Monoplegia of upper limb following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
I69.34	Monoplegia of lower limb following cerebral infarction	Diagnosis	ICD-10-CM
I69.341	Monoplegia of lower limb following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
I69.342	Monoplegia of lower limb following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
I69.343	Monoplegia of lower limb following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.344	Monoplegia of lower limb following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.349	Monoplegia of lower limb following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
I69.35	Hemiplegia and hemiparesis following cerebral infarction	Diagnosis	ICD-10-CM
I69.351	Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.352	Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
I69.353	Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.354	Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.359	Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
I69.36	Other paralytic syndrome following cerebral infarction	Diagnosis	ICD-10-CM
I69.361	Other paralytic syndrome following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
I69.362	Other paralytic syndrome following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
I69.363	Other paralytic syndrome following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.364	Other paralytic syndrome following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.365	Other paralytic syndrome following cerebral infarction, bilateral	Diagnosis	ICD-10-CM
I69.369	Other paralytic syndrome following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
I69.39	Other sequelae of cerebral infarction	Diagnosis	ICD-10-CM
I69.390	Apraxia following cerebral infarction	Diagnosis	ICD-10-CM
I69.391	Dysphagia following cerebral infarction	Diagnosis	ICD-10-CM
I69.392	Facial weakness following cerebral infarction	Diagnosis	ICD-10-CM
I69.393	Ataxia following cerebral infarction	Diagnosis	ICD-10-CM
I69.398	Other sequelae of cerebral infarction	Diagnosis	ICD-10-CM
I69.8	Sequelae of other cerebrovascular diseases	Diagnosis	ICD-10-CM
I69.80	Unspecified sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.81	Cognitive deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.810	Attention and concentration deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.811	Memory deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.812	Visuospatial deficit and spatial neglect following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.813	Psychomotor deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.814	Frontal lobe and executive function deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.815	Cognitive social or emotional deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.818	Other symptoms and signs involving cognitive functions following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.819	Unspecified symptoms and signs involving cognitive functions following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.82	Speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.820	Aphasia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.821	Dysphasia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.822	Dysarthria following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.823	Fluency disorder following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.828	Other speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.83	Monoplegia of upper limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.831	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.834	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.84	Monoplegia of lower limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.841	Monoplegia of lower limb following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.842	Monoplegia of lower limb following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.843	Monoplegia of lower limb following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.844	Monoplegia of lower limb following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.849	Monoplegia of lower limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.85	Hemiplegia and hemiparesis following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.851	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.86	Other paralytic syndrome following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.861	Other paralytic syndrome following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.862	Other paralytic syndrome following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.863	Other paralytic syndrome following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.864	Other paralytic syndrome following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.865	Other paralytic syndrome following other cerebrovascular disease, bilateral	Diagnosis	ICD-10-CM
I69.869	Other paralytic syndrome following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.89	Other sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.890	Apraxia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.891	Dysphagia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.892	Facial weakness following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.893	Ataxia following other cerebrovascular disease	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.898	Other sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.9	Sequelae of unspecified cerebrovascular diseases	Diagnosis	ICD-10-CM
I69.90	Unspecified sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.91	Cognitive deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.910	Attention and concentration deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.911	Memory deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.912	Visuospatial deficit and spatial neglect following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.913	Psychomotor deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.914	Frontal lobe and executive function deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.915	Cognitive social or emotional deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.918	Other symptoms and signs involving cognitive functions following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.919	Unspecified symptoms and signs involving cognitive functions following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.92	Speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.920	Aphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.921	Dysphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.922	Dysarthria following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.923	Fluency disorder following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.928	Other speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.93	Monoplegia of upper limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.939	Monoplegia of upper limb following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.94	Monoplegia of lower limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.942	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.943	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.944	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.949	Monoplegia of lower limb following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.95	Hemiplegia and hemiparesis following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.96	Other paralytic syndrome following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.961	Other paralytic syndrome following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.962	Other paralytic syndrome following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.963	Other paralytic syndrome following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.964	Other paralytic syndrome following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.965	Other paralytic syndrome following unspecified cerebrovascular disease, bilateral	Diagnosis	ICD-10-CM
I69.969	Other paralytic syndrome following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.99	Other sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.990	Apraxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.991	Dysphagia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.992	Facial weakness following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.993	Ataxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.998	Other sequelae following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
P91.82	Neonatal cerebral infarction	Diagnosis	ICD-10-CM
P91.821	Neonatal cerebral infarction, right side of brain	Diagnosis	ICD-10-CM
P91.822	Neonatal cerebral infarction, left side of brain	Diagnosis	ICD-10-CM
P91.823	Neonatal cerebral infarction, bilateral	Diagnosis	ICD-10-CM
P91.829	Neonatal cerebral infarction, unspecified side	Diagnosis	ICD-10-CM
Q28.0	Arteriovenous malformation of precerebral vessels	Diagnosis	ICD-10-CM
Q28.2	Arteriovenous malformation of cerebral vessels	Diagnosis	ICD-10-CM
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits	Diagnosis	ICD-10-CM
61630	Balloon angioplasty, intracranial (eg, atherosclerotic stenosis), percutaneous	Procedure	CPT-4
61635	Transcatheter placement of intravascular stent(s), intracranial (eg, atherosclerotic stenosis), including balloon angioplasty, if performed	Procedure	CPT-4
Chronic Kidney Disease			
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.1	Hypertensive heart and chronic kidney disease without heart failure	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
R34	Anuria and oliguria	Diagnosis	ICD-10-CM
Z49.01	Encounter for fitting and adjustment of extracorporeal dialysis catheter	Diagnosis	ICD-10-CM
Z49.02	Encounter for fitting and adjustment of peritoneal dialysis catheter	Diagnosis	ICD-10-CM
Z49.31	Encounter for adequacy testing for hemodialysis	Diagnosis	ICD-10-CM
Z49.32	Encounter for adequacy testing for peritoneal dialysis	Diagnosis	ICD-10-CM
Z99.2	Dependence on renal dialysis	Diagnosis	ICD-10-CM
36147	Introduction of needle and/or catheter, arteriovenous shunt created for dialysis (graft/fistula); initial access with complete radiological evaluation of dialysis access, including fluoroscopy, image documentation and report (includes access of shunt, injection[s] of contrast, and all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava)	Procedure	CPT-4
36148	Introduction of needle and/or catheter, arteriovenous shunt created for dialysis (graft/fistula); additional access for therapeutic intervention (List separately in addition to code for primary procedure)	Procedure	CPT-4
36818	Arteriovenous anastomosis, open; by upper arm cephalic vein transposition	Procedure	CPT-4
36819	Arteriovenous anastomosis, open; by upper arm basilic vein transposition	Procedure	CPT-4
36820	Arteriovenous anastomosis, open; by forearm vein transposition	Procedure	CPT-4
36821	Arteriovenous anastomosis, open; direct, any site (eg, Cimino type) (separate procedure)	Procedure	CPT-4
36825	Creation of arteriovenous fistula by other than direct arteriovenous anastomosis (separate procedure); autogenous graft	Procedure	CPT-4
36830	Creation of arteriovenous fistula by other than direct arteriovenous anastomosis (separate procedure); nonautogenous graft (eg, biological collagen, thermoplastic graft)	Procedure	CPT-4
36831	Thrombectomy, open, arteriovenous fistula without revision, autogenous or nonautogenous dialysis graft (separate procedure)	Procedure	CPT-4
36832	Revision, open, arteriovenous fistula; without thrombectomy, autogenous or nonautogenous dialysis graft (separate procedure)	Procedure	CPT-4
36833	Revision, open, arteriovenous fistula; with thrombectomy, autogenous or nonautogenous dialysis graft (separate procedure)	Procedure	CPT-4
36870	Thrombectomy, percutaneous, arteriovenous fistula, autogenous or nonautogenous graft (includes mechanical thrombus extraction and intra-graft thrombolysis)	Procedure	CPT-4
50360	Renal allotransplantation, implantation of graft; without recipient nephrectomy	Procedure	CPT-4
50365	Renal allotransplantation, implantation of graft; with recipient nephrectomy	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
75791	Angiography, arteriovenous shunt (eg, dialysis patient fistula/graft), complete evaluation of dialysis access, including fluoroscopy, image documentation and report (includes injections of contrast and all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava), radiological supervision and interpretation	Procedure	CPT-4
90935	Hemodialysis procedure with single evaluation by a physician or other qualified health care professional	Procedure	CPT-4
90937	Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription	Procedure	CPT-4
90945	Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single evaluation by a physician or other qualified health care professional	Procedure	CPT-4
90947	Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluations by a physician or other qualified health care professional, with or without substantial revision of dialysis prescription	Procedure	CPT-4
90951	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90952	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90953	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90954	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90955	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90956	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
90957	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90958	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90959	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90960	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90961	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90962	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90963	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90964	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90965	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90966	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older	Procedure	CPT-4
90967	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients younger than 2 years of age	Procedure	CPT-4
90968	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 2-11 years of age	Procedure	CPT-4
90969	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 12-19 years of age	Procedure	CPT-4
90970	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 20 years of age and older	Procedure	CPT-4
Chronic Obstructive Pulmonary Disease			
J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
Congenital Heart Disease			
I97.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
I97.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
I97.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
P29.3	Persistent fetal circulation	Diagnosis	ICD-10-CM
P29.38	Other persistent fetal circulation	Diagnosis	ICD-10-CM
P29.8	Other cardiovascular disorders originating in the perinatal period	Diagnosis	ICD-10-CM
Q20	Congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM
Q20.0	Common arterial trunk	Diagnosis	ICD-10-CM
Q20.1	Double outlet right ventricle	Diagnosis	ICD-10-CM
Q20.2	Double outlet left ventricle	Diagnosis	ICD-10-CM
Q20.3	Discordant ventriculoarterial connection	Diagnosis	ICD-10-CM
Q20.4	Double inlet ventricle	Diagnosis	ICD-10-CM
Q20.5	Discordant atrioventricular connection	Diagnosis	ICD-10-CM
Q20.6	Isomerism of atrial appendages	Diagnosis	ICD-10-CM
Q20.8	Other congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM
Q20.9	Congenital malformation of cardiac chambers and connections, unspecified	Diagnosis	ICD-10-CM
Q21	Congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.0	Ventricular septal defect	Diagnosis	ICD-10-CM
Q21.1	Atrial septal defect	Diagnosis	ICD-10-CM
Q21.2	Atrioventricular septal defect	Diagnosis	ICD-10-CM
Q21.3	Tetralogy of Fallot	Diagnosis	ICD-10-CM
Q21.4	Aortopulmonary septal defect	Diagnosis	ICD-10-CM
Q21.8	Other congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.9	Congenital malformation of cardiac septum, unspecified	Diagnosis	ICD-10-CM
Q22	Congenital malformations of pulmonary and tricuspid valves	Diagnosis	ICD-10-CM
Q22.0	Pulmonary valve atresia	Diagnosis	ICD-10-CM
Q22.1	Congenital pulmonary valve stenosis	Diagnosis	ICD-10-CM
Q22.2	Congenital pulmonary valve insufficiency	Diagnosis	ICD-10-CM
Q22.3	Other congenital malformations of pulmonary valve	Diagnosis	ICD-10-CM
Q22.4	Congenital tricuspid stenosis	Diagnosis	ICD-10-CM
Q22.5	Ebstein's anomaly	Diagnosis	ICD-10-CM
Q22.6	Hypoplastic right heart syndrome	Diagnosis	ICD-10-CM
Q22.8	Other congenital malformations of tricuspid valve	Diagnosis	ICD-10-CM
Q22.9	Congenital malformation of tricuspid valve, unspecified	Diagnosis	ICD-10-CM
Q23	Congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.0	Congenital stenosis of aortic valve	Diagnosis	ICD-10-CM
Q23.1	Congenital insufficiency of aortic valve	Diagnosis	ICD-10-CM
Q23.2	Congenital mitral stenosis	Diagnosis	ICD-10-CM
Q23.3	Congenital mitral insufficiency	Diagnosis	ICD-10-CM
Q23.4	Hypoplastic left heart syndrome	Diagnosis	ICD-10-CM
Q23.8	Other congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.9	Congenital malformation of aortic and mitral valves, unspecified	Diagnosis	ICD-10-CM
Q24	Other congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.0	Dextrocardia	Diagnosis	ICD-10-CM
Q24.1	Levocardia	Diagnosis	ICD-10-CM
Q24.2	Cor triatriatum	Diagnosis	ICD-10-CM
Q24.3	Pulmonary infundibular stenosis	Diagnosis	ICD-10-CM
Q24.4	Congenital subaortic stenosis	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
Q24.5	Malformation of coronary vessels	Diagnosis	ICD-10-CM
Q24.6	Congenital heart block	Diagnosis	ICD-10-CM
Q24.8	Other specified congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.9	Congenital malformation of heart, unspecified	Diagnosis	ICD-10-CM
Q25.0	Patent ductus arteriosus	Diagnosis	ICD-10-CM
Q25.1	Coarctation of aorta	Diagnosis	ICD-10-CM
Q25.21	Interruption of aortic arch	Diagnosis	ICD-10-CM
Q25.29	Other atresia of aorta	Diagnosis	ICD-10-CM
Q25.3	Supravalvular aortic stenosis	Diagnosis	ICD-10-CM
Q25.40	Congenital malformation of aorta unspecified	Diagnosis	ICD-10-CM
Q25.41	Absence and aplasia of aorta	Diagnosis	ICD-10-CM
Q25.42	Hypoplasia of aorta	Diagnosis	ICD-10-CM
Q25.43	Congenital aneurysm of aorta	Diagnosis	ICD-10-CM
Q25.44	Congenital dilation of aorta	Diagnosis	ICD-10-CM
Q25.45	Double aortic arch	Diagnosis	ICD-10-CM
Q25.46	Tortuous aortic arch	Diagnosis	ICD-10-CM
Q25.47	Right aortic arch	Diagnosis	ICD-10-CM
Q25.48	Anomalous origin of subclavian artery	Diagnosis	ICD-10-CM
Q25.49	Other congenital malformations of aorta	Diagnosis	ICD-10-CM
Q25.5	Atresia of pulmonary artery	Diagnosis	ICD-10-CM
Q25.6	Stenosis of pulmonary artery	Diagnosis	ICD-10-CM
Q25.71	Coarctation of pulmonary artery	Diagnosis	ICD-10-CM
Q25.72	Congenital pulmonary arteriovenous malformation	Diagnosis	ICD-10-CM
Q25.79	Other congenital malformations of pulmonary artery	Diagnosis	ICD-10-CM
Q25.8	Other congenital malformations of other great arteries	Diagnosis	ICD-10-CM
Q25.9	Congenital malformation of great arteries, unspecified	Diagnosis	ICD-10-CM
Q26.0	Congenital stenosis of vena cava	Diagnosis	ICD-10-CM
Q26.1	Persistent left superior vena cava	Diagnosis	ICD-10-CM
Q26.2	Total anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.3	Partial anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.4	Anomalous pulmonary venous connection, unspecified	Diagnosis	ICD-10-CM
Q87.40	Marfan's syndrome, unspecified	Diagnosis	ICD-10-CM
Q87.41	Marfan's syndrome with cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.410	Marfan's syndrome with aortic dilation	Diagnosis	ICD-10-CM
Q87.418	Marfan's syndrome with other cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.82	Arterial tortuosity syndrome	Diagnosis	ICD-10-CM
Q90.0	Trisomy 21, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.1	Trisomy 21, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.2	Trisomy 21, translocation	Diagnosis	ICD-10-CM
Q90.9	Down syndrome, unspecified	Diagnosis	ICD-10-CM
Q91.0	Trisomy 18, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.1	Trisomy 18, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.2	Trisomy 18, translocation	Diagnosis	ICD-10-CM
Q91.3	Trisomy 18, unspecified	Diagnosis	ICD-10-CM
Q91.4	Trisomy 13, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.5	Trisomy 13, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.6	Trisomy 13, translocation	Diagnosis	ICD-10-CM
Q91.7	Trisomy 13, unspecified	Diagnosis	ICD-10-CM
Q93.81	Velo-cardio-facial syndrome	Diagnosis	ICD-10-CM
Q93.82	Williams syndrome	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
02Q50ZZ	Repair Atrial Septum, Open Approach	Procedure	ICD-10-PCS
02QM0ZZ	Repair Ventricular Septum, Open Approach	Procedure	ICD-10-PCS
02U507Z	Supplement Atrial Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02U50JZ	Supplement Atrial Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02U53JZ	Supplement Atrial Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02UM07Z	Supplement Ventricular Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02UM0JZ	Supplement Ventricular Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02UM3JZ	Supplement Ventricular Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
33647	Repair of atrial septal defect and ventricular septal defect, with direct or patch closure	Procedure	CPT-4
33720	Repair sinus of Valsalva aneurysm, with cardiopulmonary bypass	Procedure	CPT-4
33741	Transcatheter atrial septostomy (TAS) for congenital cardiac anomalies to create effective atrial flow, including all imaging guidance by the proceduralist, when performed, any method (eg, Rashkind, Sang-Park, balloon, cutting balloon, blade)	Procedure	CPT-4
33745	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catheterization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); initial intracardiac shunt	Procedure	CPT-4
33746	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catheterization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); each additional intracardiac shunt location (List separately in addition to code for primary procedure)	Procedure	CPT-4
33924	Ligation and takedown of a systemic-to-pulmonary artery shunt, performed in conjunction with a congenital heart procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
75572	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)	Procedure	CPT-4
75573	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function and evaluation of venous structures, if performed)	Procedure	CPT-4
93303	Transthoracic echocardiography for congenital cardiac anomalies; complete	Procedure	CPT-4
93304	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study	Procedure	CPT-4
93315	Transesophageal echocardiography for congenital cardiac anomalies; including probe placement. image acquisition. interpretation and report	Procedure	CPT-4
93316	Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
93317	Transesophageal echocardiography for congenital cardiac anomalies; image acquisition, interpretation and report only	Procedure	CPT-4
93530	Right heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93531	Combined right heart catheterization and retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93532	Combined right heart catheterization and transseptal left heart catheterization through intact septum with or without retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93533	Combined right heart catheterization and transseptal left heart catheterization through existing septal opening, with or without retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93563	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective coronary angiography during congenital heart catheterization (List separately in addition to code for primary procedure)	Procedure	CPT-4
93564	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective opacification of aortocoronary venous or arterial bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal mammary), whether native or used for bypass to one or more coronary arteries during congenital heart catheterization, when performed (List separately in addition to code for primary procedure)	Procedure	CPT-4
93580	Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan fenestration, atrial septal defect) with implant	Procedure	CPT-4
93581	Percutaneous transcatheter closure of a congenital ventricular septal defect with implant	Procedure	CPT-4
Heart Failure			
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease. or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease. or end stage renal disease	Diagnosis	ICD-10-CM
I50	Heart failure	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.2	Systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.3	Diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.4	Combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.8	Other heart failure	Diagnosis	ICD-10-CM
I50.81	Right heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
I97.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
I97.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
I97.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertensive Disease			
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.1	Hypertensive heart and chronic kidney disease without heart failure	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I16.0	Hypertensive urgency	Diagnosis	ICD-10-CM
I16.1	Hypertensive emergency	Diagnosis	ICD-10-CM
I16.9	Hypertensive crisis, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Thyroid Disease			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Ischemic Heart Disease/Coronary Artery Disease/Myocardial Infarction			
I20	Angina pectoris	Diagnosis	ICD-10-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24	Other acute ischemic heart diseases	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.11	Atherosclerotic heart disease of native coronary artery with angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.7	Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
I25.70	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.71	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.72	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.73	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.75	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.76	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.79	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
0210083	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210088	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210089	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210093	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210098	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210099	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210483	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210488	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0210489	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210493	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210498	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210499	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211083	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211088	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211089	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211093	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0211098	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0211099	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0211483	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211488	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211489	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211493	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211498	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211499	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212083	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0212088	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0212089	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0212093	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0212098	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0212099	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0212483	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212488	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212489	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212493	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212498	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212499	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213083	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213088	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213089	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213093	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0213098	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0213099	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0213483	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213488	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213489	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213493	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213498	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213499	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270046	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0270056	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0270066	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0270076	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271046	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0271056	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0271066	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0271076	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272046	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0272056	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0272066	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0272076	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273046	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0273056	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0273066	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0273076	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02700E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02710E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02720E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02730E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021008C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021008F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021008W	Bypass Coronary Artery, One Artery from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021009C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021009F	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021009W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02100A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02100AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100JF	Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100JW	Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100K3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02100Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02100Z9	Bypass Coronary Artery, One Artery from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02100ZC	Bypass Coronary Artery, One Artery from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02100ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021048C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021048F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021048W	Bypass Coronary Artery, One Artery from Aorta with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021049C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021049F	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
021049W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JF	Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JW	Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104K3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104Z9	Bypass Coronary Artery, One Artery from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02104ZC	Bypass Coronary Artery, One Artery from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021108C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021108F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021108W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021109C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021109F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021109W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02110A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110A8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110AW	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110K8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02110K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02110Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02110ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021148C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021148F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021148W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021149C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021149F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021149W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114A8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114AW	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02114JC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021208C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021208F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021208W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021209C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021209F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021209W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02120A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120A8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02120A9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AW	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120J3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120J8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120J9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JW	Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120K3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120K8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120K9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KW	Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02120Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02120Z9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02120ZC	Bypass Coronary Artery, Three Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02120ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021248C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021248F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021248W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
021249C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021249F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021249W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124A8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124A9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124AC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124AF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124AW	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124J3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124J8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124J9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124JC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124JF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124JW	Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124K3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124K8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124K9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KW	Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02124Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124ZC	Bypass Coronary Artery, Three Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021308C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021308F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021308W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021309C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021309F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021309W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02130A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130J8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02130K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130K9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02130Z8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02130Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02130ZC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02130ZF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021348C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021348F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021348W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02134J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134J8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134K9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134ZC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134ZF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K0Z8	Bypass Right Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021K0Z9	Bypass Right Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021K0ZC	Bypass Right Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZF	Bypass Right Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZW	Bypass Right Ventricle to Aorta, Open Approach	Procedure	ICD-10-PCS
021K4Z8	Bypass Right Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4Z9	Bypass Right Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4ZC	Bypass Right Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4ZF	Bypass Right Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
021K4ZW	Bypass Right Ventricle to Aorta, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L08P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08Q	Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L09P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0Z8	Bypass Left Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0Z9	Bypass Left Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0ZC	Bypass Left Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZF	Bypass Left Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZP	Bypass Left Ventricle to Pulmonary Trunk, Open Approach	Procedure	ICD-10-PCS
021L0ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZR	Bypass Left Ventricle to Left Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS
021L48P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L48Q	Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L48R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L49P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
021L49Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L49R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4Z8	Bypass Left Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4Z9	Bypass Left Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZC	Bypass Left Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZF	Bypass Left Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZP	Bypass Left Ventricle to Pulmonary Trunk, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZR	Bypass Left Ventricle to Left Pulmonary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027004Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027005Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027006Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027007Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02700FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02700ZZ	Dilation of Coronary Artery, One Artery, Open Approach	Procedure	ICD-10-PCS
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027104Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027105Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027106Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027107Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02710TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02710ZZ	Dilation of Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027136Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027144Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027145Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027146Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027147Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027204Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027205Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027206Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027207Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02720ZZ	Dilation of Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027245Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027304Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027305Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027306Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027307Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02730ZZ	Dilation of Coronary Artery, Four or More Arteries, Open Approach	Procedure	ICD-10-PCS
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027345Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C00Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C00ZZ	Extirpation of Matter from Coronary Artery, One Artery, Open Approach	Procedure	ICD-10-PCS
02C03Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02C03ZZ	Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Approach	Procedure	ICD-10-PCS
02C04Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C04ZZ	Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C10Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C10ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
02C13Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C13ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C14Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C14ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C20Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C20ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
02C23Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C23ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C24Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C24ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C30Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C30ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Open Approach	Procedure	ICD-10-PCS
02C33Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C33ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C34Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C34ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
3E07017	Introduction of Other Thrombolytic into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E070PZ	Introduction of Platelet Inhibitor into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E07317	Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E073PZ	Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
X2C0361	Extirpation of Matter from Coronary Artery, One Artery using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
X2C1361	Extirpation of Matter from Coronary Artery, Two Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
X2C2361	Extirpation of Matter from Coronary Artery, Three Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
X2C3361	Extirpation of Matter from Coronary Artery, Four or More Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts	Procedure	CPT-4
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More Coronary Grafts	Procedure	CPT-4
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month after original operation (List separately in addition to code for primary procedure)	Procedure	CPT-4
33533	Coronary artery bypass, using arterial graft(s); single arterial graft	Procedure	CPT-4
33534	Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure	CPT-4
33535	Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts	Procedure	CPT-4
33536	Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts	Procedure	CPT-4
33560	Myocardial Operation Combined With Coronary Bypass Procedure	Procedure	CPT-4
33570	CORONARY ANGIOPLASTY W/BYPASS	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or right coronary artery performed in conjunction with coronary artery bypass graft procedure, each vessel (List separately in addition to primary procedure)	Procedure	CPT-4
33575	CORON ANGIOPLSTY W/BYPASS; COMBO W/VASCULARIZAT	Procedure	CPT-4
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	CPT-4
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92973	Percutaneous transluminal coronary thrombectomy mechanical (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
92974	Transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy (List separately in addition to code for primary procedure)	Procedure	CPT-4
92977	Thrombolysis, coronary; by intravenous infusion	Procedure	CPT-4
92980	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	Procedure	CPT-4
92981	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
92982	Percutaneous transluminal coronary balloon angioplasty; single vessel	Procedure	CPT-4
92984	Percutaneous transluminal coronary balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
92995	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; single vessel	Procedure	CPT-4
92996	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
C1034	Catheter, coronary angioplasty, surpass superfusion catheter, long 30 surpass superfusion catheter	Procedure	HCPCS
C1100	Guide wire, percutaneous transluminal coronary angioplasty, medtronic ave gt1 guide wire, medtronic ave gt2 fusion guide wire, interventional technologies trackwire, interventional technologies trackwire support, interventional technologies trackwire extra support	Procedure	HCPCS
C1101	Catheter, percutaneous transluminal coronary angioplasty guide, medtronic ave 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave z2 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave vector guide catheter, medtronic ave vector x guide catheter. note: only the medtronic ave z2 zuma guide catheters are effective october 1, 2000. the medtronic ave zuma guide catheters were effective august 1, 2000.	Procedure	HCPCS
C1366	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque iron man, hi-torque balance middleweight, hi-torque all star, hi-torque balance heavyweight, hi-torque balance trek	Procedure	HCPCS
C1367	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque cross it, hi-torque cross-it 100xt, hi-torque cross-it 200xt, hi-torque cross-it 300xt, hi-torque wiggle	Procedure	HCPCS
C1500	Atherectomy system, peripheral, rotablator rotational angioplasty system with rotalink exchangeable catheter, advancer, and guide wire	Procedure	HCPCS
C1725	Catheter, transluminal angioplasty, nonlaser (may include guidance, infusion/perfusion capability)	Procedure	HCPCS
C1885	Catheter, transluminal angioplasty, laser	Procedure	HCPCS
C1930	Catheter, percutaneous transluminal coronary angioplasty, coyote dilatation catheter 20mm/30mm/40mm	Procedure	HCPCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
C1933	Catheter, opti-plast centurion 5.5f pta catheter (shaft length 50 cm to 120 cm), opti-plast xl 5.5f pta catheter (shaft length 75 cm to 120 cm), opti-plast pta catheter (5.5 fr), tru trac 5fr percutaneous transluminal angioplasty balloon dilatation catheter, optiplast xt 5 fr percutaneous transluminal angioplasty catheter (various sizes)	Procedure	HCPCS
C1948	Catheter, pursuit balloon angioplasty catheter, cook accent balloon angioplasty catheter	Procedure	HCPCS
C1981	Catheter ,coronary angioplasty balloon, adante, bonnie, bonnie 15mm, bonnie monorail 30mm or 40mm, bonnie sliding rail, bypass speedy, chubby, chubby sliding rail, coyote 20mm, coyote 9/15/25mm, maxxum, nc ranger, nc ranger 9mm, ranger 20mm, long ranger 30mm or 40mm, nc ranger 16/18mm, nc ranger 22/25/30mm, nc big ranger, quantum ranger, quantum ranger 1/4 sizes, quantum ranger 9/16/18mm, quantum ranger 22/30mm, quantum ranger 25mm, ranger lp 20/30/40, viva/long viva, ace - 1cm, ace - 2cm, ace graft, long ace, pivot cobra (10, 14, 18, 30, 40mm in lengths) note: only the bonnie monorail 30mm or 40mm, long ranger 30mm or 40mm, and ranger 20mm are effective 01/01/01. the other catheters were effective 08/01/00.	Procedure	HCPCS
C2605	Catheter, spectranetics extreme laser catheter, spectranetics extreme 0.9mm coronary angioplasty catheter (model 110-001)	Procedure	HCPCS
C2623	Catheter, transluminal angioplasty, drug-coated, nonlaser	Procedure	HCPCS
C3551	Guide wire, percutaneous transluminal coronary angioplasty, choice, luge, patriot, pt graphix intermediate, trooper, mailman 182/300 cm, glidewire gold guidewire, platinum plus guidewire, platinum plus guidewire with glidex hydrophilic coating, jagwire single-use high performance guide wire, merit medical systems extender guidewire, merit medical systems tomcat ptca guidewire, platinum plus guidewire (0.014 and 0.018 in diameters)	Procedure	HCPCS
C8526	Optiplast xt 5f percutaneous transluminal angioplasty catheter (various sizes)	Procedure	HCPCS
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	HCPCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (list separately in addition to code for primary procedure)	Procedure	HCPCS
G0290	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	Procedure	HCPCS
G0291	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel	Procedure	HCPCS
S2205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
S2206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), 2 coronary arterial grafts	Procedure	HCPCS
S2207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS
S2208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS
S2209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using 2 arterial grafts and single venous graft	Procedure	HCPCS
Left Ventricular Hypertrophy			
I42.1	Obstructive hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.2	Other hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I51.7	Cardiomegaly	Diagnosis	ICD-10-CM
Peripheral Artery Disease			
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I70.201	Unspecified atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.202	Unspecified atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
I70.203	Unspecified atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.208	Unspecified atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
I70.209	Unspecified atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.211	Atherosclerosis of native arteries of extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.212	Atherosclerosis of native arteries of extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.213	Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.218	Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.219	Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.221	Atherosclerosis of native arteries of extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.222	Atherosclerosis of native arteries of extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.223	Atherosclerosis of native arteries of extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.228	Atherosclerosis of native arteries of extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.229	Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.231	Atherosclerosis of native arteries of right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.232	Atherosclerosis of native arteries of right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.233	Atherosclerosis of native arteries of right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.234	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.235	Atherosclerosis of native arteries of right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.238	Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.239	Atherosclerosis of native arteries of right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.241	Atherosclerosis of native arteries of left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.242	Atherosclerosis of native arteries of left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.243	Atherosclerosis of native arteries of left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.244	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.245	Atherosclerosis of native arteries of left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.248	Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.249	Atherosclerosis of native arteries of left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.25	Atherosclerosis of native arteries of other extremities with ulceration	Diagnosis	ICD-10-CM
I70.261	Atherosclerosis of native arteries of extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.262	Atherosclerosis of native arteries of extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.263	Atherosclerosis of native arteries of extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.268	Atherosclerosis of native arteries of extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.269	Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.291	Other atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM
I70.292	Other atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
I70.293	Other atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.298	Other atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
I70.299	Other atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.301	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.302	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.303	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.308	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.309	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.311	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.312	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.313	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.318	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.319	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.321	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.322	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.323	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.328	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.329	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.331	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.332	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.333	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.334	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.335	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.338	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.339	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.341	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.342	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.343	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.344	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.345	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.348	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.349	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.35	Atherosclerosis of unspecified type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.361	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.362	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.363	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.368	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.369	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.391	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.392	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.393	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.398	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.399	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.501	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.502	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.503	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.508	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.509	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.511	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.512	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.513	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.518	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.519	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.521	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.522	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.523	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.528	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.529	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.531	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.532	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.533	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.534	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.535	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.538	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.539	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.541	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.542	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.543	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.544	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.545	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.548	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.549	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.55	Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.561	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.562	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.563	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.568	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.569	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.591	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.592	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.593	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.598	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.599	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.601	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.602	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.603	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.608	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.609	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.611	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.612	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.613	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.618	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.619	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.621	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.622	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.623	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.628	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.629	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.631	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.632	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.633	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.634	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.635	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.638	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.639	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.641	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.642	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.643	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.644	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.645	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.648	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.649	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.65	Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.661	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.662	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.663	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.668	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.669	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.691	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.692	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.693	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.698	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.699	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.701	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.702	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.703	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.708	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.709	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.711	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.712	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.713	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.718	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.719	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.721	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.722	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.723	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.728	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.729	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.731	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.732	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.733	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.734	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.735	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.738	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.739	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.741	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.742	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.743	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.744	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.745	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.748	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.749	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.75	Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.761	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.762	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.763	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.768	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.769	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.791	Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.792	Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.793	Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.798	Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.799	Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.8	Atherosclerosis of other arteries	Diagnosis	ICD-10-CM
I70.90	Unspecified atherosclerosis	Diagnosis	ICD-10-CM
I70.91	Generalized atherosclerosis	Diagnosis	ICD-10-CM
I70.92	Chronic total occlusion of artery of the extremities	Diagnosis	ICD-10-CM
I72.0	Aneurysm of carotid artery	Diagnosis	ICD-10-CM
I72.1	Aneurysm of artery of upper extremity	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
I72.3	Aneurysm of iliac artery	Diagnosis	ICD-10-CM
I72.4	Aneurysm of artery of lower extremity	Diagnosis	ICD-10-CM
I72.8	Aneurysm of other specified arteries	Diagnosis	ICD-10-CM
I72.9	Aneurysm of unspecified site	Diagnosis	ICD-10-CM
I73.89	Other specified peripheral vascular diseases	Diagnosis	ICD-10-CM
I73.9	Peripheral vascular disease, unspecified	Diagnosis	ICD-10-CM
I77.71	Dissection of carotid artery	Diagnosis	ICD-10-CM
I77.72	Dissection of iliac artery	Diagnosis	ICD-10-CM
I77.73	Dissection of renal artery	Diagnosis	ICD-10-CM
I77.74	Dissection of vertebral artery	Diagnosis	ICD-10-CM
I77.79	Dissection of other specified artery	Diagnosis	ICD-10-CM
I79.8	Other disorders of arteries, arterioles and capillaries in diseases classified elsewhere	Diagnosis	ICD-10-CM
Z95.820	Peripheral vascular angioplasty status with implants and grafts	Diagnosis	ICD-10-CM
Z95.828	Presence of other vascular implants and grafts	Diagnosis	ICD-10-CM
0312090	Bypass Innominate Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312091	Bypass Innominate Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0312092	Bypass Innominate Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312093	Bypass Innominate Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312094	Bypass Innominate Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312095	Bypass Innominate Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312096	Bypass Innominate Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312097	Bypass Innominate Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312098	Bypass Innominate Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312099	Bypass Innominate Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313090	Bypass Right Subclavian Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313091	Bypass Right Subclavian Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313092	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313093	Bypass Right Subclavian Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313094	Bypass Right Subclavian Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313095	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313096	Bypass Right Subclavian Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313097	Bypass Right Subclavian Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313098	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313099	Bypass Right Subclavian Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314090	Bypass Left Subclavian Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314091	Bypass Left Subclavian Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314092	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0314093	Bypass Left Subclavian Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314094	Bypass Left Subclavian Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314095	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314096	Bypass Left Subclavian Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314097	Bypass Left Subclavian Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314098	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314099	Bypass Left Subclavian Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315090	Bypass Right Axillary Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315091	Bypass Right Axillary Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315092	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315093	Bypass Right Axillary Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315094	Bypass Right Axillary Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315095	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315096	Bypass Right Axillary Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315097	Bypass Right Axillary Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315098	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315099	Bypass Right Axillary Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316090	Bypass Left Axillary Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316091	Bypass Left Axillary Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316092	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316093	Bypass Left Axillary Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0316094	Bypass Left Axillary Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316095	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316096	Bypass Left Axillary Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316097	Bypass Left Axillary Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316098	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316099	Bypass Left Axillary Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0317090	Bypass Right Brachial Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0317093	Bypass Right Brachial Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0318091	Bypass Left Brachial Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0318094	Bypass Left Brachial Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0319093	Bypass Right Ulnar Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0373046	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0373056	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0373066	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0373076	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0373346	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0373356	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0373366	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0373376	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0373446	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0373456	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0373466	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0373476	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0374046	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0374056	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0374066	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0374076	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0374346	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0374356	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0374366	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0374376	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0374446	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0374456	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0374466	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0374476	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375046	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0375056	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0375066	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0375076	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0375346	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0375356	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0375366	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0375376	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0375446	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375456	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375466	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375476	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376046	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0376056	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376066	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376076	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376346	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0376356	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376366	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376376	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376446	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376456	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376466	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376476	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377046	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0377056	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0377066	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0377076	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0377346	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0377356	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0377366	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0377376	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0377446	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377456	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377466	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377476	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0378046	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0378056	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0378066	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0378076	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0378346	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0378356	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0378366	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0378376	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0378446	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0378456	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0378466	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0378476	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379046	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0379056	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0379066	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0379076	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0379346	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0379356	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0379366	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0379376	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0379446	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379456	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379466	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379476	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410096	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0410097	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0410098	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0410099	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0410496	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410497	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410498	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410499	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0470046	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0470056	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0470066	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0470076	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0470346	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0470356	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0470366	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0470376	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0470446	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0470456	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0470466	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0470476	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03730E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03733E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03734E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03740E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03743E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03744E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03750E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03753E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03754E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03760E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03763E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03764E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03770E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03773E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03774E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03780E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03783E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03784E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03790E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03793E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03794E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04700E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04703E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04704E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E041	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047E046	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E056	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E066	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E076	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
031209B	Bypass Innominate Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031209C	Bypass Innominate Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
03120A0	Bypass Innominate Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03120A1	Bypass Innominate Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A3	Bypass Innominate Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A4	Bypass Innominate Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A6	Bypass Innominate Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A7	Bypass Innominate Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A9	Bypass Innominate Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120AB	Bypass Innominate Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120AC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120J0	Bypass Innominate Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J1	Bypass Innominate Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J3	Bypass Innominate Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J4	Bypass Innominate Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J6	Bypass Innominate Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J7	Bypass Innominate Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J9	Bypass Innominate Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03120JB	Bypass Innominate Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120JC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120K0	Bypass Innominate Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K1	Bypass Innominate Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K3	Bypass Innominate Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K4	Bypass Innominate Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K6	Bypass Innominate Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K7	Bypass Innominate Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K9	Bypass Innominate Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120KB	Bypass Innominate Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120KC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120Z0	Bypass Innominate Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z1	Bypass Innominate Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z2	Bypass Innominate Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z3	Bypass Innominate Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z4	Bypass Innominate Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z5	Bypass Innominate Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z6	Bypass Innominate Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120Z7	Bypass Innominate Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120Z8	Bypass Innominate Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120Z9	Bypass Innominate Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120ZB	Bypass Innominate Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120ZC	Bypass Innominate Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031309B	Bypass Right Subclavian Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031309C	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03130A0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130AB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130AC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130J0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03130JB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130JC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130K0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130KB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130KC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130Z0	Bypass Right Subclavian Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z1	Bypass Right Subclavian Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z3	Bypass Right Subclavian Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z4	Bypass Right Subclavian Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z6	Bypass Right Subclavian Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z7	Bypass Right Subclavian Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z9	Bypass Right Subclavian Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130ZB	Bypass Right Subclavian Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130ZC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031409B	Bypass Left Subclavian Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031409C	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03140A0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140AB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140AC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140J0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03140JB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140JC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140K0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140KB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140KC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140Z0	Bypass Left Subclavian Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z1	Bypass Left Subclavian Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z3	Bypass Left Subclavian Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z4	Bypass Left Subclavian Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z6	Bypass Left Subclavian Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140Z7	Bypass Left Subclavian Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140Z8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140Z9	Bypass Left Subclavian Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140ZB	Bypass Left Subclavian Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140ZC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031509B	Bypass Right Axillary Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031509C	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03150A0	Bypass Right Axillary Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A1	Bypass Right Axillary Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A3	Bypass Right Axillary Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A4	Bypass Right Axillary Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A6	Bypass Right Axillary Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A7	Bypass Right Axillary Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A9	Bypass Right Axillary Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150AB	Bypass Right Axillary Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150AC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150J0	Bypass Right Axillary Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J1	Bypass Right Axillary Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J3	Bypass Right Axillary Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J4	Bypass Right Axillary Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J6	Bypass Right Axillary Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J7	Bypass Right Axillary Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J9	Bypass Right Axillary Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03150JB	Bypass Right Axillary Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150JC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150K0	Bypass Right Axillary Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K1	Bypass Right Axillary Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K3	Bypass Right Axillary Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K4	Bypass Right Axillary Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K6	Bypass Right Axillary Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K7	Bypass Right Axillary Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K9	Bypass Right Axillary Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150KB	Bypass Right Axillary Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150KC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150Z0	Bypass Right Axillary Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z1	Bypass Right Axillary Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z3	Bypass Right Axillary Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z4	Bypass Right Axillary Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z6	Bypass Right Axillary Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z7	Bypass Right Axillary Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z9	Bypass Right Axillary Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150ZB	Bypass Right Axillary Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150ZC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031609B	Bypass Left Axillary Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031609C	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03160A0	Bypass Left Axillary Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A1	Bypass Left Axillary Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A3	Bypass Left Axillary Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A4	Bypass Left Axillary Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A6	Bypass Left Axillary Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A7	Bypass Left Axillary Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A9	Bypass Left Axillary Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160AB	Bypass Left Axillary Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160AC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160J0	Bypass Left Axillary Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J1	Bypass Left Axillary Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J3	Bypass Left Axillary Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J4	Bypass Left Axillary Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J6	Bypass Left Axillary Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J7	Bypass Left Axillary Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J9	Bypass Left Axillary Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03160JB	Bypass Left Axillary Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160JC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160K0	Bypass Left Axillary Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K1	Bypass Left Axillary Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K3	Bypass Left Axillary Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K4	Bypass Left Axillary Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K6	Bypass Left Axillary Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K7	Bypass Left Axillary Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K9	Bypass Left Axillary Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160KB	Bypass Left Axillary Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160KC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160Z0	Bypass Left Axillary Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z1	Bypass Left Axillary Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z3	Bypass Left Axillary Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z4	Bypass Left Axillary Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z6	Bypass Left Axillary Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z7	Bypass Left Axillary Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z9	Bypass Left Axillary Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160ZB	Bypass Left Axillary Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160ZC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03170A0	Bypass Right Brachial Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03170A3	Bypass Right Brachial Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03170J0	Bypass Right Brachial Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03170J3	Bypass Right Brachial Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03170K0	Bypass Right Brachial Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03170K3	Bypass Right Brachial Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03170Z0	Bypass Right Brachial Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03170Z3	Bypass Right Brachial Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03180A1	Bypass Left Brachial Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03180A4	Bypass Left Brachial Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03180J1	Bypass Left Brachial Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03180J4	Bypass Left Brachial Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03180K1	Bypass Left Brachial Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03180K4	Bypass Left Brachial Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03180Z1	Bypass Left Brachial Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03180Z4	Bypass Left Brachial Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03190A3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03190J3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03190K3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03190Z3	Bypass Right Ulnar Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031A094	Bypass Left Ulnar Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031A0A4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
031A0J4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
031A0K4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
031A0Z4	Bypass Left Ulnar Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031B093	Bypass Right Radial Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031B0A3	Bypass Right Radial Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
031B0J3	Bypass Right Radial Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
031B0K3	Bypass Right Radial Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
031B0Z3	Bypass Right Radial Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031C094	Bypass Left Radial Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031C0A4	Bypass Left Radial Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
031C0J4	Bypass Left Radial Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
031C0K4	Bypass Left Radial Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
031C0Z4	Bypass Left Radial Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
037304Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037305Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037306Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037307Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03730DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03730EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730Z6	Dilation of Right Subclavian Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03730ZZ	Dilation of Right Subclavian Artery, Open Approach	Procedure	ICD-10-PCS
037334Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037335Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037336Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037337Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03733D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03733DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03733EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733Z6	Dilation of Right Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03733ZZ	Dilation of Right Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037344Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037345Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037346Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037347Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734Z6	Dilation of Right Subclavian Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734ZZ	Dilation of Right Subclavian Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037404Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037405Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037406Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037407Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03740DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03740EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740Z6	Dilation of Left Subclavian Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03740ZZ	Dilation of Left Subclavian Artery, Open Approach	Procedure	ICD-10-PCS
037434Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037435Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037436Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037437Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03743DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03743EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743Z6	Dilation of Left Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03743ZZ	Dilation of Left Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037444Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037445Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037446Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037447Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744Z6	Dilation of Left Subclavian Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744ZZ	Dilation of Left Subclavian Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037504Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037505Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037506Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037507Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03750DZ	Dilation of Right Axillary Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03750EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750Z6	Dilation of Right Axillary Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03750ZZ	Dilation of Right Axillary Artery, Open Approach	Procedure	ICD-10-PCS
037534Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037535Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037536Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037537Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03753DZ	Dilation of Right Axillary Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03753EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753Z6	Dilation of Right Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03753ZZ	Dilation of Right Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037544Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037545Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037546Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037547Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754DZ	Dilation of Right Axillary Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754Z6	Dilation of Right Axillary Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03754ZZ	Dilation of Right Axillary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037604Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037605Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037606Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037607Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03760DZ	Dilation of Left Axillary Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03760EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760Z6	Dilation of Left Axillary Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03760ZZ	Dilation of Left Axillary Artery, Open Approach	Procedure	ICD-10-PCS
037634Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037635Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037636Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037637Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03763DZ	Dilation of Left Axillary Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03763EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763Z6	Dilation of Left Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03763ZZ	Dilation of Left Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037644Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037645Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037646Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037647Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764DZ	Dilation of Left Axillary Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764Z6	Dilation of Left Axillary Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764ZZ	Dilation of Left Axillary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037704Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037705Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037706Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037707Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03770DZ	Dilation of Right Brachial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03770EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770Z6	Dilation of Right Brachial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03770ZZ	Dilation of Right Brachial Artery, Open Approach	Procedure	ICD-10-PCS
037734Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037735Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037736Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037737Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03773DZ	Dilation of Right Brachial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03773EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773Z6	Dilation of Right Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03773ZZ	Dilation of Right Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037744Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037745Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037746Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037747Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774DZ	Dilation of Right Brachial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774Z6	Dilation of Right Brachial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03774ZZ	Dilation of Right Brachial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037804Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037805Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037806Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037807Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03780DZ	Dilation of Left Brachial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03780EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780Z6	Dilation of Left Brachial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03780ZZ	Dilation of Left Brachial Artery, Open Approach	Procedure	ICD-10-PCS
037834Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037835Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037836Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037837Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03783DZ	Dilation of Left Brachial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03783EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783Z6	Dilation of Left Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03783ZZ	Dilation of Left Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037844Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037845Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037846Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037847Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784DZ	Dilation of Left Brachial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784Z6	Dilation of Left Brachial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784ZZ	Dilation of Left Brachial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037904Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037905Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037906Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037907Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03790DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03790EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790Z6	Dilation of Right Ulnar Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03790ZZ	Dilation of Right Ulnar Artery, Open Approach	Procedure	ICD-10-PCS
037934Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037935Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037936Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037937Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03793DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03793EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793Z6	Dilation of Right Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03793ZZ	Dilation of Right Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037944Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037945Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037946Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037947Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794Z6	Dilation of Right Ulnar Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03794ZZ	Dilation of Right Ulnar Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A046	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A04Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A056	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A05Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A066	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A06Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A076	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A07Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A0DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A0E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0Z6	Dilation of Left Ulnar Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037A0ZZ	Dilation of Left Ulnar Artery, Open Approach	Procedure	ICD-10-PCS
037A346	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A34Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A356	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A35Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A366	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A36Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A376	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A37Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037A3D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A3DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A3E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3Z6	Dilation of Left Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037A3ZZ	Dilation of Left Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037A446	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A44Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A456	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A45Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A466	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A46Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A476	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A47Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037A4G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4Z6	Dilation of Left Ulnar Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4ZZ	Dilation of Left Ulnar Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B046	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B04Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B056	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B05Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B066	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B06Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B076	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B07Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B0DZ	Dilation of Right Radial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B0E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0Z6	Dilation of Right Radial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037B0ZZ	Dilation of Right Radial Artery, Open Approach	Procedure	ICD-10-PCS
037B346	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B34Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B356	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B35Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037B366	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B36Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B376	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B37Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B3DZ	Dilation of Right Radial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B3E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3Z6	Dilation of Right Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037B3ZZ	Dilation of Right Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037B446	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B44Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B456	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B45Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B466	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B46Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B476	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B47Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037B4DZ	Dilation of Right Radial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4Z6	Dilation of Right Radial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4ZZ	Dilation of Right Radial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C046	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C04Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C056	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C05Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C066	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C06Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C076	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C07Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C0DZ	Dilation of Left Radial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C0E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0Z6	Dilation of Left Radial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037C0ZZ	Dilation of Left Radial Artery, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037C346	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037C34Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037C356	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C35Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C366	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C36Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C376	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C37Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037C3DZ	Dilation of Left Radial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037C3E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3Z6	Dilation of Left Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037C3ZZ	Dilation of Left Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037C446	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C44Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C456	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C45Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C466	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C46Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037C476	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C47Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4DZ	Dilation of Left Radial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4Z6	Dilation of Left Radial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4ZZ	Dilation of Left Radial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D046	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D04Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D056	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D05Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D066	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D06Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D076	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D07Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D0DZ	Dilation of Right Hand Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D0E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037D0FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0Z6	Dilation of Right Hand Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037D0ZZ	Dilation of Right Hand Artery, Open Approach	Procedure	ICD-10-PCS
037D346	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D34Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D356	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D35Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D366	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D36Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D376	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D37Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D3DZ	Dilation of Right Hand Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D3E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3Z6	Dilation of Right Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037D3ZZ	Dilation of Right Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037D446	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D44Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037D456	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D45Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D466	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D46Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D476	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D47Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4DZ	Dilation of Right Hand Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4Z6	Dilation of Right Hand Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4ZZ	Dilation of Right Hand Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F046	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F04Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F056	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F05Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F066	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F06Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037F076	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F07Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F0DZ	Dilation of Left Hand Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F0E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0Z6	Dilation of Left Hand Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037F0ZZ	Dilation of Left Hand Artery, Open Approach	Procedure	ICD-10-PCS
037F346	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F34Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F356	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F35Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F366	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F36Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F376	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F37Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F3DZ	Dilation of Left Hand Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F3E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037F3GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3Z6	Dilation of Left Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037F3ZZ	Dilation of Left Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037F446	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F44Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F456	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F45Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F466	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F46Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F476	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F47Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4DZ	Dilation of Left Hand Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4Z6	Dilation of Left Hand Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4ZZ	Dilation of Left Hand Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03C33Z6	Extirpation of Matter from Right Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C33ZZ	Extirpation of Matter from Right Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C43Z6	Extirpation of Matter from Left Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C43ZZ	Extirpation of Matter from Left Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03C53Z6	Extirpation of Matter from Right Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C53ZZ	Extirpation of Matter from Right Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C63Z6	Extirpation of Matter from Left Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C63ZZ	Extirpation of Matter from Left Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C73Z6	Extirpation of Matter from Right Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C73ZZ	Extirpation of Matter from Right Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C83Z6	Extirpation of Matter from Left Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C83ZZ	Extirpation of Matter from Left Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C93Z6	Extirpation of Matter from Right Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C93ZZ	Extirpation of Matter from Right Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CA3Z6	Extirpation of Matter from Left Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CA3ZZ	Extirpation of Matter from Left Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CB3Z6	Extirpation of Matter from Right Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CB3ZZ	Extirpation of Matter from Right Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CC3Z6	Extirpation of Matter from Left Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CC3ZZ	Extirpation of Matter from Left Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CD3Z6	Extirpation of Matter from Right Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CD3ZZ	Extirpation of Matter from Right Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CF3Z6	Extirpation of Matter from Left Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CF3ZZ	Extirpation of Matter from Left Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
041009B	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009C	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009D	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009F	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009G	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009H	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009J	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009K	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009Q	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
04100A6	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100A7	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100A8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04100A9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AD	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AF	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AH	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AJ	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AQ	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AR	Bypass Abdominal Aorta to Lower Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100J6	Bypass Abdominal Aorta to Right Common Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100J7	Bypass Abdominal Aorta to Left Common Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100J8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100J9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JD	Bypass Abdominal Aorta to Right External Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JF	Bypass Abdominal Aorta to Left External Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JH	Bypass Abdominal Aorta to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JJ	Bypass Abdominal Aorta to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04100JK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JQ	Bypass Abdominal Aorta to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100K6	Bypass Abdominal Aorta to Right Common Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100K7	Bypass Abdominal Aorta to Left Common Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100K8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100K9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KD	Bypass Abdominal Aorta to Right External Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KF	Bypass Abdominal Aorta to Left External Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KH	Bypass Abdominal Aorta to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KJ	Bypass Abdominal Aorta to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KQ	Bypass Abdominal Aorta to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KR	Bypass Abdominal Aorta to Lower Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100Z6	Bypass Abdominal Aorta to Right Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100Z7	Bypass Abdominal Aorta to Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100Z8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries, Open Approach	Procedure	ICD-10-PCS
04100Z9	Bypass Abdominal Aorta to Right Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZB	Bypass Abdominal Aorta to Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04100ZD	Bypass Abdominal Aorta to Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZF	Bypass Abdominal Aorta to Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries, Open Approach	Procedure	ICD-10-PCS
04100ZH	Bypass Abdominal Aorta to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04100ZJ	Bypass Abdominal Aorta to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04100ZK	Bypass Abdominal Aorta to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
04100ZQ	Bypass Abdominal Aorta to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041049B	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049C	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049D	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049F	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049G	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049H	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049J	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049K	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049Q	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A6	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A7	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04104AD	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AF	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AH	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AJ	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AQ	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104J6	Bypass Abdominal Aorta to Right Common Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104J7	Bypass Abdominal Aorta to Left Common Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104J8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104J9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JD	Bypass Abdominal Aorta to Right External Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JF	Bypass Abdominal Aorta to Left External Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JH	Bypass Abdominal Aorta to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JJ	Bypass Abdominal Aorta to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JQ	Bypass Abdominal Aorta to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104K6	Bypass Abdominal Aorta to Right Common Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104K7	Bypass Abdominal Aorta to Left Common Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04104K8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104K9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KD	Bypass Abdominal Aorta to Right External Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KF	Bypass Abdominal Aorta to Left External Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KH	Bypass Abdominal Aorta to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KJ	Bypass Abdominal Aorta to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KQ	Bypass Abdominal Aorta to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z6	Bypass Abdominal Aorta to Right Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z7	Bypass Abdominal Aorta to Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z9	Bypass Abdominal Aorta to Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZB	Bypass Abdominal Aorta to Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZD	Bypass Abdominal Aorta to Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZF	Bypass Abdominal Aorta to Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZH	Bypass Abdominal Aorta to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZJ	Bypass Abdominal Aorta to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04104ZK	Bypass Abdominal Aorta to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZQ	Bypass Abdominal Aorta to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C09H	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041C09J	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041C09K	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041C0AH	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041C0AJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041C0AK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041C0JH	Bypass Right Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041C0JJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041C0JK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041C0KH	Bypass Right Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041C0KJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041C0KK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041C0ZH	Bypass Right Common Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041C0ZJ	Bypass Right Common Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041C0ZK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041C49H	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C49J	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C49K	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4AH	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4AJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4AK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041C4JH	Bypass Right Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4JJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4JK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KH	Bypass Right Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZH	Bypass Right Common Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZJ	Bypass Right Common Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D09H	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D09J	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D09K	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AH	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0JH	Bypass Left Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0JJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0JK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KH	Bypass Left Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0ZH	Bypass Left Common Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041D0ZJ	Bypass Left Common Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041D0ZK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041D49H	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D49J	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D49K	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4AH	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4AJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4AK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4JH	Bypass Left Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4JJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4JK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4KH	Bypass Left Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4KJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4KK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4ZH	Bypass Left Common Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4ZJ	Bypass Left Common Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4ZK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E09H	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041E09J	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041E09K	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041E0AH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041E0AJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041E0AK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041E0JH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041E0JJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041E0JK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041E0KH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041E0KJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041E0KK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041E0ZH	Bypass Right Internal Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041E0ZJ	Bypass Right Internal Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041E0ZK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041E49H	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E49J	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E49K	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4AH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4AJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4AK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4JH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4JJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4JK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4KH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4KJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4KK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4ZH	Bypass Right Internal Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4ZJ	Bypass Right Internal Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041E4ZK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F09H	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041F09J	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041F09K	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041F0AH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041F0AJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041F0AK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041F0JH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041F0JJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041F0JK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041F0KH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041F0KJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041F0KK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041F0ZH	Bypass Left Internal Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041F0ZJ	Bypass Left Internal Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041F0ZK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041F49H	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F49J	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F49K	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4AH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4AJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4AK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4JH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041F4JJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4JK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4KH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4KJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4KK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZH	Bypass Left Internal Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZJ	Bypass Left Internal Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H09H	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H09J	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H09K	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H0AH	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041H0AJ	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041H0AK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041H0JH	Bypass Right External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041H0JJ	Bypass Right External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041H0JK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041H0KH	Bypass Right External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041H0KJ	Bypass Right External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041H0KK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041H0ZH	Bypass Right External Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041H0ZJ	Bypass Right External Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041H0ZK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041H49H	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H49J	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H49K	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4AH	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4AJ	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4AK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4JH	Bypass Right External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4JJ	Bypass Right External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4JK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4KH	Bypass Right External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4KJ	Bypass Right External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4KK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZH	Bypass Right External Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZJ	Bypass Right External Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J09H	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041J09J	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041J09K	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041J0AH	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041J0AJ	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041J0AK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041J0JH	Bypass Left External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041J0JJ	Bypass Left External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041J0JK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041J0KH	Bypass Left External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041J0KJ	Bypass Left External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041J0KK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041J0ZH	Bypass Left External Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041J0ZJ	Bypass Left External Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041J0ZK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041J49H	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J49J	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J49K	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4AH	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4AJ	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4AK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4JH	Bypass Left External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4JJ	Bypass Left External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4JK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4KH	Bypass Left External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4KJ	Bypass Left External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4KK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4ZH	Bypass Left External Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4ZJ	Bypass Left External Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041J4ZK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K09H	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09J	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09K	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09L	Bypass Right Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09M	Bypass Right Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09N	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09P	Bypass Right Femoral Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09Q	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09S	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AH	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AJ	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AL	Bypass Right Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AM	Bypass Right Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AN	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AP	Bypass Right Femoral Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AQ	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AS	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0JH	Bypass Right Femoral Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JJ	Bypass Right Femoral Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041K0JK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JL	Bypass Right Femoral Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JM	Bypass Right Femoral Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JN	Bypass Right Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JP	Bypass Right Femoral Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JQ	Bypass Right Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JS	Bypass Right Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KH	Bypass Right Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KJ	Bypass Right Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KL	Bypass Right Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KM	Bypass Right Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KN	Bypass Right Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KP	Bypass Right Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KQ	Bypass Right Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KS	Bypass Right Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0ZH	Bypass Right Femoral Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZJ	Bypass Right Femoral Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZK	Bypass Right Femoral Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041K0ZL	Bypass Right Femoral Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZM	Bypass Right Femoral Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZN	Bypass Right Femoral Artery to Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZP	Bypass Right Femoral Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZQ	Bypass Right Femoral Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZS	Bypass Right Femoral Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041K49H	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49J	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041K49K	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49L	Bypass Right Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49M	Bypass Right Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49N	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49P	Bypass Right Femoral Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49Q	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49S	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AH	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AJ	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AL	Bypass Right Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AM	Bypass Right Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AN	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AP	Bypass Right Femoral Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AQ	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AS	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JH	Bypass Right Femoral Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JJ	Bypass Right Femoral Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JL	Bypass Right Femoral Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JM	Bypass Right Femoral Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041K4JN	Bypass Right Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JP	Bypass Right Femoral Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JQ	Bypass Right Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JS	Bypass Right Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KH	Bypass Right Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KJ	Bypass Right Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KL	Bypass Right Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KM	Bypass Right Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KN	Bypass Right Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KP	Bypass Right Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KQ	Bypass Right Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KS	Bypass Right Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZH	Bypass Right Femoral Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZJ	Bypass Right Femoral Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZK	Bypass Right Femoral Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZL	Bypass Right Femoral Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZM	Bypass Right Femoral Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZN	Bypass Right Femoral Artery to Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZP	Bypass Right Femoral Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZQ	Bypass Right Femoral Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZS	Bypass Right Femoral Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041L09H	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09J	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09K	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09L	Bypass Left Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09M	Bypass Left Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09N	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09P	Bypass Left Femoral Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09Q	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09S	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AH	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AJ	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AL	Bypass Left Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AM	Bypass Left Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AN	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AP	Bypass Left Femoral Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AQ	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AS	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0JH	Bypass Left Femoral Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JJ	Bypass Left Femoral Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041L0JL	Bypass Left Femoral Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JM	Bypass Left Femoral Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JN	Bypass Left Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JP	Bypass Left Femoral Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JQ	Bypass Left Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JS	Bypass Left Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KH	Bypass Left Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KJ	Bypass Left Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KL	Bypass Left Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KM	Bypass Left Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KN	Bypass Left Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KP	Bypass Left Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KQ	Bypass Left Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KS	Bypass Left Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0ZH	Bypass Left Femoral Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZJ	Bypass Left Femoral Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZK	Bypass Left Femoral Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041L0ZL	Bypass Left Femoral Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZM	Bypass Left Femoral Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZN	Bypass Left Femoral Artery to Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZP	Bypass Left Femoral Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZQ	Bypass Left Femoral Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZS	Bypass Left Femoral Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041L49H	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49J	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49K	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041L49L	Bypass Left Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49M	Bypass Left Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49N	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49P	Bypass Left Femoral Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49Q	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49S	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AH	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AJ	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AL	Bypass Left Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AM	Bypass Left Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AN	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AP	Bypass Left Femoral Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AQ	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AS	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JH	Bypass Left Femoral Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JJ	Bypass Left Femoral Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JL	Bypass Left Femoral Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JM	Bypass Left Femoral Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JN	Bypass Left Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JP	Bypass Left Femoral Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041L4JQ	Bypass Left Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JS	Bypass Left Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KH	Bypass Left Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KJ	Bypass Left Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KL	Bypass Left Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KM	Bypass Left Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KN	Bypass Left Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KP	Bypass Left Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KQ	Bypass Left Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KS	Bypass Left Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZH	Bypass Left Femoral Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZJ	Bypass Left Femoral Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZK	Bypass Left Femoral Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZL	Bypass Left Femoral Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZM	Bypass Left Femoral Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZN	Bypass Left Femoral Artery to Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZP	Bypass Left Femoral Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZQ	Bypass Left Femoral Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZS	Bypass Left Femoral Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M09L	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M09M	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M09P	Bypass Right Popliteal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041M09Q	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M09S	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AL	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AM	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AP	Bypass Right Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AS	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0JL	Bypass Right Popliteal Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JM	Bypass Right Popliteal Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JP	Bypass Right Popliteal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JS	Bypass Right Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KL	Bypass Right Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KM	Bypass Right Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KP	Bypass Right Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KS	Bypass Right Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0ZL	Bypass Right Popliteal Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZM	Bypass Right Popliteal Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZP	Bypass Right Popliteal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZQ	Bypass Right Popliteal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZS	Bypass Right Popliteal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041M49L	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M49M	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041M49P	Bypass Right Popliteal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M49Q	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M49S	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AL	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AM	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AP	Bypass Right Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AS	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JL	Bypass Right Popliteal Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JM	Bypass Right Popliteal Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JP	Bypass Right Popliteal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JS	Bypass Right Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KL	Bypass Right Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KM	Bypass Right Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KP	Bypass Right Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KS	Bypass Right Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZL	Bypass Right Popliteal Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZM	Bypass Right Popliteal Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZP	Bypass Right Popliteal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZQ	Bypass Right Popliteal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZS	Bypass Right Popliteal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041N09L	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09M	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09P	Bypass Left Popliteal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09Q	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09S	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AL	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AM	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AP	Bypass Left Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AS	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0JL	Bypass Left Popliteal Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JM	Bypass Left Popliteal Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JP	Bypass Left Popliteal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JS	Bypass Left Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KL	Bypass Left Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KM	Bypass Left Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KP	Bypass Left Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KS	Bypass Left Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0ZL	Bypass Left Popliteal Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZM	Bypass Left Popliteal Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZP	Bypass Left Popliteal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZQ	Bypass Left Popliteal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZS	Bypass Left Popliteal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041N49L	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N49M	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N49P	Bypass Left Popliteal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N49Q	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N49S	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AL	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AM	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AP	Bypass Left Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AS	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JL	Bypass Left Popliteal Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JM	Bypass Left Popliteal Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JP	Bypass Left Popliteal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JS	Bypass Left Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KL	Bypass Left Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KM	Bypass Left Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KP	Bypass Left Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KS	Bypass Left Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZL	Bypass Left Popliteal Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZM	Bypass Left Popliteal Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZP	Bypass Left Popliteal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041N4ZQ	Bypass Left Popliteal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZS	Bypass Left Popliteal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T09P	Bypass Right Peroneal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T09Q	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T09S	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AP	Bypass Right Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AS	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0JP	Bypass Right Peroneal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041T0JQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041T0JS	Bypass Right Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KP	Bypass Right Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KS	Bypass Right Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0ZP	Bypass Right Peroneal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041T0ZQ	Bypass Right Peroneal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041T0ZS	Bypass Right Peroneal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041T49P	Bypass Right Peroneal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T49Q	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T49S	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AP	Bypass Right Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AS	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4JP	Bypass Right Peroneal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041T4JQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4JS	Bypass Right Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4KP	Bypass Right Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4KQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4KS	Bypass Right Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4ZP	Bypass Right Peroneal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4ZQ	Bypass Right Peroneal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4ZS	Bypass Right Peroneal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U09P	Bypass Left Peroneal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041U09Q	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041U09S	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041U0AP	Bypass Left Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041U0AQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041U0AS	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041U0JP	Bypass Left Peroneal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041U0JQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041U0JS	Bypass Left Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041U0KP	Bypass Left Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041U0KQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041U0KS	Bypass Left Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041U0ZP	Bypass Left Peroneal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041U0ZQ	Bypass Left Peroneal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041U0ZS	Bypass Left Peroneal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041U49P	Bypass Left Peroneal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041U49Q	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U49S	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4AP	Bypass Left Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4AQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4AS	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4JP	Bypass Left Peroneal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4JQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4JS	Bypass Left Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4KP	Bypass Left Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4KQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4KS	Bypass Left Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4ZP	Bypass Left Peroneal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4ZQ	Bypass Left Peroneal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4ZS	Bypass Left Peroneal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V09P	Bypass Right Foot Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041V09Q	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041V09S	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041V0AP	Bypass Right Foot Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041V0AQ	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041V0AS	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041V0JP	Bypass Right Foot Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041V0JQ	Bypass Right Foot Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041V0JS	Bypass Right Foot Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041V0KP	Bypass Right Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041V0KQ	Bypass Right Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041V0KS	Bypass Right Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041V0ZP	Bypass Right Foot Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041V0ZQ	Bypass Right Foot Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041V0ZS	Bypass Right Foot Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041V49P	Bypass Right Foot Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V49Q	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V49S	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AP	Bypass Right Foot Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AQ	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AS	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JP	Bypass Right Foot Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JQ	Bypass Right Foot Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JS	Bypass Right Foot Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KP	Bypass Right Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KQ	Bypass Right Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KS	Bypass Right Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZP	Bypass Right Foot Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZQ	Bypass Right Foot Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZS	Bypass Right Foot Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W09P	Bypass Left Foot Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041W09Q	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041W09S	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AP	Bypass Left Foot Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AQ	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AS	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0JP	Bypass Left Foot Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041W0JQ	Bypass Left Foot Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041W0JS	Bypass Left Foot Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KP	Bypass Left Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KQ	Bypass Left Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KS	Bypass Left Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0ZP	Bypass Left Foot Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041W0ZQ	Bypass Left Foot Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041W0ZS	Bypass Left Foot Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041W49P	Bypass Left Foot Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W49Q	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W49S	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AP	Bypass Left Foot Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AQ	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AS	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JP	Bypass Left Foot Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JQ	Bypass Left Foot Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JS	Bypass Left Foot Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4KP	Bypass Left Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041W4KQ	Bypass Left Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4KS	Bypass Left Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZP	Bypass Left Foot Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZQ	Bypass Left Foot Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZS	Bypass Left Foot Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04700D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
04700F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04700G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04700Z6	Dilation of Abdominal Aorta, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04703D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
04703F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04703G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04703Z6	Dilation of Abdominal Aorta, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04704D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704Z6	Dilation of Abdominal Aorta, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C041	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047C046	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C04Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C056	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C05Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C066	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C06Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047C076	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C07Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047C0D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C0DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C0E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047C0Z6	Dilation of Right Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047C0ZZ	Dilation of Right Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047C341	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047C346	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C34Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C356	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C35Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C366	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C36Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C376	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C37Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047C3D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047C3D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C3DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C3E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047C3Z6	Dilation of Right Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047C3ZZ	Dilation of Right Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047C441	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C446	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C44Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C456	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C45Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C466	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C46Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C476	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C47Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047C4D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4Z6	Dilation of Right Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4ZZ	Dilation of Right Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D041	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047D046	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D04Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D056	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D05Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D066	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D06Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D076	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D07Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047D0D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D0DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D0E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047D0Z6	Dilation of Left Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047D0ZZ	Dilation of Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047D341	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D346	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D34Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D356	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D35Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D366	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D36Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D376	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D37Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D3D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D3DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D3E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047D3EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D3Z6	Dilation of Left Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047D3ZZ	Dilation of Left Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047D441	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D446	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D44Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D456	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D45Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D466	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D46Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D476	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D47Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047D4F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4Z6	Dilation of Left Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4ZZ	Dilation of Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E04Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E05Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E06Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E07Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047E0D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E0DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E0E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047E0Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047E0ZZ	Dilation of Right Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047E341	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047E346	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E34Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E356	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E35Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E366	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E36Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E376	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E37Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047E3D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E3DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E3E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047E3Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047E3ZZ	Dilation of Right Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047E441	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E446	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047E44Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E456	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E45Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E466	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E46Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E476	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E47Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4ZZ	Dilation of Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F041	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047F046	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F04Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047F056	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F05Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F066	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F06Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F076	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F07Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047F0D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F0DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F0E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047F0Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047F0ZZ	Dilation of Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047F341	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047F346	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F34Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F356	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F35Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F366	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F36Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047F376	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F37Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047F3D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F3DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F3E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047F3Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047F3ZZ	Dilation of Left Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047F441	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F446	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F44Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F456	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F45Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F466	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F46Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F476	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047F47Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4ZZ	Dilation of Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H041	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H046	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H04Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H056	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H05Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H066	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H06Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H076	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H07Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047H0D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H0D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H0DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H0E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H0Z6	Dilation of Right External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047H0ZZ	Dilation of Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047H341	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H346	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H34Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H356	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H35Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H366	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H36Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H376	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H37Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H3D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H3DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047H3E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H3Z6	Dilation of Right External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047H3ZZ	Dilation of Right External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047H441	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H446	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H44Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H456	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H45Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H466	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H46Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H476	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H47Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047H4EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4Z6	Dilation of Right External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4ZZ	Dilation of Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J041	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J046	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J04Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J056	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J05Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J066	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J06Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J076	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J07Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J0D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J0DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J0E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047J0FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J0Z6	Dilation of Left External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047J0ZZ	Dilation of Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047J341	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J346	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047J34Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047J356	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J35Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J366	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J36Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J376	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J37Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J3D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047J3DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047J3E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047J3GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J3Z6	Dilation of Left External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047J3ZZ	Dilation of Left External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047J441	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J446	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J44Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J456	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J45Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J466	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J46Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J476	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J47Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047J4Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4Z6	Dilation of Left External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4ZZ	Dilation of Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K041	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K046	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K04Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K056	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K05Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K066	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K06Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K076	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K07Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K0D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K0DZ	Dilation of Right Femoral Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K0E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K0Z6	Dilation of Right Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047K0ZZ	Dilation of Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
047K341	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047K346	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K34Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K356	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K35Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K366	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K36Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K376	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K37Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047K3D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K3DZ	Dilation of Right Femoral Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K3E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047K3Z6	Dilation of Right Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047K3ZZ	Dilation of Right Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047K441	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K446	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K44Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047K456	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K45Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K466	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K46Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K476	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K47Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4DZ	Dilation of Right Femoral Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4Z6	Dilation of Right Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4ZZ	Dilation of Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L041	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L046	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L04Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L056	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047L05Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L066	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L06Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L076	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L07Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L0D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L0DZ	Dilation of Left Femoral Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L0E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L0Z6	Dilation of Left Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047L0ZZ	Dilation of Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
047L341	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047L346	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L34Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L356	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L35Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L366	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L36Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047L376	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L37Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047L3D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L3DZ	Dilation of Left Femoral Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L3E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047L3Z6	Dilation of Left Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047L3ZZ	Dilation of Left Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047L441	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L446	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L44Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L456	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L45Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L466	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L46Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L476	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L47Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047L4D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4DZ	Dilation of Left Femoral Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4Z6	Dilation of Left Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4ZZ	Dilation of Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M041	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047M046	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M04Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M056	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M05Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M066	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M06Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M076	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M07Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047M0D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M0DZ	Dilation of Right Popliteal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M0E6	Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047M0Z6	Dilation of Right Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047M0ZZ	Dilation of Right Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
047M341	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M346	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M34Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M356	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M35Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M366	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M36Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M376	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M37Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M3D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M3DZ	Dilation of Right Popliteal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M3E6	Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047M3F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M3Z6	Dilation of Right Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047M3ZZ	Dilation of Right Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047M441	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M446	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M44Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M456	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M45Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M466	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M46Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M476	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M47Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4DZ	Dilation of Right Popliteal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4E6	Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047M4FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4Z6	Dilation of Right Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4ZZ	Dilation of Right Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N041	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047N046	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N04Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N056	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N05Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N066	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N06Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N076	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N07Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047N0D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N0DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N0E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047N0Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047N0Z6	Dilation of Left Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047N0ZZ	Dilation of Left Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
047N341	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047N346	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N34Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N356	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N35Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N366	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N36Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N376	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N37Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047N3D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N3DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N3E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047N3Z6	Dilation of Left Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047N3ZZ	Dilation of Left Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047N441	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047N446	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N44Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N456	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N45Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N466	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N46Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N476	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N47Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4Z6	Dilation of Left Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4ZZ	Dilation of Left Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P041	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047P046	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047P04Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047P056	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P05Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P066	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P06Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P076	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P07Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047P0D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047P0DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047P0E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047P0Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047P0ZZ	Dilation of Right Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047P341	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047P346	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047P34Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047P356	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P35Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P366	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P36Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P376	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P37Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047P3D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047P3DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047P3E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047P3Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047P3ZZ	Dilation of Right Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047P441	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P446	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P44Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P456	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047P45Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P466	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P46Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P476	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P47Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4ZZ	Dilation of Right Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q041	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047Q046	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q04Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q056	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q05Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047Q066	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q06Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q076	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q07Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047Q0D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q0DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q0E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047Q0Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047Q0ZZ	Dilation of Left Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047Q341	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047Q346	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q34Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q356	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q35Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q366	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q36Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q376	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047Q37Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3ZZ	Dilation of Left Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047Q441	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q446	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q44Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q456	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q45Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q466	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q46Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q476	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q47Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047Q4D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4ZZ	Dilation of Left Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R041	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R046	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R04Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R056	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R05Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R066	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R06Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R076	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R07Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R0D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R0DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047R0E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R0Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047R0ZZ	Dilation of Right Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047R341	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047R346	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R34Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R356	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R35Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R366	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R36Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R376	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R37Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047R3D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R3DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R3E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047R3F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047R3Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047R3ZZ	Dilation of Right Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047R441	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R446	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R44Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R456	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R45Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R466	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R46Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R476	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R47Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047R4G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4ZZ	Dilation of Right Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S041	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047S046	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S04Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S056	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S05Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S066	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S06Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S076	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S07Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047S0D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S0DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S0E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047S0Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047S0Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047S0ZZ	Dilation of Left Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047S341	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S346	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S34Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S356	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S35Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S366	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S36Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S376	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S37Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S3D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S3DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S3E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S3Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047S3ZZ	Dilation of Left Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047S441	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S446	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S44Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S456	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S45Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S466	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S46Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S476	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S47Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4ZZ	Dilation of Left Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T041	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047T046	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T04Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T056	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T05Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T066	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T06Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T076	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T07Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047T0D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T0DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T0E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047T0Z6	Dilation of Right Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047T0ZZ	Dilation of Right Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
047T341	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047T346	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047T34Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047T356	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T35Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047T366	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T36Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T376	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T37Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047T3D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047T3DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047T3E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047T3Z6	Dilation of Right Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047T3ZZ	Dilation of Right Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047T441	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T446	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T44Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T456	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T45Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T466	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T46Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047T476	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T47Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4Z6	Dilation of Right Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4ZZ	Dilation of Right Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U041	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047U046	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U04Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U056	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U05Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U066	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U06Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U076	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U07Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047U0D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047U0D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U0DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U0E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047U0Z6	Dilation of Left Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047U0ZZ	Dilation of Left Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
047U341	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U346	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U34Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U356	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U35Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U366	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U36Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U376	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U37Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U3D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U3DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U3E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047U3F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U3Z6	Dilation of Left Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047U3ZZ	Dilation of Left Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047U441	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U446	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U44Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U456	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U45Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U466	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U46Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U476	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U47Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047U4G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4Z6	Dilation of Left Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4ZZ	Dilation of Left Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V041	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047V046	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V04Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V056	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V05Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V066	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V06Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V076	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V07Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047V0D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V0DZ	Dilation of Right Foot Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V0E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047V0Z6	Dilation of Right Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047V0ZZ	Dilation of Right Foot Artery, Open Approach	Procedure	ICD-10-PCS
047V341	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047V346	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047V34Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047V356	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V35Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V366	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V36Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V376	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V37Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047V3D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047V3DZ	Dilation of Right Foot Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047V3E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047V3Z6	Dilation of Right Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047V3ZZ	Dilation of Right Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047V441	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V446	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V44Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V456	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V45Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047V466	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V46Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V476	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V47Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4DZ	Dilation of Right Foot Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4Z6	Dilation of Right Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4ZZ	Dilation of Right Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W041	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047W046	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W04Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W056	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W05Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W066	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W06Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047W076	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W07Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047W0D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W0DZ	Dilation of Left Foot Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W0E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047W0Z6	Dilation of Left Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047W0ZZ	Dilation of Left Foot Artery, Open Approach	Procedure	ICD-10-PCS
047W341	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047W346	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W34Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W356	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W35Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W366	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W36Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W376	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W37Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047W3D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W3DZ	Dilation of Left Foot Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W3E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047W3EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047W3Z6	Dilation of Left Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047W3ZZ	Dilation of Left Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047W441	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W446	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W44Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W456	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W45Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W466	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W46Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W476	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W47Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4DZ	Dilation of Left Foot Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047W4G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4Z6	Dilation of Left Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4ZZ	Dilation of Left Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04C00Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04C03Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04C04Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CC0Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CC0ZZ	Extirpation of Matter from Right Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CC3Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CC3ZZ	Extirpation of Matter from Right Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CC4Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CC4ZZ	Extirpation of Matter from Right Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CD0Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CD0ZZ	Extirpation of Matter from Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CD3Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CD3ZZ	Extirpation of Matter from Left Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CD4Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CD4ZZ	Extirpation of Matter from Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CE0Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CE0ZZ	Extirpation of Matter from Right Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CE3Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CE3ZZ	Extirpation of Matter from Right Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CE4Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CE4ZZ	Extirpation of Matter from Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CF0Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CF0ZZ	Extirpation of Matter from Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CF3Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CF3ZZ	Extirpation of Matter from Left Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CF4Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04CF4ZZ	Extirpation of Matter from Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CH0Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CH0ZZ	Extirpation of Matter from Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CH3Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CH3ZZ	Extirpation of Matter from Right External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CH4Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CH4ZZ	Extirpation of Matter from Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CJ0Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CJ0ZZ	Extirpation of Matter from Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CJ3Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CJ3ZZ	Extirpation of Matter from Left External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CJ4Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CJ4ZZ	Extirpation of Matter from Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CK0Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CK0ZZ	Extirpation of Matter from Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04CK3Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CK3ZZ	Extirpation of Matter from Right Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CK4Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CK4ZZ	Extirpation of Matter from Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CL0Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CL0ZZ	Extirpation of Matter from Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04CL3Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CL3ZZ	Extirpation of Matter from Left Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CL4Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CL4ZZ	Extirpation of Matter from Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CM0Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CM0ZZ	Extirpation of Matter from Right Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
04CM3Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CM3ZZ	Extirpation of Matter from Right Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CM4Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CM4ZZ	Extirpation of Matter from Right Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CN0Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CN0ZZ	Extirpation of Matter from Left Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
04CN3Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04CN3ZZ	Extirpation of Matter from Left Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CN4Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CN4ZZ	Extirpation of Matter from Left Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CP0Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CP0ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CP3Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CP3ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CP4Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CP4ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CQ0Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CQ0ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CQ3Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CQ3ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CQ4Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CQ4ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CR0Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CR0ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CR3Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CR3ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CR4Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CR4ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CS0Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CS0ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CS3Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CS3ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CS4Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CS4ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CT0Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CT0ZZ	Extirpation of Matter from Right Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
04CT3Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CT3ZZ	Extirpation of Matter from Right Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04CT4Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CT4ZZ	Extirpation of Matter from Right Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CU0Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CU0ZZ	Extirpation of Matter from Left Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
04CU3Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CU3ZZ	Extirpation of Matter from Left Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CU4Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CU4ZZ	Extirpation of Matter from Left Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CV0Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CV0ZZ	Extirpation of Matter from Right Foot Artery, Open Approach	Procedure	ICD-10-PCS
04CV3Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CV3ZZ	Extirpation of Matter from Right Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CV4Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CV4ZZ	Extirpation of Matter from Right Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CW0Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CW0ZZ	Extirpation of Matter from Left Foot Artery, Open Approach	Procedure	ICD-10-PCS
04CW3Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CW3ZZ	Extirpation of Matter from Left Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CW4Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CW4ZZ	Extirpation of Matter from Left Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Y6C0Z1	Detachment at Right Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z2	Detachment at Right Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z3	Detachment at Right Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z1	Detachment at Left Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z2	Detachment at Left Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z3	Detachment at Left Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6F0ZZ	Detachment at Right Knee Region, Open Approach	Procedure	ICD-10-PCS
0Y6G0ZZ	Detachment at Left Knee Region, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z1	Detachment at Right Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z2	Detachment at Right Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z3	Detachment at Right Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z1	Detachment at Left Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z2	Detachment at Left Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z3	Detachment at Left Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z0	Detachment at Right Foot, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z4	Detachment at Right Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z5	Detachment at Right Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z6	Detachment at Right Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z7	Detachment at Right Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z8	Detachment at Right Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z9	Detachment at Right Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZB	Detachment at Right Foot, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZC	Detachment at Right Foot, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
OY6M0ZD	Detachment at Right Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
OY6M0ZF	Detachment at Right Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0Z0	Detachment at Left Foot, Complete, Open Approach	Procedure	ICD-10-PCS
OY6N0Z4	Detachment at Left Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0Z5	Detachment at Left Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0Z6	Detachment at Left Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0Z7	Detachment at Left Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0Z8	Detachment at Left Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0Z9	Detachment at Left Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0ZB	Detachment at Left Foot, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0ZC	Detachment at Left Foot, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0ZD	Detachment at Left Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
OY6N0ZF	Detachment at Left Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
OY6P0Z0	Detachment at Right 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS
OY6P0Z1	Detachment at Right 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
OY6P0Z2	Detachment at Right 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
OY6P0Z3	Detachment at Right 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
OY6Q0Z0	Detachment at Left 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS
OY6Q0Z1	Detachment at Left 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
OY6Q0Z2	Detachment at Left 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
OY6Q0Z3	Detachment at Left 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
OY6R0Z0	Detachment at Right 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
OY6R0Z1	Detachment at Right 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
OY6R0Z2	Detachment at Right 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
OY6R0Z3	Detachment at Right 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
OY6S0Z0	Detachment at Left 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
OY6S0Z1	Detachment at Left 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
OY6S0Z2	Detachment at Left 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
OY6S0Z3	Detachment at Left 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
OY6T0Z0	Detachment at Right 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
OY6T0Z1	Detachment at Right 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
OY6T0Z2	Detachment at Right 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
OY6T0Z3	Detachment at Right 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
OY6U0Z0	Detachment at Left 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
OY6U0Z1	Detachment at Left 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
OY6U0Z2	Detachment at Left 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
OY6U0Z3	Detachment at Left 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
OY6V0Z0	Detachment at Right 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
OY6V0Z1	Detachment at Right 4th Toe, High, Open Approach	Procedure	ICD-10-PCS
OY6V0Z2	Detachment at Right 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
OY6V0Z3	Detachment at Right 4th Toe, Low, Open Approach	Procedure	ICD-10-PCS
OY6W0Z0	Detachment at Left 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
OY6W0Z1	Detachment at Left 4th Toe, High, Open Approach	Procedure	ICD-10-PCS
OY6W0Z2	Detachment at Left 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
OY6W0Z3	Detachment at Left 4th Toe, Low, Open Approach	Procedure	ICD-10-PCS
OY6X0Z0	Detachment at Right 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
OY6X0Z1	Detachment at Right 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
OY6X0Z2	Detachment at Right 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
OY6X0Z3	Detachment at Right 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
OY6Y0Z0	Detachment at Left 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0Y6Y0Z1	Detachment at Left 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z2	Detachment at Left 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z3	Detachment at Left 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
33877	Repair of thoracoabdominal aortic aneurysm with graft, with or without cardiopulmonary bypass	Procedure	CPT-4
34151	Embolectomy or thrombectomy, with or without catheter; renal, celiac, mesentery, aortoiliac artery, by abdominal incision	Procedure	CPT-4
34201	Embolectomy or thrombectomy, with or without catheter; femoropopliteal, aortoiliac artery, by leg incision	Procedure	CPT-4
34808	Endovascular placement of iliac artery occlusion device (List separately in addition to code for primary procedure)	Procedure	CPT-4
34820	Open iliac artery exposure for delivery of endovascular prosthesis or iliac occlusion during endovascular therapy, by abdominal or retroperitoneal incision, unilateral (List separately in addition to code for primary procedure)	Procedure	CPT-4
34825	Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; initial vessel	Procedure	CPT-4
34826	Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
35081	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, abdominal aorta	Procedure	CPT-4
35102	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, abdominal aorta involving iliac vessels (common, hypogastric, external)	Procedure	CPT-4
35131	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, iliac artery (common, hypogastric, external)	Procedure	CPT-4
35132	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for ruptured aneurysm, iliac artery (common, hypogastric, external)	Procedure	CPT-4
35141	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, common femoral artery (profunda femoris, superficial femoral)	Procedure	CPT-4
35142	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for ruptured aneurysm, common femoral artery (profunda femoris, superficial femoral)	Procedure	CPT-4
35450	Transluminal balloon angioplasty, open; renal or other visceral artery	Procedure	CPT-4
35452	Transluminal balloon angioplasty, open; aortic	Procedure	CPT-4
35454	Transluminal balloon angioplasty, open; iliac	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
35471	Transluminal balloon angioplasty, percutaneous; renal or visceral artery	Procedure	CPT-4
35472	Transluminal balloon angioplasty, percutaneous; aortic	Procedure	CPT-4
35473	Transluminal balloon angioplasty, percutaneous; iliac	Procedure	CPT-4
35480	Transluminal peripheral atherectomy, open; renal or other visceral artery	Procedure	CPT-4
35490	Transluminal peripheral atherectomy, percutaneous; renal or other visceral artery	Procedure	CPT-4
35537	Bypass graft, with vein; aortoiliac	Procedure	CPT-4
35538	Bypass graft, with vein; aortobi-iliac	Procedure	CPT-4
35540	Bypass graft, with vein; aortobifemoral	Procedure	CPT-4
35548	Bypass graft, with vein; aortoiliofemoral, unilateral	Procedure	CPT-4
35549	Bypass graft, with vein; aortoiliofemoral, bilateral	Procedure	CPT-4
35563	Bypass graft, with vein; ilioiliac	Procedure	CPT-4
35566	Bypass graft, with vein; femoral-anterior tibial, posterior tibial, peroneal artery or other distal vessels	Procedure	CPT-4
35621	Bypass graft, with other than vein; axillary-femoral	Procedure	CPT-4
35637	Bypass graft, with other than vein; aortoiliac	Procedure	CPT-4
35638	Bypass graft, with other than vein; aortobi-iliac	Procedure	CPT-4
35646	Bypass graft, with other than vein; aortobifemoral	Procedure	CPT-4
35647	Bypass graft, with other than vein; aortofemoral	Procedure	CPT-4
35651	Bypass graft, with other than vein; aortofemoral-popliteal	Procedure	CPT-4
35654	Bypass graft, with other than vein; axillary-femoral-femoral	Procedure	CPT-4
35656	Bypass graft, with other than vein; femoral-popliteal	Procedure	CPT-4
35661	Bypass graft, with other than vein; femoral-femoral	Procedure	CPT-4
35663	Bypass graft, with other than vein; ilioiliac	Procedure	CPT-4
35665	Bypass graft, with other than vein; iliofemoral	Procedure	CPT-4
35666	Bypass graft, with other than vein; femoral-anterior tibial, posterior tibial, or peroneal artery	Procedure	CPT-4
Valvular/Mitral Valve Disease			
I05.0	Rheumatic mitral stenosis	Diagnosis	ICD-10-CM
I05.1	Rheumatic mitral insufficiency	Diagnosis	ICD-10-CM
I05.2	Rheumatic mitral stenosis with insufficiency	Diagnosis	ICD-10-CM
I05.8	Other rheumatic mitral valve diseases	Diagnosis	ICD-10-CM
I05.9	Rheumatic mitral valve disease, unspecified	Diagnosis	ICD-10-CM
I06.0	Rheumatic aortic stenosis	Diagnosis	ICD-10-CM
I06.1	Rheumatic aortic insufficiency	Diagnosis	ICD-10-CM
I06.2	Rheumatic aortic stenosis with insufficiency	Diagnosis	ICD-10-CM
I06.8	Other rheumatic aortic valve diseases	Diagnosis	ICD-10-CM
I06.9	Rheumatic aortic valve disease, unspecified	Diagnosis	ICD-10-CM
I07.0	Rheumatic tricuspid stenosis	Diagnosis	ICD-10-CM
I07.1	Rheumatic tricuspid insufficiency	Diagnosis	ICD-10-CM
I07.2	Rheumatic tricuspid stenosis and insufficiency	Diagnosis	ICD-10-CM
I07.8	Other rheumatic tricuspid valve diseases	Diagnosis	ICD-10-CM
I07.9	Rheumatic tricuspid valve disease, unspecified	Diagnosis	ICD-10-CM
I08.0	Rheumatic disorders of both mitral and aortic valves	Diagnosis	ICD-10-CM
I08.1	Rheumatic disorders of both mitral and tricuspid valves	Diagnosis	ICD-10-CM
I08.2	Rheumatic disorders of both aortic and tricuspid valves	Diagnosis	ICD-10-CM
I08.3	Combined rheumatic disorders of mitral, aortic and tricuspid valves	Diagnosis	ICD-10-CM
I08.8	Other rheumatic multiple valve diseases	Diagnosis	ICD-10-CM
I08.9	Rheumatic multiple valve disease, unspecified	Diagnosis	ICD-10-CM
I09.1	Rheumatic diseases of endocardium, valve unspecified	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I09.89	Other specified rheumatic heart diseases	Diagnosis	ICD-10-CM
I09.9	Rheumatic heart disease, unspecified	Diagnosis	ICD-10-CM
Z95.2	Presence of prosthetic heart valve	Diagnosis	ICD-10-CM
Z95.3	Presence of xenogenic heart valve	Diagnosis	ICD-10-CM
Z95.4	Presence of other heart-valve replacement	Diagnosis	ICD-10-CM
027F04Z	Dilation of Aortic Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027F0DZ	Dilation of Aortic Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027F0ZZ	Dilation of Aortic Valve, Open Approach	Procedure	ICD-10-PCS
027G04Z	Dilation of Mitral Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027G0DZ	Dilation of Mitral Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027G0ZZ	Dilation of Mitral Valve, Open Approach	Procedure	ICD-10-PCS
027H04Z	Dilation of Pulmonary Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027H0DZ	Dilation of Pulmonary Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027H0ZZ	Dilation of Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
027J04Z	Dilation of Tricuspid Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027J0DZ	Dilation of Tricuspid Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027J0ZZ	Dilation of Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02NF0ZZ	Release Aortic Valve, Open Approach	Procedure	ICD-10-PCS
02NG0ZZ	Release Mitral Valve, Open Approach	Procedure	ICD-10-PCS
02NH0ZZ	Release Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
02NJ0ZZ	Release Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02QF0ZZ	Repair Aortic Valve, Open Approach	Procedure	ICD-10-PCS
02QG0ZZ	Repair Mitral Valve, Open Approach	Procedure	ICD-10-PCS
02QH0ZZ	Repair Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
02QJ0ZZ	Repair Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02RF07Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RF08Z	Replacement of Aortic Valve with Zooplasic Tissue, Open Approach	Procedure	ICD-10-PCS
02RF0JZ	Replacement of Aortic Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RF0KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RF47Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RF48Z	Replacement of Aortic Valve with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RF4JZ	Replacement of Aortic Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RF4KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG07Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RG08Z	Replacement of Mitral Valve with Zooplasic Tissue, Open Approach	Procedure	ICD-10-PCS
02RG0JZ	Replacement of Mitral Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RG0KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RG37Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RG38Z	Replacement of Mitral Valve with Zooplasic Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
02RG3JZ	Replacement of Mitral Valve with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RG3KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02RG47Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG48Z	Replacement of Mitral Valve with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG4JZ	Replacement of Mitral Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG4KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH07Z	Replacement of Pulmonary Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RH08Z	Replacement of Pulmonary Valve with Zooplasic Tissue, Open Approach	Procedure	ICD-10-PCS
02RH0JZ	Replacement of Pulmonary Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RH0KZ	Replacement of Pulmonary Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RH47Z	Replacement of Pulmonary Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH48Z	Replacement of Pulmonary Valve with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH4JZ	Replacement of Pulmonary Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH4KZ	Replacement of Pulmonary Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ07Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ08Z	Replacement of Tricuspid Valve with Zooplasic Tissue, Open Approach	Procedure	ICD-10-PCS
02RJ0JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ0KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ37Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ38Z	Replacement of Tricuspid Valve with Zooplasic Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ3JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ3KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ47Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ48Z	Replacement of Tricuspid Valve with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ4JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ4KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02VG0ZZ	Restriction of Mitral Valve, Open Approach	Procedure	ICD-10-PCS
X2RF03Z	Replacement of Aortic Valve using Zooplasic Tissue, Rapid Deployment Technique, Open Approach, New Technology Group 2	Procedure	ICD-10-PCS
X2RF43Z	Replacement of Aortic Valve using Zooplasic Tissue, Rapid Deployment Technique, Percutaneous Endoscopic Approach, New Technology Group 2	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0257T	Implantation of catheter-delivered prosthetic aortic heart valve; open thoracic approach (eg, transapical, transventricular)	Procedure	CPT-4, Category III
0258T	Transthoracic cardiac exposure (eg, sternotomy, thoracotomy, subxiphoid) for catheter-delivered aortic valve replacement; without cardiopulmonary bypass	Procedure	CPT-4, Category III
0259T	Transthoracic cardiac exposure (eg, sternotomy, thoracotomy, subxiphoid) for catheter-delivered aortic valve replacement; with cardiopulmonary bypass	Procedure	CPT-4, Category III
0262T	Implantation of catheter-delivered prosthetic pulmonary valve, endovascular approach	Procedure	CPT-4, Category III
33400	Valvuloplasty, aortic valve; open, with cardiopulmonary bypass	Procedure	CPT-4
33401	Valvuloplasty, aortic valve; open, with inflow occlusion	Procedure	CPT-4
33403	Valvuloplasty, aortic valve; using transventricular dilation, with cardiopulmonary bypass	Procedure	CPT-4
33420	Valvotomy, mitral valve; closed heart	Procedure	CPT-4
33422	Valvotomy, mitral valve; open heart, with cardiopulmonary bypass	Procedure	CPT-4
33425	Valvuloplasty, mitral valve, with cardiopulmonary bypass;	Procedure	CPT-4
33426	Valvuloplasty, mitral valve, with cardiopulmonary bypass; with prosthetic ring	Procedure	CPT-4
33427	Valvuloplasty, mitral valve, with cardiopulmonary bypass; radical reconstruction, with or without ring	Procedure	CPT-4
33430	Replacement, mitral valve, with cardiopulmonary bypass	Procedure	CPT-4
33460	Valvectomy, tricuspid valve, with cardiopulmonary bypass	Procedure	CPT-4
33463	Valvuloplasty, tricuspid valve; without ring insertion	Procedure	CPT-4
33464	Valvuloplasty, tricuspid valve; with ring insertion	Procedure	CPT-4
33465	Replacement, tricuspid valve, with cardiopulmonary bypass	Procedure	CPT-4
33468	Tricuspid valve repositioning and plication for Ebstein anomaly	Procedure	CPT-4
33475	Replacement, pulmonary valve	Procedure	CPT-4
33496	Repair of non-structural prosthetic valve dysfunction with cardiopulmonary bypass (separate procedure)	Procedure	CPT-4
33660	Repair of incomplete or partial atrioventricular canal (ostium primum atrial septal defect), with or without atrioventricular valve repair	Procedure	CPT-4
33665	Repair of intermediate or transitional atrioventricular canal, with or without atrioventricular valve repair	Procedure	CPT-4
Diseases of Veins and Lymphatics and Other Diseases of the Circulatory System			
I80	Phlebitis and thrombophlebitis	Diagnosis	ICD-10-CM
I80.0	Phlebitis and thrombophlebitis of superficial vessels of lower extremities	Diagnosis	ICD-10-CM
I80.00	Phlebitis and thrombophlebitis of superficial vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
I80.01	Phlebitis and thrombophlebitis of superficial vessels of right lower extremity	Diagnosis	ICD-10-CM
I80.02	Phlebitis and thrombophlebitis of superficial vessels of left lower extremity	Diagnosis	ICD-10-CM
I80.03	Phlebitis and thrombophlebitis of superficial vessels of lower extremities, bilateral	Diagnosis	ICD-10-CM
I80.1	Phlebitis and thrombophlebitis of femoral vein	Diagnosis	ICD-10-CM
I80.10	Phlebitis and thrombophlebitis of unspecified femoral vein	Diagnosis	ICD-10-CM
I80.11	Phlebitis and thrombophlebitis of right femoral vein	Diagnosis	ICD-10-CM
I80.12	Phlebitis and thrombophlebitis of left femoral vein	Diagnosis	ICD-10-CM
I80.13	Phlebitis and thrombophlebitis of femoral vein, bilateral	Diagnosis	ICD-10-CM
I80.2	Phlebitis and thrombophlebitis of other and unspecified deep vessels of lower extremities	Diagnosis	ICD-10-CM
I80.20	Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities	Diagnosis	ICD-10-CM
I80.201	Phlebitis and thrombophlebitis of unspecified deep vessels of right lower extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I80.202	Phlebitis and thrombophlebitis of unspecified deep vessels of left lower extremity	Diagnosis	ICD-10-CM
I80.203	Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities, bilateral	Diagnosis	ICD-10-CM
I80.209	Phlebitis and thrombophlebitis of unspecified deep vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
I80.21	Phlebitis and thrombophlebitis of iliac vein	Diagnosis	ICD-10-CM
I80.211	Phlebitis and thrombophlebitis of right iliac vein	Diagnosis	ICD-10-CM
I80.212	Phlebitis and thrombophlebitis of left iliac vein	Diagnosis	ICD-10-CM
I80.213	Phlebitis and thrombophlebitis of iliac vein, bilateral	Diagnosis	ICD-10-CM
I80.219	Phlebitis and thrombophlebitis of unspecified iliac vein	Diagnosis	ICD-10-CM
I80.22	Phlebitis and thrombophlebitis of popliteal vein	Diagnosis	ICD-10-CM
I80.221	Phlebitis and thrombophlebitis of right popliteal vein	Diagnosis	ICD-10-CM
I80.222	Phlebitis and thrombophlebitis of left popliteal vein	Diagnosis	ICD-10-CM
I80.223	Phlebitis and thrombophlebitis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
I80.229	Phlebitis and thrombophlebitis of unspecified popliteal vein	Diagnosis	ICD-10-CM
I80.23	Phlebitis and thrombophlebitis of tibial vein	Diagnosis	ICD-10-CM
I80.231	Phlebitis and thrombophlebitis of right tibial vein	Diagnosis	ICD-10-CM
I80.232	Phlebitis and thrombophlebitis of left tibial vein	Diagnosis	ICD-10-CM
I80.233	Phlebitis and thrombophlebitis of tibial vein, bilateral	Diagnosis	ICD-10-CM
I80.239	Phlebitis and thrombophlebitis of unspecified tibial vein	Diagnosis	ICD-10-CM
I80.24	Phlebitis and thrombophlebitis of peroneal vein	Diagnosis	ICD-10-CM
I80.241	Phlebitis and thrombophlebitis of right peroneal vein	Diagnosis	ICD-10-CM
I80.242	Phlebitis and thrombophlebitis of left peroneal vein	Diagnosis	ICD-10-CM
I80.243	Phlebitis and thrombophlebitis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
I80.249	Phlebitis and thrombophlebitis of unspecified peroneal vein	Diagnosis	ICD-10-CM
I80.25	Phlebitis and thrombophlebitis of calf muscular vein	Diagnosis	ICD-10-CM
I80.251	Phlebitis and thrombophlebitis of right calf muscular vein	Diagnosis	ICD-10-CM
I80.252	Phlebitis and thrombophlebitis of left calf muscular vein	Diagnosis	ICD-10-CM
I80.253	Phlebitis and thrombophlebitis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
I80.259	Phlebitis and thrombophlebitis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
I80.29	Phlebitis and thrombophlebitis of other deep vessels of lower extremities	Diagnosis	ICD-10-CM
I80.291	Phlebitis and thrombophlebitis of other deep vessels of right lower extremity	Diagnosis	ICD-10-CM
I80.292	Phlebitis and thrombophlebitis of other deep vessels of left lower extremity	Diagnosis	ICD-10-CM
I80.293	Phlebitis and thrombophlebitis of other deep vessels of lower extremity, bilateral	Diagnosis	ICD-10-CM
I80.299	Phlebitis and thrombophlebitis of other deep vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
I80.3	Phlebitis and thrombophlebitis of lower extremities, unspecified	Diagnosis	ICD-10-CM
I80.8	Phlebitis and thrombophlebitis of other sites	Diagnosis	ICD-10-CM
I80.9	Phlebitis and thrombophlebitis of unspecified site	Diagnosis	ICD-10-CM
I81	Portal vein thrombosis	Diagnosis	ICD-10-CM
I82	Other venous embolism and thrombosis	Diagnosis	ICD-10-CM
I82.0	Budd-Chiari syndrome	Diagnosis	ICD-10-CM
I82.1	Thrombophlebitis migrans	Diagnosis	ICD-10-CM
I82.2	Embolism and thrombosis of vena cava and other thoracic veins	Diagnosis	ICD-10-CM
I82.21	Embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
I82.210	Acute embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
I82.211	Chronic embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
I82.22	Embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM
I82.220	Acute embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM
I82.221	Chronic embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I82.29	Embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
I82.290	Acute embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
I82.291	Chronic embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
I82.3	Embolism and thrombosis of renal vein	Diagnosis	ICD-10-CM
I82.4	Acute embolism and thrombosis of deep veins of lower extremity	Diagnosis	ICD-10-CM
I82.40	Acute embolism and thrombosis of unspecified deep veins of lower extremity	Diagnosis	ICD-10-CM
I82.401	Acute embolism and thrombosis of unspecified deep veins of right lower extremity	Diagnosis	ICD-10-CM
I82.402	Acute embolism and thrombosis of unspecified deep veins of left lower extremity	Diagnosis	ICD-10-CM
I82.403	Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.409	Acute embolism and thrombosis of unspecified deep veins of unspecified lower extremity	Diagnosis	ICD-10-CM
I82.41	Acute embolism and thrombosis of femoral vein	Diagnosis	ICD-10-CM
I82.411	Acute embolism and thrombosis of right femoral vein	Diagnosis	ICD-10-CM
I82.412	Acute embolism and thrombosis of left femoral vein	Diagnosis	ICD-10-CM
I82.413	Acute embolism and thrombosis of femoral vein, bilateral	Diagnosis	ICD-10-CM
I82.419	Acute embolism and thrombosis of unspecified femoral vein	Diagnosis	ICD-10-CM
I82.42	Acute embolism and thrombosis of iliac vein	Diagnosis	ICD-10-CM
I82.421	Acute embolism and thrombosis of right iliac vein	Diagnosis	ICD-10-CM
I82.422	Acute embolism and thrombosis of left iliac vein	Diagnosis	ICD-10-CM
I82.423	Acute embolism and thrombosis of iliac vein, bilateral	Diagnosis	ICD-10-CM
I82.429	Acute embolism and thrombosis of unspecified iliac vein	Diagnosis	ICD-10-CM
I82.43	Acute embolism and thrombosis of popliteal vein	Diagnosis	ICD-10-CM
I82.431	Acute embolism and thrombosis of right popliteal vein	Diagnosis	ICD-10-CM
I82.432	Acute embolism and thrombosis of left popliteal vein	Diagnosis	ICD-10-CM
I82.433	Acute embolism and thrombosis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
I82.439	Acute embolism and thrombosis of unspecified popliteal vein	Diagnosis	ICD-10-CM
I82.44	Acute embolism and thrombosis of tibial vein	Diagnosis	ICD-10-CM
I82.441	Acute embolism and thrombosis of right tibial vein	Diagnosis	ICD-10-CM
I82.442	Acute embolism and thrombosis of left tibial vein	Diagnosis	ICD-10-CM
I82.443	Acute embolism and thrombosis of tibial vein, bilateral	Diagnosis	ICD-10-CM
I82.449	Acute embolism and thrombosis of unspecified tibial vein	Diagnosis	ICD-10-CM
I82.45	Acute embolism and thrombosis of peroneal vein	Diagnosis	ICD-10-CM
I82.451	Acute embolism and thrombosis of right peroneal vein	Diagnosis	ICD-10-CM
I82.452	Acute embolism and thrombosis of left peroneal vein	Diagnosis	ICD-10-CM
I82.453	Acute embolism and thrombosis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
I82.459	Acute embolism and thrombosis of unspecified peroneal vein	Diagnosis	ICD-10-CM
I82.46	Acute embolism and thrombosis of calf muscular vein	Diagnosis	ICD-10-CM
I82.461	Acute embolism and thrombosis of right calf muscular vein	Diagnosis	ICD-10-CM
I82.462	Acute embolism and thrombosis of left calf muscular vein	Diagnosis	ICD-10-CM
I82.463	Acute embolism and thrombosis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
I82.469	Acute embolism and thrombosis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
I82.49	Acute embolism and thrombosis of other specified deep vein of lower extremity	Diagnosis	ICD-10-CM
I82.491	Acute embolism and thrombosis of other specified deep vein of right lower extremity	Diagnosis	ICD-10-CM
I82.492	Acute embolism and thrombosis of other specified deep vein of left lower extremity	Diagnosis	ICD-10-CM
I82.493	Acute embolism and thrombosis of other specified deep vein of lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.499	Acute embolism and thrombosis of other specified deep vein of unspecified lower extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I82.4Y	Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Y1	Acute embolism and thrombosis of unspecified deep veins of right proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Y2	Acute embolism and thrombosis of unspecified deep veins of left proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Y3	Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.4Y9	Acute embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Z	Acute embolism and thrombosis of unspecified deep veins of distal lower extremity	Diagnosis	ICD-10-CM
I82.4Z1	Acute embolism and thrombosis of unspecified deep veins of right distal lower extremity	Diagnosis	ICD-10-CM
I82.4Z2	Acute embolism and thrombosis of unspecified deep veins of left distal lower extremity	Diagnosis	ICD-10-CM
I82.4Z3	Acute embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.4Z9	Acute embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity	Diagnosis	ICD-10-CM
I82.5	Chronic embolism and thrombosis of deep veins of lower extremity	Diagnosis	ICD-10-CM
I82.50	Chronic embolism and thrombosis of unspecified deep veins of lower extremity	Diagnosis	ICD-10-CM
I82.501	Chronic embolism and thrombosis of unspecified deep veins of right lower extremity	Diagnosis	ICD-10-CM
I82.502	Chronic embolism and thrombosis of unspecified deep veins of left lower extremity	Diagnosis	ICD-10-CM
I82.503	Chronic embolism and thrombosis of unspecified deep veins of lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.509	Chronic embolism and thrombosis of unspecified deep veins of unspecified lower extremity	Diagnosis	ICD-10-CM
I82.51	Chronic embolism and thrombosis of femoral vein	Diagnosis	ICD-10-CM
I82.511	Chronic embolism and thrombosis of right femoral vein	Diagnosis	ICD-10-CM
I82.512	Chronic embolism and thrombosis of left femoral vein	Diagnosis	ICD-10-CM
I82.513	Chronic embolism and thrombosis of femoral vein, bilateral	Diagnosis	ICD-10-CM
I82.519	Chronic embolism and thrombosis of unspecified femoral vein	Diagnosis	ICD-10-CM
I82.52	Chronic embolism and thrombosis of iliac vein	Diagnosis	ICD-10-CM
I82.521	Chronic embolism and thrombosis of right iliac vein	Diagnosis	ICD-10-CM
I82.522	Chronic embolism and thrombosis of left iliac vein	Diagnosis	ICD-10-CM
I82.523	Chronic embolism and thrombosis of iliac vein, bilateral	Diagnosis	ICD-10-CM
I82.529	Chronic embolism and thrombosis of unspecified iliac vein	Diagnosis	ICD-10-CM
I82.53	Chronic embolism and thrombosis of popliteal vein	Diagnosis	ICD-10-CM
I82.531	Chronic embolism and thrombosis of right popliteal vein	Diagnosis	ICD-10-CM
I82.532	Chronic embolism and thrombosis of left popliteal vein	Diagnosis	ICD-10-CM
I82.533	Chronic embolism and thrombosis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
I82.539	Chronic embolism and thrombosis of unspecified popliteal vein	Diagnosis	ICD-10-CM
I82.54	Chronic embolism and thrombosis of tibial vein	Diagnosis	ICD-10-CM
I82.541	Chronic embolism and thrombosis of right tibial vein	Diagnosis	ICD-10-CM
I82.542	Chronic embolism and thrombosis of left tibial vein	Diagnosis	ICD-10-CM
I82.543	Chronic embolism and thrombosis of tibial vein, bilateral	Diagnosis	ICD-10-CM
I82.549	Chronic embolism and thrombosis of unspecified tibial vein	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I82.55	Chronic embolism and thrombosis of peroneal vein	Diagnosis	ICD-10-CM
I82.551	Chronic embolism and thrombosis of right peroneal vein	Diagnosis	ICD-10-CM
I82.552	Chronic embolism and thrombosis of left peroneal vein	Diagnosis	ICD-10-CM
I82.553	Chronic embolism and thrombosis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
I82.559	Chronic embolism and thrombosis of unspecified peroneal vein	Diagnosis	ICD-10-CM
I82.56	Chronic embolism and thrombosis of calf muscular vein	Diagnosis	ICD-10-CM
I82.561	Chronic embolism and thrombosis of right calf muscular vein	Diagnosis	ICD-10-CM
I82.562	Chronic embolism and thrombosis of left calf muscular vein	Diagnosis	ICD-10-CM
I82.563	Chronic embolism and thrombosis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
I82.569	Chronic embolism and thrombosis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
I82.59	Chronic embolism and thrombosis of other specified deep vein of lower extremity	Diagnosis	ICD-10-CM
I82.591	Chronic embolism and thrombosis of other specified deep vein of right lower extremity	Diagnosis	ICD-10-CM
I82.592	Chronic embolism and thrombosis of other specified deep vein of left lower extremity	Diagnosis	ICD-10-CM
I82.593	Chronic embolism and thrombosis of other specified deep vein of lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.599	Chronic embolism and thrombosis of other specified deep vein of unspecified lower extremity	Diagnosis	ICD-10-CM
I82.5Y	Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Y1	Chronic embolism and thrombosis of unspecified deep veins of right proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Y2	Chronic embolism and thrombosis of unspecified deep veins of left proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Y3	Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.5Y9	Chronic embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Z	Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity	Diagnosis	ICD-10-CM
I82.5Z1	Chronic embolism and thrombosis of unspecified deep veins of right distal lower extremity	Diagnosis	ICD-10-CM
I82.5Z2	Chronic embolism and thrombosis of unspecified deep veins of left distal lower extremity	Diagnosis	ICD-10-CM
I82.5Z3	Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.5Z9	Chronic embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity	Diagnosis	ICD-10-CM
I82.6	Acute embolism and thrombosis of veins of upper extremity	Diagnosis	ICD-10-CM
I82.60	Acute embolism and thrombosis of unspecified veins of upper extremity	Diagnosis	ICD-10-CM
I82.601	Acute embolism and thrombosis of unspecified veins of right upper extremity	Diagnosis	ICD-10-CM
I82.602	Acute embolism and thrombosis of unspecified veins of left upper extremity	Diagnosis	ICD-10-CM
I82.603	Acute embolism and thrombosis of unspecified veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.609	Acute embolism and thrombosis of unspecified veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.61	Acute embolism and thrombosis of superficial veins of upper extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I82.611	Acute embolism and thrombosis of superficial veins of right upper extremity	Diagnosis	ICD-10-CM
I82.612	Acute embolism and thrombosis of superficial veins of left upper extremity	Diagnosis	ICD-10-CM
I82.613	Acute embolism and thrombosis of superficial veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.619	Acute embolism and thrombosis of superficial veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.62	Acute embolism and thrombosis of deep veins of upper extremity	Diagnosis	ICD-10-CM
I82.621	Acute embolism and thrombosis of deep veins of right upper extremity	Diagnosis	ICD-10-CM
I82.622	Acute embolism and thrombosis of deep veins of left upper extremity	Diagnosis	ICD-10-CM
I82.623	Acute embolism and thrombosis of deep veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.629	Acute embolism and thrombosis of deep veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.7	Chronic embolism and thrombosis of veins of upper extremity	Diagnosis	ICD-10-CM
I82.70	Chronic embolism and thrombosis of unspecified veins of upper extremity	Diagnosis	ICD-10-CM
I82.701	Chronic embolism and thrombosis of unspecified veins of right upper extremity	Diagnosis	ICD-10-CM
I82.702	Chronic embolism and thrombosis of unspecified veins of left upper extremity	Diagnosis	ICD-10-CM
I82.703	Chronic embolism and thrombosis of unspecified veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.709	Chronic embolism and thrombosis of unspecified veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.71	Chronic embolism and thrombosis of superficial veins of upper extremity	Diagnosis	ICD-10-CM
I82.711	Chronic embolism and thrombosis of superficial veins of right upper extremity	Diagnosis	ICD-10-CM
I82.712	Chronic embolism and thrombosis of superficial veins of left upper extremity	Diagnosis	ICD-10-CM
I82.713	Chronic embolism and thrombosis of superficial veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.719	Chronic embolism and thrombosis of superficial veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.72	Chronic embolism and thrombosis of deep veins of upper extremity	Diagnosis	ICD-10-CM
I82.721	Chronic embolism and thrombosis of deep veins of right upper extremity	Diagnosis	ICD-10-CM
I82.722	Chronic embolism and thrombosis of deep veins of left upper extremity	Diagnosis	ICD-10-CM
I82.723	Chronic embolism and thrombosis of deep veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.729	Chronic embolism and thrombosis of deep veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.8	Embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
I82.81	Embolism and thrombosis of superficial veins of lower extremities	Diagnosis	ICD-10-CM
I82.811	Embolism and thrombosis of superficial veins of right lower extremity	Diagnosis	ICD-10-CM
I82.812	Embolism and thrombosis of superficial veins of left lower extremity	Diagnosis	ICD-10-CM
I82.813	Embolism and thrombosis of superficial veins of lower extremities, bilateral	Diagnosis	ICD-10-CM
I82.819	Embolism and thrombosis of superficial veins of unspecified lower extremity	Diagnosis	ICD-10-CM
I82.89	Embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
I82.890	Acute embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
I82.891	Chronic embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
I82.9	Embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
I82.90	Acute embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
I82.91	Chronic embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
I82.A	Embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
I82.A1	Acute embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
I82.A11	Acute embolism and thrombosis of right axillary vein	Diagnosis	ICD-10-CM
I82.A12	Acute embolism and thrombosis of left axillary vein	Diagnosis	ICD-10-CM
I82.A13	Acute embolism and thrombosis of axillary vein, bilateral	Diagnosis	ICD-10-CM
I82.A19	Acute embolism and thrombosis of unspecified axillary vein	Diagnosis	ICD-10-CM
I82.A2	Chronic embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
I82.A21	Chronic embolism and thrombosis of right axillary vein	Diagnosis	ICD-10-CM
I82.A22	Chronic embolism and thrombosis of left axillary vein	Diagnosis	ICD-10-CM
I82.A23	Chronic embolism and thrombosis of axillary vein, bilateral	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I82.A29	Chronic embolism and thrombosis of unspecified axillary vein	Diagnosis	ICD-10-CM
I82.B	Embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
I82.B1	Acute embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
I82.B11	Acute embolism and thrombosis of right subclavian vein	Diagnosis	ICD-10-CM
I82.B12	Acute embolism and thrombosis of left subclavian vein	Diagnosis	ICD-10-CM
I82.B13	Acute embolism and thrombosis of subclavian vein, bilateral	Diagnosis	ICD-10-CM
I82.B19	Acute embolism and thrombosis of unspecified subclavian vein	Diagnosis	ICD-10-CM
I82.B2	Chronic embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
I82.B21	Chronic embolism and thrombosis of right subclavian vein	Diagnosis	ICD-10-CM
I82.B22	Chronic embolism and thrombosis of left subclavian vein	Diagnosis	ICD-10-CM
I82.B23	Chronic embolism and thrombosis of subclavian vein, bilateral	Diagnosis	ICD-10-CM
I82.B29	Chronic embolism and thrombosis of unspecified subclavian vein	Diagnosis	ICD-10-CM
I82.C	Embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
I82.C1	Acute embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
I82.C11	Acute embolism and thrombosis of right internal jugular vein	Diagnosis	ICD-10-CM
I82.C12	Acute embolism and thrombosis of left internal jugular vein	Diagnosis	ICD-10-CM
I82.C13	Acute embolism and thrombosis of internal jugular vein, bilateral	Diagnosis	ICD-10-CM
I82.C19	Acute embolism and thrombosis of unspecified internal jugular vein	Diagnosis	ICD-10-CM
I82.C2	Chronic embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
I82.C21	Chronic embolism and thrombosis of right internal jugular vein	Diagnosis	ICD-10-CM
I82.C22	Chronic embolism and thrombosis of left internal jugular vein	Diagnosis	ICD-10-CM
I82.C23	Chronic embolism and thrombosis of internal jugular vein, bilateral	Diagnosis	ICD-10-CM
I82.C29	Chronic embolism and thrombosis of unspecified internal jugular vein	Diagnosis	ICD-10-CM
I83	Varicose veins of lower extremities	Diagnosis	ICD-10-CM
I83.0	Varicose veins of lower extremities with ulcer	Diagnosis	ICD-10-CM
I83.00	Varicose veins of unspecified lower extremity with ulcer	Diagnosis	ICD-10-CM
I83.001	Varicose veins of unspecified lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
I83.002	Varicose veins of unspecified lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
I83.003	Varicose veins of unspecified lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
I83.004	Varicose veins of unspecified lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
I83.005	Varicose veins of unspecified lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
I83.008	Varicose veins of unspecified lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
I83.009	Varicose veins of unspecified lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
I83.01	Varicose veins of right lower extremity with ulcer	Diagnosis	ICD-10-CM
I83.011	Varicose veins of right lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
I83.012	Varicose veins of right lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
I83.013	Varicose veins of right lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
I83.014	Varicose veins of right lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
I83.015	Varicose veins of right lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
I83.018	Varicose veins of right lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
I83.019	Varicose veins of right lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
I83.02	Varicose veins of left lower extremity with ulcer	Diagnosis	ICD-10-CM
I83.021	Varicose veins of left lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
I83.022	Varicose veins of left lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
I83.023	Varicose veins of left lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
I83.024	Varicose veins of left lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
I83.025	Varicose veins of left lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
I83.028	Varicose veins of left lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
I83.029	Varicose veins of left lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
I83.1	Varicose veins of lower extremities with inflammation	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I83.10	Varicose veins of unspecified lower extremity with inflammation	Diagnosis	ICD-10-CM
I83.11	Varicose veins of right lower extremity with inflammation	Diagnosis	ICD-10-CM
I83.12	Varicose veins of left lower extremity with inflammation	Diagnosis	ICD-10-CM
I83.2	Varicose veins of lower extremities with both ulcer and inflammation	Diagnosis	ICD-10-CM
I83.20	Varicose veins of unspecified lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
I83.201	Varicose veins of unspecified lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
I83.202	Varicose veins of unspecified lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
I83.203	Varicose veins of unspecified lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
I83.204	Varicose veins of unspecified lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
I83.205	Varicose veins of unspecified lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
I83.208	Varicose veins of unspecified lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
I83.209	Varicose veins of unspecified lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
I83.21	Varicose veins of right lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
I83.211	Varicose veins of right lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
I83.212	Varicose veins of right lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
I83.213	Varicose veins of right lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
I83.214	Varicose veins of right lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
I83.215	Varicose veins of right lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
I83.218	Varicose veins of right lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
I83.219	Varicose veins of right lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
I83.22	Varicose veins of left lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
I83.221	Varicose veins of left lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
I83.222	Varicose veins of left lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
I83.223	Varicose veins of left lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
I83.224	Varicose veins of left lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
I83.225	Varicose veins of left lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
I83.228	Varicose veins of left lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
I83.229	Varicose veins of left lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
I83.8	Varicose veins of lower extremities with other complications	Diagnosis	ICD-10-CM
I83.81	Varicose veins of lower extremities with pain	Diagnosis	ICD-10-CM
I83.811	Varicose veins of right lower extremity with pain	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I83.812	Varicose veins of left lower extremity with pain	Diagnosis	ICD-10-CM
I83.813	Varicose veins of bilateral lower extremities with pain	Diagnosis	ICD-10-CM
I83.819	Varicose veins of unspecified lower extremity with pain	Diagnosis	ICD-10-CM
I83.89	Varicose veins of lower extremities with other complications	Diagnosis	ICD-10-CM
I83.891	Varicose veins of right lower extremity with other complications	Diagnosis	ICD-10-CM
I83.892	Varicose veins of left lower extremity with other complications	Diagnosis	ICD-10-CM
I83.893	Varicose veins of bilateral lower extremities with other complications	Diagnosis	ICD-10-CM
I83.899	Varicose veins of unspecified lower extremity with other complications	Diagnosis	ICD-10-CM
I83.9	Asymptomatic varicose veins of lower extremities	Diagnosis	ICD-10-CM
I83.90	Asymptomatic varicose veins of unspecified lower extremity	Diagnosis	ICD-10-CM
I83.91	Asymptomatic varicose veins of right lower extremity	Diagnosis	ICD-10-CM
I83.92	Asymptomatic varicose veins of left lower extremity	Diagnosis	ICD-10-CM
I83.93	Asymptomatic varicose veins of bilateral lower extremities	Diagnosis	ICD-10-CM
I85	Esophageal varices	Diagnosis	ICD-10-CM
I85.0	Esophageal varices	Diagnosis	ICD-10-CM
I85.00	Esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.01	Esophageal varices with bleeding	Diagnosis	ICD-10-CM
I85.1	Secondary esophageal varices	Diagnosis	ICD-10-CM
I85.10	Secondary esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.11	Secondary esophageal varices with bleeding	Diagnosis	ICD-10-CM
I86	Varicose veins of other sites	Diagnosis	ICD-10-CM
I86.0	Sublingual varices	Diagnosis	ICD-10-CM
I86.1	Scrotal varices	Diagnosis	ICD-10-CM
I86.2	Pelvic varices	Diagnosis	ICD-10-CM
I86.3	Vulval varices	Diagnosis	ICD-10-CM
I86.4	Gastric varices	Diagnosis	ICD-10-CM
I86.8	Varicose veins of other specified sites	Diagnosis	ICD-10-CM
I87	Other disorders of veins	Diagnosis	ICD-10-CM
I87.0	Postthrombotic syndrome	Diagnosis	ICD-10-CM
I87.00	Postthrombotic syndrome without complications	Diagnosis	ICD-10-CM
I87.001	Postthrombotic syndrome without complications of right lower extremity	Diagnosis	ICD-10-CM
I87.002	Postthrombotic syndrome without complications of left lower extremity	Diagnosis	ICD-10-CM
I87.003	Postthrombotic syndrome without complications of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.009	Postthrombotic syndrome without complications of unspecified extremity	Diagnosis	ICD-10-CM
I87.01	Postthrombotic syndrome with ulcer	Diagnosis	ICD-10-CM
I87.011	Postthrombotic syndrome with ulcer of right lower extremity	Diagnosis	ICD-10-CM
I87.012	Postthrombotic syndrome with ulcer of left lower extremity	Diagnosis	ICD-10-CM
I87.013	Postthrombotic syndrome with ulcer of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.019	Postthrombotic syndrome with ulcer of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.02	Postthrombotic syndrome with inflammation	Diagnosis	ICD-10-CM
I87.021	Postthrombotic syndrome with inflammation of right lower extremity	Diagnosis	ICD-10-CM
I87.022	Postthrombotic syndrome with inflammation of left lower extremity	Diagnosis	ICD-10-CM
I87.023	Postthrombotic syndrome with inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.029	Postthrombotic syndrome with inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.03	Postthrombotic syndrome with ulcer and inflammation	Diagnosis	ICD-10-CM
I87.031	Postthrombotic syndrome with ulcer and inflammation of right lower extremity	Diagnosis	ICD-10-CM
I87.032	Postthrombotic syndrome with ulcer and inflammation of left lower extremity	Diagnosis	ICD-10-CM
I87.033	Postthrombotic syndrome with ulcer and inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I87.039	Postthrombotic syndrome with ulcer and inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.09	Postthrombotic syndrome with other complications	Diagnosis	ICD-10-CM
I87.091	Postthrombotic syndrome with other complications of right lower extremity	Diagnosis	ICD-10-CM
I87.092	Postthrombotic syndrome with other complications of left lower extremity	Diagnosis	ICD-10-CM
I87.093	Postthrombotic syndrome with other complications of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.099	Postthrombotic syndrome with other complications of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.1	Compression of vein	Diagnosis	ICD-10-CM
I87.2	Venous insufficiency (chronic) (peripheral)	Diagnosis	ICD-10-CM
I87.3	Chronic venous hypertension (idiopathic)	Diagnosis	ICD-10-CM
I87.30	Chronic venous hypertension (idiopathic) without complications	Diagnosis	ICD-10-CM
I87.301	Chronic venous hypertension (idiopathic) without complications of right lower extremity	Diagnosis	ICD-10-CM
I87.302	Chronic venous hypertension (idiopathic) without complications of left lower extremity	Diagnosis	ICD-10-CM
I87.303	Chronic venous hypertension (idiopathic) without complications of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.309	Chronic venous hypertension (idiopathic) without complications of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.31	Chronic venous hypertension (idiopathic) with ulcer	Diagnosis	ICD-10-CM
I87.311	Chronic venous hypertension (idiopathic) with ulcer of right lower extremity	Diagnosis	ICD-10-CM
I87.312	Chronic venous hypertension (idiopathic) with ulcer of left lower extremity	Diagnosis	ICD-10-CM
I87.313	Chronic venous hypertension (idiopathic) with ulcer of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.319	Chronic venous hypertension (idiopathic) with ulcer of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.32	Chronic venous hypertension (idiopathic) with inflammation	Diagnosis	ICD-10-CM
I87.321	Chronic venous hypertension (idiopathic) with inflammation of right lower extremity	Diagnosis	ICD-10-CM
I87.322	Chronic venous hypertension (idiopathic) with inflammation of left lower extremity	Diagnosis	ICD-10-CM
I87.323	Chronic venous hypertension (idiopathic) with inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.329	Chronic venous hypertension (idiopathic) with inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.33	Chronic venous hypertension (idiopathic) with ulcer and inflammation	Diagnosis	ICD-10-CM
I87.331	Chronic venous hypertension (idiopathic) with ulcer and inflammation of right lower extremity	Diagnosis	ICD-10-CM
I87.332	Chronic venous hypertension (idiopathic) with ulcer and inflammation of left lower extremity	Diagnosis	ICD-10-CM
I87.333	Chronic venous hypertension (idiopathic) with ulcer and inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.339	Chronic venous hypertension (idiopathic) with ulcer and inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.39	Chronic venous hypertension (idiopathic) with other complications	Diagnosis	ICD-10-CM
I87.391	Chronic venous hypertension (idiopathic) with other complications of right lower extremity	Diagnosis	ICD-10-CM
I87.392	Chronic venous hypertension (idiopathic) with other complications of left lower extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I87.393	Chronic venous hypertension (idiopathic) with other complications of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.399	Chronic venous hypertension (idiopathic) with other complications of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.8	Other specified disorders of veins	Diagnosis	ICD-10-CM
I87.9	Disorder of vein, unspecified	Diagnosis	ICD-10-CM
I88	Nonspecific lymphadenitis	Diagnosis	ICD-10-CM
I88.0	Nonspecific mesenteric lymphadenitis	Diagnosis	ICD-10-CM
I88.1	Chronic lymphadenitis, except mesenteric	Diagnosis	ICD-10-CM
I88.8	Other nonspecific lymphadenitis	Diagnosis	ICD-10-CM
I88.9	Nonspecific lymphadenitis, unspecified	Diagnosis	ICD-10-CM
I89	Other noninfective disorders of lymphatic vessels and lymph nodes	Diagnosis	ICD-10-CM
I89.0	Lymphedema, not elsewhere classified	Diagnosis	ICD-10-CM
I89.1	Lymphangitis	Diagnosis	ICD-10-CM
I89.8	Other specified noninfective disorders of lymphatic vessels and lymph nodes	Diagnosis	ICD-10-CM
I89.9	Noninfective disorder of lymphatic vessels and lymph nodes, unspecified	Diagnosis	ICD-10-CM
I95	Hypotension	Diagnosis	ICD-10-CM
I95.0	Idiopathic hypotension	Diagnosis	ICD-10-CM
I95.1	Orthostatic hypotension	Diagnosis	ICD-10-CM
I95.2	Hypotension due to drugs	Diagnosis	ICD-10-CM
I95.3	Hypotension of hemodialysis	Diagnosis	ICD-10-CM
I95.8	Other hypotension	Diagnosis	ICD-10-CM
I95.81	Postprocedural hypotension	Diagnosis	ICD-10-CM
I95.89	Other hypotension	Diagnosis	ICD-10-CM
I95.9	Hypotension, unspecified	Diagnosis	ICD-10-CM
I96	Gangrene, not elsewhere classified	Diagnosis	ICD-10-CM
I97	Intraoperative and postprocedural complications and disorders of circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
I97.0	Postcardiotomy syndrome	Diagnosis	ICD-10-CM
I97.1	Other postprocedural cardiac functional disturbances	Diagnosis	ICD-10-CM
I97.11	Postprocedural cardiac insufficiency	Diagnosis	ICD-10-CM
I97.110	Postprocedural cardiac insufficiency following cardiac surgery	Diagnosis	ICD-10-CM
I97.111	Postprocedural cardiac insufficiency following other surgery	Diagnosis	ICD-10-CM
I97.12	Postprocedural cardiac arrest	Diagnosis	ICD-10-CM
I97.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM
I97.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM
I97.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
I97.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
I97.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
I97.19	Other postprocedural cardiac functional disturbances	Diagnosis	ICD-10-CM
I97.190	Other postprocedural cardiac functional disturbances following cardiac surgery	Diagnosis	ICD-10-CM
I97.191	Other postprocedural cardiac functional disturbances following other surgery	Diagnosis	ICD-10-CM
I97.2	Postmastectomy lymphedema syndrome	Diagnosis	ICD-10-CM
I97.3	Postprocedural hypertension	Diagnosis	ICD-10-CM
I97.4	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a procedure	Diagnosis	ICD-10-CM
I97.41	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a circulatory system procedure	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I97.410	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a cardiac catheterization	Diagnosis	ICD-10-CM
I97.411	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a cardiac bypass	Diagnosis	ICD-10-CM
I97.418	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating other circulatory system procedure	Diagnosis	ICD-10-CM
I97.42	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I97.5	Accidental puncture and laceration of a circulatory system organ or structure during a procedure	Diagnosis	ICD-10-CM
I97.51	Accidental puncture and laceration of a circulatory system organ or structure during a circulatory system procedure	Diagnosis	ICD-10-CM
I97.52	Accidental puncture and laceration of a circulatory system organ or structure during other procedure	Diagnosis	ICD-10-CM
I97.6	Postprocedural hemorrhage, hematoma and seroma of a circulatory system organ or structure following a procedure	Diagnosis	ICD-10-CM
I97.61	Postprocedural hemorrhage of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM
I97.610	Postprocedural hemorrhage of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
I97.611	Postprocedural hemorrhage of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
I97.618	Postprocedural hemorrhage of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
I97.62	Postprocedural hemorrhage, hematoma and seroma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
I97.620	Postprocedural hemorrhage of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
I97.621	Postprocedural hematoma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
I97.622	Postprocedural seroma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
I97.63	Postprocedural hematoma of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM
I97.630	Postprocedural hematoma of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
I97.631	Postprocedural hematoma of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
I97.638	Postprocedural hematoma of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
I97.64	Postprocedural seroma of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I97.640	Postprocedural seroma of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
I97.641	Postprocedural seroma of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
I97.648	Postprocedural seroma of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
I97.7	Intraoperative cardiac functional disturbances	Diagnosis	ICD-10-CM
I97.71	Intraoperative cardiac arrest	Diagnosis	ICD-10-CM
I97.710	Intraoperative cardiac arrest during cardiac surgery	Diagnosis	ICD-10-CM
I97.711	Intraoperative cardiac arrest during other surgery	Diagnosis	ICD-10-CM
I97.79	Other intraoperative cardiac functional disturbances	Diagnosis	ICD-10-CM
I97.790	Other intraoperative cardiac functional disturbances during cardiac surgery	Diagnosis	ICD-10-CM
I97.791	Other intraoperative cardiac functional disturbances during other surgery	Diagnosis	ICD-10-CM
I97.8	Other intraoperative and postprocedural complications and disorders of the circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
I97.81	Intraoperative cerebrovascular infarction	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.82	Postprocedural cerebrovascular infarction	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
I97.88	Other intraoperative complications of the circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
I97.89	Other postprocedural complications and disorders of the circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
I99	Other and unspecified disorders of circulatory system	Diagnosis	ICD-10-CM
I99.8	Other disorder of circulatory system	Diagnosis	ICD-10-CM
I99.9	Unspecified disorder of circulatory system	Diagnosis	ICD-10-CM
Obstructive Sleep Apnea			
G47.3	Sleep apnea	Diagnosis	ICD-10-CM
G47.30	Sleep apnea, unspecified	Diagnosis	ICD-10-CM
G47.31	Primary central sleep apnea	Diagnosis	ICD-10-CM
G47.33	Obstructive sleep apnea (adult) (pediatric)	Diagnosis	ICD-10-CM
G47.37	Central sleep apnea in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.39	Other sleep apnea	Diagnosis	ICD-10-CM
R06.81	Apnea, not elsewhere classified	Diagnosis	ICD-10-CM
Hypertrophic Cardiomyopathy			
I42.1	Obstructive hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.2	Other hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I42.9	Cardiomyopathy, unspecified	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
O90.3	Peripartum cardiomyopathy	Diagnosis	ICD-10-CM
I42	Cardiomyopathy	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
A36.81	Diphtheritic cardiomyopathy	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
B33.24	Viral cardiomyopathy	Diagnosis	ICD-10-CM
I42.3	Endomyocardial (eosinophilic) disease	Diagnosis	ICD-10-CM
I42.4	Endocardial fibroelastosis	Diagnosis	ICD-10-CM
Tachyarrhythmia			
I46	Cardiac arrest	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I47	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
I47.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
I48	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
I48.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM
I49	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
I49.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
I49.02	Ventricular flutter	Diagnosis	ICD-10-CM
I49.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
I49.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
I49.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
I49.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.49	Other premature depolarization	Diagnosis	ICD-10-CM
I49.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
History of Serious Hypoglycemia			
E08.64	Diabetes mellitus due to underlying condition with hypoglycemia	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.64	Drug or chemical induced diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.64	Other specified diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E16.0	Drug-induced hypoglycemia without coma	Diagnosis	ICD-10-CM
E16.1	Other hypoglycemia	Diagnosis	ICD-10-CM
E16.2	Hypoglycemia, unspecified	Diagnosis	ICD-10-CM
P70.3	Iatrogenic neonatal hypoglycemia	Diagnosis	ICD-10-CM
P70.4	Other neonatal hypoglycemia	Diagnosis	ICD-10-CM

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
Alpha-Glucosidase Inhibitor	
acarbose	acarbose
acarbose	Precose
miglitol	miglitol
Amylin Analogs	
pramlintide acetate	SymlinPen 60
pramlintide acetate	SymlinPen 120
Dipeptidyl Peptidase 4 (DPP-4) Inhibitors	
alogliptin benzoate	alogliptin
alogliptin benzoate	Nesina
dapagliflozin propanediol/saxagliptin HCl	Qtern
empagliflozin/linagliptin	Glyxambi
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
linagliptin	Tradjenta
saxagliptin HCl	Onglyza
sitagliptin phosphate	Januvia
Incretin Mimetics	
dulaglutide	Trulicity
exenatide	Byetta
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
insulin degludec/liraglutide	Xultophy 100/3.6
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lixisenatide	Adlyxin
semaglutide	Ozempic
semaglutide	Rybelsus
semaglutide	Wegovy
tirzepatide	Mounjaro
Meglitinides	
nateglinide	nateglinide
repaglinide	repaglinide
repaglinide/metformin HCl	repaglinide-metformin
Insulin	
insulin aspart	insulin aspart U-100
insulin aspart	Novolog FlexPen U-100 Insulin
insulin aspart	Novolog PenFill U-100 Insulin
insulin aspart	Novolog U-100 Insulin aspart
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
insulin aspart (niacinamide)	Fiasp U-100 Insulin
insulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insulin
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100
insulin degludec	insulin degludec
insulin degludec	Tresiba FlexTouch U-100
insulin degludec	Tresiba FlexTouch U-200
insulin degludec	Tresiba U-100 Insulin
insulin detemir	Levemir FlexPen
insulin detemir	Levemir FlexTouch U-100 Insulin
insulin detemir	Levemir U-100 Insulin
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
insulin glargine,human recombinant analog	Basaglar Tempo Pen(U-100)Insln
insulin glargine,human recombinant analog	insulin glargine
insulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin
insulin glargine,human recombinant analog	Lantus U-100 Insulin
insulin glargine,human recombinant analog	Semglee Pen U-100 Insulin
insulin glargine,human recombinant analog	Semglee U-100 Insulin
insulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
insulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
insulin glargine-yfgn	insulin glargine-yfgn
insulin glargine-yfgn	Semglee(insulin glargine-yfgn)
insulin glargine-yfgn	Semglee(insulin glarg-yfgn)Pen
insulin glulisine	Apidra SoloStar U-100 Insulin
insulin glulisine	Apidra U-100 Insulin
insulin lispro	Admelog SoloStar U-100 Insulin
insulin lispro	Admelog U-100 Insulin lispro
insulin lispro	Humalog Junior KwikPen U-100
insulin lispro	Humalog KwikPen Insulin
insulin lispro	Humalog Tempo Pen(U-100)Insuln
insulin lispro	Humalog U-100 Insulin
insulin lispro	insulin lispro
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln
insulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
insulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
insulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
insulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insuln
insulin lispro-aabc	Lyumjev U-100 Insulin
insulin NPH human isophane	Humulin N NPH Insulin KwikPen
insulin NPH human isophane	Humulin N NPH U-100 Insulin
insulin NPH human isophane	Novolin N FlexPen
insulin NPH human isophane	Novolin N NPH U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
insulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
insulin regular, human	Afrezza
insulin regular, human	Humulin R Regular U-100 Insuln
insulin regular, human	Humulin R U-500 (Conc) Insulin
insulin regular, human	Humulin R U-500 (Conc) Kwikpen
insulin regular, human	Novolin R FlexPen
insulin regular, human	Novolin R Regular U-100 Insulin
insulin regular, human in 0.9 % sodium chloride	Myxredlin
Biguanides	
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/metformin HCl	Kazano
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate/metformin HCl	Segluromet

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
glipizide/metformin HCl	glipizide-metformin
glyburide/metformin HCl	glyburide-metformin
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glumetza
metformin HCl	metformin
metformin HCl	Riomet
metformin HCl	Riomet ER
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	pioglitazone-metformin
repaglinide/metformin HCl	repaglinide-metformin
saxagliptin HCl/metformin HCl	Kombiglyze XR
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors	
canagliflozin	Invokana
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/saxagliptin HCl	Qtern
empagliflozin	Jardiance
empagliflozin/linagliptin	Glyxambi
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
Sulfonylurea	
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	glipizide
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide/metformin HCl	glipizide-metformin
glyburide	glyburide
glyburide,micronized	glyburide micronized
glyburide,micronized	Glynase
glyburide/metformin HCl	glyburide-metformin
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
Thiazolidinedione	
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
alogliptin benzoate/pioglitazone HCl	Oseni
pioglitazone HCl	Actos
pioglitazone HCl	pioglitazone
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	pioglitazone-metformin
Other Antidiabetic Drugs (Bromocriptine, Mifepristone)	
bromocriptine mesylate	Cycloset
mifepristone	Korlym
Sodium Channel Blocker	
disopyramide phosphate	disopyramide phosphate
disopyramide phosphate	Norpace
disopyramide phosphate	Norpace CR
flecainide acetate	flecainide
lidocaine HCl in dextrose 5% in water/PF	lidocaine in 5 % dextrose (PF)

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
lidocaine HCl in sodium chloride, iso-osmotic/PF	lidocaine in NaCl,iso-osmo(PF)
lidocaine HCl/PF	lidocaine (PF)
lidocaine HCl/PF	Xylocaine (Cardiac) (PF)
mexiletine HCl	mexiletine
phenytoin sodium	phenytoin sodium
procainamide HCl	procainamide
propafenone HCl	propafenone
propafenone HCl	Rythmol SR
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate
Beta Blocker	
acebutolol HCl	acebutolol
atenolol	atenolol
atenolol	Tenormin
atenolol/chlorthalidone	atenolol-chlorthalidone
atenolol/chlorthalidone	Tenoretic 100
atenolol/chlorthalidone	Tenoretic 50
betaxolol HCl	betaxolol
bisoprolol fumarate	bisoprolol fumarate
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
canakinumab/PF	Ilaris (PF)
carvedilol	carvedilol
carvedilol	Coreg
carvedilol phosphate	carvedilol phosphate
carvedilol phosphate	Coreg CR
esmolol HCl	Brevibloc
esmolol HCl	esmolol
esmolol HCl in sodium chloride, iso-osmotic	Brevibloc in NaCl (iso-osm)
esmolol HCl in sodium chloride, iso-osmotic	esmolol in NaCl (iso-osm)
esmolol HCl in sterile water	esmolol in sterile water
labetalol HCl	labetalol
labetalol HCl in dextrose, iso-osmotic	labetalol in dextrose,iso-osm
labetalol HCl in sodium chloride, iso-osmotic	labetalol in NaCl (iso-osmot)
metoprolol succinate	Kaspargo Sprinkle
metoprolol succinate	metoprolol succinate
metoprolol succinate	Toprol XL
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol tartrate	Lopressor
metoprolol tartrate	metoprolol tartrate
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
nadolol	Corgard
nadolol	nadolol
nebivolol HCl	Bystolic
nebivolol HCl	nebivolol
pindolol	pindolol
propranolol HCl	Hemangeol
propranolol HCl	Inderal LA
propranolol HCl	Inderal XL
propranolol HCl	InnoPran XL
propranolol HCl	propranolol
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
sotalol HCl	Betapace
sotalol HCl	Betapace AF

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
sotalol HCl	Sorine
sotalol HCl	sotalol
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
timolol maleate	timolol maleate
Potassium Channel Blocker/Openers	
amiodarone HCl	amiodarone
amiodarone HCl	Pacerone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
bretylum tosylate	bretylum tosylate
dofetilide	dofetilide
dofetilide	Tikosyn
dronedarone HCl	Multaq
ibutilide fumarate	Corvert
ibutilide fumarate	ibutilide fumarate
Non-Dihydropyridine Calcium Channel Blockers	
diltiazem HCl	diltiazem HCl
verapamil HCl	verapamil
Digoxin	
digoxin	Digitek
digoxin	Digox
digoxin	digoxin
digoxin	Lanoxin
digoxin	Lanoxin Pediatric
Other Antiarrhythmic Agents	
adenosine	adenosine
Angiotensin-Converting-Enzyme (ACE) Inhibitors	
amlodipine besylate/benazepril HCl	amlodipine-benazepril
amlodipine besylate/benazepril HCl	Lotrel
benazepril HCl	benazepril
benazepril HCl	Lotensin
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
benazepril HCl/hydrochlorothiazide	Lotensin HCT
captopril	captopril
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
enalapril maleate	enalapril maleate
enalapril maleate	Epaned
enalapril maleate	Vasotec
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
enalapril maleate/hydrochlorothiazide	Vaseretic
enalaprilat dihydrate	enalaprilat
fosinopril sodium	fosinopril
fosinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
lisinopril	lisinopril
lisinopril	Prinivil
lisinopril	Qbrelis
lisinopril	Zestril
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
lisinopril/hydrochlorothiazide	Zestoretic
moexipril HCl	moexipril
perindopril arginine/amlodipine besylate	Prestalia
perindopril erbumine	perindopril erbumine
quinapril HCl	Accupril

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
quinapril HCl	quinapril
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
ramipril	Altace
ramipril	ramipril
trandolapril	trandolapril
trandolapril/verapamil HCl	Tarka
trandolapril/verapamil HCl	trandolapril-verapamil
Angiotensin II Receptor Blockers (ARBs)	
amlodipine besylate/olmesartan medoxomil	amlodipine-olmesartan
amlodipine besylate/olmesartan medoxomil	Azor
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
azilsartan medoxomil	Edarbi
azilsartan medoxomil/chlorthalidone	Edarbyclor
candesartan cilexetil	Atacand
candesartan cilexetil	candesartan
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
eprosartan mesylate	eprosartan
irbesartan	Avapro
irbesartan	irbesartan
irbesartan/hydrochlorothiazide	Avalide
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
losartan potassium	Cozaar
losartan potassium	losartan
losartan potassium/hydrochlorothiazide	Hyzaar
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
olmesartan medoxomil	Benicar
olmesartan medoxomil	olmesartan
olmesartan medoxomil/amlodipine	
besylate/hydrochlorothiazide	olmesartan-amlodipin-hcthiazid
olmesartan medoxomil/amlodipine	
besylate/hydrochlorothiazide	Tribenzor
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
sacubitril/valsartan	Entresto
telmisartan	Micardis
telmisartan	telmisartan
telmisartan/amlodipine besylate	telmisartan-amlodipine
telmisartan/amlodipine besylate	Twynsta
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
valsartan	Diovan
valsartan	valsartan
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
Dihydropyridines	
amlodipine benzoate	Katerzia
amlodipine besylate	amlodipine
amlodipine besylate	Norliqva
amlodipine besylate	Norvasc

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
amlodipine besylate/celecoxib	Consensi
clevipine butyrate	Cleviprex
felodipine	felodipine
isradipine	isradipine
levamlodipine maleate	Conjupri
levamlodipine maleate	levamlodipine
nicardipine HCl	Cardene IV
nicardipine HCl	nicardipine
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose
nicardipine in sodium chloride, iso-osmotic	Cardene IV in sodium chloride
nicardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)
nifedipine	nifedipine
nifedipine	Procardia
nifedipine	Procardia XL
nimodipine	nimodipine
nimodipine	Nymalize
nisoldipine	nisoldipine
nisoldipine	Sular
Diuretics	
acetazolamide	acetazolamide
acetazolamide sodium	acetazolamide sodium
amiloride HCl	amiloride
amiloride HCl/hydrochlorothiazide	amiloride-hydrochlorothiazide
bumetanide	bumetanide
chlorothiazide	Diuril
chlorothiazide sodium	chlorothiazide sodium
chlorothiazide sodium	Diuril IV
chlorthalidone	chlorthalidone
chlorthalidone	Thalitone
conivaptan HCl/dextrose 5 % in water	Vaprisol in 5 % dextrose
eplerenone	eplerenone
eplerenone	Inspra
ethacrynate sodium	ethacrynate sodium
ethacrynate sodium	Sodium Edecrin
ethacrynic acid	Edecrin
ethacrynic acid	ethacrynic acid
furosemide	Furoscix
furosemide	furosemide
furosemide	Lasix
furosemide in 0.9 % sodium chloride	furosemide in 0.9 % NaCl
hydrochlorothiazide	hydrochlorothiazide
indapamide	indapamide
methazolamide	methazolamide
metolazone	metolazone
spironolactone	Aldactone
spironolactone	CaroSpir
spironolactone	spironolactone
spironolactone/hydrochlorothiazide	Aldactazide
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz
tolvaptan	Samsca
tolvaptan	tolvaptan
torsemide	Soanz
torsemide	torsemide

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
triamterene	Dyrenium
triamterene	triamterene
triamterene/hydrochlorothiazide	Maxzide
triamterene/hydrochlorothiazide	Maxzide-25mg
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid
Other Antihypertensives	
aliskiren hemifumarate	aliskiren
aliskiren hemifumarate	Tekturna
aliskiren hemifumarate/hydrochlorothiazide	Tekturna HCT
atenolol/chlorthalidone	atenolol-chlorthalidone
atenolol/chlorthalidone	Tenoretic 100
atenolol/chlorthalidone	Tenoretic 50
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
clonidine	Catapres-TTS-1
clonidine	Catapres-TTS-2
clonidine	Catapres-TTS-3
clonidine	clonidine
clonidine HCl	clonidine HCl
clonidine HCl	Nexiclon XR
doxazosin mesylate	Cardura
doxazosin mesylate	Cardura XL
doxazosin mesylate	doxazosin
fenoldopam mesylate	Corlopam
finerenone	Kerendia
guanfacine HCl	guanfacine
hydralazine HCl	hydralazine
isosorbide dinitrate/hydralazine HCl	BiDil
isosorbide dinitrate/hydralazine HCl	isosorbide-hydralazine
isoxsuprine HCl	isoxsuprine
mecamylamine HCl	Vecamyl
methyldopa	methyldopa
methyldopa/hydrochlorothiazide	methyldopa-hydrochlorothiazide
methyldopate HCl	methyldopate
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
metirosine	Demser
metirosine	metirosine
minoxidil	minoxidil
nitroprusside sodium	Nitropress
nitroprusside sodium	sodium nitroprusside
nitroprusside sodium in 0.9 % sodium chloride	Nipride RTU
papaverine HCl	papaverine
phenoxybenzamine HCl	Dibenzylamine
phenoxybenzamine HCl	phenoxybenzamine
phentolamine mesylate	phentolamine
prazosin HCl	Minipress
prazosin HCl	prazosin
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
terazosin HCl	terazosin
Oral Anticoagulants	
apixaban	Eliquis
apixaban	Eliquis DVT-PE Treat 30D Start
dabigatran etexilate mesylate	dabigatran etexilate

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dabigatran etexilate mesylate	Pradaxa
edoxaban tosylate	Savaysa
rivaroxaban	Xarelto
rivaroxaban	Xarelto DVT-PE Treat 30d Start
Vitamin K Antagonists	
warfarin sodium	Jantoven
warfarin sodium	warfarin
Other Cardiac Medications (Not Including Oral Anticoagulants or Vitamin K Antagonists)	
ambrisentan	ambrisentan
ambrisentan	Letairis
amyl nitrite	amyl nitrite
bosentan	bosentan
bosentan	Tracleer
epoprostenol sodium	epoprostenol
epoprostenol sodium	Velettri
epoprostenol sodium (glycine)	epoprostenol (glycine)
epoprostenol sodium (glycine)	Flolan
iloprost tromethamine	Ventavis
isosorbide dinitrate	Dilatrate-SR
isosorbide dinitrate	Isordil
isosorbide dinitrate	Isordil Titradose
isosorbide dinitrate	isosorbide dinitrate
isosorbide mononitrate	isosorbide mononitrate
ivabradine HCl	Corlanor
macitentan	Opsumit
nitroglycerin	GoNitro
nitroglycerin	Minitran
nitroglycerin	Nitro-Bid
nitroglycerin	Nitro-Dur
nitroglycerin	nitroglycerin
nitroglycerin	Nitrolingual
nitroglycerin	Nitromist
nitroglycerin	Nitrostat
nitroglycerin	Nitro-Time
nitroglycerin in 5 % dextrose in water	nitroglycerin in 5 % dextrose
ranolazine	Aspruzo Sprinkle
ranolazine	Ranexa
ranolazine	ranolazine
riociguat	Adempas
selexipag	Upravi
sildenafil citrate	Revatio
sildenafil citrate	sildenafil (pulm.hypertension)
tadalafil	Adcirca
tadalafil	Alyq
tadalafil	tadalafil (pulm. hypertension)
tadalafil	Tadliq
treprostinil	Tyvaso
treprostinil	Tyvaso DPI
treprostinil diolamine	Orenitram
treprostinil sodium	Remodulin
treprostinil sodium	treprostinil sodium
treprostinil/nebulizer accessories	Tyvaso Refill Kit
treprostinil/nebulizer and accessories	Tyvaso Institutional Start Kit
treprostinil/nebulizer and accessories	Tyvaso Starter Kit

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
vericiguat	Verquvo
Lipid Lowering Therapy	
alirocumab	Praluent Pen
amlodipine besylate/atorvastatin calcium	amlodipine-atorvastatin
amlodipine besylate/atorvastatin calcium	Caduet
atorvastatin calcium	atorvastatin
atorvastatin calcium	Lipitor
bempedoic acid	Nexletol
bempedoic acid/ezetimibe	Nexlizet
cholestyramine (with sugar)	cholestyramine (with sugar)
cholestyramine (with sugar)	Questran
cholestyramine/aspartame	Cholestyramine Light
cholestyramine/aspartame	cholestyramine-aspartame
cholestyramine/aspartame	Prevalite
cholestyramine/aspartame	Questran Light
colesevelam HCl	colesevelam
colesevelam HCl	WelChol
colestipol HCl	Colestid
colestipol HCl	Colestid Flavored
colestipol HCl	colestipol
evinacumab-dgnb	Evkeeza
evolocumab	Repatha Pushtronex
evolocumab	Repatha SureClick
evolocumab	Repatha Syringe
ezetimibe	ezetimibe
ezetimibe	Zetia
ezetimibe/atorvastatin calcium	ezetimibe-atorvastatin
ezetimibe/rosuvastatin calcium	ezetimibe-rosuvastatin
ezetimibe/rosuvastatin calcium	Roszet
ezetimibe/simvastatin	ezetimibe-simvastatin
ezetimibe/simvastatin	Vytorin 10-10
ezetimibe/simvastatin	Vytorin 10-20
ezetimibe/simvastatin	Vytorin 10-40
ezetimibe/simvastatin	Vytorin 10-80
fenofibrate	fenofibrate
fenofibrate	Fenoglide
fenofibrate	Lipofen
fenofibrate nanocrystallized	fenofibrate nanocrystallized
fenofibrate nanocrystallized	Tricor
fenofibrate,micronized	Antara
fenofibrate,micronized	fenofibrate micronized
fenofibric acid	fenofibric acid
fenofibric acid	Fibricor
fenofibric acid (choline)	fenofibric acid (choline)
fenofibric acid (choline)	Trilipix
fluvastatin sodium	fluvastatin
fluvastatin sodium	Lescol XL
gemfibrozil	gemfibrozil
gemfibrozil	Lopid
icosapent ethyl	icosapent ethyl
icosapent ethyl	Vascepa
inclisiran sodium	Leqvio
lomitapide mesylate	Juxtapid
lovastatin	Altoprev

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
lovastatin	lovastatin
niacin	niacin
niacin	Niacor
niacin	Niaspan Extended-Release
omega-3 acid ethyl esters	Lovaza
omega-3 acid ethyl esters	omega-3 acid ethyl esters
pitavastatin calcium	Livalo
pitavastatin magnesium	Zypitamag
pravastatin sodium	pravastatin
rosuvastatin calcium	Crestor
rosuvastatin calcium	Ezallor Sprinkle
rosuvastatin calcium	rosuvastatin
simvastatin	FloLipid
simvastatin	simvastatin
simvastatin	Zocor
Drugs with a Known Risk of Prolonged QT and Torsades de Pointes	
amiodarone HCl	amiodarone
amiodarone HCl	Pacerone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
anagrelide HCl	Agrylin
anagrelide HCl	anagrelide
arsenic trioxide	arsenic trioxide
arsenic trioxide	Trisenox
azithromycin	AzaSite
azithromycin	azithromycin
azithromycin	Zithromax
azithromycin	Zithromax TRI-PAK
azithromycin	Zithromax Z-Pak
azithromycin/chondroitin sulfate A sodium/PF	Klarity-A (azithro-chondr)(PF)
chloroquine phosphate	chloroquine phosphate
chlorpromazine HCl	chlorpromazine
cilostazol	cilostazol
ciprofloxacin	Cipro
ciprofloxacin	ciprofloxacin
ciprofloxacin	Otiprio
ciprofloxacin HCl	Cetralax
ciprofloxacin HCl	Ciloxan
ciprofloxacin HCl	Cipro
ciprofloxacin HCl	ciprofloxacin HCl
ciprofloxacin HCl/dexamethasone	Ciprodex
ciprofloxacin HCl/dexamethasone	ciprofloxacin-dexamethasone
ciprofloxacin HCl/fluocinolone acetonide	ciprofloxacin-fluocinolone
ciprofloxacin HCl/fluocinolone acetonide	Otovel
ciprofloxacin HCl/hydrocortisone	Cipro HC
ciprofloxacin lactate/dextrose 5 % in water	ciprofloxacin in 5 % dextrose
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clarithromycin	clarithromycin
cocaine HCl	cocaine
cocaine HCl	Goprelto
cocaine HCl	Numbrino
dexamethasone sod ph/moxifloxacin HCl in NaCl,iso-osmotic/PF	dexameth-moxiflox(PF)-NaCl,iso

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
dextromethorphan Hbr/quinidine sulfate	Nuedexta
disopyramide phosphate	disopyramide phosphate
disopyramide phosphate	Norpace
disopyramide phosphate	Norpace CR
dofetilide	dofetilide
dofetilide	Tikosyn
donepezil HCl	Adlarity
donepezil HCl	Aricept
donepezil HCl	donepezil
dronedarone HCl	Multaq
droperidol	droperidol
erythromycin base	Ery-Tab
erythromycin base	erythromycin
erythromycin ethylsuccinate	E.E.S. 400
erythromycin ethylsuccinate	E.E.S. Granules
erythromycin ethylsuccinate	EryPed 200
erythromycin ethylsuccinate	EryPed 400
erythromycin ethylsuccinate	erythromycin ethylsuccinate
erythromycin lactobionate	Erythrocin
erythromycin lactobionate	erythromycin lactobionate
erythromycin stearate	Erythrocin (as stearate)
erythromycin stearate	erythromycin stearate
escitalopram oxalate	escitalopram oxalate
escitalopram oxalate	Lexapro
flecainide acetate	flecainide
fluconazole	Diflucan
fluconazole	fluconazole
fluconazole in sodium chloride, iso-osmotic	fluconazole in NaCl (iso-osm)
gatifloxacin	gatifloxacin
gatifloxacin	Zymaxid
haloperidol	haloperidol
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
haloperidol lactate	Haldol
haloperidol lactate	haloperidol lactate
hydroxychloroquine sulfate	hydroxychloroquine
hydroxychloroquine sulfate	Plaquenil
ibutilide fumarate	Corvert
ibutilide fumarate	ibutilide fumarate
lansoprazole/amoxicillin trihydrate/clarithromycin	amoxicil-clarithromy-lansopraz
levofloxacin	levofloxacin
levofloxacin/dextrose 5 % in water	levofloxacin in D5W
memantine HCl/donepezil HCl	Namzaric
methadone HCl	Diskets
methadone HCl	methadone
methadone HCl	Methadone Intensol
methadone HCl	Methadose
methadone hydrochloride in 0.9 % sodium chloride	methadone in 0.9 % sod.chlorid
midazolam/ketamine HCl/ondansetron HCl	MKO (Midazolam-Ketamine-Ondan)
mobocertinib succinate	Exkivity
moxifloxacin HCl	Moxeza
moxifloxacin HCl	moxifloxacin

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
moxifloxacin HCl	Vigamox
moxifloxacin HCl in balanced salt solution no.2/PF	moxifloxacin (PF)-BSS
moxifloxacin HCl in sodium acetate and sulfate,water,iso-osm	moxifloxacin-sod.ace,sul-water
moxifloxacin HCl in sodium chloride, iso-osmotic	Avelox in NaCl (iso-osmotic)
moxifloxacin HCl in sodium chloride, iso-osmotic	moxifloxacin-sod.chloride(iso)
moxifloxacin HCl in sodium chloride,iso-osmotic/PF	moxifloxacin-sod chlor,iso(PF)
omeprazole/clarithromycin/amoxicillin trihydrate	Omeclamox-Pak
ondansetron	ondansetron
ondansetron	Zuplenz
ondansetron HCl	ondansetron HCl
ondansetron HCl	Zofran
ondansetron HCl in 0.9 % sodium chloride	ondansetron in 0.9 % sod chlor
ondansetron HCl/PF	ondansetron HCl (PF)
oxaliplatin	oxaliplatin
papaverine HCl	papaverine
papaverine HCl/phentolamine mesylate in water	IFE-BiMix 30/1
papaverine HCl/phentolamine mesylate/alprostadi	Tri-Mix (papavrn-phntlmn-PGE1)
pentamidine isethionate	Nebupent
pentamidine isethionate	Pentam
pentamidine isethionate	pentamidine
pimozide	pimozide
prednisolone acetate/gatifloxacin	prednisolone acet-gatifloxacin
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/moxifloxacin HCl	prednisolone-moxifloxacin HCl
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl	prednisolone sod ph-moxiflox
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac sod	prednisoln sp-moxiflox-bromfen
procainamide HCl	procainamide
propofol	Anesthesia S/I-40 (propofol)
propofol	Anesthesia S/I-40A (propofol)
propofol	Anesthesia S/I-40H (propofol)
propofol	Anesthesia S/I-40S (propofol)
propofol	Anesthesia S/I-60 (propofol)
propofol	Diprivan
propofol	propofol
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propofol-Lipuro (PF)
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propoven (EUA) (PF)
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate
sevoflurane	sevoflurane
sevoflurane	Ultane
sotalol HCl	Betapace
sotalol HCl	Betapace AF
sotalol HCl	Sorine
sotalol HCl	sotalol
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
terlipressin acetate	Terlivaz
thioridazine HCl	thioridazine
triamcinolone acetonide/moxifloxacin HCl/water/PF	triamcinolon-moxiflox-watr(PF)

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
vandetanib	Caprelsa
vonoprazan fumarate/amoxicillin trihydrate/clarithromycin	Voquezna Triple Pak
Drugs with a Known/Possible/Conditional Risk of Prolonged QT and Torsades de Pointes	
abiraterone acetate	abiraterone
abiraterone acetate	Zytiga
abiraterone acetate, submicronized	Yonsa
acetaminophen/diphenhydramine citrate	Goody's PM
acetaminophen/diphenhydramine citrate	Headache Relief PM
acetaminophen/diphenhydramine citrate	Midol PM
acetaminophen/diphenhydramine HCl	Acetadryl
acetaminophen/diphenhydramine HCl	Acetaminophen PM
acetaminophen/diphenhydramine HCl	Acetaminophen PM Extra Str
acetaminophen/diphenhydramine HCl	EaZZZe The Pain
acetaminophen/diphenhydramine HCl	Headache PM
acetaminophen/diphenhydramine HCl	Night Time Pain Medicine
acetaminophen/diphenhydramine HCl	Non-Aspirin PM
acetaminophen/diphenhydramine HCl	Pain and Sleep
acetaminophen/diphenhydramine HCl	Pain Relief PM
acetaminophen/diphenhydramine HCl	Pain Relief PM Rapid Release
acetaminophen/diphenhydramine HCl	Pain Reliever PM Ex-Strength
acetaminophen/diphenhydramine HCl	Percogesic
acetaminophen/diphenhydramine HCl	Percogesic Extra Strength
acetaminophen/diphenhydramine HCl	Severe Allergy
acetaminophen/diphenhydramine HCl	Tylenol PM Extra Strength
acetaminophen/diphenhydramine HCl	Unisom PM Pain
acetaminophen/diphenhydramine HCl	Wal-Nadol PM
adagrasib	Krazati
alfuzosin HCl	alfuzosin
alfuzosin HCl	Uroxatral
aliskiren hemifumarate/hydrochlorothiazide	Tektura HCT
amantadine HCl	amantadine HCl
amantadine HCl	Gocovri
amantadine HCl	Osmolex ER
amiloride HCl/hydrochlorothiazide	amiloride-hydrochlorothiazide
amiodarone HCl	amiodarone
amiodarone HCl	Pacerone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
amisulpride	Barhemsys
amitriptyline HCl	amitriptyline
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiiazide
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
amphetamine	Adzenys ER
amphetamine	Adzenys XR-ODT
amphetamine	amphetamine
amphetamine	Dyanavel XR
amphetamine sulfate	amphetamine sulfate
amphetamine sulfate	Evekeo
amphetamine sulfate	Evekeo ODT
amphotericin B	amphotericin B
amphotericin B lipid complex	Abelcet
amphotericin B liposome	AmBisome
amphotericin B liposome	amphotericin B liposome

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
anagrelide HCl	Agrylin
anagrelide HCl	anagrelide
apalutamide	Erleada
apomorphine HCl	APOKYN
apomorphine HCl	apomorphine
apomorphine HCl	Kynmobi
aripiprazole	Abilify
aripiprazole	Abilify Maintena
aripiprazole	Abilify MyCite
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	aripiprazole
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
arsenic trioxide	arsenic trioxide
arsenic trioxide	Trisenox
artemether/lumefantrine	Coartem
asenapine	Secuado
asenapine maleate	asenapine maleate
asenapine maleate	Saphris
aspirin/acetaminophen/diphenhydramine citrate	Pain Relief PM (w-aspirin)
aspirin/diphenhydramine citrate	Bayer PM
aspirin/omeprazole	aspirin-omeprazole
aspirin/omeprazole	Yosprala
atazanavir sulfate	atazanavir
atazanavir sulfate	Reyataz
atazanavir sulfate/cobicistat	Evotaz
atomoxetine HCl	atomoxetine
atomoxetine HCl	Strattera
azithromycin	AzaSite
azithromycin	azithromycin
azithromycin	Zithromax
azithromycin	Zithromax TRI-PAK
azithromycin	Zithromax Z-Pak
azithromycin/chondroitin sulfate A sodium/PF	Klarity-A (azithro-chondr)(PF)
bedaquiline fumarate	Sirturo
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
benazepril HCl/hydrochlorothiazide	Lotensin HCT
bendamustine HCl	Belrapzo
bendamustine HCl	bendamustine
bendamustine HCl	Bendeka
bendamustine HCl	Treanda
bendamustine HCl	Vivimusta
benzhydrocodone HCl/acetaminophen	Apadaz
benzhydrocodone HCl/acetaminophen	benzhydrocodone-acetaminophen
bicalutamide	bicalutamide
bicalutamide	Casodex
bismuth subsalicylate/metronidazole/tetracycline HCl	Helidac
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
bortezomib	bortezomib
bortezomib	Velcade
bosutinib	Bosulif
buprenorphine	buprenorphine

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
buprenorphine	Butrans
buprenorphine	Sublocade
buprenorphine HCl	Belbuca
buprenorphine HCl	Buprenex
buprenorphine HCl	buprenorphine HCl
buprenorphine HCl	Probuphine
buprenorphine HCl/naloxone HCl	Bunavail
buprenorphine HCl/naloxone HCl	buprenorphine-naloxone
buprenorphine HCl/naloxone HCl	Suboxone
buprenorphine HCl/naloxone HCl	Zubsolv
cabotegravir/rilpivirine	Cabenuva
cabozantinib s-malate	Cabometyx
cabozantinib s-malate	Cometriq
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
capecitabine	capecitabine
capecitabine	Xeloda
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
ceritinib	Zykadia
chloroquine phosphate	chloroquine phosphate
chlorpromazine HCl	chlorpromazine
cilostazol	cilostazol
cimetidine	Acid Reducer (cimetidine)
cimetidine	cimetidine
cimetidine	Heartburn Relief (cimetidine)
cimetidine	Tagamet HB
cimetidine HCl	cimetidine HCl
ciprofloxacin	Cipro
ciprofloxacin	ciprofloxacin
ciprofloxacin	Otiprio
ciprofloxacin HCl	Cetraxal
ciprofloxacin HCl	Ciloxan
ciprofloxacin HCl	Cipro
ciprofloxacin HCl	ciprofloxacin HCl
ciprofloxacin HCl/dexamethasone	Ciprodex
ciprofloxacin HCl/dexamethasone	ciprofloxacin-dexamethasone
ciprofloxacin HCl/fluocinolone acetonide	ciprofloxacin-fluocinolone
ciprofloxacin HCl/fluocinolone acetonide	Otovel
ciprofloxacin HCl/hydrocortisone	Cipro HC
ciprofloxacin lactate/dextrose 5 % in water	ciprofloxacin in 5 % dextrose
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clarithromycin	clarithromycin
clomipramine HCl	Anafranil
clomipramine HCl	clomipramine
clozapine	clozapine
clozapine	Clozaril
clozapine	Versacloz
cobimetinib fumarate	Cotellic
cocaine HCl	cocaine
cocaine HCl	Goprelto
cocaine HCl	Numbrino
colloidal bismuth subcitrate/metronidazole/tetracycline HCl	Pylera
crizotinib	Xalkori

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dabrafenib mesylate	Tafinlar
dasatinib	Sprycel
degarelix acetate	Firmagon
degarelix acetate	Firmagon kit w diluent syringe
desipramine HCl	desipramine
desipramine HCl	Norpramin
desvenlafaxine	desvenlafaxine
desvenlafaxine succinate	desvenlafaxine succinate
desvenlafaxine succinate	Pristiq
deutetrabenazine	Austedo
deutetrabenazine	Austedo 12mg Start Titr(Wk1-4)
deutetrabenazine	Austedo TD Titratn Pk (Wk 1-2)
dexamethasone sod ph/moxifloxacin HCl in NaCl,iso-osmotic/PF	dexameth-moxiflox(PF)-NaCl,iso
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
dexlansoprazole	Dexilant
dexlansoprazole	dexlansoprazole
dexmedetomidine HCl	dexmedetomidine
dexmedetomidine HCl	Igalmi
dexmedetomidine HCl	Precedex
dexmedetomidine HCl in 0.9 % sodium chloride	dexmedetomidine in 0.9 % NaCl
dexmedetomidine HCl in 0.9 % sodium chloride	Precedex in 0.9 % sodium chlor
dexmedetomidine in 5 % dextrose in water	dexmedetomidine in dextrose 5%
dextroamphetamine	Xelstrym
dextroamphetamine sulfate	Dexedrine Spansule
dextroamphetamine sulfate	dextroamphetamine sulfate
dextroamphetamine sulfate	ProCentra
dextroamphetamine sulfate	Zenzedi
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall XR
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mydayis
dextromethorphan HBr/acetaminophen/diphenhydramine HCl	Diabetic Tussin Night Time
dextromethorphan HBr/quinidine sulfate	Nuedexta
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Day-Night Severe Cold-Flu
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	HerbioMed Deep Cold-Flu Night
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Multi-Symptom Severe Cold-Nt
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Wal-Flu Day-Night Cold-Cough
diltiazem HCl	Cardizem
diltiazem HCl	Cardizem CD
diltiazem HCl	Cardizem LA
diltiazem HCl	Cartia XT
diltiazem HCl	diltiazem HCl
diltiazem HCl	DILT-XR
diltiazem HCl	Matzim LA
diltiazem HCl	Taztia XT

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diltiazem HCl	Tiadyt ER
diltiazem HCl	Tiazac
diltiazem HCl in 0.9 % sodium chloride	diltiazem HCl in 0.9% NaCl
diltiazem HCl/dextrose 5 % in water	diltiazem in dextrose 5 %
diluent for lefamulin(10mM citrate buffered 0.9 % sod chlor)	Diluent for lefamulin(Xenleta)
diluent for leuprolide (polyglactin)	Diluent for Eligard
diluent for romidepsin (propylene glycol)	Diluent For Istodax
diluent for romidepsin (propylene glycol)	diluent, romidepsin (prop gly)
diphenhydramine HCl	Aler-Cap
diphenhydramine HCl	Alka-Seltzer Plus Allergy
diphenhydramine HCl	Aller-G-Time
diphenhydramine HCl	Allergy
diphenhydramine HCl	Allergy (diphenhydramine)
diphenhydramine HCl	Allergy Medication
diphenhydramine HCl	Allergy Medicine
diphenhydramine HCl	Allergy Relief(diphenhydramin)
diphenhydramine HCl	Banophen
diphenhydramine HCl	Benadryl
diphenhydramine HCl	Benadryl Allergy
diphenhydramine HCl	Child Allergy Relief (diphen)
diphenhydramine HCl	Children's Allergy (diphenhyd)
diphenhydramine HCl	Children's Benadryl Allergy
diphenhydramine HCl	Children's Diphenhydramine
diphenhydramine HCl	Children's Wal-Dryl Allergy
diphenhydramine HCl	Complete Allergy
diphenhydramine HCl	Complete Allergy Medicine
DIPHENHYDRAMINE HCL	Dicopanor
diphenhydramine HCl	Diphedryl
diphenhydramine HCl	Diphedryl Allergy
diphenhydramine HCl	Diphen
diphenhydramine HCl	Diphenhist
diphenhydramine HCl	diphenhydramine HCl
diphenhydramine HCl	EZ Nite Sleep
diphenhydramine HCl	Geri-Dryl
diphenhydramine HCl	M-Dryl
diphenhydramine HCl	Naramin
diphenhydramine HCl	Nighttime Sleep
diphenhydramine HCl	Nighttime Allergy Relief
diphenhydramine HCl	NightTime Sleep Aid (diphen)
diphenhydramine HCl	Nytol
diphenhydramine HCl	PediaClear Cough
diphenhydramine HCl	Pharbedryl
diphenhydramine HCl	Siladryl SA
diphenhydramine HCl	Simply Sleep
diphenhydramine HCl	Sleep Aid (diphenhydramine)
diphenhydramine HCl	Sleep Aid Max Str (diphenhydr)
diphenhydramine HCl	Sleep II
diphenhydramine HCl	Sleep Tablet (diphenhydramine)
diphenhydramine HCl	Sleep Time
diphenhydramine HCl	Sleeping
diphenhydramine HCl	Sleep-Tabs
diphenhydramine HCl	Sominex
diphenhydramine HCl	Sominex Maximum Strength
diphenhydramine HCl	Total Allergy Medicine

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diphenhydramine HCl	Unisom (diphenhydramine)
diphenhydramine HCl	Unisom SleepGels
diphenhydramine HCl	Unisom SleepMelts
diphenhydramine HCl	Unisom SleepMinis
diphenhydramine HCl	Wal-Dryl Allergy
diphenhydramine HCl	Wal-Sleep Z
diphenhydramine HCl	Wal-Som (diphenhydramine)
diphenhydramine HCl	Z-Sleep
diphenhydramine HCl	ZzzQuil
diphenhydramine HCl in 0.9 % sodium chloride	diphenhydramine-0.9 % sod.chlr
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy Sinus Headache (PE)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Child Delsym Cough-Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Child Mucinex M-S Cold Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children Dimetapp M-S Cold-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children's Mucinex Night Time
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cold and Flu Relief(diphen-pe)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cough and Severe Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Delsym Cough-Cold NightTime
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu Severe Cold-Night(diph-pe)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu-Severe Cold-Cough Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Herbiomed Allergy Cold-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Fast-Max Nite Cold-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Sinus-Max Nite Congest
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Robitussin Cold-Flu Night (PE)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Allergy-Sinus Headache
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold Cough-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold PE
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu ExpressMax Cold Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Night Severe Cold-Cgh
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Nighttime PowerPod
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Dryl Severe Allergy-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Night Severe Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Severe Cold and Cough
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Phed PE Nighttime Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-phed PE Severe Cold
diphenhydramine HCl/phenylephrine HCl/dextromethorphan	Child Cold-Cough Day-Night
diphenhydramine	
HCl/phenylephrine/acetaminophen/guaifenesin	Mucinex Sinus-Max D-N (diphen)
diphenhydramine	
HCl/phenylephrine/acetaminophen/guaifenesin	Sinus Relief Max Str Day-Night
diphenhydramine/brompheniramine/phenyleph/dextromethorphan	
han	Children's Dimetapp Day Night
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Child Delsym Cough Plus Dy-Nt
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Child Mucinex M-S Cold Day-Nte
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Children's M-S Cold Day-Night
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Daytime-Cold Nighttime-Cld-Flu
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Delsym Cough Plus Day-Night
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Mucinex Fast-Max Day-Nite Cold

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diphenhydramine/phenylephrin/dextromethorph/acetaminophe n/GG	Mucinex Fast-Max Day-Nite Cong
diphenhydramine/phenylephrin/dextromethorph/acetaminophe n/GG	Mucinex Fst-Mx Dy-Nt Cold(dph)
diphenhydramine/phenylephrin/dextromethorph/acetaminophe n/GG	Wal-Phed PE Day-Night
disopyramide phosphate	disopyramide phosphate
disopyramide phosphate	Norpace
disopyramide phosphate	Norpace CR
dofetilide	dofetilide
dofetilide	Tikosyn
dolasetron mesylate	Anzemet
dolutegravir sodium/rilpivirine HCl	Juluca
donepezil HCl	Adlarity
donepezil HCl	Aricept
donepezil HCl	donepezil
doxepin HCl	doxepin
doxepin HCl	Silenor
dronedarone HCl	Multaq
droperidol	droperidol
efavirenz	efavirenz
efavirenz	Sustiva
efavirenz/emtricitabine/tenofovir disoproxil fumarate	Atripla
efavirenz/emtricitabine/tenofovir disoproxil fumarate	efavirenz-emtricitabin-tenofov
efavirenz/lamivudine/tenofovir disoproxil fumarate	efavirenz-lamivu-tenofov disop
efavirenz/lamivudine/tenofovir disoproxil fumarate	Symfi
efavirenz/lamivudine/tenofovir disoproxil fumarate	Symfi Lo
eliglustat tartrate	Cerdelga
emtricitabine/rilpivirine HCl/tenofovir alafenamide fumarate	Odefsey
emtricitabine/rilpivirine HCl/tenofovir disoproxil fumarate	Complera
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
enalapril maleate/hydrochlorothiazide	Vaseretic
encorafenib	Braftovi
entrectinib	Rozlytrek
epirubicin HCl	Ellence
epirubicin HCl	epirubicin
eribulin mesylate	Halaven
erythromycin base	Ery-Tab
erythromycin base	erythromycin
erythromycin ethylsuccinate	E.E.S. 400
erythromycin ethylsuccinate	E.E.S. Granules
erythromycin ethylsuccinate	EryPed 200
erythromycin ethylsuccinate	EryPed 400
erythromycin ethylsuccinate	erythromycin ethylsuccinate
erythromycin lactobionate	Erythrocin
erythromycin lactobionate	erythromycin lactobionate
erythromycin stearate	Erythrocin (as stearate)
erythromycin stearate	erythromycin stearate
escitalopram oxalate	escitalopram oxalate
escitalopram oxalate	Lexapro
esomeprazole magnesium	esomeprazole magnesium
esomeprazole magnesium	Nexium
esomeprazole magnesium	Nexium 24HR
esomeprazole magnesium	Nexium Packet

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
esomeprazole magnesium/glycerin	Esomep-EZS
esomeprazole sodium	esomeprazole sodium
esomeprazole sodium	Nexium IV
esomeprazole strontium	esomeprazole strontium
famotidine	Acid Controller
famotidine	Acid Reducer (famotidine)
famotidine	Acid-Pep
famotidine	famotidine
famotidine	Heartburn Prevention
famotidine	Heartburn Relief (famotidine)
famotidine	Pepcid
famotidine	Pepcid AC
famotidine	Pepcid AC Maximum Strength
famotidine	Zantac-360 (famotidine)
famotidine in sodium chloride, iso-osmotic/PF	famotidine (PF)-NaCl (iso-os)
famotidine/calcium carbonate/magnesium hydroxide	Acid Controller Complete
famotidine/calcium carbonate/magnesium hydroxide	Acid Reducer Complete (famot)
famotidine/calcium carbonate/magnesium hydroxide	Complete
famotidine/calcium carbonate/magnesium hydroxide	Dual Action Complete
famotidine/calcium carbonate/magnesium hydroxide	Pepcid Complete
famotidine/calcium carbonate/magnesium hydroxide	Tums Dual Action (famotidine)
famotidine/PF	famotidine (PF)
felbamate	felbamate
felbamate	Felbatol
fingolimod HCl	fingolimod
fingolimod HCl	Gilenya
fingolimod lauryl sulfate	Tascenso ODT
flecainide acetate	flecainide
fluconazole	Diflucan
fluconazole	fluconazole
fluconazole in sodium chloride, iso-osmotic	fluconazole in NaCl (iso-osm)
fluorouracil	Adrucil
fluorouracil	fluorouracil
fluoxetine HCl	fluoxetine
fluoxetine HCl	Prozac
fluvoxamine maleate	fluvoxamine
fosinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
fosnetupitant chloride HCl/palonosetron HCl	Akynzeo (fosnetupitant)
furosemide	Furoscix
furosemide	furosemide
furosemide	Lasix
furosemide in 0.9 % sodium chloride	furosemide in 0.9 % NaCl
galantamine HBr	galantamine
galantamine HBr	Razadyne ER
gatifloxacin	gatifloxacin
gatifloxacin	Zymaxid
gemifloxacin mesylate	Factive
gilteritinib fumarate	Xospata
glasdegib maleate	Daurismo
granisetron	Sancuso
granisetron	Sustol
granisetron HCl	granisetron HCl
granisetron HCl/PF	granisetron (PF)
haloperidol	haloperidol

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
haloperidol lactate	Haldol
haloperidol lactate	haloperidol lactate
hydrochlorothiazide	hydrochlorothiazide
hydrocodone bitartrate	hydrocodone bitartrate
hydrocodone bitartrate	Hysingla ER
hydrocodone bitartrate	Zohydro ER
hydrocodone bitartrate/acetaminophen	hydrocodone-acetaminophen
hydrocodone bitartrate/acetaminophen	Lortab Elixir
hydrocodone bitartrate/guaifenesin	Obredon
hydrocodone bitartrate/homatropine methylbromide	Hycodan
hydrocodone bitartrate/homatropine methylbromide	Hycodan (with homatropine)
hydrocodone bitartrate/homatropine methylbromide	Hydrocodone Compound
hydrocodone bitartrate/homatropine methylbromide	hydrocodone-homatropine
hydrocodone bitartrate/homatropine methylbromide	Hydromet
hydrocodone polistirex/chlorpheniramine polistirex	hydrocodone-chlorpheniramine
hydrocodone polistirex/chlorpheniramine polistirex	TussiCaps
hydrocodone/ibuprofen	hydrocodone-ibuprofen
hydroxyamphetamine hbr/tropicamide	Paremyd
hydroxychloroquine sulfate	hydroxychloroquine
hydroxychloroquine sulfate	Plaquenil
hydroxyzine HCl	hydroxyzine HCl
hydroxyzine pamoate	hydroxyzine pamoate
hydroxyzine pamoate	Vistaril
ibuprofen/diphenhydramine citrate	Advil PM
ibuprofen/diphenhydramine citrate	Ibuprofen PM
ibuprofen/diphenhydramine citrate	Motrin PM
ibuprofen/diphenhydramine HCl	Advil PM Liqui-Gels
ibuprofen/diphenhydramine HCl	Ibuprofen PM
ibuprofen/famotidine	Duexis
ibuprofen/famotidine	ibuprofen-famotidine
ibutilide fumarate	Corvert
ibutilide fumarate	ibutilide fumarate
iloperidone	Fanapt
imatinib mesylate	Gleevec
imatinib mesylate	imatinib
imipramine HCl	imipramine HCl
imipramine pamoate	imipramine pamoate
indapamide	indapamide
inotuzumab ozogamicin	Besponsa
irbesartan/hydrochlorothiazide	Avalide
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
isradipine	isradipine
itraconazole	itraconazole
itraconazole	Sporanox
itraconazole	Sporanox Pulsepak
itraconazole	Tolsura
ivabradine HCl	Corlanor
ivosidenib	Tibsovo
ketoconazole	ketoconazole
LANSOPRAZOLE	FIRST-Lansoprazole
lansoprazole	lansoprazole
lansoprazole	Prevacid

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
lansoprazole	Prevacid 24Hr
lansoprazole	Prevacid SoluTab
lansoprazole/amoxicillin trihydrate/clarithromycin	amoxicil-clarithromy-lansopraz
lapatinib ditosylate	lapatinib
lapatinib ditosylate	Tykerb
lefamulin acetate	Xenleta
lenvatinib mesylate	Lenvima
leuprolide acetate	Eligard
leuprolide acetate	Eligard (3 month)
leuprolide acetate	Eligard (4 month)
leuprolide acetate	Eligard (6 month)
leuprolide acetate	Fensolvi
leuprolide acetate	leuprolide
leuprolide acetate	leuprolide (3 month)
leuprolide acetate	Lupron Depot
leuprolide acetate	Lupron Depot (3 month)
leuprolide acetate	Lupron Depot (4 month)
leuprolide acetate	Lupron Depot (6 Month)
leuprolide acetate	Lupron Depot-Ped
leuprolide acetate	Lupron Depot-Ped (3 month)
leuprolide acetate/norethindrone acetate	Lupaneta Pack (1 month)
leuprolide acetate/norethindrone acetate	Lupaneta Pack (3 month)
leuprolide mesylate	Camcevi (6 month)
levetiracetam	Elepsia XR
levetiracetam	Keppra
levetiracetam	Keppra XR
levetiracetam	levetiracetam
levetiracetam	Roweepra
levetiracetam	Roweepra XR
levetiracetam	Spritam
levetiracetam in sodium chloride, iso-osmotic	levetiracetam in NaCl (iso-os)
levofloxacin	levofloxacin
levofloxacin/dextrose 5 % in water	levofloxacin in D5W
levoketoconazole	Recorlev
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
lisinopril/hydrochlorothiazide	Zestoretic
lithium aspartate	Lithate
lithium carbonate	lithium carbonate
lithium carbonate	Lithobid
lofexidine HCl	Lucemyra
loperamide HCl	Anti-Diarrheal (loperamide)
loperamide HCl	Diamode
loperamide HCl	Imodium A-D
loperamide HCl	loperamide
loperamide HCl	Ultra A-D
loperamide HCl/simethicone	Anti-Diarrheal (loperamide)-Anti-Gas
loperamide HCl/simethicone	Imodium Multi-Symptom Relief
loperamide HCl/simethicone	loperamide-simethicone
lopinavir/ritonavir	Kaletra
lopinavir/ritonavir	lopinavir-ritonavir
losartan potassium/hydrochlorothiazide	Hyzaar
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
lumateperone tosylate	Caplyta
lurasidone HCl	Latuda

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
macimorelin acetate	Macrilen
MAG HYDROXIDE/AL	
HYDROXIDE/SIMETH/DIPHENHYDRAMINE/LIDOCAINE	FIRST-Mouthwash BLM
memantine HCl/donepezil HCl	Namzaric
methadone HCl	Diskets
methadone HCl	methadone
methadone HCl	Methadone Intensol
methadone HCl	Methadose
methadone hydrochloride in 0.9 % sodium chloride	methadone in 0.9 % sod.chlorid
methamphetamine HCl	Desoxyn
methamphetamine HCl	methamphetamine
methyldopa/hydrochlorothiazide	methyldopa-hydrochlorothiazide
metoclopramide HCl	Gimoti
metoclopramide HCl	metoclopramide HCl
metoclopramide HCl	Reglan
metolazone	metolazone
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
metronidazole	Flagyl
metronidazole	Metrogel Vaginal
metronidazole	metronidazole
metronidazole	Nuversa
metronidazole	Vandazole
metronidazole in sodium chloride	Metro I.V.
metronidazole in sodium chloride	metronidazole in NaCl (iso-os)
midazolam/ketamine HCl/ondansetron HCl	MKO (Midazolam-Ketamine-Ondan)
midostaurin	Rydapt
mifepristone	Korlym
mifepristone	Mifeprex
mifepristone	mifepristone
mirabegron	Myrbetriq
mirtazapine	mirtazapine
mirtazapine	Remeron
mirtazapine	Remeron SolTab
mobocertinib succinate	Exkivity
moxifloxacin HCl	Moxeza
moxifloxacin HCl	moxifloxacin
moxifloxacin HCl	Vigamox
moxifloxacin HCl in balanced salt solution no.2/PF	moxifloxacin (PF)-BSS
moxifloxacin HCl in sodium acetate and sulfate,water,iso-osm	moxifloxacin-sod.ace,sul-water
moxifloxacin HCl in sodium chloride, iso-osmotic	Avelox in NaCl (iso-osmotic)
moxifloxacin HCl in sodium chloride, iso-osmotic	moxifloxacin-sod.chloride(iso)
moxifloxacin HCl in sodium chloride,iso-osmotic/PF	moxifloxacin-sod chlor,iso(PF)
naproxen sodium/diphenhydramine HCl	Aleve PM
naproxen/esomeprazole magnesium	naproxen-esomeprazole
naproxen/esomeprazole magnesium	Vimovo
necitumumab	Portrazza
nelfinavir mesylate	Viracept
netupitant/palonosetron HCl	Akynzeo (netupitant)
nicardipine HCl	Cardene IV
nicardipine HCl	nicardipine
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose
nicardipine in sodium chloride, iso-osmotic	Cardene IV in sodium chloride

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
nicardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)
nilotinib HCl	Tasigna
nortriptyline HCl	nortriptyline
nortriptyline HCl	Pamelor
nusinersen sodium/PF	Spinraza (PF)
NYSTATIN/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Duke's
NYSTATIN/LIDOCAINE HCL/DIPHENHYDRAMINE HCL	First-BXN
NYSTATIN/TETRACYCLINE	
HCL/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Mary's Mouthwash
ofloxacin	Ocuflox
ofloxacin	ofloxacin
olanzapine	olanzapine
olanzapine	Zyprexa
olanzapine	Zyprexa Zydis
olanzapine pamoate	Zyprexa Relprevv
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
olanzapine/fluoxetine HCl	Symbyax
olanzapine/samidorphan malate	Lybalvi
oliceridine fumarate	Olinvyk
olmesartan medoxomil/amlodipine	
besylate/hydrochlorothiazide	olmesartan-amlodipin-hcthiazid
olmesartan medoxomil/amlodipine	
besylate/hydrochlorothiazide	Tribenzor
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
OMEPRAZOLE	FIRST-Omeprazole
omeprazole	omeprazole
OMEPRAZOLE	Omeprazole+SyrSpend SF Alka
omeprazole magnesium	Acid Reducer (omeprazole)
omeprazole magnesium	omeprazole magnesium
omeprazole magnesium	Prilosec
omeprazole magnesium	Prilosec OTC
omeprazole magnesium/amoxicillin trihydrate/rifabutin	Talicia
omeprazole/clarithromycin/amoxicillin trihydrate	Omeclamox-Pak
omeprazole/sodium bicarbonate	omeprazole-sodium bicarbonate
omeprazole/sodium bicarbonate	Zegerid
omeprazole/sodium bicarbonate	Zegerid OTC
ondansetron	ondansetron
ondansetron	Zuplenz
ondansetron HCl	ondansetron HCl
ondansetron HCl	Zofran
ondansetron HCl in 0.9 % sodium chloride	ondansetron in 0.9 % sod chlor
ondansetron HCl/PF	ondansetron HCl (PF)
osilodrostat phosphate	Isturisa
osimertinib mesylate	Tagrisso
oxaliplatin	oxaliplatin
oxytocin	oxytocin
oxytocin	Pitocin
oxytocin in 0.9 % sodium chloride	oxytocin in 0.9 % sod chloride
oxytocin in dextrose 5 %-lactated ringers	oxytocin in dextrose 5 % in LR
oxytocin/Ringer's solution,lactated	oxytocin in lactated ringers
ozanimod hydrochloride	Zeposia
ozanimod hydrochloride	Zeposia Starter Kit
ozanimod hydrochloride	Zeposia Starter Pack

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
paliperidone	Invega
paliperidone	paliperidone
paliperidone palmitate	Invega Hafyera
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
palonosetron HCl	palonosetron
panobinostat lactate	Farydak
pantoprazole sodium	pantoprazole
pantoprazole sodium	Protonix
papaverine HCl	papaverine
papaverine HCl/phentolamine mesylate in water	IFE-BiMix 30/1
papaverine HCl/phentolamine mesylate/alprostadil	Tri-Mix (papavrn-phntlmn-PGE1)
paroxetine HCl	paroxetine HCl
paroxetine HCl	Paxil
paroxetine HCl	Paxil CR
paroxetine mesylate	Brisdelle
paroxetine mesylate	paroxetine mesylate(menop.sym)
paroxetine mesylate	Pexeva
pasireotide diaspargate	Signifor
pasireotide pamoate	Signifor LAR
pazopanib HCl	Votrient
pentamidine isethionate	Nebupent
pentamidine isethionate	Pentam
pentamidine isethionate	pentamidine
perphenazine	perphenazine
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
phenylephrine HCl/diphenhydramine HCl	Allergy and Sinus Relief
phenylephrine HCl/diphenhydramine HCl	Benadryl Allergy Plus Congest
phenylephrine HCl/diphenhydramine HCl	Child Allergy Plus Congestion
phenylephrine HCl/diphenhydramine HCl	Child Benadryl Plus Congestion
phenylephrine HCl/diphenhydramine HCl	Children Night Time Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Childs Triacting Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Dimetapp Cold-Congestion
phenylephrine HCl/diphenhydramine HCl	Dr Manzanilla Cough-Cold
phenylephrine HCl/diphenhydramine HCl	KinderMed Kid Night Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Sudafed PE Day and Night
phenylephrine HCl/diphenhydramine HCl	Triaminic Cold and CoughNT(PE)
phenylephrine HCl/diphenhydramine HCl	Wal-Dryl-D Allergy and Sinus
phenylephrine HCl/promethazine HCl	Promethazine VC
phenylephrine HCl/promethazine HCl	promethazine-phenylephrine
pimavanserin tartrate	Nuplazid
pimozide	pimozide
piperacillin and tazobactam in dextrose, iso-osmotic	Zosyn in dextrose (iso-osm)
piperacillin sodium/tazobactam sodium	piperacillin-tazobactam
pitolisant HCl	Wakix
ponesimod	Ponvory
ponesimod	Ponvory 14-Day Starter Pack
posaconazole	Noxafil
posaconazole	posaconazole
pralsetinib	Gavreto
prednisolone acetate/gatifloxacin	prednisolone acet-gatifloxacin
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/moxifloxacin HCl	prednisolone-moxifloxacin HCl
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl	prednisolone sod ph-moxiflox
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac sod	prednisoln sp-moxiflox-bromfen
pretomanid	pretomanid
primaquine phosphate	primaquine
procainamide HCl	procainamide
promethazine HCl	Phenergan
promethazine HCl	promethazine
promethazine HCl	Promethegan
promethazine HCl in 0.9 % sodium chloride	promethazine in 0.9 % NaCl
promethazine HCl/codeine	promethazine-codeine
promethazine HCl/dextromethorphan HBr	promethazine-DM
promethazine/phenylephrine HCl/codeine	Promethazine VC-Codeine
promethazine/phenylephrine HCl/codeine	promethazine-phenyleph-codeine
propafenone HCl	propafenone
propafenone HCl	Rythmol SR
propofol	Anesthesia S/I-40 (propofol)
propofol	Anesthesia S/I-40A (propofol)
propofol	Anesthesia S/I-40H (propofol)
propofol	Anesthesia S/I-40S (propofol)
propofol	Anesthesia S/I-60 (propofol)
propofol	Diprivan
propofol	propofol
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propofol-Lipuro (PF)
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propoven (EUA) (PF)
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
quetiapine fumarate	quetiapine
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate
quinine sulfate	Qualaquin
quinine sulfate	quinine sulfate
ranolazine	Aspruzyo Sprinkle
ranolazine	Ranexa
ranolazine	ranolazine
relugolix	Orgovyx
relugolix/estradiol/norethindrone acetate	Myfembree
remdesivir	remdesivir
remdesivir	Veklury
remimazolam besylate	Byfavo
ribociclib succinate	Kisqali
ribociclib succinate/letrozole	Kisqali Femara Co-Pack
rilpivirine	rilpivirine
rilpivirine HCl	Edurant
risperidone	Perseris
risperidone	Risperdal
risperidone	risperidone
risperidone microspheres	Risperdal Consta

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
romidepsin	Istodax
romidepsin	romidepsin
rucaparib camsylate	Rubraca
saquinavir mesylate	Invirase
selpercatinib	Retevmo
sertraline HCl	sertraline
sertraline HCl	Zoloft
sevoflurane	sevoflurane
sevoflurane	Ultane
siponimod	Mayzent
siponimod	Mayzent Starter(for 1mg maint)
siponimod	Mayzent Starter(for 2mg maint)
solifenacin succinate	solifenacin
solifenacin succinate	Vesicare
solifenacin succinate	Vesicare LS
sorafenib tosylate	Nexavar
sorafenib tosylate	sorafenib
sotalol HCl	Betapace
sotalol HCl	Betapace AF
sotalol HCl	Sorine
sotalol HCl	sotalol
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
spironolactone/hydrochlorothiazide	Aldactazide
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz
sunitinib malate	sunitinib
sunitinib malate	Sutent
tacrolimus	Astagraf XL
tacrolimus	Envarsus XR
tacrolimus	Prograf
tacrolimus	tacrolimus
tamoxifen citrate	Soltamox
tamoxifen citrate	tamoxifen
tazemetostat hydrobromide	Tazverik
tebentafusp-tebn	Kimmtrak
telavancin HCl	Vibativ
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
terlipressin acetate	Terlivaz
tetrabenazine	tetrabenazine
tetrabenazine	Xenazine
thioridazine HCl	thioridazine
tizanidine HCl	tizanidine
tizanidine HCl	Zanaflex
tizanidine HCl/irritant counter-irritants combination no.2	Comfort Pac-tizanidine
tolterodine tartrate	Detrol
tolterodine tartrate	Detrol LA
tolterodine tartrate	tolterodine
toremifene citrate	Fareston
toremifene citrate	toremifene
torsemide	Soaanz
torsemide	torsemide
tramadol HCl	ConZip
tramadol HCl	Qdolo

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
tramadol HCl	tramadol
tramadol HCl	Ultram
tramadol HCl/acetaminophen	tramadol-acetaminophen
tramadol HCl/acetaminophen	Ultracet
tramadol HCl/celecoxib	Seglantis
TRAMADOL HCL/GLUCOSAMINE SULFATE	Synapryn
trazodone HCl	trazodone
triamcinolone acetonide/moxifloxacin HCl/water/PF	triamcinolon-moxiflox-watr(PF)
triamterene/hydrochlorothiazide	Maxzide
triamterene/hydrochlorothiazide	Maxzide-25mg
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid
trifluridine/tipiracil HCl	Lonsurf
trimipramine maleate	trimipramine
valbenazine tosylate	Ingrezza
valbenazine tosylate	Ingrezza Initiation Pack
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
vandetanib	Caprelsa
vardenafil HCl	vardenafil
vemurafenib	Zelboraf
venlafaxine besylate	venlafaxine besylate
venlafaxine HCl	Effexor XR
venlafaxine HCl	venlafaxine
voclosporin	Lupkynis
vonoprazan fumarate/amoxicillin trihydrate/clarithromycin	Voquezna Triple Pak
voriconazole	Vfend
voriconazole	Vfend IV
voriconazole	voriconazole
vorinostat	Zolinza
ziprasidone HCl	Geodon
ziprasidone HCl	ziprasidone HCl
ziprasidone mesylate	Geodon
ziprasidone mesylate	ziprasidone mesylate

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

To describe the incidence rate of hospitalized tachyarrhythmia, defined as principal diagnosis of tachyarrhythmia in the emergency department visit or inpatient hospital setting, overall and by subtype, that occurred between May 13, 2022 (the approval date of Mounjaro in the U.S.) to June 30, 2023 (the end date of the latest available data), in adult type 2 diabetes mellitus (T2DM) patients who newly initiated tirzepatide or other long-acting glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), by product and patient characteristics including race/ethnicity groups.

- report 03 allows events on Day 0 (index date) (sensitivity analysis)

Query period start date (binds Index Date): May 13, 2022 (tirzepatide approval date in U.S.)

Query period end date (binds Index Date): June 30, 2023

Coverage requirement: Medical & Drug Coverage

Pre-index enrollment requirement: 365 days

Post-index enrollment requirement: N/A

Enrollment gap: 45 days

Age groups: 0-40, 41-64, 65-74, 75-84, ≥85

Sex groups: Male, Female

Race groups: White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial

Stratifications: Age group (0-40, 41-64, 65-74, 75-84, ≥85)
Sex (M F)
Calendar Year
Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial)
Calendar Year * Race
Age group * Race
Arrhythmia at baseline
Other cardiac disease at baseline (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea, and hypertrophic cardiomyopathy)

Censor output stratifications: Categorical (0-30 31-60 61-90 91-183 184-365 366-455+); Continuous

Follow up time stratifications: Categorical (0-30 31-60 61-90 91-183 184-365 366-455+); Continuous

Envelope macro: No reclassification

Features: Censoring table, followup time table, exposure/HOI code distribution tables
Plus programming:
- Disease severity risk score and comorbidity score categorical bins
- Report baseline characteristics, effect estimates by race
- Truncation code distribution

Freeze data: No

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Drug/Exposure	Exposure	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Washout (days)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)
	Exposure Episode Truncation Criteria	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? (This does not apply to index-defining criteria)	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Cohort Definition	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)
	Prevalent Cohort creation?	No	No	No
	Exposure Episode Gap	5 days	5 days	5 days
	Exposure Extension Period	5 days	5 days	5 days
	Minimum Episode Duration	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day
	Point Exposure?	No	No	No
	Maximum Episode Duration	N/A	N/A	N/A
Base Cohort Outcome	Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
	Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

Outcome		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Outcome	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
	Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Outcome	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Blackout Period	0 days	0 days	0 days
Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia	Supraventricular tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)

Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	0 days	0 days	0 days
Blackout Period	0 days	0 days	0 days

Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
Event washout (days)	0 days	0 days	0 days

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

Outcome		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
	Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
	Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

Outcome		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
	Event/Outcome	Ventricular tachycardia	Ventricular tachycardia	Ventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Inclusion/Exclusion Criteria	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND	AND	AND
Inclusion/Exclusion Criteria	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND (	AND (	AND (
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Insulin	Insulin	Insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

Inclusion/Exclusion Criteria	Cohort Group 1			Cohort Group 2			Cohort Group 3		
	Tirzepatide (Mounjaro)			Exenatide synthetic (Bydureon, Bydureon BCISE)			Semaglutide (Ozempic)		
	No			No			No		
	N/A			N/A			N/A		
Number of Code Occurrences			1x	1x			1x		
AND NOT				AND NOT			AND NOT		
Inclusion/Exclusion Criteria	Exclusion			Exclusion			Exclusion		
	Any anti-diabetic drug other than insulin			Any anti-diabetic drug other than insulin			Any anti-diabetic drug other than		
	Dispensing (RX) codes			Dispensing (RX) codes			Dispensing (RX) codes		
	Any			Any			Any		
	(-365, -1)			(-365, -1)			(-365, -1)		
	No			No			No		
	N/A			N/A			N/A		
Number of Code Occurrences			1x	1x			1x		
Inclusion/Exclusion Criteria	) OR			) OR			) OR		
	Exclusion			Exclusion			Exclusion		
	Type 1 Diabetes			Type 1 Diabetes			Type 1 Diabetes		
	Diagnosis (DX) codes			Diagnosis (DX) codes			Diagnosis (DX) codes		
	Any			Any			Any		
	(-365, -1)			(-365, -1)			(-365, -1)		
	No			No			No		
Number of Code Occurrences			1x	1x			1x		
Inclusion/Exclusion Criteria	OR			OR			OR		
	Exclusion			Exclusion			Exclusion		

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

Inclusion/Exclusion Criteria		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
OR		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illness
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
OR		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

Inclusion/Exclusion Criteria		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	OR	OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Pregnancy	Pregnancy	Pregnancy
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	OR	OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

Inclusion/Exclusion (Washout) Criteria		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
Stockpiling	Group(s) Affected by Custom Stockpiling Rules	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)
	Same Day Processing (days)	Max	Max	Max
	Same Day Processing (amount supply)	Max	Max	Max
	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount supply)	Greater than 0	Greater than 0	Greater than 0
	Maximum Amount of Percentage Overlap Allowed Prior to Shifting Dispensing Date	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)
Baseline Covariates	Covariates	(See Appendix I)	(See Appendix I)	(See Appendix I)
	Code Details (type, days supply, etc.)	(See Appendix I)	(See Appendix I)	(See Appendix I)
	Care Setting/PDX	N/A	N/A	N/A
	Covariate evaluation window (days)	(See Appendix I)	(See Appendix I)	(See Appendix I)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 1-3)

Utilization/ Comorbidity Score	Cohort Group 1		Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)		Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Comorbidity Score evaluation window (days)	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
	Drug Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

Drug/Exposure				
		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Exposure	Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Washout (days)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)
	Exposure Episode Truncation Criteria	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? (This does not apply to index-defining criteria)	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Cohort Definition	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)
Prevalent Cohort creation?	No	No	No
Exposure Episode Gap	5 days	5 days	5 days
Exposure Extension Period	5 days	5 days	5 days
Minimum Episode Duration	1 day	1 day	1 day
Minimum Days Supplied	1 day	1 day	1 day
Point Exposure?	No	No	No
Maximum Episode Duration	N/A	N/A	N/A

Base Cohort Outcome	Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days

	Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Outcome	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
Outcome	Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Outcome	Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia	Supraventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
Outcome	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
	Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	0 days	0 days	0 days
Blackout Period	0 days	0 days	0 days

Outcome	Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days

Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Outcome	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
Outcome	Event/Outcome	Ventricular tachycardia	Ventricular tachycardia	Ventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

Inclusion/Exclusion Criteria		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Inclusion/Exclusion Criteria		AND	AND	AND
	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	Include or Exclude	Exclusion	Exclusion	Exclusion
Inclusion/Exclusion Criteria	Conditions	Insulin	Insulin	Insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND NOT	AND NOT	AND NOT
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Inclusion/Exclusion Criteria	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		) OR	) OR	) OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Inclusion/Exclusion Criteria	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illness
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Inclusion/Exclusion Criteria		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Short-acting GLP-1 RA (Bvetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Bvetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Bvetta, Adlyxin, Soliqua)
	Code Details (type, days supply, Care Setting/PDX)	Dispensing (RX) code Any	Dispensing (RX) code Any	Dispensing (RX) code Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
Inclusion/Exclusion Criteria	Conditions	Pregnancy	Pregnancy	Pregnancy
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
		OR	OR	OR
Inclusion/Exclusion (Washout) Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
Stockpiling	Group(s) Affected by Custom Stockpiling Rules	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)
	Same Day Processing (days supply)	Max	Max	Max
	Same Day Processing (amount supply)	Max	Max	Max
	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount supply)	Greater than 0	Greater than 0	Greater than 0
	Maximum Amount of Percentage Overlap Allowed Prior to Shifting Dispensing Date	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 4-6)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Baseline Covariates	Covariates	(See "Covariates" tab)	(See "Covariates" tab)	(See "Covariates" tab)
	Code Details (type, days supply, etc.)	(See "Covariates" tab)	(See "Covariates" tab)	(See "Covariates" tab)
	Care Setting/PDX	N/A	N/A	N/A
	Covariate evaluation window	(See "Covariates" tab)	(See "Covariates" tab)	(See "Covariates" tab)
Utilization/ Comorbidity	Comorbidity Score evaluation window (days)	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
	Drug Utilization Evaluation	(-365, -1)	(-365, -1)	(-365, -1)

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

Drug/Exposure				
	Cohort Group 7		Cohort Group 8	
	Liraglutide (Victoza)		Dulaglutide (Trulicity)	
	Insulin degludec and liraglutide (Xultophy)			
	Exposure	Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Washout (days)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)
	Exposure Episode Truncation Criteria	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? (This does not apply to index-defining criteria)	No	No	No

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Forced supply to attach to codes	N/A	N/A	N/A
Cohort Definition	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)
Prevalent Cohort creation?	No	No	No
Exposure Episode Gap	5 days	5 days	5 days
Exposure Extension Period	5 days	5 days	5 days
Minimum Episode Duration	1 day	1 day	1 day
Minimum Days Supplied	1 day	1 day	1 day
Point Exposure?	No	No	No
Maximum Episode Duration	N/A	N/A	N/A

Base Cohort Outcome	Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days

Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

Outcome				
		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
	Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
Outcome	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
	Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to	N/A	N/A	N/A
Start of at-risk period	0 days	0 days	0 days
Blackout Period	0 days	0 days	0 days

Outcome	Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to	N/A	N/A	N/A

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days

Outcome	Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days

	Event/Outcome	Ventricular tachycardia	Ventricular tachycardia	Ventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Outcome	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	0 days	0 days	0 days
	Blackout Period	0 days	0 days	0 days
Inclusion/Exclusion Criteria	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	AND		AND	
	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Inclusion/Exclusion Criteria	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND (	AND (	AND (
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Insulin	Insulin	Insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND NOT	AND NOT	AND NOT
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Inclusion/Exclusion Criteria	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		) OR	) OR	) OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Inclusion/Exclusion Criteria	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illness
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Forced supply to attach to	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Pregnancy	Pregnancy	Pregnancy
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclusion/Exclusion (Washout) Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
Stockpiling	Group(s) Affected by Custom Stockpiling Rules	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)
	Same Day Processing (days supply)	Max	Max	Max
	Same Day Processing (amount supply)	Max	Max	Max
	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount supply)	Greater than 0	Greater than 0	Greater than 0
	Maximum Amount of Percentage Overlap Allowed Prior to Shifting Dispensing Date	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)
Baseline Covariates	Code Details (type, days supply, etc.)	(See Appendix I)	(See Appendix I)	(See Appendix I)
	Care Setting/PDX	N/A	N/A	N/A
	Covariate evaluation window (days)	(See Appendix I)	(See Appendix I)	(See Appendix I)

Appendix H. Specifications Defining Parameters for this Request (Sensitivity Analysis for Day 0 Event Window, Cohorts 7-9) (Continued)

Utilization/ Comorbidity Score				
		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Comorbidity Score evaluation window (days)	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
	Drug Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Sensitivity Analysis for Day 0 Event Window)

							Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
Group	No.	Characteristic	Care Setting	Covariate Window	Code Type	Minimum # of Instances		
Demographic Characteristics	N/A	Continuous age	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Age groups (18-29 30-39 40-49 50-59 60-69 70-79 80+)	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial)	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Sex (M F)	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Calendar year	N/A	Index Day	N/A	N/A	N/A	N/A
Lifestyle Risk Factor	1	Alcohol use or abuse	Any	(-365, -1)	Diagnosis	1x	No	N/A
	2	Obesity	Any	(-365, -1)	Diagnosis	1x	N/A	N/A
	3	Tobacco Use	Any	(-365, -1)	Diagnosis	1x	No	N/A
Medical History	4	Arrhythmia	Any	(-365, -1)	Diagnosis	1x	No	N/A
	5	Cerebrovascular disease/stroke/transient ischemic attack	Any	(-365, -1)	Diagnosis	1x	No	N/A
	6	Chronic kidney disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	7	Chronic obstructive pulmonary disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	8	Congenital heart disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	9	Heart failure	Any	(-365, -1)	Diagnosis	1x	No	N/A
	10	Hyperlipidemia	Any	(-365, -1)	Diagnosis	1x	No	N/A
	11	Hypertensive disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	12	Thyroid disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	13	Ischemic heart disease/coronary artery disease/myocardial infarction	Any	(-365, -1)	Diagnosis	1x	No	N/A
	14	Left ventricular hypertrophy	Any	(-365, -1)	Diagnosis	1x	No	N/A
	15	Peripheral artery disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	16	Valvular/mitral valve disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	17	Diseases of veins and lymphatics, and other diseases of circulatory systemstem	Any	(-365, -1)	Diagnosis	1x	No	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Sensitivity Analysis for Day 0 Event Window)

							Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
Group	No.	Characteristic	Care Setting	Covariate Window	Code Type	Minimum # of Instances		
	18	Obstructive sleep apnea	Any	(-365, -1)	Diagnosis	1x	No	N/A
	19	Hypertrophic cardiomyopathy	Any	(-365, -1)	Diagnosis	1x	No	N/A
	20	Other cardiac disease (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea, and hypertrophic cardiomyopathy)	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	21	Tachyarrhythmia Day 0	Any	(0, 0)	Diagnosis	1x	No	N/A
	22	Hospitalized Tachyarrhythmia Day 0	ED*, IP*	(0, 0)	Diagnosis	1x	No	N/A
	Risk score	Charlson/Elixhauser combined comorbidity index	N/A	(-365, -1)	N/A	N/A	N/A	N/A
	Risk score	Charlson/Elixhauser combined comorbidity index (0)	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
	Risk score	Charlson/Elixhauser combined comorbidity index (1 or 2)	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
	Risk score	Charlson/Elixhauser combined comorbidity index (3 or 4)	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
	Risk score	Charlson/Elixhauser combined comorbidity index (5 or greater)	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
Severity of Diabetes	Risk	Diabetes complications severity index	Any	(-365, -1)	Risk Score	1x	No	N/A
	Risk score	Diabetes complications severity index (0)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	Risk score	Diabetes complications severity index (1)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	Risk score	Diabetes complications severity index (2)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	Risk score	Diabetes complications severity index (3)	Any	(-365, -1)	Custom Coding	1x	No	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Sensitivity Analysis for Day 0 Event Window)

Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?								
Group	No.	Characteristic	Care Setting	Covariate Window	Code Type	Minimum # of Instances	ignore days supply (after stockpiling)?	Forced supply to attach to codes
	Risk score	Diabetes complications severity index (4)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	Risk score	Diabetes complications severity index (5 or greater)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	25	History of serious hypoglycemia (emergency department visit and/or inpatient care)	ED*, IP*	(-365, -1)	Diagnosis	1x	No	N/A
Baseline Use of Antidiabetic Drug	26	Alpha-glucosidase inhibitors	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	27	Amylin analogs (Pramlintide)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	28	Dipeptidyl peptidase 4 (DPP-4) inhibitors	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	29	Incretin mimetics (DPP-4 inhibitors, Victoza, Byetta, Bydureon, Bydureon BCISE)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	30	Meglitinides	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	31	Insulin	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	32	Biguanides (metformin)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Sensitivity Analysis for Day 0 Event Window)

Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?								
Group	No.	Characteristic	Care Setting	Covariate Window	Code Type	Minimum # of Instances	Forced supply to attach to codes	
	33	SGLT2 Inhibitors	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	34	Sulfonylurea	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	35	Thiazolidinedione	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	36	No baseline use of any of the above antidiabetic drugs	N/A	N/A	Dispensings (Dispensings Table)	1x	No	N/A
	37	Other antidiabetic drugs (bromocriptine, mifepristone)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
Baseline Use of Other Medications	38	Sodium channel blockers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	39	Beta blockers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	40	Potassium channel blockers/openers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	41	Non-dihydropyridine calcium channel blockers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	42	Digoxin	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Sensitivity Analysis for Day 0 Event Window)

Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?								
Group	No.	Characteristic	Care Setting	Covariate Window	Code Type	Minimum # of Instances	Forced supply to attach to codes	
	43	Other antiarrhythmic agents	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	44	Antiarrhythmic agents (any of the above antiarrhythmic agents)	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	45	Angiotensin-converting-enzyme (ACE) inhibitor	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	46	Angiotensin II receptor blockers (ARB)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	47	Dihydropyridines	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	48	Diuretics	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	49	Other antihypertensives	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	50	Antihypertensives (any of the above antihypertensives)	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	51	Oral anticoagulants	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	52	Vitamin K antagonists	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Sensitivity Analysis for Day 0 Event Window)

Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?								
Group	No.	Characteristic	Care Setting	Covariate Window	Code Type	Minimum # of Instances	ignore days supply (after stockpiling)?	Forced supply to attach to codes
	53	Other cardiac medications (not including oral anticoagulants or vitamin K antagonists)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	54	Other cardiac medications (any of above "other" medications")	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	55	Lipid lowering therapy	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	56	Drugs with a known risk of Prolong QT and Torsades de Pointes	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	57	Drugs with a known/possible/conditional risk of Prolong QT and Torsades de Pointes	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
Concomitant use of drugs with a risk of Prolong QT and Torsades de Pointes	58	Drugs with a known risk of Prolong QT and Torsades de Pointes	N/A	(0, 0)	Dispensings (Dispensings Table)	1x	No	N/A
	59	Drugs with a known/possible/conditional risk of Prolong QT and Torsades de Pointes	N/A	(0, 0)	Dispensings (Dispensings Table)	1x	No	N/A
Intensity of Health Care Utilization		Number of inpatient hospital stays	IP*	(-365, -1)	N/A	N/A	N/A	N/A
		Number of non-acute institutional stays	IS*	(-365, -1)	N/A	N/A	N/A	N/A
		Number of emergency department visits	ED*	(-365, -1)	N/A	N/A	N/A	N/A
		Number of ambulatory visits	AV*	(-365, -1)	N/A	N/A	N/A	N/A
		Number of other ambulatory visits	OA*	(-365, -1)	N/A	N/A	N/A	N/A
		(includes other non overnight ambulatory encounters such as home health visits, telemedicine, telephone and email consultations)						

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Sensitivity Analysis for Day 0 Event Window)								
							Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	
Group	No.	Characteristic	Care Setting	Covariate Window	Code Type	Minimum # of Instances	Forced supply to attach to codes	
Intensity of Drug Utilization		Number of dispensings	N/A	(-365, -1)	N/A	N/A	N/A	N/A
		Number of unique generics dispensed	N/A	(-365, -1)	N/A	N/A	N/A	N/A
		Number of unique drug classes dispensed	N/A	(-365, -1)	N/A	N/A	N/A	N/A

N/A: Not Applicable

Appendix J. Specifications Defining Combination Code Parameters Used in this Request

Order	Combo description	Purpose	Final Combo	Order within Combo	Base component	Time window between components	AND / AND NOT?	Combined-to component	New Anchor Date	New Episode Length	Details
1	IP encounter Other than Non-HOI Hospitalized Tachyarrhythmia	Truncation	RX (IPENCOUNTER)	1	IP or ED encounter (EN01)	(0, 0)	AND NOT	Pregnancy (any) or Tachyarrhythmia (any)	Start date of base component	Start date of IP encounter	- This will prevent IP/ED encounters from reporting IP/ED pregnancy codes in the code distribution for truncation codes. '- All tachyarrhythmia codes in all care settings are excluded in this combo so that hospitalized tachyarrhythmia (IPP, ED*) will be used as truncation criteria for cohorts where the hospitalized tachyarrhythmia code is not used in the HOI definition.
2	ED encounter Other than Non-HOI Hospitalized Tachyarrhythmia	Truncation	RX (EDENCOUNTER)	1	IP or ED encounter (EN01)	(0, 0)	AND NOT	Pregnancy (any) or Tachyarrhythmia (any)	Start date of base component	Start date of ED encounter	- This will prevent IP/ED encounters from reporting IP/ED pregnancy codes in the code distribution for truncation codes. '- All tachyarrhythmia codes in all care settings are excluded in this combo so that hospitalized tachyarrhythmia (IPP, ED*) will be used as truncation criteria for cohorts where the hospitalized tachyarrhythmia code is not used in the HOI definition.


Abbreviations:

IP: Inpatient

ED: Emergency Department

Appendix K. Design Diagram for this Request

Type 2 design diagram: Sensitivity analysis (Day 0 at risk)



Abbreviations:
 DP: Data Partner
 ER: Emergency Room
 HOI: Health Outcome of Interest
 GLP-1 RA: Glucagon-like Peptide 1 Receptor Agonist

Appendix K. Design Diagram for this Request

*Exclusion Criteria	**Inclusion Criteria	***Covariates:
Window 1: use of insulin without other anti-diabetic drugs, type 1 diabetes, gestational diabetes, other secondary diabetes illnesses, short-acting GLP-1 RAs, pregnancy, long-acting GLP-1 RAs	Window A: type 2 diabetes, any oral anti-diabetic drug	Window I: Age, year, race, sex Window II: <u>Charlson/Elixhauser</u> combined comorbidity index, adapted Diabetes Complications Severity Index (ADCSI), alcohol use or abuse, obesity, tobacco use, arrhythmia, cerebrovascular disease/stroke/transient ischemic attack, chronic kidney disease, COPD, congenital heart disease, heart failure, hyperlipidemia, hypertensive disease, thyroid disease, ischemic heart disease/coronary artery disease/myocardial infarction, left ventricular hypertrophy, peripheral artery disease, valvular/mitral valve disease, diseases of veins and lymphatics and other diseases of circulatory system, obstructive sleep apnea, hypertrophic cardiomyopathy, other cardiac diseases, history of serious hypoglycemia, alpha-glucosidase inhibitor, amylin analogs (pramlintide), DPP-4 inhibitors, incretin mimetics, meglitinides, insulin, biguanides, SGLT-2 inhibitors, sulfonylurea, thiazolidinedione, no baseline use of above mentioned antidiabetic drugs, sodium channel blocker, beta blocker, potassium channel blockers/openers, non-dihydropyridine calcium channel blockers, digoxin, other antiarrhythmic agents, any of the above mentioned antiarrhythmic agents, ACE inhibitor, ARBs, dihydropyridines, diuretic, other antihypertensives, any of the above mentioned antihypertensives, oral anticoagulants, vitamin K antagonists, other cardiac medications (not including oral anticoagulants or vitamin K antagonists), any of the above mentioned “other” medications, lipid lowering therapy, drugs with a known risk of Prolong QT and <u>Torsades</u> de Pointes, drugs with a known/possible/conditional risk of Prolong QT and <u>Torsades</u> de Pointes, healthcare and utilization metrics Window III: tachyarrhythmia, hospitalized tachyarrhythmia, drugs with a known risk of Prolong QT and <u>Torsades</u> de Pointes, drugs with a known/possible/conditional risk of Prolong QT and <u>Torsades</u> de Pointes